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Abstract 
Members of the Mycobacterium abscessus complex (MABSC) are a highly antibiotic-
resistant complex of organisms within the genus Mycobacterium, increasingly 
acknowledged as a significant cause of lung infection in patients with cystic fibrosis (CF) 
and associated with poor clinical outcomes. Current methods of isolation of MABSC are 
hindered by the fact that they grow at a slower rate in culture than other microorganisms 
with many patient samples having to be discarded due to the overgrowth of more rapidly 
growing species. Decontamination of samples has shown to have an adverse effect upon 
the viability of MABSC, therefore improvements in the isolation of MABSC are urgently 
required in order to offer the possibility of a more rapid and accurate diagnosis. 
A novel medium (RGM) was developed for the isolation of MABSC. Commercially available 
pre-poured media were compared with RGM and challenged with isolates of rapidly growing 
mycobacteria and other species. In addition, in a multi-centre study sputum samples 
collected from patients with CF were inoculated onto RGM medium, BCSA and standard 
automated liquid culture method and assessed for growth. RGM demonstrated superior 
sensitivity over currently used methods without any requirement for decontamination and 
could easily be incorporated into any laboratory alongside routine culture for other CF 
pathogens.  
Chromogenic and fluorogenic substrates were investigated for the possibility of 
differentiating between subspecies within the MABSC complex. However, the results 
established that these would not provide any additional benefit to RGM. 
Possible environmental sources were explored in order to establish how patients with CF 
were acquiring MABSC. Although person-to-person transmission has been suggested, 
there are very few reports to substantiate this at present and many questions remain 
unanswered. In this study, MABSC was not isolated from any of the environments screened. 
Finally, a selection of antimicrobials were investigated against MABSC with the purpose of 
ascertaining susceptibility and whether any may be used for a more successful treatment 
outcome. There were no clinically applicable results therefore further work is required in this 
area. 
To conclude, RGM is a novel culture medium, which can be embedded alongside routine 
culture for other CF pathogens without any requirement for decontamination. This means 
that all respiratory samples submitted from patients with CF can be conveniently cultured 
for NTM, considerably improving the service offered to clinicians and patients. Furthermore, 
it is likely that formal AFB culture methods could be replaced by use of such a medium, 
potentially enabling substantial savings in terms of materials and labour time.  
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1. The genus Mycobacterium 
The genus Mycobacterium is one of the earliest defined, with the name 
mycobacterium originating from the Greek prefix for fungus “myco”, initially 
designated to a group of organisms that grew as mould like pellicles on the surface 
of liquid media (Rastogi et al., 2001).  
Published in 1896 by Lehmann and Neumann in their Atlas of Bacteriology, the 
genus Mycobacterium at the time contained only two species, Mycobacterium 
tuberculosis and Mycobacterium leprae.  
Taxonomically, mycobacteria belong to the genus Mycobacterium, a genus within 
the family of Mycobacteriaceae in the order of Corynebacteriales. The 
Mycobacterium genus to date comprises more than 170 diverse species (Euzeby, 
2015), and with respect to pathogenicity three groups can be subdivided (Ng et al., 
2014); M. tuberculosis complex, M. leprae and non-tuberculous mycobacteria 
(NTM). 
1.1 History of mycobacteria 
M. tuberculosis was first discovered to be the causative agent of tuberculosis (TB) 
in 1882 by Robert Koch. On 24th March 1882, Koch declared to the Berlin 
Physiological Society that he had established the cause of TB (Koch, 1882). This 
was a principal event in the history of medicine, and a defining moment in the 
understanding of the deadly disease that had plagued mankind for centuries. Koch 
modified previously used staining techniques, and developed a solid culture medium 
rather than the liquid broths that were used at that time and was able to isolate, 
cultivate and observe the bacteria. He demonstrated that the disease was due to an 
external infectious agent by observing lesions characteristic of the disease, that 
were not present in normal tissues, then by culturing in vitro, outside the infected 
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animal, and reintroducing in vivo into a healthy animal subsequently leading to TB 
lesions (Cambau and Drancourt, 2014). 
Only a few years later many other species of mycobacteria had been described 
(Migliori et al., 2007), which at the time were all considered “atypical mycobacteria”. 
The pathogenicity of these “atypical” mycobacteria to humans was increasingly 
documented following a significant publication (Buhler and Pollak, 1953) where two 
cases of pulmonary disease comparable to TB and caused by what the authors 
termed the “yellow bacillus” after the bright yellow pigment observed upon exposure 
to light, were described. Today this species is known as Mycobacterium kansasii. 
As these “atypical” mycobacteria currently make up the majority of species within 
the genus Mycobacterium, the term atypical is contentious, and they are today more 
frequently known as non-tuberculous mycobacteria.  
1.2 Species of mycobacteria 
1.2.1 Mycobacterium tuberculosis complex 
Mycobacterium tuberculosis complex includes M. tuberculosis, Mycobacterium 
africanum, Mycobacterium caprae, Mycobacterium bovis, Mycobacterium bovis 
Bacille Calmette-Guerin (BCG), Mycobacterium canettii, Mycobacterium microti, 
Mycobacterium mungi and Mycobacterium pinnipedii. 
With the exclusion of M. bovis BCG, which is a vaccine against TB prepared from a 
live attenuated strain of M. bovis (Orduna et al., 2011), these species are considered 
to cause TB in both humans and animals, and despite their genomic similarity, their 
epidemiology, pathogenicity and host continuum vary substantially. 
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1.2.2 Non-cultivable mycobacteria 
Mycobacterium leprae, also known as Hansen`s bacillus, was the first acid-fast 
bacterium to be recognised as a source of a human disease in 1873 by Gerhard 
Armauer Hansen in the skin nodules of patients with leprosy.  
Previously termed “the bacteriologist’s enigma” (Stewart-Tull, 1982) the causative 
organism of leprosy has to date obstinately eluded all attempts to culture it in vitro 
never having been successfully grown on artificial culture medium as it is only able 
to proliferate whilst acting as a intracellular parasite (Davis et al., 2013; Kumar et 
al., 2014). Mycobacterium leprae has the slowest doubling time of all known bacteria 
taking around fourteen days for cells to divide. 
1.2.3 Non-tuberculous mycobacteria  
NTM, also known as mycobacteria other than tuberculosis, or atypical mycobacteria, 
denote all species of mycobacteria that can cause human disease, other than TB 
and leprosy. NTM can be classified into two categories; slow-growing and rapid 
growing. This is based on interval to colony formation by subculture onto solid 
media, with the cut off distinguishing the two estimated at around seven days. To 
simplify organised clinical and taxonomical study, Runyon suggested the first 
classification system for NTM based on their colony morphology, growth rates and 
pigmentation (Runyon, 1959), (see Table 1-1), although this is now somewhat 
obsolete with the widespread use of molecular techniques. A more applicable 
method of categorising these organisms is based on the type of clinical disease they 
produce; pulmonary, cutaneous, lymphadenitis or disseminated disease (Koh et al., 
2002). 
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1.2.3.1 Slow-growing non-tuberculous mycobacteria 
This is a group of NTM that generally require more than seven-day’s incubation to 
form visible colonies on culture media. The most common clinically relevant species 
are Mycobacterium avium complex (MAC), including but not limited to M. avium and 
Mycobacterium intracellulare, as well as other significant species such as 
Mycobacterium kansasii, Mycobacterium xenopi, Mycobacterium malmoense, 
Mycobacterium simiae, Mycobacterium scrofulaceum, Mycobacterium marinum, 
Mycobacterium terrae, Mycobacterium gordonae and Mycobacterium szulgai. 
Mycobacterium ulcerans is an environmental slow-growing NTM responsible for 
causing the Buruli ulcer, a chronic and often debilitating disease frequently seen in 
children and characterised by necrosis of subcutaneous tissue, affecting mainly the 
skin, but occasionally bones. The exact mode of transmission is unknown and there 
are currently no preventative measures that may be undertaken (Doig et al., 2012). 
Early determination of whether the causative organisms are rapidly-growing or slow-
growing NTM is advantageous for selecting appropriate treatments; since antibiotic 
regimens can vastly differ, and those that are effective for slow-growing 
mycobacteria may not be effective for rapid growers (Kim et al., 2013).   
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Table 1-1: Classification of non-tuberculous mycobacteria according to 
Runyon (Runyon, 1959) 
Group Characteristics Important Species 
I Photochromogens Slow growth > 7 days 
Pigmentation after exposure 
to light 
Mycobacterium kansasii 
Mycobacterium szulgai 
Mycobacterium simiae 
 
II Scotochromogens Slow growth > 7 days 
Pigmentation with or without 
light exposure 
Mycobacterium xenopi 
Mycobacterium gordonae 
Mycobacterium 
scrofulaceum 
 
III Non-Chromogens Slow growth > 7 days 
No pigmentation 
Mycobacterium avium 
Mycobacterium 
intracellulare 
Mycobacterium 
malmoense 
IV Rapid Growers Rapid growth < 7 days Mycobacterium fortuitum 
Mycobacterium 
abscessus 
Mycobacterium chelonae 
 
1.2.3.2 Rapidly-growing non-tuberculous mycobacteria 
The group of NTM that are categorised as rapidly-growing will form visible colonies 
on culture media in less than seven days. As in the slow-growing mycobacteria, time 
to growth detection can vary between species with some rapid growers being 
detected in three to four days. These include but not limited to Mycobacterium 
abscessus complex (MABSC); (MABSC includes M. abscessus subsp. abscessus, 
Mycobacterium abscessus subsp. bolletii and Mycobacterium abscessus subsp. 
massiliese), Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium 
neoaurum, Mycobacterium smegmatis and Mycobacterium mucogenicum. 
1.3 The structure of the mycobacterial cell 
Described as one of the most complex in nature, many of the distinctive 
characteristics of the mycobacterial cell are to be found in their intricate cell wall 
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(Figure 1-1), where a  key finding in the past decade has been the remarkably low 
permeability of mycobacteria to nutrients and antimicrobial agents. This decelerates 
growth of mycobacteria, as well as making any disease instigated by pathogenic 
species very challenging to treat due to their inherent resistance to most 
antimicrobials and chemotherapeutic agents. 
The cell wall of mycobacteria is extremely complex with its most prominent 
distinguishing feature being its high lipid content, said to account for around 60% of 
the cell wall weight, compared to 5% in other Gram-positive bacteria and 10% in 
Gram-negative bacteria (Jarlier and Nikaido, 1990), which could explain the 
tendency for NTM to grow in clumps. Its unusual structure makes it challenging for 
any host to impair the cell wall and while intact this offers substantial protection to 
the mycobacterium from any damage. The cell wall is composed of mycolic acids, 
complex waxes, and distinctive glycolipids, peptidoglycan (PG) and arabinogalactan 
(AG). Mycolic acids are a homologous succession of C60-C90 exceptionally 
elongated side-chain alpha-alkyl and beta-hydroxy fatty acids joined to the muramic 
acid moiety of the peptidoglycan by phosphodiester bridges, and to arabinogalactan 
(D-arabinose and D-galactose) by esterified glycolipid linkages, signifying crucial 
components of the mycobacterial cell wall. They are imperative to mycobacterial 
growth, survival, and pathogenicity. 
A major component of the mycobacterial cell wall is a macromolecule of 
peptidoglycan covalently-linked through a phosphodiester group to an arabinan-
capped linear galactan. The arabinan cap is adapted with numerous mycolic acids. 
Aside from the mycolyl–arabinogalactan–peptidoglycan complex, the cell wall 
contains non-covalently associated lipids, glycolipids, glycophospholipids, 
glycopeptidolipids, sulfolipids, and sulfoglycolipids. Among the most abundant of 
these are a family of associated glycophospholipids containing mannose, termed 
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the phosphatidylinositol mannosides (PIMs), lipomannan (LM) and 
lipoarabinomannan (LAM). These molecules share a phosphatidylinositol (PI) 
anchor, and biochemical and genetic studies support a proposed biosynthesis 
pathway of PI → PIMs → LM → LAM (Khoo et al., 1995; Schaeffer et al., 1999; 
Kordulakova et al., 2002). 
PIMs are distinctive glycolipids found in abundance in the inner and outer 
membranes of all mycobacterium species. They are centred on a 
phosphatidylmyoinositol lipid anchor carrying one to six mannose residues and up 
to four acyl chains. Phosphatidylmyoinositol mannosides are considered to be 
crucial structural components of the cell envelope (Guerin et al., 2009). 
Glycolipids LAM and LM are key virulence factors in mycobacteria species. Besides 
their role in the cell wall structure, it is thought they function as toll-like receptors 
with immunoregulatory and anti-inflammatory effects (Fukuda et al., 2013) allowing 
their survival by damaging host resistance and acquired immune responses. These 
mechanisms consist of the inhibition of T-cell proliferation and of macrophage 
microbicidal activity through reduced IFN-Ƴ response (Knutson et al., 1998).  
Arabinogalactan (AG) is a major structural component of the cell wall. It is a highly 
branched polysaccharide providing a molecular framework facilitating the 
connection of peptidoglycan to the outer mycolic acid layer and a range of 
glycolsyltransferases are employed for its assembly. The biosynthesis of the 
arabinan domains of AG and LAM occurs via a combination of membrane bound 
arabinofuranosyltransferases (Alderwick et al., 2011).  
The role of the complex hydrophobic mycobacterial cell wall has been widely 
studied, and many of its properties including its characteristic acid-fastness, high 
lipid content, and the slow rate of growth are thought to play a large part in the poor 
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diffusion of hydrophilic molecules, including antibiotics (Jarlier and Nikaido, 1990). 
Genomic analysis has also revealed the presence of other prospective drug 
resistance elements such as predicted ß-lactamases, aminoglycoside 
phosphotransferases and aminoglycoside acetyltransferases (Ripoll et al., 2009). 
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Figure 1-1: Structure of the cell wall of mycobacteria (Medjahed et al., 2010) 
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Different species are characterised by variation in sugar substitutions in the 
glycolipids or peptidoglycolipids. Other significant cell wall components are 
trehalose dimycolate (cord factor), as it is thought to induce growth in serpentine 
cords on artificial medium, and mycobacterial sulfolipids, which are believed to play 
a role in virulence (Mendum et al., 2015).  
Mycobacteria are categorised as acid-fast organisms, signifying that they are 
resistant to decolourisation by acids during staining techniques and retain the carbol 
fuchsin dye when exposed to acid-ethanol. 
The presence of porins protects the cell against harmful extracellular composites by 
allowing the passage of compounds and hydrophilic antibiotics where they can 
reach the cytoplasm and activate the expression of drug resistance genes (Trias et 
al., 1992).  
The permeability barrier of cell walls of mycobacteria was found to be between 10 
– 100 fold lower than that of Pseudomonas aeruginosa with the chemical nature of 
the cell wall being unlike both Gram-negative and Gram-positive bacteria (Figure 
1-2). 
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Gram negative Gram positive Mycobacteria 
 
Figure 1-2: Typical bacterial cell walls showings the cell wall of Gram-negative bacteria (a) consists of a thin layer of peptidoglycan 
between the inner and outer lipid membranes. The outer membrane contains lipopolysaccharides and facilitates transport through 
channels such as porins. Gram-positive bacteria (b) have a single lipid membrane surrounded by a cell wall composed of a thick layer 
of peptidoglycan and lipoteichoic acid, anchored to the cell membrane by diacylglycerol. Cell walls of mycobacteria (c) entail thin 
layers of peptidoglycan and arabinogalactan, and a thick layer of mycolic acids with glycolipids and porins also found in the cell walls, 
as well as lipoarabinomannan, which is anchored to the cell membrane by diacylglycerol (Brown et al., 2015).  
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1.4 Pathogenicity of non-tuberculous mycobacteria and risk factors for 
infection.  
NTM are ubiquitous environmental organisms found in soil, dust particles, biofilms 
and water. The virulence of NTM varies by species, but is usually low in 
immunocompetent individuals. As exposure to these organisms is widespread and 
disease is infrequent, it can be established that host defences are normally 
adequate to impede infection. The infective dose for NTM infection is unknown, 
however it follows that individuals that develop disease are thought to have 
abnormal susceptibility, intense exposure or immune defects that permit infection 
with NTM (Sexton and Harrison, 2008; Al-Anazi et al., 2014). 
Due to their profound immune suppression, individuals with HIV infection are 
frequently identified as having increased morbidity due to NTM (Corti and Palmero, 
2008), and a CD4+ T cell count of less than 50 cells/μL is associated with increased 
risk of disseminated NTM disease (Mirsaeidi et al., 2014). However the prevalence 
of NTM infections is also increasing in non-HIV patients, for example in patients on 
tumour necrosis factor α (TNF-α) pathway blockers (Winthrop et al., 2009), 
individuals with bronchiectasis (Griffith and Aksamit, 2012) or chronic obstructive 
pulmonary disease (Huang et al., 2012). Patients with genetic syndromes relating 
to mutations in the interleukin-12 or interferon γ pathways are also at risk for 
developing opportunistic infections such as those caused by NTM and the same 
applies to those with immunodeficiency syndromes (Sexton and Harrison, 2008). 
Additionally, female non-smokers aged between 50 and 80 with a lean body and 
some with characteristic features such as scoliosis, pectus excavatum, or mitral 
valve prolapse are more susceptible to pulmonary NTM compared to the rest of the 
population (Chan and Iseman, 2010). The body morphotype itself may be an 
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influential characteristic through features such as poor tracheobronchial secretion 
drainage or ineffective mucociliary clearance (Griffith et al., 2007). Cystic fibrosis 
(CF) has also been progressively associated with an increased prevalence of NTM 
infection (Olivier et al., 2003). 
Typically the cause of morbidity and mortality is through slowly progressive and 
chronic lung disease, however NTM have the potential to infect any organ in the 
human body and have frequently been isolated from skin and soft tissue, bone, joint, 
septic arthritis and central nervous system disease. Disseminated disease generally 
occurs in patients who are immunocompromised, and lymphadenitis can occur in 
otherwise healthy young children (Mirsaeidi et al., 2014). 
The most common NTM species associated with pulmonary infection are members 
of MAC. Mycobacterium kansasii, another slow-growing NTM, is the second most 
common cause of pulmonary infection, followed by members of the rapidly-growing 
MABSC (Johnson and Odell, 2014). 
1.5 Association of non-tuberculous mycobacteria with cystic fibrosis 
Interest is now being paid to pulmonary disease in CF patients caused by NTM. 
Although the occurrence of NTM disease in the general population is around 1 in 
100,000, there is a 10,000-fold greater prevalence within patients with CF. It is 
becoming progressively difficult to recognise and treat (Wentworth et al., 2013) with 
overall prevalence of NTM in CF sputum varying between 6% to 13% (Olivier et al., 
2003; Martiniano et al., 2016). The predominant species of NTM within the CF 
population in the UK are rapid growers within the MABSC (62% of NTM cases in 
adults, 68% of NTM cases in children) followed by slow-growing MAC (28% of NTM 
cases in adults, 27% of NTM cases in children) (Seddon et al., 2013). Other species 
(M. gordonae, M. kansasii, M. xenopi, M. fortuitum, M. simiae, M. malmoense, M. 
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mucogenicum, M. perigrinum) together make up 8% of the total. In the US, major 
species are MAC 72% and MABSC 16% (Olivier et al., 2003; Seddon et al., 2013). 
This was consistent with similar studies completed in France (Roux et al., 2009). A 
study in Israel had high rates of NTM with 22.6% isolation among patients with CF. 
Both MAC (14.3% of patients tested) and MABSC (31% of patients tested) were 
frequent; however the principal species was M. simiae, with 40.5% of all CF patients 
tested being infected with this species (Levy et al., 2008). Intriguingly, of the two 
predominant species, MAC was rarely seen in patients younger than fifteen years, 
whereas MABSC was isolated from all ages (Pierre-Audigier et al., 2005). 
Before 1990, NTM were not predominantly linked to CF, with only 16 cases reported 
(Brown, 2010). Since then, NTM have been progressively isolated from the sputum 
of CF patients and are presenting increasingly complex diagnostic concerns. This 
could be for a variety of reasons, for example, the rising lifespan of CF patients, 
recent improvements in culture techniques and increased testing frequency, actively 
probing for NTM, transmission via contaminated water supplies, biofilms in 
showerheads (Feazel et al., 2009), and hosts becoming more predisposed (Olivier 
et al., 1996). Immune impairment due to chronic azithromycin therapy has recently 
been associated with an increase in the development of NTM infection. For long-
term azithromycin therapy, it was demonstrated in primary macrophages that 
concentrations of azithromycin blocked autophagosome clearance by inhibiting 
lysosomal acidification, thus impairing autophagic and phagosomal degradation in 
mice infection models. As a consequence azithromycin treatment repressed 
intracellular killing of mycobacteria within macrophages consequently resulting in 
chronic infection with NTM (Renna et al., 2011). Conflicting reports however state 
that patients with NTM on azithromycin treatment were not more likely to develop 
active NTM disease than those not taking azithromycin, and were also not less likely 
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to clear NTM upon treatment (Martiniano et al., 2014). Recent data exists that NTM 
may also be spread by person to person transmission (Bryant et al., 2013) however 
conflicting reports suggests there is no evidence for this (Harris et al., 2015). 
1.6 Cystic fibrosis 
Cystic fibrosis is a complex genetic disease first described in 1938 by Dorothy 
Andersen, a pathologist at The Babies and Children’s Hospital of Columbia 
University in New York (Andersen, 1938). However the gene responsible for CF was 
not identified and cloned until over half a century later in 1989 (Kerem et al., 1989). 
CF is an autosomal-recessive disorder inherited in a typical Mendelian manner and 
triggered by molecular defects in the CF transmembrane conductance regulator 
(CFTR) gene (Cutting, 2015). The CFTR gene is located on the long arm of 
chromosome 7 at position q31.2, and encodes a 1480 residue multidomain protein 
for an ion channel responsible for the regulation and transportation of chloride 
(Gadsby et al., 2006), bicarbonate (Chan et al., 2006) and glutathione (Kogan et al., 
2003) across epithelial cell membranes.   
The CFTR protein is a member of the ATP-binding cassette (ABC) transporter 
superfamily (Lewis et al., 2004), controlled by cyclic adenosine monophosphate 
(cAMP), and is essential for the regulation of cell surface salt-water homeostasis, 
and the natural functioning of epithelia lining the intestinal tract and airways, as well 
as the salivary, sweat gland and pancreatic ducts. Defects in this gene, such as 
impaired protein folding, chloride channel gating or translation, subsequently result 
in a decreased permeability for chloride ions across the epithelial membrane. This 
in turn is responsible for the characteristic build-up of a thick sticky mucus 
accumulating in the airways, intestines and pancreas resulting in compromised 
mucociliary clearance, a predisposition to chronic infection, inflammation and 
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destruction or loss of tissues (Figure 1-3). This provides an ideal environment for 
harbouring frequent and often severe bacterial infections. The accumulative effect 
of chronic infection and inflammation over time will erode the function of the lungs, 
and this is frequently observed in patients with CF. 
Figure 1-3: Transport in CF versus non-CF airways. In the CF airways due to 
defective or absent CFTR, mucociliary clearance is not able to occur 
(Kunzelmann, 2013) 
 
1.6.1 Inheritance of cystic fibrosis 
To date there are almost 2000 known CFTR defects (Cystic Fibrosis Mutation 
Database, 2011), and depending on their effect at the protein level, they are grouped 
into six classes (Kreindler, 2010; Boyle and De Boeck, 2013). Under normal 
circumstances, the CFTR gene is transcribed into mRNA, transferred to the 
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endoplasmic reticulum and in combination with tRNA will be translated into a fully 
functioning CFTR protein, which is subsequently folded, matured and transferred to 
the Golgi apparatus for post-translational modification and packaging into transport 
vesicles. Lastly, the channel is transported to the cell surface for final expression on 
the apical membrane of epithelial cells.  Mutations in the CFTR gene can impact 
each step in protein synthesis: from gene transcription, through protein translation, 
folding and trafficking, to expression and gating of the channel on the cell surface 
(Tsui and Dorfman, 2013). 
The most frequent mutation, although the frequency does vary among ethnic 
groups, occurring in around 70% of CF chromosomes is known as CFTRΔF508. 
This involves a deletion of phenylalanine at position 508 producing an abnormal 
CFTR protein (Villella et al., 2013). As a result of this, the protein will be misfolded 
and subsequently retained within the endoplasmic reticulum failing to reach the cell 
membrane and function as a chloride channel in the apical membrane of epithelial 
cells.   
As CF is a recessive disorder, two copies of the defective gene must be inherited, 
however patients can display severe or mild disease, depending on which clinical 
genotype they possess and whether it is homozygous or heterozygous. Many 
individuals possess only one copy of the defective gene and are unaware they are 
carriers of CF (see Figure 1-4). Reports suggest that in the UK one person in every 
25 will carry a mutated CF gene, and in the US, one in 31 will unknowingly carry a 
mutated gene (Cystic Fibrosis Foundation, 2015; Cystic Fibrosis Trust, 2015). 
Prevalence of CF worldwide differs and is said to be underdiagnosed in Asia as 
existing evidence suggests it is rare. In the US the incidence is reported to be one 
in every 3500 births, and in Europe one in every 2000-3000 births (World Health 
Organization, 2013). 
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Figure 1-4: Ways in which an individual can be affected with cystic fibrosis 
(Cystic Fibrosis Foundation, 2015) 
 
1.6.2 Symptoms of cystic fibrosis 
The severity of symptoms can vary between individuals, and also fluctuates over 
time, however characteristic CF symptoms can manifest very early in life, some 
within days of birth and include salty tasting skin, meconium ileus, wheezing and 
failure to thrive (Farrell et al., 2008). Patients may have recurrent or chronic lower 
respiratory tract infections, with approximately one third of infants aged three 
months being positive for Staphylococcus aureus infection rising to 47% by age 17 
months alongside Haemophilus influenzae 15%, and Pseudomonas aeruginosa 
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13% (Metersky, 2012). Most patients with CF will be infected with P. aeruginosa by 
their late teens. This bacterium has the ability to form biofilms on damaged 
respiratory epithelium tissue, therefore establishing chronic infection and antibiotic 
resistance associated with early degeneration in lung function and a rise in mortality 
(Hurley et al., 2014). Allergic bronchopulmonary aspergillosis (ABPA) is the most 
frequent fungal infection amongst CF patients (Smyth and Elborn, 2008).  Other CF 
symptoms include stomach pain, nausea, weight loss, increased coughing, 
shortness of breath, pancreatitis, excess sputum, infertility and loss of appetite. Most 
patients with CF will die of respiratory failure with the majority of symptoms 
instigated by chronic and intermittent bacterial infections (FitzSimmons, 1994). 
1.6.3 Lung disease in patients with cystic fibrosis  
Patients with CF have a median survival of 40 years (Dodge et al., 2006; Hardy et 
al., 2015)  and lung disease is the leading cause of morbidity and mortality. CF 
patients are predisposed to chronic pulmonary infections, with the lungs frequently 
colonised and/or infected with multiple species of bacteria concurrently due to 
defects within the transport of epithelial Na+, Cl-, HCO3- and unbalanced fluid 
secretions. It is these defects, which underlie the majority of clinical manifestations 
observed in CF. 
CF patients enter a typically described “vicious cycle” of compromised mucociliary 
clearance and mucus retention, followed by infection and inflammation 
subsequently leading to tissue damage (Chmiel and Davis, 2003). This tissue 
damage, lack of fluid secretion and extreme electrolyte absorption, cause excess 
viscous and dense mucus to accumulate within the respiratory and gastrointestinal 
tracts, blocking the airways and preventing mucociliary clearance (Figure 1-5). 
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Consequently, this provides an ideal environment to promote bacterial growth whilst 
trapping and enabling inhaled pathogens to accumulate. 
  
Figure 1-5: Normal airway with lumen free of secretions (left). In contrast, 
airway obstructed and distended by mucus secretions (right) (Quinton, 2010) 
 
1.6.4 Common pathogens involved in lung disease of patients with cystic 
fibrosis  
During childhood, the first bacterial pathogens to be detected are usually S. aureus 
and H. influenza. These pathogens are eventually superseded in adolescence and 
adulthood where the dominant pathogen is P. aeruginosa, and less frequently 
Burkholderia cepacia complex, Achromobacter xylosoxidans, Aspergillus fumigatus 
and NTM -  in particular members of the MABSC (Coutinho et al., 2008). 
1.7 Mycobacterium abscessus complex 
MABSC is a highly antibiotic-resistant complex of organisms within the 
Mycobacterium genus (Leung and Olivier, 2013) and increasingly acknowledged as 
a significant cause of lung infection in patients with CF. Infection with MABSC, 
predominantly M. abscessus subsp. abscessus, is associated with poor clinical 
outcome (Esther et al., 2005) particularly following lung transplantation, with many 
CF centres eliminating patients infected with MABSC from undergoing transplant 
22 
 
(Gilljam et al., 2010; Watkins and Lemonovich, 2012). Elevated resistance is 
attributed to a combination of the permeability barrier of the intricate multilayer cell 
membrane, drug export systems, enzymes that neutralize antibiotics in the 
cytoplasm and antibiotic targets with low affinity (Nessar et al., 2012).  
The genome of M. abscessus (CIP 104536T), as shown in Figure 1-6, consists of a 
5,067,172 base pair circular chromosome including 4920 predicted coding 
sequences, an 81kb full length prophage, five insertion sequences and a 23kb 
mercury resistance plasmid (Ripoll et al., 2009). 
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Figure 1-6: The M. abscessus CIP 104536T genome. 
Figure 1-6 scale is in Mb with the outer blue circles displaying forward and reverse genes, light green phage genes and third circle tRNA genes (red) and rRNA 
operon (dark green).  The fourth circle shows genes acquired from non-mycobacterial organisms, by horizontal gene transfer (purple) and insertion sequence 
elements (black). The inner black histogram shows the G + C content. The 23kb mercury resistance plasmid, (scale in kb) indicates the forward and reverse 
genes and the G+C content with the same code as the chromosome map. The plasmid carries a mercury resistance operon flanked by two genes encoding site-
specific recombinases (MAB_p04c and MAB_p10, orange); it also encodes a relaxase/helicase that may function in conjugation or mobilization (MAB_p15c, 
yellow) (Ripoll et al., 2009). 
 24 
 
Members of the MABSC are rapidly-growing non-motile, Gram-positive, acid-fast 
rods of around 0.5 µm in width and 1 - 2.5 µm in length, and can grow on solid agar 
as either smooth non-cording biofilm-forming colonies, or rough cording, non-biofilm 
forming colonies as shown in Figure 1-7 (Roux et al., 2016). The rough morphotype 
is associated with more severe and unrelenting infection and has been shown to 
persist for many years in an infected host. Glycopeptidolipids are accountable for 
the formation of smooth colonies and contribute to colonisation of NTMs in the 
environment through biofilm formation, whereas the loss of these glycopeptidolipids 
is associated with the formation of rough colonies and expedites survival in 
macrophages (Jonsson et al., 2007). The rough colony types can evade 
internalisation by forming cords which compared to the size of most phagocytic cells 
are particularly large, therefore difficult for macrophages and neutrophils  to 
surround and internalise (Bernut et al., 2014). Strains are also reported to undergo 
frequent transition between smooth and rough morphotypes during the course of 
infection, however recent evidence suggests clearly distinct genetic lesions  are 
responsible for the loss of production and transport of glycopeptidolipids making 
frequent switching between morphotypes questionable (Pawlik et al., 2013).  
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Figure 1-7: Growth characteristics of rough (left) and smooth (right) M. 
abscessus subsp. abscessus cultured on Middlebrook 7H11 agar. Image 
taken from (Ruger et al., 2014) 
 
Since M. abscessus was first described in 1953 by Moore and Frerichs after a case 
report of a human knee infection with deep subcutaneous abscess-like lesions 
(Moore and Frerichs, 1953), it has undergone numerous changes in its taxonomic 
status owing to indistinguishable results in discrimination. Prior to 1992, M. 
abscessus and M. chelonae were thought to be the same organism or subspecies 
within the M. chelonae-abscessus group (Kusunoki and Ezaki, 1992), and M. 
abscessus has also been grouped within the M. fortuitum complex (Kubica et al., 
1972).  
A further two emerging species of mycobacteria closely related to M. abscessus 
have been discovered In the last decade; M. abscessus subsp. massiliense 
(Adekambi and Drancourt, 2004) and M. abscessus subsp. bolletii  (Adekambi et 
al., 2006). Collectively these three species are frequently referred to as the MABSC, 
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however, the taxonomy of these organisms, which cannot be distinguished by 
phenotypic techniques, has initiated some dispute in the literature. 
All three species have identical 16S rRNA gene sequences; therefore, 
discrimination has proved challenging. Blauwendraat et al (2012) described a two-
gene sequencing approach using PCR and the sequencing of housekeeping gene 
targets hsp65 and rpoB, which claimed to accurately distinguish the three species 
(Blauwendraat et al., 2012), however several others have reported findings that 
partial sequencing of rpoB, hsp65, and secA provided ambiguous results, 
suggesting members of the M. abscessus group undergo genetic exchange 
(Zelazny et al., 2009). Reports have suggested that the three species are too 
strongly correlated to be considered as separate species (Macheras et al., 2009), 
and Leao et al. combined M. bolletii and M. massiliense into one subspecies, named 
M. abscessus subspecies bolletii comb. nov and recognised a second subspecies 
named M. abscessus subspecies abscessus (Leao et al., 2011). Conflicting reports 
from higher resolution typing including whole genome sequencing recently 
supported the suggestion that the species should be divided into three subspecies; 
M. abscessus subsp. abscessus, M. abscessus subsp. bolletii and M. abscessus 
subsp. Massiliense (Harris and Kenna, 2014; Nakanaga et al., 2014; Tortoli et al., 
2016). Despite consensus not being reached to date, the three species are known 
to have differing antibiotic resistance phenotypes and genotypes (Kim et al., 2010b), 
therefore strain typing is advantageous for patients with CF who have MABSC 
infection to receive the correct course of treatment. The use of comparative rRNA 
sequencing is frequently done to infer natural relationships between 
microorganisms (Woese and Fox, 1977). Figure 1-8 shows a phylogenetic tree of 
29 mycobacterium species, clearly defining the separation of slow growers from 
rapid growers and also demonstrates the closeness of the three MABSC species. 
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 Figure 1-8: Neighbour-joining tree (Saitou and Nei, 1987) based on almost 
complete 16S rRNA gene sequences showing the positions of 29 members of 
the genus Mycobacterium discussed within this thesis, with representatives of 
the order Corynebacteriales. The numbers at the nodes indicate the levels of 
bootstrap support based on a neighbour-joining analysis of 1,000 resampled 
datasets; only values above 50 % are given. The scale bar indicates 0.01 
substitutions per nucleotide position. Tree was produced using MEGA7 program 
(MEGA, 2017). 
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1.8 Host immune response to mycobacterial infection 
Very little is known about the host response to NTM (Chan et al., 2010) and despite 
the fact that they are ubiquitous in the environment only an small proportion of 
individuals exposed to NTM develop lung disease. Identifying these individuals with 
conditions that predispose them to NTM infection can provide an insight into what 
host immune factors are essential in protection against NTM. 
As chronic respiratory infections due to NTM, particularly MABSC are increasingly 
seen in patients with CF this leads to the hypothesis that these patients may have 
an inherent susceptibility to NTM, or it could be that persistent bacterial infection is 
able to provide a suitable environment for colonisation by environmental 
mycobacteria.  
CF is also known to cause a functional defect in antimicrobial peptides known as β-
defensins found in epithelial cells. These protect against Gram-positive and Gram-
negative bacteria, fungi and certain viruses by interacting with the membrane of 
invading microorganisms (Dalcin and Ulanova, 2013). The surface fluid of normal 
airways is low in salt, which favours the activity of defensins, however CF fluid has 
been described to be very high in salt due to dysfunction of CFTR protein that forms 
chloride ion channels. This high salt environment may inhibit defensin activity and 
compromise host respiratory defence, therefore patients with CF may have innate 
susceptibility to NTM infection (Chan et al., 2010). 
1.9 Diagnosing non-tuberculous mycobacteria in patients with cystic 
fibrosis 
Identifying patients with NTM is challenging, with conventional culture and acid-fast 
microscopy continuing to be the mainstay of mycobacterial diagnostics. Current 
guidelines (Floto et al., 2016) suggest that for any patient suspected of having NTM 
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lung disease, the following evaluation must be completed: (1) chest radiograph or, 
in the absence of cavitation, chest high resolution computed tomography (HRCT) 
(2) three or more sputum samples showing the presence of acid-fast bacilli (AFB) 
and (3) exclusion of other disorders, for example TB. All are equally significant and 
must be met. The following criteria have been established for symptomatic patients 
with radiographic opacities, nodular or cavitatary or an HRCT scan that shows 
multifocal bronchiectasis with multiple small nodules (Floto et al., 2016). The criteria 
best fit with MAC, MABSC and M. kansasii, as there are still too many ambiguities 
with regard to other NTM to ascertain whether these criteria are unanimously 
appropriate for all NTM respiratory pathogens. 
Clinical:  
(i) Pulmonary symptoms, nodular or cavitary opacities on chest radiograph or an 
HRCT scan that shows multifocal bronchiectasis with multiple small nodules. 
(ii) Appropriate exclusion of other diagnoses 
Microbiological: 
(i) At least two separate expectorated sputum samples with positive results OR 
(ii) A positive culture result obtained from a bronchial lavage or wash OR 
(iii) Transbronchial or other lung biopsy with mycobacterial histopathologic features 
(granulomatous inflammation or AFB) and positive culture for NTM or biopsy 
showing mycobacterial histopathologic features (granulomatous inflammation or 
AFB) and one or more sputum or bronchial washings that are culture positive for 
NTM. 
Patients who do not meet the diagnostic criteria but are suspected of having NTM 
lung disease should be regularly monitored until a positive diagnosis is definitively 
documented or can be excluded (Griffith et al., 2007). 
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1.9.1 Collection of samples from patients with cystic fibrosis  
There are numerous methods that can be used for the collection of respiratory 
samples from patients with CF. The traditionally preferred method being the 
collection of sputum; however, in CF patients who do not expectorate, samples can 
be obtained preferably by cough swab, as this is less invasive than other methods. 
Cough swabs however can contain higher levels of oral flora and are less sensitive 
for detection of mycobacteria compared to culture of sputum. Bronchoalveolar 
lavage, cough plate, oropharyngeal culture, laryngeal or naso-pharyngeal aspirate 
can also be used. Current guidelines (Floto et al., 2016) recommend against the use 
of oropharyngeal swabs as they are said to poorly reflect lung microbiota due to 
insufficient material for culture, and although culture of bronchoalveolar lavage gives 
an accurate representation of microorganisms present, it is a method that should be 
avoided in children as general anaesthesia is often required (Burns and Rolain, 
2013). Transbronchial biopsies are to be circumvented, as there is a substantial risk 
of bleeding and pneumothorax. Updated evidence-based draft guidelines on the 
Management of Non-tuberculous Mycobacteria in individuals with Cystic Fibrosis 
have recently been published recommending that preference should be given to 
sputum, induced sputum, bronchial washings or bronchial lavage samples (Floto et 
al., 2016).  
1.9.2 Current detection methods of non-tuberculous mycobacteria in 
patients with cystic fibrosis  
Although classed as “rapidly-growing” mycobacteria (RGM), the ‘rapidity’ of the 
growth rate is only relative to that of other mycobacteria, and they show slower 
growth when compared to most other CF pathogens (Esther et al., 2011).  
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Conventionally, a time to detection cut-off of seven days has been used to 
differentiate rapidly-growing and slow-growing mycobacteria on solid media, 
however growth detection can fluctuate depending on the number of organisms in 
the sample and detection times become shorter as the mycobacterial burden rises. 
Other factors affecting this can include the type of medium used and the age of the 
sample. In comparison to RGM, M. tuberculosis has a TTD of around six to eight 
weeks.  Liquid culture has a more rapid TTD, with a cut off between RGM and SGM 
of six days, however the rate of contamination of non-mycobacterial species is 
greater (Chihota et al., 2010). 
Overgrowth of cultures by a variety of other faster growing microorganisms, 
particularly P. aeruginosa, is commonly observed in patients with CF, (Bange et al., 
1999). Due to this overgrowth, laboratory detection and identification of NTM pose 
a major challenge, and mycobacterial infections can often be misdiagnosed, or 
concealed and completely overlooked in routine culture.  
To decrease the commensal flora associated with the airways and digestive tract 
and consequently reduce overgrowth of cultures, samples are decontaminated prior 
to inoculating them on selective media (See Chapter 2 section 1.9.5 for information 
on current media used for isolation of NTM).  
1.9.3 Decontamination steps performed upon receipt of a patient sample 
Decontamination methods take advantage of the fact that mycobacteria 
demonstrate relative resistance to acids, bases and other antimicrobial agents, 
compared with non-acid-fast bacteria. P. aeruginosa characteristically survives 
routine sputum decontamination using N-acetyl-L-cysteine–2% sodium hydroxide 
(NALC-NaOH), therefore to ensure eradication, the most universally used laboratory 
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decontamination process is NALC-NaOH-OxA using  5% oxalic acid (De Bel et al., 
2013). 
Following a study by Whitter et al (1997), it was shown that NALC-NaOH treatment 
followed by oxalic acid significantly reduced overgrowth by P. aeruginosa. This 
method was further evaluated and results confirmed that although this two-step 
NALC-NaOH-OxA process improved the yield of mycobacteria as well as reducing 
other microorganisms, it can also affect the viability of mycobacteria (Whittier et al., 
1997). 
Bange et al., (1999) reported that treatment with oxalic acid may lead to false 
negatives being produced, particularly from specimens with low inocula of 
mycobacteria. Based on this, they reported that samples should be initially 
decontaminated with NALC-NaOH, and then inoculated for culture. Only those that 
still contained heavy growth of other species should then be subjected to a second 
round of decontamination with oxalic acid. This is the strategy currently 
recommended in the newly published guidelines produced by the US and European 
Cystic Fibrosis Societies (Floto et al., 2016) (Bange et al., 1999). 
A comparison of four decontamination processes for stool samples from patients 
known to have M. avium was carried out by Yajko et al., (1993). These were NALC-
NaOH, cetylpyridinium chloride-sodium chloride (CPC-NaCl), NALC-NaOH-OxA 
and benzalkonium chloride-trisodium phosphate (BC-TSP). Results demonstrated 
that a higher yield of colony forming units (CFU) of M. avium was obtained following 
oxalic acid treatment, whereas NALC-NaOH produced around half the number of 
CFU per millilitre when compared with treatment by oxalic acid. CPC-NaCl and BC-
TSP had the lowest rates of survival of non-mycobacterial species, but also yielded 
the lowest number of CFU of M. avium. These results show that although the 
process of decontamination is essential for the recovery of mycobacteria using 
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traditional culture methods, a fine sense of balance must be sought as the process 
of decontamination can still influence the viability of mycobacteria, as well as 
reducing the growth of non-acid-fast bacteria (Yajko et al., 1993).  
The NALC-NaOH-OxA method was compared to a chlorhexidine-based method and 
it was found that although rates of growth of non-mycobacteria were higher with the 
chlorhexidine-based method, a higher yield of NTM was also recovered (Ferroni et 
al., 2006). Although this study used sputum samples from patients with CF, it did 
not include clinical samples containing M. abscessus, a strain most frequently found 
in these patients so this may not provide an accurate representation. It was 
confirmed by De Bel et al. (2013) that the use of chlorhexidine did yield more 
mycobacteria than NALC-NaOH-Oxa, however if liquid culture is used as opposed 
to solid culture, the recovery of mycobacteria was consistent for both methods (De 
Bel et al., 2013). A short study undertaken by the Health Protection Agency, 
Newcastle upon Tyne, UK (personal communication, March 15th 2013) over a 4-
month period in 2012 exhibited the following rates of contamination of sputum 
samples in CF patients (See Table 1-2). The decontamination processes used in 
this study were 4% sodium hydroxide (NaOH) or 0.5N (N/2) sulphuric acid (H2SO4) 
and culture method used was BACTEC mycobacterial growth indicator tube (MGIT) 
960 Mycobacterial Detection System with eight weeks incubation. 
Current recommendations by the UK Cystic Fibrosis Trust are that either NALC-
NaOH-OxA or chlorhexidine methods should be used in order to significantly reduce 
the viability of other microorganisms, particularly P. aeruginosa (The UK Cystic 
Fibrosis Trust Microbiology Laboratory Standards Working Group, 2010). 
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Table 1-2: Audit of respiratory samples from cystic fibrosis patients received 
by the Public Health England Laboratory, Newcastle upon Tyne showing 
contamination rates over a 4 month period in 2012 
 SEPTEMBER OCTOBER NOVEMBER DECEMBER 
Number of samples 
received 
39 41 49 33 
Culture negative 
after 8 weeks 
incubation 
27 (69.23%) 29 (70.73%) 29 (60%) 24 (72.7%) 
Culture abandoned. 
Contamination after 
decontamination 
10 (25.64%) 8 (19.51%) 16 (33%) 6 (18.2%) 
Culture positive for 
mycobacteria 
2 (5.13%) 4 (9.75%) 3 (6%) 3 (9.1%) 
1.9.4 Staining of sputum smears for acid-fast bacilli (AFB) 
Staining of sputum smears for AFB can be done, preferably using the fluorochrome 
method with auramine–phenol as opposed to staining by the Ziehl-Neelsen method 
as the former is reported to be more sensitive and can be advantageous in 
assessing the burden of organisms in the lungs (Cystic Fibrosis Trust, 2010). 
The Ziehl-Neelsen stain is a low cost procedure but is burdensome and carries a 
higher risk to laboratory workers as it requires heat application during the carbol-
fuchsin staining. Overheating may crack the slide, and also cause splashing of the 
stain. Slides are examined under oil immersion and acid-fast bacteria appear 
red/pink, and non-acid-fast bacteria as well as other organisms and cellular 
materials appear blue. 
Fluorescent staining, utilises the same approach as Ziehl-Neelsen staining, but 
carbol fuchsin is replaced by a fluorescent dye (auramine-O, rhodamine). The 
advantage of the fluorescence method is that it is more sensitive and slides can be 
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observed at lower magnification therefore allowing the examination of a much larger 
area in a shorter time period (Annam et al., 2009). 
1.9.5 Current media used for isolation of non-tuberculous mycobacteria 
The most frequently used solid-based culture media for the isolation of NTM are 
agar-based Middlebrook 7H10 and 7H11 media or egg-based Lowenstein–Jensen 
medium (Burns and Rolain, 2013).  Culture on Burkholderia cepacia selective agar 
(BCSA) has been shown to be effective for isolation of NTM if incubation is 
prolonged from five to fourteen days and Esther et al., (2011) demonstrated that 
extended incubation of BCSA afforded an increased recovery rate of NTM from 
0.7% to 2.8% using routine culture methods. However, not all NTM will grow on 
BCSA and overgrowth, particularly by fungi and Gram-negative bacteria, remains 
problematic (Esther et al., 2011). Although some endorse this method, it is not 
specifically recommended in the CF guidelines for management of NTM (Floto et 
al., 2016). M. avium complex cannot be recovered from BCSA, Mycobacterium 
haemophilum requires ferric ammonium citrate in order to grow and Mycobacterium 
ulcerans needs egg yolk supplement in the medium (Griffith et al., 2007).  
Other media that have been used for the isolation of mycobacteria include Kirchner 
medium (Sparham et al., 1984), Stonebrink medium (Stonebrink et al., 1969), 
Ogawa and modified Ogowa medium (Kalich et al., 1976), however these are most 
suited to the culture of MTb, rather than NTM. It is recommended that samples 
should also be cultured in liquid broth medium as this can provide more rapid results 
as well as an increased yield of mycobacteria (Johnson and Odell, 2014).  
The most commonly used liquid broth is the MGIT which contains modified 
Middlebrook 79H broth base, casein peptone, oleic albumin dextrose catalase 
(OADC) and PANTA antibiotic mixture comprising of polymyxin B, amphotericin B, 
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nalidixic acid, trimethoprim and azlocillin (Assawy et al., 2014). A fluorescent 
compound embedded within the tube is sensitive to dissolved oxygen and when 
actively respiring bacteria consume the oxygen this allows the fluorescence to be 
visualised under ultra violet light and detected using sensitive instrumentation e.g. 
the BACTEC MGIT 960 Mycobacterial Detection System (Tortoli et al., 1999). 
BacT/ALERT 3D is an automated microbial detection system based on the 
colorimetric detection of CO2 produced by growing microorganisms. The growth 
medium contains oleic acid, glycerol, bovine serum albumin, and amaranth in water, 
as well as amphotericin B, azlocillin, nalidixic acid, polymyxin B, trimethoprim, and 
vancomycin (Angeby et al., 2003). 
The use of solid media also has the added benefit that colony morphology can be 
observed, as well as growth rate, the option  to perform  antibiotic susceptibility tests 
and recognising if more than one species of NTM is present (Griffith et al., 2007). 
Detection of NTM is routinely achieved by culture of sputum onto both solid media, 
(e.g. Lowenstein–Jensen medium) and automated broth-based methods following 
decontamination of samples (Whittier et al., 1993; Burns and Rolain, 2013). 
1.9.6 Molecular detection methods for non-tuberculous mycobacteria  
Although a typical diagnosis of NTM is achieved by direct analysis and culture, 
molecular based diagnostics are now becoming frequently used to diagnose 
disease, offering increased sensitivity and specificity (Lima et al., 2013). Despite 
their availability they can however be costly, labour intensive, demand greater 
training requirements, and sample contamination could be responsible for producing 
false results. Sequencing of genes such as rpoB, 16S rRNA, and hsp65 offer prompt 
and accurate identification although still have technical restrictions, and these 
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methods may not be readily available in many laboratories (Harris and Kenna, 
2014). 
Commercial line probe assays such as Genotype Mycobacterium CM (common 
mycobacteria) and Genotype Mycobacterium AS (additional species) (HAIN 
Lifescience, 2015), or INNO-LiPA MYCOBACTERIA v2 (Fujirebio, 2015) can 
accurately identify many of the frequently encountered NTM species. INNO-LiPA 
MYCOBACTERIA can identify sixteen different mycobacterial species targeting the 
16S-23S rRNA internal transcribed spacer (ITS) region (Tortoli et al., 2003). The 
GenoType Mycobacterium is centred on the reverse line probe hybridization assay, 
and utilises commercial DNA strip assays used for the detection and identification 
to the species level of mycobacteria isolated from positive liquid or solid cultures. It 
comprises two kits: the GenoType CM, for common mycobacteria and GenoType 
AS, for additional species assays. Genotype Mycobacterium CM (Figure 1-9) targets 
the 23S rRNA gene and is able to identify 24 NTM species and Genotype 
Mycobacterium AS (Figure 1-10), which also targets the 23S rRNA gene, can 
identify an additional 19 NTM species (Gitti et al., 2006). 
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Figure 1-9: GenoType Mycobacterium CM permits the identification of the following mycobacterial species: M. avium subspecies, M. 
chelonae, M. abscessus, M. fortuitum, M. gordonae, M. intracellulare, M. scrofulaceum, M. interjectum, M. kansasii, M. malmoense, 
M. marinum/M. ulcerans, M. peregrinum, M. tuberculosis complex, and M. xenopi. 
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Figure 1-10: GenoType Mycobacterium AS provides probes for a series of additional NTM, namely, M. simiae, M. mucogenicum, M. 
goodie, M. cellatum, M. smegmatis, M. genavense, M. lentiflavum, M. heckeshornense, M. szulgai, M. phlei, M. hemophilum, M. kansasii, 
M. ulcerans, M. gastri, M. asiaticum, and M. shimoidei
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The disadvantage of these kits is that the distinction between MABSC and M. 
chelonae can be questionable and is often a subjective judgement (Portaels et al., 
1996; Richter et al., 2006; Arnold et al., 2012). Genotype Mycobacterium CM kit has 
only one variance at position six between these two sub-species where M. 
abscessus has one extra band (as shown by circle on Figure 1-9), which on 
occasion can be very difficult to visualise, with often very faint and barely detectable 
bands subsequently giving a false identification of M. chelonae. Neither assay, CM 
or AM can discriminate between the three M. abscessus subspecies (Scarparo et 
al., 2001). This lack of accuracy in identification is a cause for concern as it may 
influence patient management, in particular in making a judgement of whether to list 
patients for lung transplantation due to MABSC being linked to poorer clinical 
outcomes than those witnessed in patients infected with M. chelonae. 
More accurate identification can be attained by performing PCR and sequencing of 
house-keeping gene targets such as hsp65, sodA,  rpoB and secA, and whilst most 
isolates can be identified with the use of two target genes (Adekambi and Drancourt, 
2004; Blauwendraat et al., 2012), multilocus sequence analysis (MLSA) is required 
to differentiate between the three MABSC subspecies as often inconclusive results 
are attained where isolates have chimeric housekeeping gene sequences, likely as 
a result of recombination or horizontal gene transfer (Macheras et al., 2011). 
Many molecular methods for differentiation of MABSC isolates have been 
developed, including pulsed-field gel electrophoresis (Jonsson et al., 2007), rep-
PCR (Jamal et al., 2014), multilocus/multispacer sequence typing (Macheras et al., 
2011) and variable number tandem repeat profiling (Harris et al., 2012; Davidson et 
al., 2013), however whole genome sequencing permits a much higher degree of 
resolution and improved typing than any other method (Kreutzfeldt et al., 2013), and 
41 
 
can also provide valuable information about the transmission of MABSC (Bryant et 
al., 2013). In many of these methods, the techniques used to lyse the mycobacterial 
cell wall can also fragment the genomic DNA therefore smearing can occur 
subsequently preventing identification. 
To bypass the need for culture and afford a more rapid diagnosis, molecular 
methods can be used for the detection of NTM directly from clinical samples, 
however these methods also have limitations which can include difficulty in NTM cell 
lysis, and often the bacterial burden in NTM infection is of a low level in comparison 
to other CF pathogens (Caverly et al., 2016).  
In a recent study by Scoleri et al., (2106), encouraging results were obtained from 
a quantitative PCR assay described to detect NTM directly from clinical samples 
based on the hsp65 gene. However, restrictions to this are that DNA sequencing is 
not readily available or practical in many laboratories to identify PCR results and 
can be very costly and time consuming. The use of a single target can also give 
ambiguous results where chimeric housekeeping genes occur in some isolates 
(Harris and Kenna, 2014).  In addition recently described NTM species where DNA 
sequence data is not yet available were unable to be identified (Scoleri et al., 2016). 
1.10 Treatment of non-tuberculous mycobacteria in patients with cystic 
fibrosis 
The existence of NTM in the sputum of patients with CF may be indicative of 
transient contamination, colonisation or infection, which can pose a substantial 
diagnostic dilemma and not all patients will benefit from treatment for NTM. Although 
some patients with persistent NTM in their sputum have diminishing radiographic 
and clinical factors, this is not so for all patients and if treatment is required it should 
be customised according to the specific species of NTM isolated (Stout et al., 2016). 
42 
 
The main threat posed by mycobacteria is predominantly due to their high resistance 
to antibiotics with M. abscessus subspecies abscessus recognised as one of the 
most resistant organisms to antibiotic therapies (Griffith, 2014). This resistance can 
be either natural or acquired, and where acquired, it is described as being via 
spontaneous mutation at targeted genes in the presence of antibiotics rather than 
through plasmid or transposon transmission (Nessar et al., 2012). 
Members of the MABSC are consistently resistant to typical anti-tuberculosis agents 
and due to varying in vitro drug susceptibilities, antibiotic susceptibility testing should 
be undertaken for all clinically significant isolates.  NTM, in particular MABSC are 
notoriously difficult to treat, requiring a multi-drug regimen often extending up to 
twelve months and beyond (see Chapter 5) and treatment success is generally 
defined as having sustained culture conversion for at least twelve months (Griffith 
et al., 2007). 
1.10.1 Significance of a first positive non-tuberculous mycobacteria 
culture in patients with cystic fibrosis 
Many patients will spontaneously clear their sputum after one single isolation of 
NTM, demonstrating that it is transiently present and has no clinical significance. 
Other patients may continue to have NTM-positive sputum samples, but require no 
treatment and do not progress to active NTM disease (Martiniano et al., 2014). 
1.11 Mycobacterium abscessus complex and lung transplantation 
Lung disease caused by MABSC is often considered a relatively strong 
contraindication to lung transplantation with fatal post-transplant infection often 
being reported (Gilljam et al., 2010). There are however more recent reports of 
positive transplantation outcomes for patients infected with MABSC with both 
positive short and long term success being documented (Qvist et al., 2013) 
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In a study performed by the University of North Carolina, Chapel Hill, between 1990 
and 2003 one hundred and forty patients with CF underwent lung transplantation 
and thirty-one were listed for transplantation. Of the patients referred, 19.7% were 
NTM positive. Following transplantation, 3.4% were identified as having NTM 
infection and those with infection prior to transplant were noted as having a higher 
risk of reoccurrence post-transplant (Chalermskulrat et al., 2006). 
Although severe infections can occur, the isolation of NTM prior to transplantation 
in patients with CF should not typically be an exclusion criterion for lung 
transplantation (Chalermskulrat et al., 2006; Zaidi et al., 2009). The most current 
NTM guidelines also recommend that in the presence of persistent MABSC 
infection, treatment should commence prior to transplant listing and this should not 
be an absolute contraindication to transplant approval (Floto et al., 2016). 
1.12 What does the future hold regarding Mycobacterium abscessus 
complex? 
New treatment regimens are urgently required for the treatment of MABSC 
comparing and using a combination of longstanding and novel antimicrobials.  
Furthermore, due to the complexity of the current techniques required in order to 
differentiate between the three MABSC species, a prompter and more economical 
identification method is essential. 
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1.13 Research aims and objectives 
It is apparent from the literature reviewed that there are numerous areas of research 
that essentially require addressing with respect to mycobacteria, in particular 
MABSC. A reliable and convenient method of detection is vital in order to promptly 
diagnose NTM infection and fully understand the true prevalence in CF patients. 
Identification to the species level is fundamental in providing the correct treatments, 
as well as investigating new and improved treatment options for patients. 
Discovering means of possible transmission and whether they can be preventable 
or if they are entirely unavoidable is vital in preventing the spread of this infection.  
With all of these in mind, this research will focus on the following issues: 
 Development and evaluation of a novel culture medium for rapidly-growing 
mycobacteria 
 Methods of identification 
 Environmental studies on transmission methods 
 Exploration of potential antimicrobial treatments through in vitro susceptibility 
studies 
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2. Introduction: Chapter 2  
2.1 The origins of culture media 
The origins of culture media date back to 1860 when Louis Pasteur published the 
first semi-synthetic medium, a nutrient broth, designed for the growth of bacteria and 
consisting of ammonium salts, yeast ash and sugar thus providing vitamins and 
trace elements as well as a nitrogen and carbon source (Pasteur, 1860). Developed 
further in 1872 by Ferdinand Cohn, a formula for what Cohn named a normal 
bacterial liquid, was published (Cohn, 1872). In 1881, Robert Koch described a 
medium containing aqueous meat extract, peptones and sodium chloride, the basic 
ingredients of many culture media still currently used (Koch, 1881). 
The first solid culture medium was also developed by Robert Koch and published in 
1881 using the cut surface of a boiled potato as this was a solid surface on which 
he could inoculate the bacteria (Koch, 1881). In the same year Frederick Loeffler 
published the formula for his nutrient broth, a meat extract peptone medium 
(Loeffler, 1881). Although this simple culture medium was used in the discovery of 
the anthrax pathogen Bacillus anthracis, potato slices were not deemed suitable for 
many microorganisms, as many could not thrive (Koch, 1884). Koch replaced the 
nutrient broth with silver salts in gelatin, obtaining this idea from photographic plates 
he made by coating glass plates with a solution of silver salts in gelatin, thus 
developing a solid culture medium superior to the sliced potato (Koch, 1887; Collard 
and Collard, 1976). Many bacteria however possessed enzymes that could digest 
the gelatin, and also on a warm day, the medium would liquefy, as the gelatin did 
not remain solid at 37oC, the ideal temperature that most human pathogens required 
for growth. The main aims of Koch’s work were that he wanted to be able to isolate 
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pure cultures of pathogenic bacteria in order to demonstrate a set of postulates that 
could be used to determine the cause of most infectious diseases (Koch, 1887). 
Walter and Fanny Hesse, who were working in Koch’s laboratory, suggested the 
use of agar as a replacement to gelatin, as Fanny had previously used this in the 
preparation of fruit jellies and puddings. Koch added this agar to the nutrient broths, 
and it proved to be far superior to the gelatin medium, as it remained solid at higher 
temperatures, produced a transparent medium, and was not often digested by 
bacterial enzymes (Koch, 1882).  
Agar is a complex mix of polysaccharides acquired from species of the red algae 
agarophytes and comprising of two dominant polysaccharides.  Agarose, which is 
responsible for the high strength gelling properties and is a (1-4) linked 3,6-anhydro-
α-L-galactose alternating with (1-3) linked ß-D-galactose. The charged polymer 
agaropectin provides the viscous properties, and has the same repeating unit as 
agarose but with some of the 3,6-anhydro-L-galactose residues replaced with L-
galactose sulphate residues, together with partial replacement of the D-galactose 
residues with pyruvic acid acetal 4,6-0-(1-carboxyethylidene)-D-galactose (Phillips 
and Williams, 2000).  
Relatively unknown Italian pharmacist, Bartolomea Bizio, preceded Koch’s work by 
many years, when in 1819 he discovered a chromogenic bacterium, which he 
named Serratia marcescens, growing as red spots on polenta. Bizio believed this to 
be a microorganism and to test his hypothesis placed some polenta in a saturated 
atmosphere at a constant temperature, and noted that within eight hours, red spots 
had appeared, and within twenty-four hours, the entire surface was discoloured. His 
findings were published in the Gazetta Privilegiata, however in the present day both 
Robert Koch and Louis Pasteur are principally credited for the discovery of culture 
media (Yu, 1979). 
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There are many different components used in culture media contributing to a variety 
of functions. Proteins, peptides and amino acids offer nutrients, energy is provided 
by carbohydrates, and components such as calcium, magnesium, iron, trace metals, 
phosphates and sulphates deliver essential metals and minerals that can be used 
as cofactors for certain enzymatic reactions, inorganic cellular cation and 
components of cytochromes and non-haem iron proteins (Morgan et al., 1950). 
Buffering agents such as phosphates and acetates can be added, as well as pH 
indicators, for example phenol red, neutral red and bromothymol blue (Reznikov, 
1972). Antibiotics and chemicals such as bile salts, selenite, tellurite and azide act 
as selective agents in culture media added at explicit concentrations to supress the 
growth of undesirable microorganisms in a polymicrobial sample. They must 
however be added at the correct concentration so as not to inhibit the desired 
organisms (Perlman, 1979). As bacteria can rapidly adapt it can be very challenging 
to obtain a completely specific selective medium, and the ultimate formulation is 
customarily a compromise which will supress most of the unwanted organisms 
whilst still allowing the growth of the majority of target organisms. 
2.1.1 General purpose culture media 
General purpose media are extensively used for the growth of a vast range of 
microorganisms. They do not contain any growth inhibitors and are generally rich in 
nutrients, therefore providing bacteria with carbohydrates, peptones, essential 
minerals, trace metals and other vital nutrients. These include nutrient agar, with or 
without the addition of blood and brain-heart infusion agar. The addition of blood 
enriches the medium and facilitates the growth of fastidious organisms such as 
Haemophilus spp. and Neisseria gonorrhoeae, and also supports the classification 
of certain microorganisms based upon their haemolytic reactions. When α-
haemolysis is present, for example in Streptococcus pneumoniae, the agar beneath 
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the colony shows as a dark green colour. This is triggered by the bacterium’s 
production of hydrogen peroxide subsequently oxidising haemoglobin to 
methemoglobin (Pericone et al., 2000). β-haemolysis, also referred to as complete 
haemolysis, displays complete lysis of the red blood cells causing a yellow and 
transparent appearance beneath and around the colonies. Exotoxins, streptolysin 
O and streptolysin S produced by the bacteria, can be responsible for this, for 
example in Streptococcus pyogenes, however this species is not the only 
haemolytic bacteria. Staphylococci species can produce cytolytic toxins that can 
result in β-haemolysis as can Enterococcus faecalis and many more (Chopra et al., 
1991). 
If an organism does not trigger haemolysis, this is known as γ-haemolysis, an 
example of this is in Staphylococcus epidermidis, and the agar remains unaltered 
(Pinheiro et al., 2015). 
2.1.2 Selective and differential culture media 
Antimicrobials and chemicals can be included in culture media in order to inhibit the 
growth of unwanted microorganisms in a polymicrobial sample, permitting the 
growth of the desired pathogenic bacteria. There is a vast range of both synthetic 
and natural selective agents, depending on the selective requirements of the 
medium, with common selective agents including bile salts, selenite, tellurite, azide 
and many dyes and antibiotics (Bonev et al., 2008).  
Differential media employ biochemical tests in order to distinguish different species 
with the most frequent test being sugar utilisation. Lactose is metabolised to release 
gas and acid, and in the presence of a pH indicator dye, the acid released by the 
bacteria is detected as a colour change as the pH value decreases. Therefore, there 
is no colour change observed when bacteria are unable to utilise lactose. When an 
50 
 
acid is added to an indicator solution, the acid will donate protons to the water 
molecules. This increases the concentration of H3O+ ions in the solution. The H3O+ 
ions will subsequently donate protons to the indicator molecules causing the 
indicator to change colour. 
Selective media will allow the growth of certain bacteria whilst inhibiting any 
unwanted bacteria. This can be achieved by adding certain ingredients, which can 
be utilised by particular species but not others. If certain species of bacteria are 
resistant to a specific antibiotic, this can be added to the medium to prevent the 
growth of other species and select only the desired bacteria. Eosin methylene blue 
(EMB) medium contains methylene blue which is toxic to Gram-positive bacteria, 
thereby only allowing the growth of Gram-negative species (Delost, 2015). 
Sodium desoxycholate is a natural component in bile and used in many culture 
media. An example of such a medium is xylose lysine desoxycholate (XLD) agar 
which is both selective and differential and used for the isolation of Salmonella and 
Shigella species (Nye et al., 2002). XLD works by utilising sodium desoxycholate as 
the selective agent thus making it inhibitory to commensal Gram-positive bacteria. 
Xylose incorporated into the medium as a differential agent is fermented by almost 
all enteric bacteria except for Shigella spp. and lysine enables Salmonella spp. to 
be differentiated from non-pathogenic bacteria. After the Salmonellae consume the 
supply of xylose, they decarboxylate the lysine via the enzyme lysine 
decarboxylase, thereby altering the pH to alkaline. Lactose and sucrose are added 
to the medium to produce excess acid by fermentation in order to prevent other 
lysine positive coliforms reverting the pH to alkaline. Degradation of xylose, lactose 
and sucrose to acid causes the phenol red indicator in the medium to change its 
colour from red to yellow. Bacteria that decarboxylate lysine can be identified by the 
appearance of a red colouration around the colonies due to an increase in the pH.  
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For further differentiation between Salmonellae and Shigellae, an H2S indicator 
system, consisting of sodium thiosulfate and ferric ammonium citrate, is included in 
the medium for the identification of the hydrogen sulfide produced, resulting in the 
formation of black centred colonies. The non-pathogenic H2S producers do not 
decarboxylate lysine hence the acid reaction produced by them prevents the 
blackening of the colonies which occurs only at neutral or alkaline pH (Taylor and 
Schelhart, 1971; Zajc-Satler and Gragas, 1977). 
Other examples of selective media are modified charcoal cefoperazone 
desoxycholate agar (Chon et al., 2012) for the detection of Campylobacter species, 
and modified buffered charcoal yeast extract agar (Feeley et al., 1979) for the 
growth of Legionella species. Both of these contain charcoal as a key ingredient 
which absorbs bacterial toxins that would otherwise inhibit bacterial growth. 
2.1.3 Chromogenic culture media 
Chromogenic culture media employ one of more chromogenic enzyme substrates 
that are hydrolysed to release coloured dyes. Bacteria may therefore be identified 
with high specificity based on their possession (or lack of) of certain enzymes. 
One of the first chromogenic media to be developed for use in clinical laboratories 
was Rambach agar (Kuhn et al., 1994). This takes advantage of the fact that most 
Salmonella strains do not produce β-galactosidase. As the medium contains a 
chromogenic substrate for β-galactosidase, this enables the colonies of the most 
commonly encountered strains of Enterobacteriaceae, such as Escherichia coli, 
Citrobacter spp. and Klebsiella spp. to produce a blue coloration. The medium also 
contains neutral red and propylene glycol to allow   differentiation of Salmonella from 
other species such as Pseudomonas spp. The propylene glycol is fermented by 
Salmonella to generate red-pink colonies (Heizmann, 1993).    
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Although these culture media are widely available to clinical microbiology 
laboratories for a wide range of pathogens, there are still many areas for possible 
improvement. An evident problem is their inability to detect pathogenic colonies 
beneath an overgrowth of other more rapidly-growing species, particularly where 
the pathogenic species is present in low numbers in a sample. 
This chapter reports the development and evaluation of a novel agar-based culture 
medium (RGM medium) designed for the isolation of rapidly-growing mycobacteria 
from the sputa of patients with CF. RGM medium is based on Middlebrook agar and 
contains a combination of supplementary growth factors and selective agents. In a 
preliminary study, the medium was tested with pure cultures of mycobacteria and 
other bacteria and fungi. RGM medium was then compared to other brands of agar 
for the isolation of NTM, and then compared with BCSA for the isolation of NTM 
from 502 sputum samples from patients with CF. Further studies in seven centres 
were then undertaken, including a comparison of RGM medium to the gold standard 
automated liquid culture. 
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2.2 Aims and Objectives 
Middlebrook and BCSA are both widely used solid culture media for the detection 
of NTM in patients with CF. However as demonstrated in the literature both of these 
methods are fraught with contamination caused by more rapidly-growing species 
found in CF sputa. Gold standard methods such as the MGIT also have 
contamination issues, and it may frequently be impossible to issue a result with 
respect to isolation of NTM. Such automated liquid culture methods are also time 
consuming and costly. It was therefore the aim of this study to develop a novel and 
highly selective agar-based medium for NTM based on the following objectives: 
 
(i) To screen a variety of enrichment ingredients and antimicrobials to 
identify any which would be potentially useful for the optimal growth of 
NTM whilst inhibiting any other frequently growing bacterial species 
common in patients with CF. 
(ii) To evaluate these to determine which would be the most effective in 
forming a novel agar-based medium for NTM. 
(iii) To formulate a novel solid culture medium that will allow culture for NTM 
without the requirement for sample decontamination. 
(iv) To evaluate the novel medium in different centres in comparison with 
standard methods. 
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2.3  Materials 
2.3.1 Bacterial strains used in medium development and evaluation 
A collection of 147 isolates of rapidly-growing mycobacteria previously isolated from 
CF sputum samples by standard methods was used for evaluation of all media 
including RGM. These included M. abscessus subsp. abscessus (n = 79), M. 
chelonae (n = 43), M. abscessus subsp. massiliense (n = 12), M. abscessus subsp. 
bolletii (n = 3), M. fortuitum (n = 3), M. salmoniphilum (n = 3), M. llatzerense (n = 2), 
M. immunogenum (n = 1) and M. mucogenicum (n = 1). Seventy-three of these 
isolates were obtained from the Microbiology Department, Freeman Hospital, 
Newcastle upon Tyne, UK and all were from distinct patients. Seventeen were kindly 
provided by St. Vincent’s University Hospital, Dublin, Ireland and were from distinct 
patients. The remaining 57 were consecutive clinical isolates kindly supplied by 
Public Health England, Newcastle upon Tyne, UK. Due to being consecutive 
samples, (all CF samples sent to Public Health for testing) this does not reflect the 
number of patients, which is unknown for these isolates. The species and 
subspecies identity of all strains had been previously confirmed by sequencing of at 
least two of three housekeeping genes (rpoB, hsp65 and sodA) as described by 
(Blauwendraat et al., 2012). 
A collection of non-mycobacteria were selected to represent a variety of species 
frequently recovered from the sputa of patients with CF. Non-mycobacterial strains 
(n = 185) were obtained from national culture collections (n = 23) or from the culture 
collection of the Microbiology Department, Freeman Hospital, Newcastle upon Tyne 
(n = 162) and included an international P. aeruginosa reference panel (n = 43) (De 
Soyza et al., 2013) and a Burkholderia cepacia complex experimental strain panel 
(n = 26) (Mahenthiralingam et al., 2000; Coenye et al., 2003; Vermis et al., 2004) as 
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well as clinical isolates of both species. In total, the collection comprised: P. 
aeruginosa (n = 55), B. cepacia complex (n = 43), S. aureus (n = 28), 
Enterobacteriaceae (n = 11), Achromobacter xylosoxidans (n = 8), Ralstonia 
mannitolilytica (n = 7), Stenotrophomonas maltophilia (n = 4), Streptococcus spp. (n 
= 4), Aspergillus spp. (n = 3), Bacillus subtilis (n = 1), Candida spp. (n = 3), 
Pandoraea spp. (n = 3), Acinetobacter spp. (n = 2), Enterococcus spp. (n = 2), 
Inquilinus limosus (n = 2), Scedosporium spp. (n = 2), Delftia acidovorans (n = 1), 
Elizabethkingia miricola (n = 1), Geosmithia argillacea (n = 1), Haemophilus 
influenzae (n = 1), Moraxella catarrhalis (n = 1), Neisseria flavescens (n = 1) and 
Ochrobactrum sp. (n = 1).  
A collection of fourteen isolates of slow-growing mycobacteria previously isolated 
by standard broth-based culture methods were used for evaluation of broth-based 
media (see section 2.4.18). These included M. avium (n = 6), M. tuberculosis 
complex (n = 6) and M. intracellulare (n = 2). All isolates were kindly provided and 
identified to species level by HAIN Genotyping by Public Health England, Newcastle 
upon Tyne, UK 
All strains, origins and chapter/section referred to are shown in Appendix 1. 
2.3.2 Growth media and general chemicals 
Yeast extract, ready-prepared BCSA; (product Ref: 33631), bioMérieux cepacia 
agar (product Ref: 44347), BacT/ALERT MP (product ref 259797), MB/BacT 
Mycobacteria Antibiotic Supplement Kit including reconstitution fluid (product ref 
259760) were purchased from bioMérieux, Basingstoke, UK. Blood agar was 
prepared from Columbia agar powder (Oxoid CM0331) (and supplemented with 5% 
defibrinated horse blood supplied by TCS Biosciences, Buckingham, UK), 
Burkholderia cepacia agar (product Ref: PO0938), proteose peptone, sputasol 
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liquid, Sabouraud dextrose agar (CM0041), Bacteriological agar no. 1 (LP0011) and 
Mueller-Hinton agar (CM0337) were supplied from Oxoid Ltd, Basingstoke, UK. BD 
Cepacia medium (product Ref: 256180) and BD OFPBL (oxidation-fermentation-
polymyxin-bacitracin-lactose) medium (product Ref: 254481) were purchased from 
BD Diagnostic Systems, Oxford, UK. Middlebrook 7H11 agar (Product Ref: PP4080) 
was obtained from E&O Laboratories, Bonnybridge, UK. Ammonium sulfate, 
calcium chloride, Tween-80 and sodium citrate were supplied by BDH, Poole, UK. 
Unless otherwise stated, all other ingredients were obtained from Sigma-Aldrich, 
Poole, UK.  
2.3.3 Antimicrobials 
Amphotericin B was supplied by Duchefa Biochemie BV, Haarlem, The Netherlands, 
colomycin (at 44.3% purity) was obtained from bioMérieux, Marcy l'Etoile, France, 
and C390 (9-Chloro-9-(4'-diethylamino)phenyl-9,10-dihydro-10-phenylacridine 
hydrochloride) was obtained from Biosynth, Staad, Switzerland. Derivatives of C390 
were kindly synthesised and supplied by Dr Annette Johnson at Northumbria 
University, Newcastle upon Tyne, UK. All other antimicrobials were obtained from 
Sigma-Aldrich, Poole, UK.  
2.3.4 Equipment 
Sterilisation of media and equipment where appropriate was performed using a LTE 
Touchclave-R autoclave (LTE Scientific Ltd. Oldham, UK). All chemicals and media 
components were weighed on an A&D GR200 balance from A and D Weighing, 
California, USA, which is accurate to 0.1 mg. Sterile, disposable tips were used for 
the accurate measurement of small volumes of liquid using calibrated Gilson semi-
automatic pipettes (P1000, P200 and P10) from Gilson Medical Electronics, Villiers-
le-Bel, France. Larger volumes were dispensed using sterile disposable 3 ml 
57 
 
graduated pipettes from Alpha Laboratories, Hampshire, UK and sterile disposable 
10 ml pipettes from L.I.P Limited, Shipley, UK. Antimicrobials were filter sterilised 
using 0.2 µm supor membrane filters from VWR International, Leicestershire, UK 
and Terumo two-part 20 ml syringe purchased from Medisupplies, Dorset, UK. 
Bacterial suspensions were prepared to known cell densities using a Densimat 
densitometer obtained from bioMérieux, Marcy l'Etoile, France. Glass beads (3mm) 
for vortexing rough isolates of mycobacteria were obtained from Sigma-Aldrich, 
Poole, UK. Sterile Petri dishes were obtained from Sarstedt AG & Co., Leicester, 
UK. All plates were incubated in a LEEC 30oC incubator obtained from Laboratory 
and Electrical Engineering Company, Nottingham, UK. The acidity or alkalinity of 
each medium was measured using a pH meter from Hanna Instruments Limited, 
Leighton Buzzard, UK to an accuracy of pH 0.1, and adjusted using sodium 
hydroxide or hydrochloric acid, both of which were purchased from BDH Chemicals 
Ltd., Poole, UK. Non-mycobacterial strains were inoculated using a Denley 
multipoint inoculator from Denley Instruments, Billinghurst, UK. Antimicrobials were 
injected into BacT/ALERT bottles using a Terumo 2 ml syringe and 0.8 x 40 mm 
needle also purchased from Medisupplies, Dorset, UK after being made sterile using 
Sterets swabs obtained from Molnlycke Healthcare, Bedfordshire, UK. The 
BacT/ALERT® 3D instrument used for the detection of mycobacteria was obtained 
from bioMérieux, Marcy l'Etoile, France. For identification of isolates matrix-assisted 
laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) 
(Bruker, Coventry, UK) was used. 
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2.4 Methods 
2.4.1 Evaluation of various ingredients for optimal growth of 
Mycobacterium abscessus complex 
Various ingredients including nutrients and antimicrobials were tested initially using 
twenty isolates of Mycobacteria. The initial isolates were selected as VNTR profiling 
had been performed and identification could be certain (as shown in Table 2-1). This 
number was increased to include further isolates of Mycobacteria as well as a 
selection of non-mycobacterial isolates as shown in Appendix 1. 
2.4.2 Mycobacterial Strains 
Twenty isolates of MABSC were obtained as pure cultures from the Microbiology 
Department, Freeman Hospital, Newcastle upon Tyne and were stored at -20oC in 
glycerol/skimmed milk.  Frozen isolates were subcultured twice on Columbia agar 
with 5% horse blood prior to testing. The origin and species identity of these isolates 
is detailed in Table 2-1 and Appendix 1. Identity had previously been confirmed to 
subspecies level by rpoB and hsp65 gene sequencing at Great Ormond Street 
Hospital, London, UK (Harris et al., 2012). 
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Table 2-1: Species, origin and VNTR profile of mycobacteria used in medium 
testing 
 
Species 
 
Origin 
VNTR Profile 
(variable-number tandem 
repeats) 
M. abscessus subsp. abscessus Adult CF patient 2+ 5 - 6 2 5 1+ 2+ - 
M. abscessus subsp. abscessus Adult CF patient 1+ - 3 - 2 3+ 4 2+ 2 
M. abscessus subsp. abscessus Adult CF patient 2+ 5+ 3 2 4 4+ 2+ 2+ 2 
M. abscessus subsp. abscessus Paediatric CF patient 3+ 4+ 3 2 4 3+ 2 2+ 2 
M. abscessus subsp. abscessus Paediatric CF patient 3+ 4+ 3 - 4 3+ 2 2+ - 
M. abscessus subsp. abscessus Adult CF patient - 5 3 2 7 3+ 4 1 2 
M. abscessus subsp. abscessus Paediatric CF patient 1+ 5 3 4 2 3+ 4 2+ 2 
M. abscessus subsp. abscessus Paediatric CF patient 2+ 5 3 2 4 4+ 1+ 2+ 3 
M. abscessus subsp. abscessus Adult CF patient 1+ 3+ 3 3 2 3+ 4 - 2 
M. abscessus subsp. abscessus Paediatric CF patient 3+ 5 2 3 2 5 1+ - 6 
M. abscessus subsp. abscessus Adult CF patient 1+ 5 3 3 4 2 1+ 2+ - 
M. abscessus subsp. bolletii Paediatric CF patient 1+ - 1 6 1 1+ 1+ - 2 
M. abscessus subsp. bolletii Environmental - - - - 2 - - - - 
M. abscessus subsp. massiliense Adult CF patient 1+ - 2 2 1 2 1+ 1 2 
M. abscessus subsp. massiliense Adult CF patient 1+ 5 2 4 2 3+ 1+ 2+ - 
M. abscessus subsp. massiliense Adult CF patient 2+ - 2 4+ 2 2 1+ 1 2 
M. abscessus subsp. massiliense Adult CF patient - 5+ 2 2 1 2 2+ 2 - 
M. abscessus subsp. massiliense Paediatric CF patient 1+ - 2 3 2 3+ 2+ 2+ - 
M. abscessus subsp. massiliense Paediatric CF patient - - 2 2 1 3+ 1+ 1 2 
M. abscessus complex 
(chimeric)* 
Paediatric CF patient 1+ - - - - - - - - 
*This species was confirmed as M. abscessus subspecies abscessus by hsp65 and sodA 
gene sequencing and M. abscessus subspecies massiliense by rpoB gene sequencing, 
suggesting a chimeric organism. VNTR typing failed as it would only amplify at one locus. 
 
All experiments conducted in the development and evaluation of this medium were 
performed in duplicate unless otherwise stated. 
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2.4.3 Evaluation of basal culture media 
Double-strength Middlebrook 7H9 broth base was prepared as follows: 1.0 g 
ammonium sulphate, 5.0 g disodium phosphate, 2.0 g monopotassium phosphate, 
0.2 g sodium citrate, 0.1 g magnesium sulphate, 0.001 g calcium chloride, 0.002 g 
zinc sulphate, 0.002 g copper sulphate, 0.08 g ferric ammonium citrate, 1.0 g L-
glutamic acid, 0.002 g pyridoxine, 0.001 g biotin and 8 ml glycerol were dissolved in 
992 ml of deionised water and the pH adjusted to pH 6.6 +/- 0.2 with 10M 
hydrochloric acid. The broth base was autoclaved at 116oC for 10 minutes. 
Each type of medium was prepared as shown in Table 2-2 to make a final volume 
of 100 ml with the OADC growth supplement omitted until after autoclaving. 
OADC growth supplement was prepared using 10 g bovine albumin fraction, 4 g 
dextrose, 0.008 g catalase, 126 µl oleic acid and 200 ml deionised water. This was, 
filter sterilised once all components were dissolved. 
 
Table 2-2: Ingredients of the various media used in initial basal medium 
evaluation 
Media Middlebrook 
Broth Base  
(2x strength) 
(ml) 
Glycerol 
(ml) 
Tween-
80 (g) 
Middlebrook 
OADC* Growth 
Supplement 
(ml) 
Bacteriological 
Agar (g) 
 
Columbia 
Agar (g) 
 
Deionised 
Water (ml) 
A 50.0 - - - 1.0  - 50.0 
B 50.0 0.4 - - 1.0  - 49.6 
C 50.0 - 0.1 - 1.0  - 50.0 
D 50.0 0.4 - 10.0 1.0  - 39.6 
E 50.0 - 0.1 10.0 1.0  - 40.0 
F - - - - - 3.9  100.0 
G - - - 10.0 - 3.9  90.0 
*OADC (oleic albumin dextrose catalase) 
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A further two media labelled H (ready prepared Columbia blood agar) and I (ready 
prepared bioMérieux cepacia agar) were also evaluated. 
The twenty strains of mycobacteria were inoculated onto each of the nine media 
and time to detection (TTD) and appearance of resulting colonies was recorded after 
24, 48, 72, 96 and 168 h.  
The sensitivity value of a medium relates to the appearance and growth of target 
pathogens. 
Sensitivity (%) =      Number of target strains forming colonies  x 100 
                                           Total number of target strains 
 
2.4.4 Preparation of inocula and inoculation onto basal media 
A series of suspensions containing 2 ml sterile saline (0.85%) and turbidity 
equivalent to a 0.5 McFarland standard (approx. 1.5 x 108 CFU/ml) were prepared 
for each isolate. For the rough colony types, where clumping occurred, vortexing 
with three sterile 3 mm glass beads for 10 minutes effectively dispersed all clumps.  
Each medium type was inoculated with a 1 µl aliquot of each isolate (i.e. approx. 1.5 
x 105 CFU) and incubated at 30oC.  For all subsequent experiments (unless stated 
otherwise) bacterial strains were retrieved from glycerol skimmed milk, subcultured, 
and suspensions were prepared as above. 
2.4.5 Evaluation of various nutrients for the improved growth of 
mycobacteria 
One litre of 10 x strength Middlebrook 7H9 broth base was made up using the same 
protocol as described previously adjusting the volumes accordingly. 
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Medium D from section 2.7.3 containing 10 ml aliquots of 10 x strength Middlebook 
broth base and 1% bacteriological agar had each of the following supplements 
added to separate 100 ml alliquots; 0.2 g activated charcoal (medium J), 5 ml 5% 
horse blood* (medium K), 0.4 g yeast extract (medium L), 1.5 g α-ketoglutarate 
(medium M), 0.1 g casein (medium N), 0.7 g sodium pyruvate (medium O), 1 g 
proteose peptone (medium P), 0.004 g amaranth (medium Q), 3.3 ml egg yolk 
emulison* (medium R), 0.005 g ribonucleic acid* (medium S), 0.01 g 
polyoxyethylene stearate* (medium T), 0.5 ml tyloxapol (medium U).  
A further medium containing 0.4 g activated charcoal combined with 3.3 ml egg yolk 
emulsion* was prepared (medium V). Deionised water was added to each one to 
make up to 90 ml and autoclaved for 10 minutes at 116oC.  
A further 10 ml of OADC was added to each medium to take the total volume of 
each up to 100 ml.   
*Supplements added to media K, R, S, T and the egg yolk emulsion from medium 
V were added after autoclaving, after the medium was cooled to 50°C. 
A series of suspensions were prepared as in section 2.7.4 and each medium type 
was inoculated with a 1 µl aliquot of each isolate. Plates were inoculated as 
described previously using the twenty mycobacterial isolates as shown in Table 2-1, 
and incubated at 30oC. Evaluation of all media after one week of incubation 
suggested that medium L supplemented with yeast extract demonstrated a 
noticeably improved and more rapid growth of mycobacteria in comparison to 
medium D.  
2.4.6 Investigation of various antimicrobials as putative selective agents 
Medium L was taken forward, with a selection of antimicrobials added in isolation in 
order to examine their inhibitory impact on frequently encountered bacteria and fungi 
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isolated from the sputum samples of patients with CF. The effect of the 
antimicrobials on the growth of mycobacteria was also evaluated. Antimicrobials 
evaluated were amphotericin B at 5, 10 and 20 mg/L, nalidixic acid at 16, 32 and 64 
mg/L, vancomycin at 2.5, 5 and 10 mg/L, colomycin at 32, 64 and 128 mg/L, C390 
at 32, 64 and 128 mg/L, fosfomycin at 400, 800 and 1600 mg/L and malachite green 
at 0.125, 0.25 and 0.5 mg/L. 
Medium L was prepared as described previously and antimicrobials for each 
concentration were dissolved in 20 ml sterile deionised water at 10 x strength, 
placed in a water bath at 50oC for five minutes to ensure they were fully dissolved 
then added to the medium, with the exception of amphotericin B. This was dissolved 
in 400 µl of N-methyl-2-pyrrolidone, a water-miscible organic solvent, placed in a 
water bath at 50oC for five minutes to fully dissolve then added to 19.6 ml deionised 
water prior to adding to medium. A control with no antibiotics was included. OADC 
growth supplement was made up as previously and 20 ml added to each of the 
twenty two media so that final volume of each medium was 200 ml. 
2.4.7 Non-mycobacterial strains and culture onto media containing 
antimicrobials 
A selection of 88 non-mycobacterial species were selected to represent a broad 
variety of species commonly isolated from the sputum of patients with CF. The origin 
and species identity of these isolates is detailed in Appendix 1. Frozen bacterial 
isolates were subcultured on Columbia agar with 5% blood; yeasts and fungi were 
subcultured on Sabouraud medium prior to testing. Isolates 7037 through to 7079 
are from an International P. aeruginosa reference panel collated by (De Soyza et 
al., 2013) and chosen to cover frequently studied clones, transmissible strains, 
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sequential CF isolates, strains with particular virulence characteristics, and strains 
that represent serotype, genotype, or geographic diversity.  
Isolates of mycobacteria were prepared and inoculated as previously in section 
2.7.4. Non-mycobacterial isolates were suspended in 2 ml sterile saline (0.85%) and 
turbidity equivalent to 0.5 McFarland units (approx. 1.5 x 108 CFU/ml). Each medium 
type at all antimicrobial concentrations plus a control (medium L) were inoculated 
with 20 x 1 µl inocula per plate using a multipoint inoculator. Plates were incubated 
at 30oC.  Yeasts and fungi (see Appendix 1) were inoculated onto medium 
containing amphotericin B at all three concentrations.  
2.4.8 Investigation of antimicrobial combinations in agar-based media 
Medium W was identical to Medium L except it was supplemented with colomycin 
at 32 g/L, fosfomycin at 400 mg/L, amphotericin B at 5 mg/L and glucose-6-
phosphate at 25 g/L.  Medium X contained the same as medium W with the addition 
of C390 at 32 mg/L.  
Glucose-6-phosphate was included in both media as research shows that with the 
addition of glucose-6-phosphate to the medium, fosfomycin MIC’s are significantly 
lower for certain species, therefore susceptibility testing to fosfomycin is 
recommended with the addition of glucose-6-phosphate in the medium at a 
concentration of 25 mg/L (Barry and Fuchs, 1991). 
2.4.9 Bacterial strains and culture onto media containing combined 
antimicrobials 
Isolates of mycobacteria were used as in Table 2-1 plus an additional selection of 
80 isolates of mycobacteria (Appendix 1) were included to examine the effect of the 
antibiotics on a larger selection of rapidly-growing mycobacteria. A further nine non-
mycobacterial species frequently found in the sputum CF patients were also 
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included (see Appendix 1). All isolates were prepared and inoculated as previously 
in section 2.7.4 
2.4.10 Plating efficiency studies performed on RGM medium 
Plating efficiencies were undertaken to quantify the growth of mycobacteria on 
media L, W and X. Initial testing was performed on media W and X (hereafter known 
as RGM medium) to find the concentration which would yield approximately 100 
CFU/ml. A series of suspensions containing 2 ml sterile saline (0.85%) and turbidity 
equivalent to a 0.5 McFarland standard unit was prepared for each isolate. Any 
rough colony types were vortexed as described previously in section 2.7.4 Isolates 
used in this study are shown in Appendix 1. 
Each of the three media was inoculated with a 50 µl aliquot of each suspension 
using 1/1,000, 1/10,000 and 1/50,000 dilutions. Spread plates were prepared and 
incubated at 30°C for 96 h before colonies were counted and observed to see if the 
media also had any effect on the size of colonies. 
Results showed that a 1/10,000 dilution provided the most countable number of 
colonies therefore ten isolates of mycobacteria were inoculated onto medium L, W 
and X (RGM) in triplicate as previously, using 50 µl of a 1/10,000 dilution.  Plates 
were incubated for 96 h at 30oC 
2.4.11 Statistical analysis 
Any difference in performance of media was investigated for statistical significance 
using McNemar's test with the continuity correction applied. Statistical significance 
was assigned to a probability (P) value of ≤ 0.05. Two-sample t-tests were 
performed to analyse any differences between control medium and RGM. 
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2.4.12 Evaluation of the stability of RGM medium 
Twenty-four plates of RGM medium were prepared and stored at 4oC. These were 
inoculated as described above on a weekly basis over a period of 12 weeks with 
four isolates of mycobacteria (M. abscessus subsp. abscessus, M. abscessus 
subsp. bolletii, M. abscessus subsp. massiliense and M. chelonae), seven isolates 
of fungi and yeast (A. fumigatus, A. terreus, C. albicans, C. glabrata, G. argillacea, 
S. apiospermum and S. prolificans) and six other isolates (P. aeruginosa (n = 4), B.  
multivorans and E. cloacae) (See Appendix 1). The six non-mycobacteria were 
carefully selected as indicators of deterioration of each of the selective agents in the 
medium. Media were incubated at 30°C and examined daily for up to 14 days. 
2.4.13 Investigation of various derivatives of C390 as putative selective 
agents 
C390 and the following C390 derivatives as seen in Figure 2-1 to Figure 2-7 below 
were used in the initial MIC testing using a range of 1 – 128 mg/L. 
 
Figure 2-1: A475: 4’-Diethylaminophenyl-9-methoxy-10-phenylacridan 
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Figure 2-2: A477/A488/C390: 4’-Diethylaminophenyl-9-chloro-10-
phenylacridan 
 
 
 
Figure 2-3: A480a: 4’-Diethylaminophenyl-9-chloroacridan 
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Figure 2-4: A503a: 4’-Diethylaminophenyl-9-chloro-10-methylacridan 
 
 
Figure 2-5: A503b: 4’-Diethylaminophenyl-9-chloro-10-ethylacridan 
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Figure 2-6: A505: 4’-Diethylaminophenyl-2-9-dichloro-10-phenylacridan 
 
 
Figure 2-7: A520: 4’-Diethylaminophenyl-9-chloro-10-phenyl-4”-chloroacridan 
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2.4.14 Preparation of bacterial strains and inoculation of isolates onto 
media containing C390 and various C390 derivatives to evaluate the 
effectiveness in RGM medium 
Mueller Hinton agar was made up according to manufacturer’s instructions and 
autoclaved at 116oC for 10 minutes and quantities of 5.12 mg were measured out 
for C390 and each derivative of C390. C390, A477, A488, A503a and A503b were 
dissolved in 2 ml of sterile distilled water; A475 was dissolved in 200 µl 1M HCl and 
added to 1.8 ml sterile distilled water. A480a, A505 and A520 were dissolved in 200 
µl of N-methyl-2-pyrrolidone then added to 1.8 ml sterile distilled water. The 
dissolved components underwent serial dilutions in sterile distilled water to achieve 
each desired concentration ranging from 2560 mg/L down to 20 mg/L and 1 ml of 
each was added to 19 ml agar giving a total volume of 20 ml for each compound at 
each concentration which ranged from 128 mg/L to 1 mg/L. Plates were poured into 
sterile Petri dishes and allowed to set and dry. 
A series of suspensions containing 2 ml sterile saline (0.85%) and turbidity 
equivalent to a 0.5 McFarland standard were prepared for each isolate (Appendix 
1).  Each medium type at each concentration plus Mueller Hinton control plates were 
inoculated using a multipoint inoculator with a 1 µl aliquot of each isolate (i.e. approx. 
1.5 x 105 CFU/ml), incubated at 30oC and results recorded after 24, 96, 168 and 240 
hours 
2.4.15 Preparation of bacterial strains and inoculation of isolates onto 
various media to evaluate the effectiveness of RGM medium against currently 
available media 
Strains, which consisted of 147 mycobacteria and 185 non-mycobacteria (Appendix 
1) were prepared as in section 2.7.4 and sub-cultured onto Columbia agar with 5% 
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horse blood prior to testing. A 1 μl aliquot of each suspension of mycobacteria was 
inoculated onto each medium type and the inoculum was spread using a loop. 
Filamentous fungi were inoculated in the same way. Suspensions of all other 
isolates were inoculated onto media using a multipoint inoculator to deliver inocula 
of approximately 1 μl per spot (i.e. approximately 1.5 × 105 CFU/spot). All plates 
were incubated at 30 °C and growth was recorded after four, seven days and ten 
days of incubation. The eleven media types evaluated included RGM medium using 
C390 at 32 mg/L, 64 mg/L, 128 mg/L, A477 at 32 mg/L in place of C390 (one of the 
C390 derivatives described in section 2.4.12), RGM medium minus OADC 
supplement, Middlebrook 7H11 selective (PP4080), Oxoid B. cepacia (PO0938), BD 
cepacia (256180), BD OFPBL (254481), bioMérieux cepacia (44347) and 
bioMérieux BCSA (33631). To demonstrate the viability of isolates, Columbia blood 
agar for bacterial isolates and Sabouraud agar for fungal isolates were used as 
controls. 
2.4.16 Inoculation of sputum samples onto RGM medium and bioMérieux 
cepacia agar 
Consecutive sputum samples (n = 502) obtained from 210 adults and children with 
CF were processed between February and September 2014. The age range of 
patients was < 1 year to 77 years. All samples were routine samples submitted to 
the Microbiology Department, Freeman Hospital, UK for culture. No additional 
samples were taken for the purposes of this study (See Appendix 4 for details of 
ethical approval). Sputum samples received from patients with CF were digested 
(1:1) with sputasol and 10 µL aliquots cultured onto whole plates of both RGM 
medium and bioMérieux cepacia agar. The inoculum was spread using a loop to 
obtain isolated colonies. Both media were incubated for 10 days at 30°C and growth 
was recorded after four, seven and ten days. All isolates recovered were identified 
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by MALDI-TOF MS. For any suspected mycobacteria, full protein extractions were 
performed as recommended by Saleeb et al. (2011) and species and subspecies 
identification was further confirmed at a reference laboratory as previously 
described (Saleeb et al., 2011; Blauwendraat et al., 2012). 
2.4.17 Investigation of the use of RGM medium for the isolation of 
mycobacteria from the sputum of patients with non-cystic fibrosis 
bronchiectasis  
Consecutive sputum samples (n = 400) obtained from 310 adults with 
bronchiectasis or patients undergoing transplant assessment (n = 67) from 60 
patients were processed between May and November 2015. All samples were 
routine samples submitted to the Microbiology Department, Freeman Hospital, UK 
for culture. No additional samples were taken for the purposes of this study. Sputum 
samples received were digested (1:1) with sputasol and 10 µL aliquots cultured onto 
plates of RGM medium. The inoculum was spread using a loop to obtain isolated 
colonies. The medium was incubated at 30°C and all growth was recorded after ten 
days. Identification of colonies was performed as in section 2.4.16. 
2.4.18 Adaptation and evaluation of RGM medium for recovery of 
mycobacteria including Mycobacterium tuberculosis complex in a broth-
based culture medium 
A bottle of 15 ml MB/BacT reconstitution fluid was transferred into a sterile universal 
and the following antimicrobials were weighed out to give final concentrations of; 
colomycin at 32 mg/L, fosfomycin at 400 mg/L, amphotericin B at 5 mg/L, C390 at 
32 mg/L and glucose-6-phosphate at 25 mg/L. In the following order, colomycin, 
glucose-6-phosphate and fosfomycin, were added and allowed to dissolve. C390 
and amphotericin B were each dissolved in 100 µl N-methyl-2-pyrrolidone then 
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added to the reconstitution fluid, the bottle briefly vortexed and the solution filter 
sterilised. The top of each BacT/ALERT bottle was cleaned with a sterile disposable 
wipe and 0.5 ml of reconstitution fluid containing antimicrobials was injected into 
each bottle using a 2 ml syringe and 0.8 x 40 mm needle. Bottles (designated Bottle 
B) were placed in the refrigerator at 4oC until required.  
RGM medium was prepared as described in Appendix 2 and an aliquot of 15 ml was 
poured into sterile universals, tilted and allowed to set.  
2.4.18.1 Health and safety 
Good laboratory practice was followed at all times. The processing of these samples 
was carried out inside a Class I Safety Cabinet in a category 3 containment suite. 
Disposable gloves were worn at all times, and any spillage was mopped up using 
tristel activated chlorine dioxide. 
2.4.18.2 Preparation of clinical samples from cystic fibrosis patients 
Each sample was digested and liquefied using an excess of dithiothreitol and 
vortexed at full speed until completely homogenous. The sample was centrifuged at 
3000g for 18 minutes and supernatant poured off to leave a pellet. The pellet was 
subsequently split into two equal aliquots and two different decontamination 
procedures were performed.  
2.4.18.3 Decontamination procedure for Gram-positive organisms 
A volume of 7 ml of sodium hydroxide (NaOH) (4% w/v) was added to one of the 
aliquots and left for 25 minutes during which the sample was vortexed at full speed 
every five minutes. At the end of the treatment time the sample was neutralised with 
14 ml of neutralising buffer solution (1M anhydrous monopotassium phosphate 
(KH2PO4) + 0.2% Phenol red; final pH 6.8), and re-concentrated by centrifugation at 
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3000g for 18 minutes. The sample was then re-constituted to 2 ml and using a safety 
needle and syringe one BacT/ALERT culture bottle (ref 259797) with the addition of 
MB/BacT Mycobacteria Antibiotic Supplement Kit including reconstitution fluid (ref 
259760), designated Bottle A (see Appendix 3) was inoculated with 0.5 ml of 
neutralised specimen, one BacT/ALERT culture bottle with prototype antibiotic mix, 
designated Bottle B (see Appendix 3) was inoculated with 0.5 ml of neutralised 
specimen and an aliquot also stored at –20oC. 
Using sterile disposable graduated pipettes, the surface of a neutral pyruvate 
Lowenstein Jensen (LJ) slope and an RGM medium slope were each inoculated 
with 0.2 ml of specimen. These were rotated to allow the specimen to inoculate the 
entire surface; the caps were tightly fitted and incubated at 30°C for eight weeks. 
This was repeated with a further neutral pyruvate LJ slope and an RGM medium 
slope and incubated at 37°C for eight weeks for LJ and three weeks for RGM 
medium. BacT/ALERT bottles were logged onto the system and incubated for 28 
days.  
2.4.18.4 Decontamination procedure for Gram-negative organisms 
An equal volume of N/2 sulfuric acid (H2SO4) was added to the second aliquot (as 
described in section 2.4.18.2) and treated for 60 minutes. At the end of 60 minutes, 
the sample was topped up with sterile distilled water to reduce the action of the acid, 
centrifuged at 3000g for 18 minutes and the supernatant discarded. A volume of 2 
ml of neutralising buffer solution at pH 6.8 (as previously) was added and 0.5 ml 
inoculated into both bottles A and B as previously described, and incubated for 28 
days. As in the decontamination procedure for Gram-positive organisms, the surface 
of two neutral pyruvate LJ slopes and two RGM medium slopes were each 
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inoculated with 0.2 ml of specimen and incubated for eight weeks for LJ and three 
weeks for RGM medium at both 30°C and 37°C 
In addition to this, two RGM medium slopes were inoculated with a 0.2 ml volume 
of untreated specimen. One was incubated at 30oC and the other at 37oC for three 
weeks. Fourteen control strains (Appendix 1) were inoculated into both bottle A and 
bottle B and incubated for 28 days. 
2.4.18.5 Processing of clinical samples from non-cystic fibrosis patients 
Non-CF patient samples that were pre-selected due to their AFB-positive status on 
microscopy were treated with the same procedure as above for Gram-positive 
organisms and 0.5 ml inoculated into a BacT/ALERT culture bottle with a further 0.5 
ml inoculated into one BacT/ALERT culture bottle with prototype antibiotic mix, 
logged and incubated for 28 days. The surface of two neutral pyruvate LJ slopes 
were each inoculated with 0.2 ml of specimen and incubated for eight weeks at both 
30°C and 37°C. RGM medium slopes were not included in non-CF patient samples 
as their purpose was solely to investigate the detection of RGM in CF patients. 
2.4.19 Multi-centre study to examine the effectiveness and convenience of 
RGM medium 
In order to obtain a more accurate representation of the selectivity and ease of use 
for RGM medium a multi-centre study performed in eight laboratories in six 
geographical locations was completed, with 2679 RGM plates being prepared and 
distributed in total. 
RGM plates were prepared as in Appendix 2 and sent to the eight laboratories for 
analysis using sputum samples of CF patients. These were Aarhus University 
Hospital, Aarhus, Denmark (100), Centre de Biologie et Pathologie Est, Bron, 
France (50), Centre Hospitalier Lyon Sud, France (50), Kings College Hospital, 
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London, UK (200), Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, 
Germany (280), Papworth Hospital, Cambridge, UK (930), Radboud University 
Nijmegen Medical Centre, Nijmegen, Netherlands (200) and UNC Healthcare, 
Chapel Hill, North Carolina, USA (869). 
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2.5 Results 
2.5.1 Evaluation of basal media for optimal growth of Mycobacterium 
abscessus complex 
From the data obtained, the sensitivity values of each of the nine media described 
in section 2.4.3 was calculated (Table 2-3). 
 
Table 2-3: Sensitivity values of basal media. 
 Medium Sensitivity % 
  24 h 48 h 72 h  96 h  168 h 
A Middlebrook 7H9 
 
0 0 0 0 0 
B Middlebrook with glycerol 
 
0 0 0 25 95 
C Middlebrook with Tween-80 
 
0 0 0 10 100 
D Middlebrook with glycerol and OADC 
 
0 95 100 100 100 
E Middlebrook with Tween-80 and OADC 
 
0 95 100 100 100 
F Columbia Agar 
 
0 0 75 80 100 
G Columbia with OADC 
 
0 70 100 100 100 
H Columbia with 5% horse blood 
 
0 25 100 100 100 
I bioMérieux cepacia agar (44347) 0 20 90 95 95 
 
One strain of M. abscessus subspecies abscessus, (isolate 1050) failed to grow on 
BCSA, and only a trace of isolate 1034, also M. abscessus subspecies abscessus, 
was visible on medium B after 168 h. 
Figure 2-8 shows left (medium A) Middlebrook 7H9, centre (medium B) with the 
addition of glycerol, and right (medium D) with the addition of glycerol and 
Middlebrook OADC growth supplement. Substantially improved growth of 
mycobacteria on the medium containing glycerol and Middlebrook OADC growth 
supplement is clearly visible. Although medium D and medium E had identical 
sensitivity values throughout, growth of mycobacteria on medium D was enhanced 
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in comparison to medium E. Results also demonstrate the value of the addition of 
OADC supplement as shown in Figure 2-8. 
Figure 2-8: Growth of mycobacteria with and without OADC growth 
supplement after 168 h incubation 
 
2.5.2 Evaluation of enrichment ingredients in basal media  
After analysis of growth on all media after 168 h, medium D supported the strongest 
growth and shortest TTD and was therefore selected as the basal medium to which 
further supplements were evaluated to promote mycobacterial growth and further 
enhance the medium. The twenty strains of mycobacteria were inoculated onto each 
of the thirteen media and TTD in days and appearance of resulting colonies was 
recorded after 24, 48, 72, 96 and 168 h. Results suggested that medium D, with the 
addition of yeast extract (medium L), gave noticeably improved and more rapid 
growth of mycobacteria in comparison to medium D alone. (See Figure 2-9 below). 
After only 24 h incubation, a trace of growth was visible for 65% of strains (13/20) 
as opposed to 10% (2/20) on medium D, demonstrating that yeast extract was a 
useful ingredient for the enhanced growth of mycobacteria. 
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Figure 2-9: Comparison of the growth of mycobacteria on medium D, without 
yeast extract (top) and medium L (bottom) containing yeast extract at 48, 72, 
96 and 168 h 
 
2.5.3 Investigation of various antimicrobials for the inhibition of non-
mycobacterial strains frequently encountered in sputum samples from 
patients with cystic fibrosis 
Results as shown in Table 2-4 revealed that all non-mycobacterial isolates tested 
(excluding fungi) were inhibited by a combination of 32 mg/L colomycin, 400 mg/L 
fosfomycin, 5 mg/L amphotericin B and 128 mg/L C390 with the exception of P. 
apista and P. pnomenusa. However, growth of these two species was substantially 
reduced.  Thirty-five percent of the mycobacteria tested were inhibited by the higher 
concentration of C390, but no inhibition was observed using C390 at 32 mg/L. At 
the lower concentration of 32 mg/L C390, Burkholderia and Pandoraea species 
were able to grow, although both displayed significantly reduced growth and for the 
majority of isolates of these species just a trace of growth was visible. 
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Isolate 1050, M. abscessus subspecies abscessus was susceptible to C390 and 
vancomycin at all concentrations. Malachite green was inhibitory to 35% of 
mycobacteria at the lowest concentration of 0.125 g/L. Vancomycin caused a 
reduction in the growth of 30% of mycobacteria and only inhibited 2% of 
Pseudomonas spp. and 35% of other species at the highest concentration. 
Nalidixic acid had no effect on the growth of mycobacteria, however only inhibited 
42% of non-mycobacterial species at the highest concentration (64 mg/L). 
Amphotericin B had no inhibitory effects on mycobacteria, but did not inhibit 
Aspergillis terreus, Scedosporium apiospermum and Scedosporium prolificans at 
any concentration, and Geosmithia argillacea was only inhibited at 20 mg/L. 
Colomycin inhibited 92% of Pseudomonas spp. at the lowest concentration, and 
33% of other non-mycobacterial species, with no significant effect upon the growth 
of mycobacteria. Fosfomycin had no inhibitory effects on the mycobacteria at all 
concentrations tested, and inhibition of Pseudomonas spp was 81%, 86% and 93% 
and other non-mycobacteria species were inhibited at a rate of 65%, 73% and 73% 
at concentrations 400 mg/L, 800 mg/L and 1600 mg/L respectively. 
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Table 2-4: Investigation of the growth of NTM and inhibition of non-NTM isolates after seven days of incubation at 30oC using various 
antimicrobials in agar-based media 
 Ref No.  MABSC Subspecies Control  Amphotericin B (mg/L) Nalidixic Acid (mg/L) Vancomycin (mg/L) 
   5 10 20 16 32 64 2.5 5 10 
1034 M. abscessus +++ +++ ++ +++ +++ +++ ++ ++ + ++ 
1042 M. abscessus +++ ++ +++ +++ +++ +++ ++ ++ ++ + 
1044 M. abscessus +++ +++ +++ +++ +++ +++ +++ +++ +++ ++ 
1045 M. abscessus ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ 
1047 M. abscessus +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ 
1050 M. abscessus ++ ++ ++ ++ ++ ++ ++ NG NG NG 
1051 M. abscessus ++ ++ ++ ++ ++ ++ ++ ++ ++ + 
1052 M. abscessus ++ ++ +++ +++ +++ ++ ++ ++ ++ + 
1053 M. abscessus ++ ++ ++ ++ ++ ++ ++ + + + 
1054 M. abscessus ++ ++ ++ ++ ++ ++ ++ + + + 
1055 M. abscessus +++ +++ +++ +++ +++ ++ +++ +++ ++ ++ 
1000 MABSC - (chimeric) ++ ++ ++ ++ ++ +++ ++ ++ + + 
3016 M. bolletii +++ ++ ++ ++ ++ ++ ++ ++ ++ + 
3017 M. bolletii +++ ++ + ++ ++ ++ ++ + ++ + 
3015 M. massiliense +++ +++ ++ ++ +++ +++ +++ +++ +++ +++ 
3010 M. massiliense +++ + ++ ++ ++ ++ ++ + +  +/- 
3011 M. massiliense +++ ++ +++ +++ +++ +++ +++ ++ ++ ++ 
3012 M. massiliense ++ ++ ++ ++ ++ ++ ++ + ++ + 
3013 M. massiliense ++ ++ + ++ ++ ++ ++ + ++ ++ 
3014 M. massiliense ++ +++ ++ ++ ++ ++ ++ ++ ++ ++ 
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Table 2-4 continued: Investigation of the growth of NTM and inhibition of non-NTM isolates after seven days of incubation at 30oC 
using various antimicrobials in agar-based media 
Ref No.  MABSC Subspecies Colomycin (mg/L) C390 (mg/L) Fosfomycin (mg/L) Malachite Green (mg/L) 
  32 64 128 32 64 128 400 800 1600 0.125 0.25 0.5 
1034 M. abscessus ++ ++ + +++ +++ ++ +++ +++ +++ ++ +++ +++ 
1042 M. abscessus +++ +++ ++ +++ +++ ++ +++ +++ +++ ++ +++ +++ 
1044 M. abscessus +++ +++ +++ +++ +++ +++ +++ +++ +++ ++ +++ +++ 
1045 M. abscessus ++ ++ +++ ++ ++ ++ +++ ++ ++ + ++ ++ 
1047 M. abscessus +++ ++ ++ +++ +++ +++ +++ +++ +++ ++ +++ +++ 
1050 M. abscessus ++ + + NG NG NG ++ ++ ++ NG ++ ++ 
1051 M. abscessus ++ ++ ++ ++ ++ ++ ++ ++ ++ + ++ ++ 
1052 M. abscessus ++ ++ ++ ++ +++ +++ ++ ++ ++ NG ++ ++ 
1053 M. abscessus ++ ++ ++ ++ ++ ++ ++ ++ ++ + ++ ++ 
1054 M. abscessus ++ ++ ++ ++ +++ +++ ++ ++ ++ + ++ ++ 
1055 M. abscessus +++ ++ +++ +++ +++ +++ +++ +++ +++ ++ +++ +++ 
1000 MABSC - (chimeric) ++ ++ ++ ++ ++ +++ ++ ++ ++ + ++ ++ 
3016 M. bolletii +++ +++ +++ +++ +++ +++ +++ +++ +++ ++ ++ ++ 
3017 M. bolletti + ++ +++ +++ ++ ++ +++ ++ +++ NG + ++ 
3015 M. massiliense +++ +++ +++ +++ +++ +++ +++ +++ +++ ++ +++ ++ 
3010 M. massiliense + ++ ++ ++ + ++ ++ ++ +++ NG + ++ 
3011 M. massiliense ++ +++ +++ +++ +++ +++ +++ +++ +++ ++ +++ +++ 
3012 M. massiliense ++ ++ ++ +++ +++ +++ +++ ++ ++ + ++ ++ 
3013 M. massiliense ++ ++ ++ ++ ++ ++ ++ ++ ++ + ++ ++ 
3014 M. massiliense ++ + + ++ ++ +++ +++ +++ ++ + ++ ++ 
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Table 2-4 continued: Investigation of the growth of NTM and inhibition of non-NTM isolates after seven days of incubation at 30oC 
using various antimicrobials in agar-based media 
Ref No.  
Non-mycobacteria 
Species  Control  Amphotericin B (mg/L) Nalidixic Acid (mg/L) Vancomycin (mg/L) 
   5 10 20 16 32 64 2.5 5 10 
 Gram-negatives           
8001 A..xylosoxidans + + + + + + + + + + 
8003 Acinetobacter sp. + +/- +/- +/- +/- +/- +/- NG NG NG 
8004 B. multivorans +++ +++ ++ +++ +++ +/- + ++ ++ +++ 
8006 B. cenocepacia IIIA + + + + + + + + + + 
8007 B. cepacia (G1) +++ +++ +++ +++ +++ + +/- ++ ++ +++ 
8008 B. contaminans + + + + + + + + + + 
8032 C. freundii + - - - NG NG NG + + + 
9007 E. aerogenes +++ - - - +++ NG NG +++ +++ +++ 
8038 E. cloacae +++ - - - +++ NG NG +++ +++ +++ 
8036 E. coli + - - - ++ NG NG + + + 
9010 H. influenzae NG - - - NG NG NG NG NG NG 
9009 M. catarrhalis NG - - - NG NG NG NG NG NG 
9008 N.  flavescens +/- - - - +/- +/- NG +/- +/- +/- 
8009 P. aeruginosa +++ +++ ++ ++ ++ + +/- ++ ++ ++ 
8010 P. aeruginosa + ++ + + + + NG + +/- +/- 
8014 P. aeruginosa + + + + + +/- NG + +/- +/- 
8015 P. aeruginosa + + + + + + NG + + + 
8016 P. aeruginosa + + + + + + NG + + + 
8018 P. aeruginosa + + + + + + +/- + + + 
8019 P. aeruginosa + + + + +/- + NG + +/- +/- 
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Table 2-4 continued: Investigation of the growth of NTM and inhibition of non-NTM isolates after seven days of 
incubation at 30oC using various antimicrobials in agar-based media 
Ref No.  
Non-mycobacteria 
Species  Control  Amphotericin B (mg/L) Nalidixic Acid (mg/L) Vancomycin (mg/L) 
   5 10 20 16 32 64 2.5 5 10 
7037 P. aeruginosa + + + + + + +/- + + + 
7038 P. aeruginosa +/- +/- +/- +/- +/- +/- NG + +/- +/- 
7039 P. aeruginosa + + + + + + +/- + + + 
7040 P. aeruginosa + + + + + + NG Tr + + 
7041 P. aeruginosa ++ ++ ++ +++ + ++ NG ++ + + 
7042 P. aeruginosa +++ ++ ++ ++ + ++ NG ++ ++ ++ 
7043 P. aeruginosa +++ ++ ++ ++ + + NG + ++ ++ 
7044 P. aeruginosa ++ ++ ++ ++ + + + + + + 
7045 P. aeruginosa ++ ++ ++ ++ + NG NG + + ++ 
7046 P. aeruginosa + ++ ++ ++ + NG + + + ++ 
7047 P. aeruginosa + ++ ++ ++ + NG + ++ + ++ 
7048 P. aeruginosa ++ ++ ++ ++ + + + ++ ++ +++ 
7049 P. aeruginosa + ++ + + +/- + + ++ + + 
7050 P. aeruginosa + ++ + + + + Tr ++ + + 
7051 P. aeruginosa + + + + + + Tr ++ + + 
7052 P. aeruginosa ++ ++ ++ ++ + ++ Tr ++ ++ ++ 
7053 P. aeruginosa ++ ++ ++ ++ + + NG ++ ++ ++ 
7054 P. aeruginosa ++ ++ ++ ++ + + Tr ++ ++ +++ 
7055 P. aeruginosa ++ ++ ++ ++ + + Tr ++ ++ ++ 
7056 P. aeruginosa ++ ++ ++ ++ + + + ++ ++ ++ 
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Table 2-4 continued: Investigation of the growth of NTM and inhibition of non-NTM isolates after seven days of 
incubation at 30oC using various antimicrobials in agar-based media 
Ref No.  
Non-mycobacteria 
Species  Control  Amphotericin B (mg/L) Nalidixic Acid (mg/L) Vancomycin (mg/L) 
   5 10 20 16 32 64 2.5 5 10 
7057 P. aeruginosa + + + + ++ NG NG + ++ ++ 
7058 P. aeruginosa + + + + + NG + +/- +/- +/- 
7059 P. aeruginosa + + + + +/- NG +/- + +/- +/- 
7060 P. aeruginosa +/- +/- +/- +/- +/- Tr NG + +/- Tr 
7061 P. aeruginosa ++ ++ ++ ++ + + ++ + + + 
7062 P. aeruginosa ++ +++ ++ ++ ++ + + ++ + + 
7063 P. aeruginosa ++ ++ ++ + + NG NG ++ + + 
7064 P. aeruginosa + + + ++ + + + + + + 
7065 P. aeruginosa + + + ++ + + + + + + 
7066 P. aeruginosa + + + + + + +/- + + + 
7067 P. aeruginosa + ++ + + ++ + + + + + 
7068 P. aeruginosa ++ ++ + + ++ + + ++ + + 
7069 P. aeruginosa ++ ++ + + ++ + + + ++ ++ 
7070 P. aeruginosa ++ ++ + + + + + + + + 
7071 P. aeruginosa ++ ++ + + + + + + + + 
7072 P. aeruginosa ++ ++ + + + + + ++ + + 
7073 P. aeruginosa ++ ++ + + ++ + + ++ ++ ++ 
7074 P. aeruginosa ++ ++ ++ + ++ + + ++ + + 
7075 P. aeruginosa ++ + + + + + +/- ++ + + 
7076 P. aeruginosa ++ + + + + + +/- ++ ++ ++ 
7077 P. aeruginosa + ++ ++ ++ + + + ++ ++ ++ 
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Table 2-4 continued: Investigation of the growth of NTM and inhibition of non-NTM isolates after seven days of 
incubation at 30oC using various antimicrobials in agar-based media 
Ref No.  
Non-mycobacteria 
Species  Control  Amphotericin B (mg/L) Nalidixic Acid (mg/L) Vancomycin (mg/L) 
   5 10 20 16 32  64 2.5 5 10 
7078 P. aeruginosa + + + + + + + ++ ++ ++ 
7079 P. aeruginosa + ++ ++ ++ ++ ++ ++ ++ ++ +++ 
8020 P. apista + + + + + + + + + + 
8021 P. pnomenusa + + + + + + + + + + 
8031 P. rettgeri + - - - NG NG NG + +/- + 
8037 R. planticola ++ - - - NG NG NG ++ ++ ++ 
8022 S. maltophilia + + + + + +/- Tr + + + 
8023 S. maltophilia + + + + + +/- +/- + + + 
8039 S. marcescens ++ - - - + NG NG ++ ++ ++ 
 Gram-positives           
9006 B. subtilis + - - - NG NG NG NG NG NG 
9003 E. faecalis +/- - - - +/- +/- +/- NG NG NG 
9005 E. faecium +/- - - - +/- +/- +/- NG NG NG 
9001 S. aureus + - - - + NG NG NG NG NG 
9002 S. aureus (MRSA) + - - - + + + NG NG NG 
9004 S. epidermidis + - - - + Tr NG NG NG NG 
8035 S. gordinii Tr - - - Tr Tr +/- NG NG NG 
8040 S.  pneumoniae Tr - - - Tr Tr Tr NG NG NG 
8033 S. pyogenes +/- - - - +/- +/- +/- NG NG NG 
8034 S. salivarius + - - - + + + NG NG NG 
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Table 2-4 continued: Investigation of the growth of NTM and inhibition of non-NTM isolates after seven days of 
incubation at 30oC using various antimicrobials in agar-based media 
Ref No.  
Non-mycobacteria 
Species  Control  Amphotericin B (mg/L) Nalidixic Acid (mg/L) Vancomycin (mg/L) 
   5 10 20 16 32  64 2.5 5 10 
 Fungi and Yeast           
9013 A..fumigatus* +++ +/- NG NG - - - - - - 
9014 A..fumigatus** +++ +/- NG NG - - - - - - 
9015 A..terreus +++ +++ +++ +++ - - - - - - 
9001 C. albicans +++ NG NG NG - - - - - - 
9012 C. glabrata +++ NG NG NG - - - - - - 
9018 G. argillacea +++ Tr +/- NG - - - - - - 
9016 S. apiospermum ++ +++ +++ +++ - - - - - - 
9017 S.  prolificans ++ +++ +++ +++ - - - - - - 
*3 colonies on Day 7 at 5mg/L  **4 colonies on day 7 at 5mg/L 
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Table 2-4 continued: Investigation of the growth of NTM and inhibition of non-NTM isolates after seven days of incubation at 30oC 
using various antimicrobials in agar-based media 
Ref No. 
Non-mycobacteria 
Species  
Colomycin (mg/L) C390 (mg/L) Fosfomycin (mg/L) Malachite Green (mg/L) 
  32 64 128 32 64 128 400 800 1600 0.125 0.25 0.5 
 Gram-negatives             
8001 A..xylosoxidans + + + +/- NG NG + + + + + + 
8003 Acinetobacter sp. + +/- +/- NG NG NG NG NG NG + +/- +/- 
8004 B. multivorans ++ + + NG NG NG ++ ++ ++ ++ ++ +++ 
8006 B. cenocepacia IIIA + + +/- Tr Tr NG + + +/- + + + 
8007 B. cepacia (G1) +++ ++ + Tr Tr NG + + + ++ ++ ++ 
8008 B. contaminans + + + Tr NG NG + + + + + + 
8032 C. freundii NG NG NG NG NG NG NG NG NG + + + 
9007 E. aerogenes NG NG NG NG NG NG ++ NG NG ++ ++ ++ 
8038 E. cloacae ++ ++ + NG NG NG +++ +++ + +++ +++ +++ 
8036 E. coli NG NG NG NG NG NG NG NG NG + + + 
9010 H. influenzae NG NG NG NG NG NG NG NG NG NG NG NG 
9009 M. catarrhalis NG NG NG NG NG NG NG NG NG NG NG NG 
9008 N.  flavescens NG NG NG NG NG NG NG NG NG NG  +/-  +/- 
8009 P. aeruginosa NG NG NG + + NG NG NG NG ++ ++ ++ 
8010 P. aeruginosa + +/- Tr NG NG NG +/- NG NG +/- + + 
8014 P. aeruginosa +/- +/- +/- +/- NG NG NG NG NG + + + 
8015 P. aeruginosa Tr Tr Tr NG NG NG +/- Tr Tr +/- + + 
8016 P. aeruginosa +/- +/- +/- + + NG NG NG NG + + + 
8018 P. aeruginosa NG NG NG + +/- NG + + + + + + 
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Table 2-4 continued: Investigation of the growth of NTM and inhibition of non-NTM isolates after seven days of incubation at 
30oC using various antimicrobials in agar-based media 
Ref No. 
Non-mycobacteria 
Species  
Colomycin (mg/L) C390 (mg/L) Fosfomycin (mg/L) Malachite Green (mg/L) 
  32 64 128 32 64 128 400 800 1600 0.125 0.25 0.5 
8019 P. aeruginosa +/- Tr+ Tr +/- +/- Tr NG NG NG +/- + + 
7037 P. aeruginosa NG NG NG + + NG  +/-  +/-  +/- + + + 
7038 P. aeruginosa NG NG NG  +/- Tr NG  +/-  +/- Tr  +/-  +/-  +/- 
7039 P. aeruginosa NG NG NG + +  +/- + +  +/- + + + 
7040 P. aeruginosa NG NG NG + + + +  +/- NG + + + 
7041 P. aeruginosa NG NG NG + + +  +/- NG NG + + + 
7042 P. aeruginosa NG NG NG + ++ + NG NG NG + + ++ 
7043 P. aeruginosa NG NG NG + + + NG NG NG + + ++ 
7044 P. aeruginosa NG NG NG ++ + NG NG NG NG ++ ++ ++ 
7045 P. aeruginosa NG NG NG + +  +/- NG NG NG ++ ++ ++ 
7046 P. aeruginosa NG NG NG + +  +/- NG NG NG ++ ++ ++ 
7047 P. aeruginosa NG NG NG + + Tr NG NG NG ++ ++ ++ 
7048 P. aeruginosa NG NG NG + + + NG NG NG ++ ++ +++ 
7049 P. aeruginosa NG NG NG +  +/- NG Tr NG NG + + + 
7050 P. aeruginosa NG NG NG + + + NG NG NG + + + 
7051 P. aeruginosa NG NG NG + + + NG NG NG + + + 
7052 P. aeruginosa NG NG NG + + + NG NG NG ++ ++ ++ 
7053 P. aeruginosa NG NG NG ++ + + Tr NG NG ++ ++ ++ 
7054 P. aeruginosa NG NG NG + +  +/- NG NG NG ++ ++ ++ 
7055 P. aeruginosa NG NG NG + + NG + + + ++ ++ ++ 
90 
 
Table 2-4 continued: Investigation of the growth of NTM and inhibition of non-NTM isolates after seven days of incubation at 
30oC using various antimicrobials in agar-based media 
Ref No. 
Non-mycobacteria 
Species  
Colomycin (mg/L) C390 (mg/L) Fosfomycin (mg/L) Malachite Green (mg/L) 
  32 64 128 32 64 128 400 800 1600 0.125 0.25 0.5 
7056 P. aeruginosa NG NG NG + + + NG NG NG ++ ++ ++ 
7057 P. aeruginosa NG NG NG + + NG Tr NG NG + + ++ 
7058 P. aeruginosa NG NG NG + +  +/- NG NG NG + + + 
7059 P. aeruginosa NG NG NG NG NG NG NG NG NG + + + 
7060 P. aeruginosa NG NG NG NG NG NG Tr NG NG Tr  +/-  +/- 
7061 P. aeruginosa NG NG NG ++ +++ +++ NG NG NG + ++ ++ 
7062 P. aeruginosa NG NG NG + ++ + NG NG NG ++ ++ ++ 
7063 P. aeruginosa NG NG NG + + +  +/- NG NG + + + 
7064 P. aeruginosa NG NG NG + + + +  +/- NG + + + 
7065 P. aeruginosa NG NG NG + + + NG NG NG + + + 
7066 P. aeruginosa NG NG NG + +  +/- NG NG NG + + + 
7067 P. aeruginosa NG NG NG + + + NG NG NG + + + 
7068 P. aeruginosa NG NG NG + + + NG NG NG + + ++ 
7069 P. aeruginosa NG NG NG + + + NG NG NG ++ ++ ++ 
7070 P. aeruginosa NG NG NG + + + NG NG NG + ++ ++ 
7071 P. aeruginosa NG NG NG + + + NG NG NG + + ++ 
7072 P. aeruginosa NG NG NG + + + NG NG NG + + ++ 
7073 P. aeruginosa NG NG NG + + + NG NG NG ++ ++ +++ 
7074 P. aeruginosa NG NG NG + + NG NG NG NG + ++ ++ 
7075 P. aeruginosa NG NG NG + +  +/- NG NG NG + ++ ++ 
91 
 
Table 2-4 continued: Investigation of the growth of NTM and inhibition of non-NTM isolates after seven days of incubation at 
30oC using various antimicrobials in agar-based media 
Ref No. 
Non-mycobacteria 
Species  
Colomycin (mg/L) C390 (mg/L) Fosfomycin (mg/L) Malachite Green (mg/L) 
  32 64 128 32 64 128 400 800 1600 0.125 0.25 0.5 
7076 P. aeruginosa NG NG NG ++ +  +/- NG NG NG + ++ ++ 
7077 P. aeruginosa NG NG NG ++ + + NG NG NG ++ ++ ++ 
7078 P. aeruginosa NG NG NG + + + NG NG NG ++ ++ +++ 
7079 P. aeruginosa NG NG NG + +  +/- NG NG NG ++ ++ ++ 
8020 P. apista + + + + + Tr + + +/- + + + 
8021 P. pnomenusa + + + +/- +/- Tr + + +/- + + + 
8031 P. rettgeri + + + NG NG NG NG NG NG + + + 
8037 R. planticola NG NG NG NG NG NG +++ + + + ++ ++ 
8022 S. maltophilia + + + Tr NG NG NG NG NG + + + 
8023 S. maltophilia + + + NG NG NG NG NG NG + + + 
8039 S. marcescens + + + NG NG NG NG NG NG + + + 
 Gram-positives             
9006 B. subtilis NG NG NG NG NG NG NG NG NG + + ++ 
9003 E. faecalis  +/- + + NG NG NG NG NG NG  +/-  +/-  +/- 
9005 E. faecium  +/-  +/-  +/- NG NG NG NG NG NG  +/-  +/-  +/- 
9001 S. aureus NG NG NG NG NG NG NG NG NG + + NG 
9002 S. aureus (MRSA) + + + NG NG NG NG NG NG + + + 
9004 S. epidermidis + NG NG NG NG NG NG NG NG + + + 
8035 S. gordinii  +/-  +/-  +/- NG NG NG NG NG NG Tr Tr  +/- 
8040 S.  pneumoniae NG NG NG NG NG NG NG NG NG Tr Tr Tr 
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Table 2-4 continued: Investigation of the growth of NTM and inhibition of non-NTM isolates after seven days of incubation at 
30oC using various antimicrobials in agar-based media 
Ref No. 
Non-mycobacteria 
Species  
Colomycin (mg/L) C390 (mg/L) Fosfomycin (mg/L) Malachite Green (mg/L) 
  32 64 128 32 64 128 400 800 1600 0.125 0.25 0.5 
8033 S. pyogenes  +/-  +/- NG NG NG NG NG NG NG  +/-  +/-  +/- 
8034 S. salivarius + + + NG NG NG NG NG NG + + + 
 Fungi and Yeast             
9013 A..fumigatus* - - - - - - - - - - - - 
9014 A..fumigatus** - - - - - - - - - - - - 
9015 A..terreus - - - - - - - - - - - - 
9001 C. albicans - - - - - - - - - - - - 
9012 C. glabrata - - - - - - - - - - - - 
9018 G. argillacea - - - - - - - - - - - - 
9016 S. apiospermum - - - - - - - - - - - - 
9017 S.  prolificans - - - - - - - - - - - - 
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2.5.4 Investigation of combined antimicrobials for the inhibition of non-
mycobacterial strains present in cystic fibrosis sputum  
Out of 100 isolates of mycobacteria, one was excluded due to contamination with 
C. albicans. Another isolate, M. intracellulare did not grow on any of the media 
formulations within seven days, however this was not unexpected as M. 
intracellulare is known to be a slow-growing species, and usually has a TTD of 28 
days on LJ medium (Wasilauskas and Morrell, 1994). After 168 h incubation both 
medium L and medium W had a sensitivity value of 99.0% (98/99), and medium X 
(RGM), 98.0% (97/99), however these values would rise to 100% and 99.0% if M. 
intracellulare was discounted. 
Inhibition of 93.8% and 85.6% of all non-mycobacterial species tested was 
demonstrated by RGM, and medium W respectively. Six species; Achromobacter 
sp, B. cepacia, P. apista, P. pnomenusa, B. contaminans and B. stabilis, remained 
uninhibited on RGM medium although growth was significantly reduced. Fungi that 
were uninhibited by amphotericin B, and able to grow on media L and W were 
inhibited on RGM medium when combined with C390 as shown in Figure 2-10 with 
A. terreus. This was also the case for Scedosporium apiospermum, Scedosporium 
prolificans, and Geosmithia argillacea. All isolates grew well on control media. 
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Figure 2-10: Growth of Aspergillus terreus on (left to right) Sabouraud 
control medium, Medium L, Medium W and RGM 
 
Figure 2-10 shows the growth of Aspergillus terreus on Sabouraud control medium, 
medium L, the basal medium containing no antimicrobials showing slightly reduced 
growth, medium W, with only a small amount of growth and total inhibition on RGM 
medium, containing C390. 
2.5.5 Evaluation of plating efficiency studies on RGM medium 
On average, RGM medium was 84.0% as effective for the growth of mycobacteria 
as medium L. Two-sample t - tests gave a P value for medium L (control) and RGM 
medium as P=0.052. By conventional criteria, this difference is considered to be not 
statistically significant, indicating that there is no substantial difference between the 
two media for the growth of mycobacteria. Growth of colonies established that on 
RGM medium, colonies were marginally smaller than on medium L, but with regard 
to the numbers of colonies, the difference was minimal (Figure 2-11)  
Following the addition of various antimicrobials into the medium, mycobacterial cell 
counts reduced from 225.3 ± 33.3 to 189.3 ± 28.8 (p >0.05); a decline of 36.0 ± 4.6. 
The probability of obtaining a difference of 36.0 between the mean colony counts, 
given that the media does not affect the counts, is 0.052, or 5.2%. 
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Figure 2-11: Plating efficiencies showing colonies on medium L (left) and RGM 
medium (right) 
  
2.5.6 Evaluation of the stability of RGM medium 
There was no reduction in the quality of growth of the four species of Mycobacterium 
after storage of RGM media at 4°C for 12 weeks and the medium maintained 
complete inhibition of the six non-mycobacteria and seven fungal and yeast isolates 
tested (See Appendix 1). 
2.5.7 Evaluation of various C390 derivatives in RGM medium 
Results from the testing of C390 derivatives shown in Table 2-5 and Figure 2-12 to 
Figure 2-14 showed that the MIC’s of A477 were almost equivalent to C390 with the 
only significant difference being for I. limosus. A488 also performed well, but with 
slightly higher MIC’s than A477. However, all other compounds tested were not able 
to provide sufficient inhibition of the Gram-negative species, displaying increased 
MICs for all isolates tested.
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Figure 2-12: A477 at concentrations of 1 – 128 mg/L for twenty selected Gram-negative species after four days of incubation 
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Figure 2-13: C390 at concentrations of 1 – 128 mg/L for twenty selected Gram-negative species after four days of incubation
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Table 2-5: MIC’s (mg/L) of a selection of Gram-negative bacteria for C390 and derivatives of C390 after ten days at 30oC 
Species Ref C390 A477 A475 A480a A488 A503a A503b A505 A520 
A..baumannii NCTC 12156 4 4 4 128 8 128 >128 >128 >128 
A..xylosoxidans 8001 32 64 >128 128 64 >128 >128 >128 >128 
B. cepacia NCTC 1222 8 8 >128 128 4 >128 >128 >128 >128 
B. contaminans 8008 8 8 >128 128 8 >128 >128 >128 >128 
B. multivorans 8004 8 8 >128 128 16 >128 >128 >128 >128 
B. vietnamiensis 7032 4 4 4 128 2 64 >128 64 >128 
C. albicans ATCC 90029 ≤1 ≤1 ≤1 >128 2 64 128 >128 >128 
E. cloacae NCTC 11936 16 16 >128 >128 32 >128 >128 >128 >128 
E. coli NCTC 10418 ≤1 ≤1 ≤1 128 ≤1 16 32 64 >128 
E. faecalis NCTC 775 ≤1 ≤1 2 >128 ≤1 64 64 32 >128 
I..limosus 7007 2 16 16 128 64 >128 >128 >128 >128 
R. planticola NCTC 9528 ≤1 2 ≤1 128 2 64 32 >128 >128 
P. apista 8020 64 64 >128 128 128 >128 >128 >128 >128 
P. aeruginosa NCTC 10662 64 64 128 128 128 >128 >128 >128 >128 
P. aeruginosa 7044 64 64 128 128 128 >128 >128 >128 >128 
P. aeruginosa 8009 64 64 128 128 128 >128 >128 >128 >128 
P. pnomenusa 8021 32 64 >128 128 64 >128 >128 >128 >128 
S. aureus NCTC 6571 ≤1 ≤1 ≤1 128 ≤1 16 32 8 32 
S. maltophilia NCTC 10257 ≤1 ≤1 ≤1 128 ≤1 16 32 32 >128 
S. marcescens 7020 8 8 >128 >128 16 >128 >128 >128 >128 
99 
 
 
Figure 2-14: 480a at concentrations of 1 – 128 mg/L for twenty selected Gram-negative species after four days of incubation 
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These results demonstrated that A477, being locally synthesised by Dr Annette 
Johnson at Northumbria University, could be a more cost effective substitution for 
C390, working equally as well as a crucial ingredient in RGM medium. This could 
potentially be prepared in bulk for future large-scale studies. 
2.5.8 Evaluation of selective agars in comparison to RGM for the growth 
of mycobacteria 
Clear differences were revealed between the five different brands of BCSA in terms 
of their ability to support the growth of mycobacteria (Figure 2-15 below). For 
example, on Cepacia selective agar (bioMérieux) 95.9% of mycobacteria generated 
growth within four days of incubation compared with only 40.1% of isolates on Oxoid 
B. cepacia agar as shown in Table 2-6. 
After ten days of incubation, ten isolates had failed to grow on Oxoid B. cepacia 
agar including MABSC (n = 4), M. chelonae (n = 3), M. llatzerense (n = 2) and M. 
mucogenicum (n = 1). All isolates were recovered on Cepacia selective agar 
(bioMérieux) whereas other brands of BCSA failed to support the growth of between 
four and eight isolates. All isolates were recovered on Middlebrook 7H11 selective 
agar and RGM medium with C390 at 32 mg/L. Two isolates (M. abscessus and M. 
mucogenicum) were inhibited on RGM medium with C390 at 64 mg/L, 128 mg/L and 
C390 at 32 mg/L with no OADC, and one isolate (M. abscessus) failed to grow on 
RGM medium using A477. Figure 2-15 shows the growth at day four of four isolates 
of M. abscessus subspecies abscessus. 
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Figure 2-15: Growth at day four of four isolates of M. abscessus subspecies 
abscessus on various media. Columbia blood agar, RMG with 32 mg/L, C390 
and RGM with 64 mg/L C390, (top row). RGM with C390 at 128 mg/L, RGM with 
A477 at 32 mg/L and RGM with 32 mg/L C390 minus OADC supplement 
(second row). Middlebrook, Oxoid cepacia, bioMérieux cepacia (third row), 
and bioMérieux BCSA, BD cepacia and BD OFPBL (bottom row)
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Table 2-6: Percentage of mycobacteria recovered on various selective agars at 30oC 
  
BCSA Cepacia B. cep Cepacia OFPBL M’brook RGM RGM RGM RGM RGM Blood/Sab  
n 
bioMérieux  bioMérieux  Oxoid BD BD 7H11 
C390 
32mg/L 
C390 
64mg/L 
C390 
128mg/L 
A477 
32mg/L No OADC* Controls   
33631 44347 PO0938 256180 254481 PP4080 N/A N/A N/A N/A N/A N/A 
MABSC 94 
            
Day 4 
 
92.6 96.8 57.4 96.8 93.6 98.9 98.9 98.9 97.9 97.9 98.9 100 
Day 7 
 
98.9 98.9 91.5 98.9 98.9 98.9 98.9 98.9 98.9 98.9 98.9 100 
Day 10 
 
98.9 100 95.7 100 98.9 100 100 98.9 98.9 98.9 98.9 100 
M. chelonae 43 
            
Day 4 
 
97.7 100 9.3 95.3 100 100 100 100 100 100 100 100 
Day 7 
 
100 100 69.8 95.3 100 100 100 100 100 100 100 100 
Day 10 
 
100 100 93 97.7 100 100 100 100 100 100 100 100 
Other NTM 10 
            
Day 4 
 
10 70 10 70 40 70 90 30 30 30 60 100 
Day 7 
 
30 80 60 70 40 70 90 90 60 90 70 100 
Day 10 
 
30 100 70 70 70 100 100 90 90 100 90 100 
Total NTM 147 
            
Day 4 
 
88.4 95.9 40.1 94.6 91.8 97.3 98.6 94.6 93.9 93.9 96.6 100 
Day 7 
 
94.6 98 83 95.9 95.2 97.3 98.6 98.6 96.6 98.6 97.3 100 
Day 10 
 
94.6 100 93.2 97.3 97.3 100 100 98.6 98.6 99.3 98.6 100 
*OADC: oleic acid, bovine serum albumin, dextrose, catalase 
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2.5.9 Evaluation of selective agars including RGM for the inhibition of 
non-mycobacteria 
 
Table 2-7 and Figure 2-16 shown below provide an insight into the selectivity of the 
eleven selective media with 185 non-mycobacteria. Effective inhibition of P. 
aeruginosa, an essential characteristic of such media, was demonstrated on all five 
brands of BCSA. Inhibition of other species was more inconsistent however, and of 
28 isolates of S. aureus (mainly methicillin-resistant strains (27/28)), 21 (75.0%) 
were able to grow on BD OFPBL medium whereas only three isolates were able to 
grow on Oxoid B. cepacia agar and bioMérieux BCSA. All brands of media for 
isolation of B. cepacia complex showed a poor ability to inhibit the growth of fungi 
and yeasts, particularly Aspergillus spp. Overall, bioMérieux BCSA displayed the 
greatest selectivity and BD OFPBL exhibited the weakest selectivity among the five 
brands tested.  
Although Middlebrook selective medium is designed specifically for the isolation of 
mycobacteria from clinical samples, the growth of other non-mycobacterial species 
occurred frequently with 74 out of 186 (39.8%) isolates able to grow. Overall, it 
demonstrated inferior selectivity in comparison to the two most selective media for 
B. cepacia complex, although it was able to inhibit the growth of Aspergillus 
fumigatus. The various types of RGM medium were by far the most selective of all 
of the agars tested, with between 89.9% and 98.4% of non-mycobacteria inhibited 
including all fungi and Gram-positive bacteria. Species shown in Figure 2-16 include 
Achromobacter spp (n = 2), Acinetobacter (n = 1), BCC (n = 2), P. aeruginosa (n = 
11), C. freundii (n = 1), M. morganii (n = 1) and S. maltophilia (n = 2).
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Figure 2-16: Growth of Gram-negative bacteria on various selective agars. Top row Columbia blood agar, RGM 32 mg/L C390, RGM 64 
mg/L C390 and RGM 128 mg/L C390. Middle row RGM with A477 at 32 mg/L and RGM with 32 mg/L C390 minus OADC supplement, 
Middlebrook, Oxoid cepacia and bottom row bioMérieux cepacia and (bottom row) bioMérieux BCSA, BD cepacia and BD OFPBL 
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Table 2-7: Number of non-mycobacterial isolates recovered on various selective agars after 10 days at 30oC 
 
n BCSA 
bioMérieux  
Cepacia 
bioMérieux  
B. cep 
Oxoid Cepacia BD 
OFPBL  
BD 
M’brook 
7H11 
RGM C390 
32mg/L 
RGM C390 
64mg/L 
RGM C390 
128mg/L 
RGM A477 
32mg/L 
RGM No 
OADC*   
33631 44347 PO0938 256180 254481 PP4080 N/A N/A N/A N/A N/A 
Gram Negatives 141 56 61 56 60 73 64 18 6 3 19 11 
Enterobacteriaceae 11 2 0 2 2 6 1 0 0 0 0 0 
A..xylosoxidans 8 3 3 3 5 8 3 2 0 0 2 0 
Acinetobacter sp. 2 2 0 0 0 0 0 0 0 0 0 0 
B. cepacia complex 43 37 40 36 37 41 39 12 4 2 13 8 
D. acidovorans 1 1 0 0 0 1 0 0 0 0 0 0 
E. miricola 1 1 1 1 0 1 1 0 0 0 0 0 
H. influenzae 1 0 0 0 0 0 0 0 0 0 0 0 
I..limosus 2 0 2 0 2 0 2 1 0 0 1 1 
M. catarrhalis 1 0 0 0 0 0 0 0 0 0 0 0 
N. flavescens 1 1 1 1 1 1 1 1 0 0 1 0 
Ochrobactrum sp. 1 0 1 1 1 1 1 0 0 0 0 0 
P. aeruginosa 55 0 2 1 2 2 2 0 0 0 0 0 
Pandoraea spp. 3 3 3 3 3 3 3 2 2 1 2 2 
R. mannitolilytica 7 6 6 6 6 5 7 0 0 0 0 0 
S. maltophilia 4 0 1 1 0 3 3 0 0 0 0 0 
Gram positives 35 3 11 3 14 21 7 0 0 0 0 0 
B. subtilis 1 0 0 0 0 0 0 0 0 0 0 0 
Enterococcus spp. 2 0 0 0 0 0 0 0 0 0 0 0 
S. aureus 28 3 11 3 14 21 7 0 0 0 0 0 
Streptococcus spp. 4 0 0 0 0 0 0 0 0 0 0 0 
Yeast and Fungi 9 5 8 9 8 8 3 0 0 0 0 0 
A..fumigatus 2 2 2 2 2 2 0 0 0 0 0 0 
A..terreus 1 1 1 1 1 1 1 0 0 0 0 0 
Candida spp. 3 2 3 3 3 3 1 0 0 0 0 0 
G. argillacea 1 0 0 1 0 0 0 0 0 0 0 0 
S. apiospermum 1 0 1 1 1 1 1 0 0 0 0 0 
S. prolificans 1 0 1 1 1 1 0 0 0 0 0 0 
Total 185 64 80 68 82 102 74 18 6 3 19 11 
Total excluding  
B. cepacia complex   142 27 40 32 45 61 35 6 2 1 6 3 
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2.5.10 Evaluation of the effectiveness of RGM medium versus bioMérieux 
cepacia agar using clinical samples 
Results with sputum samples showed that out of 502 samples tested from 210 
distinct patients, 55 samples from 33 distinct patients yielded NTM giving an overall 
prevalence of 15.7%. Twenty-one of the 210 patients were colonised with MABSC 
(prevalence: 10%). The mycobacteria isolated from 55 samples comprised M. 
abscessus subsp. abscessus (56.4%), M. abscessus subsp. massiliense (20%), M. 
chelonae (10.9%) M. avium (3.6%), M. llatzerense (3.6%), M. salmoniphilum (3.6%) 
and M. mucogenicum (1.8%). Table 2-8 shows the numbers of each species 
recovered by the two media, with the calculation of sensitivity shown for comparative 
purposes only and assuming that all mycobacteria were recovered by a combination 
of the two methods. Evidently, this cannot be proven and furthermore might be 
considered highly improbable for species such as M. avium and other slower 
growing NTM. RGM medium enabled the detection of NTM from 54 of 55 positive 
samples whereas BCSA recovered NTM from 17 of 55 positive samples (sensitivity: 
98% vs. 31%; P ≤ 0.0001). 
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Table 2-8: Mycobacteria recovered from culture of 502 sputum samples on 
Burkholderia cepacia selective agar (BSCA) and RGM medium 
Species or subspecies Total                          
(either 
medium) 
BCSA RGM 
  n n Sensitivity 
(%) 
n Sensitivity 
(%) 
      
M. abscessus 
subspecies abscessus 
31 13 42 31 100 
M. abscessus 
subspecies massiliense 
11 3 33 11 100 
M. chelonae 6 1 17 5 83 
M. avium  2 0 0 2 100 
M. llatzerense 2 0 0 2 100 
M. salmoniphilum 2 0 0 2 100 
M. mucogenicum 1 0 0 1 100 
            
Total mycobacteria 55 17 31 54 98 
 
For patients who had NTM found in their sputum (n = 33), 23 were detected using 
RGM medium only, one was detected using BCSA only (M. chelonae) and nine were 
detected using both media (P ≤ 0.0001). After four days of incubation, 59% of 
mycobacteria were recovered on RGM medium in comparison to 35% of 
mycobacteria isolated on BCSA. No further isolates of NTM were isolated after 
seven days of incubation using BCSA. 
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Figure 2-17: Patient sample at day 4 on BCSA (left) and RGM (right) 
demonstrating significantly reduced growth of B. multivorans on RGM 
 
 
 
Figure 2-18: Patient sample at day 4 on BCSA (left) and RGM (right) showing 
growth of C. parapsilosis and S. maltophilia on BCSA, but only M. abscessus 
subspecies abscessus on RGM 
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Figure 2-19: Patient sample at day 4 on BCSA (left) and RGM (right) showing 
A. fumigatus on BCSA and two rough colonies of M. abscessus subspecies 
abscessus on RGM 
 
 
 
Figure 2-20: Patient sample at day 4 on BCSA (left) and RGM (right) showing 
growth of A. fumigatus, C. albicans and C. lusitaniae on BCSA, and only pure 
colonies of M. abscessus subspecies massiliense on RGM 
  
110 
 
Table 2-9: Other species recovered from culture of 502 sputum samples on 
Burkholderia cepacia selective agar (BSCA) and RGM medium 
 
A remarkable feature of RGM medium was its ability to inhibit the growth of fungi 
and Gram-positive bacteria, and during ten days of incubation, no isolates of either 
of these groups were recovered from 502 sputum samples (Table 2-9). In addition, 
although both of these selective media are designed to inhibit the growth of 
  Number of isolates (n) 
  BCSA RGM 
Fungi and Yeasts 226 0 
Arthrographis kalrae 2 0 
Aspergillus fumigatus 69 0 
Aspergillus terreus 6 0 
Yeasts (Grams stain) 121 0 
Exophiala dermatitidis 23 0 
Scedosporium apiospermum 5 0 
   
Gram-negative bacteria 136 46 
Pseudomonas spp. 32 2 
Burkholderia cepacia complex 30 18 
Stenotrophomonas maltophilia 24 0 
Achromobacter spp. 21 18 
Enterobacteriaceae 14 2 
Inquilinus limosus 4 2 
Ochrobactrum spp. 4 0 
Pandoraea spp. 3 3 
Acinetobacter lwoffii 1 0 
Methylobacterium radiotolerans 1 0 
Rhizobium radiobacter 1 0 
Sphingomonas sp. 1 0 
Delftia acidovorans 0 1 
   
Gram-positive bacteria 57 0 
Staphylococcus spp. 29 0 
Enterococcus spp. 14 0 
Streptococcus spp. 8 0 
Granulicatella adiacens 2 0 
Lactobacillus paracasei 2 0 
Micrococcus luteus 1 0 
Nocardia cyriacigeorgica 1 0 
   
Total non-mycobacteria 419 46 
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Pseudomonas, RGM medium was much more effective with only two isolates 
recovered, compared with 32 isolates isolated on BCSA. Some isolates of Gram-
negative bacteria, particularly B. cepacia complex and Achromobacter spp., could 
not be wholly inhibited on RGM medium but growth was somewhat restricted. 
Additionally, mycobacteria produced bright white colonies on RGM medium (Figure 
2-21) whereas Gram-negative species that were able to grow generated blue, or 
occasionally pink, colonies. The high selectivity of RGM (Figure 2-17 to Figure 2-20) 
medium enabled the recovery of NTM in pure culture from 52 samples whereas 
BCSA enabled the recovery of a pure culture of NTM from only two samples. 
 
Figure 2-21: RGM medium demonstrating the visual appearance of both 
smooth and rough colonies of M. abscessus subspecies abscessus 
 
Figure 2-21 demonstrates the growth on RGM medium of rough M. abscessus 
subspecies abscessus colonies (left), smooth M. abscessus subspecies 
abscessus colonies (centre), and a combination of both rough and smooth 
colonies (right), which upon typing have the same VNTR profile. 
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2.5.11 Investigation of RGM medium for sputum samples of control group 
patients with non-cystic fibrosis bronchiectasis and cystic fibrosis transplant 
assessment patients 
Out of 310 bronchiectasis patients, NTM was recovered from 4.5% (n = 14) of 
patients with 1.3% of patients (n = 4) harbouring M. abscessus subsp. abscessus. 
Furthermore 6.7% (n = 4) of transplant assessment patients were positive for NTM, 
with 1.7% (1 patient) having both M. abscessus subsp. abscessus and M. neoaurum 
(See Table 2-).  
Of the 400 bronchiectasis samples, 385 were negative for NTM (96.3%), as were 
61/67 (91.0%) transplant assessment samples. As a result of this evaluation, one 
bronchiectasis patient was reviewed, and after undergoing genetic testing was 
diagnosed with CF for the first time at the age of 71.  
 
Table 2-10: Number of NTM-positive samples from bronchiectasis and 
transplant assessment samples 
Species  Positives (n) Patient (n) 
Bronchiectasis   
M. abscessus subsp. abscessus 5 4 
M. chelonae 7 7 
M. mucogenicum 3 3 
Transplant Assessment   
M. abscessus subsp. abscessus 2 1* 
M. chelonae 1 1 
M. neoaurum 1 1* 
M. species 2 2 
*Patient co-infected with both M. abscessus subsp. abscessus and M. neoaurum 
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2.5.12 Evaluation of RGM medium for optimal growth of Mycobacterium 
tuberculosis complex and other slow-growing mycobacteria in broth-based 
culture medium  
Although results were comparable in terms of isolation of slow-growing 
mycobacteria, the TTD was not as rapid using broth-based RGM as shown in Table 
2-11 below. 
 
Table 2-11: Results of 44 AFB positive bottles inoculated with non-CF samples 
 Total 
positive 
samples 
Bottle A 
positive 
samples 
Mean Time 
to 
Detection 
(days) 
Bottle B 
positive 
samples 
Mean Time 
to 
Detection 
(days) 
 
M. tuberculosis 17 17 10.8 16 13.9 
M. avium 14 11 9.7 12 10.5 
M. intracellulare 2 2 6.2 2 7.9 
M. malmoense 2 2 15.7 2 18.6 
 
In treated samples from CF patients, MABSC was detected in more of the RGM 
(bottle B) based bottles (6/56) than in the traditional (bottle A) MBacT bottles (3/56). 
A significant improvement was apparent in the rates of contamination of non-
mycobacterial species being considerably reduced as well as the TTD of MABSC in 
these samples (Table 2-12). 
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Table 2-12: Recovery of mycobacteria from 56 pairs of MBacT bottles 
inoculated with treated samples from patients with CF 
 Positive  
samples 
Time to detection 
(days) 
Contaminated 
bottles 
 MABSC M. avium M. abscessus M. avium Number Rate (%) 
Bottle A (soda 
treated 
sample) 
 
3 0 9.0 - 20/56 36 
Bottle A (acid 
treated 
sample) 
 
2 0 5.0 - 13/56 23 
Total Bottle A 
 
3 0 - - - 29 
Bottle B (soda 
treated 
sample) 
 
2 1 5.2 21.0 4/56 7 
Bottle B (acid 
treated 
sample) 
 
6 0 4.2 - 3/56 5 
Total Bottle B 
 
6 1 - - - 6 
TOTAL 6 1     
 
This was also evident across the slopes, with LJ slopes (Table 2-13) showing a 
dramatically higher rate overall of non-NTM contaminating species at both 
temperatures and after all decontamination treatments. The highest rate of NTM 
recovered was on the untreated 30oC RGM slopes at 13.9%. Although these also 
showed a contamination rate of 17.6%, it was very easy to visualise the NTM on the 
slope in comparison to the non-NTM species due to the colour difference. 
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Table 2-13: Percentage contamination of samples from patients both with CF 
and non-CF and percentage of NTM isolated using RGM and LJ slopes at 21 
days incubation at 30oC and 37oC 
 % Contamination % NTM isolated 
Soda Treated Samples 30oC   
RGM 2.8 4.6 
LJ 28.7 1.9 
   
Soda Treated Samples 37oC   
RGM 1.9 1.9 
LJ 25.9 1.9 
   
Acid Treated Samples 30oC   
RGM 2.8 8.3 
LJ 18.5 3.7 
   
Acid Treated Samples 37oC   
RGM 5.6 1.9 
LJ 14.8 3.7 
   
Untreated Samples 30oC   
RGM 17.6 13.9 
   
Untreated Samples 37oC   
RGM 4.6 7.4 
   
   
   
It was impractical to perform a direct comparison of RGM medium with standard 
AFB culture as specimens were submitted for standard AFB culture infrequently. 
For example, for the 33 patients who were found to harbour mycobacteria in this 
study (i.e. using RGM plus BCSA as described in section 2.4.10), specimens were 
only submitted for standard AFB culture for ten of these patients (30%) during the 
8-month trial period and only six of these yielded mycobacteria (18%). Equally, for 
the 177 patients that were found not to harbour mycobacteria, only 22 patients 
(12%) had specimens referred for standard AFB culture during the 8-month trial 
period. Of these 22 patients, mycobacteria was only recovered from one patient (M. 
abscessus subsp. abscessus).  
In a 15-month period where RGM medium was used routinely at the Freeman 
Hospital, Newcastle upon Tyne, 4408 respiratory samples collected from 625 
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patients, both adult and paediatric, with CF were cultured onto RGM medium and 
incubated up to ten days (Table 2-14). AFB culture was continued for those patients 
who spontaneously produced sputum. Upon analysis of these patients, only 213 
(34%) actually had AFB cultures requested, and 73 (15.5%) were contaminated and 
abandoned therefore no report could be issued with regard to the isolation of 
mycobacteria. NTM was only detected in 21 patients, in comparison to 56 patients 
with the routine use of RGM medium.  
RGM medium was able to recover NTM from cough swabs as well as sputum 
samples, and although the yield was lower (1.9%), NTM was detected for the first 
time by cough swab culture in 15 patients. 
 
Table 2-14: Comparison of RGM medium and formal AFB culture for the 
recovery of NTM from respiratory samples from patients with CF over a 15-
month period 
 
Total 
 
 
Sputum Other 
Patients tested 
using RGM 
medium 
(10 day 
incubation) 
Patients 
tested using 
formal AFB 
culturea 
 4408 2443 1557 408 625 213 
Total 
mycobacteria 
195 46 133 16 56 21b 
M. abscessus 
complex 
168 40 114 14 34 13 
M. chelonae 10 2 8 0 9 3 
M. fortuitum 2 0 2 0 1 0 
M. avium complex 0 0 0 0 0 6 
Other mycobacterial 
species 
15 4 9 2 12 0 
a 469 samples cultured from 213 patients using culture on LJ medium plus automated liquid culture 
b Two different Mycobacterium spp. Isolated from one patient sample 
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Studies have also been completed comparing RGM medium (minus 
decontamination of samples) against the gold standard MGIT method using 
decontaminated samples with one study in London, UK showing a ten-day 
incubation period of RGM was equivalent to MGIT for the recovery of NTM (P = 
1.00). Another evaluation performed in Chapel Hill, USA demonstrated that with an 
incubation period of 28 days, the sensitivity of RGM medium for the isolation of 
mycobacteria was significantly higher than combined MGIT/LJ with a P value of (P 
= 0.001) for total mycobacteria including M. avium, and (P = 0.046) for MABSC only.
2.5.13 Summary of studies in other centres using RGM medium for the 
isolation of NTM from patients with cystic fibrosis 
An evaluation similar to the one described in section 2.4.16 was performed in 
Frankfurt, Germany, and showed that RGM was significantly more sensitive than 
BCSA (P = 0.023) (Preece et al., 2016). A further study in Chapel Hill. USA 
demonstrated that from 869 samples incubated for up to 28 days also provided a 
significantly higher sensitivity for RGM medium (P = <0.0001) (Plongla et al., 2016). 
Both of these studies compared RGM against a brand of B. cepacia medium (Table 
2-15).  
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Table 2-15: Summary of studies using RGM medium for the isolation of NTM from respiratory samples from patients with CF 
Study Location No. of specimens 
/ No. of patients 
Prevalence of NTM (%) Method used Decontamination Sensitivity (5) P 
Newcastle upon Tyne, UK 502 / 210 15.7% RGM  
10 days incubation 
 
BCSA  
10 days incubation 
None 
 
 
 
None 
98.0 
 
 
 
32.0 
 
 
≤0.0001 
 
 
 
Frankfurt, Germany 224 / 133 9.0% RGM  
10 days incubation 
 
BCSA  
10 days incubation 
None 
 
 
 
None 
100 
 
 
 
41 
 
 
 
0.023 
Chapel Hill, USA 869 / 493  RGM  
28 days incubation 
 
BCSA  
28 days incubation 
None 
 
 
 
None 
96.9 
 
 
 
34.7 
 
 
 
<0.0001 
London, UK 187 / 187 15% RGM  
10 days incubation 
 
MGIT  
28 days incubation 
None 
 
 
 
3% oxalic acid 
82 
 
 
 
86 
 
 
 
1.00 
Chapel Hill, USA 212 / 172 24.1% RGM  
28 days incubation 
 
MGIT / LJ medium  
6 weeks incubation 
None 
 
 
 
NALC-NaOH then 5% oxalic acid 
93.2 
 
 
 
47.7 
 
 
 
0.0001 
Aarhus, Denmark 97 / 86 Sample size too small, 
only 1 MABSC isolated 
during test period 
RGM  
14 days incubation 
 
BCSA  
14 days incubation 
None 
 
 
 
None 
Only 1 MABSC 
isolated during 
test period, on 
both RGM and 
BCSA 
 
 
 
N/A 
Cambridge, UK 564 / 
environmental 
samples 
- RGM  
10 days incubation 
 
PANTA* 
10 days incubation 
None 
 
 
 
None 
100.0 
 
 
 
14.0 
 
 
 
 
0.04 
* PANTA solid agar plates made in house at Papworth Hospital, Cambridge, UK and contains Middlebrook 7H11 Agar   (Difco Mycobacteria 7H11 Agar - BD ) with PANTA Antimicrobial  Supplement  (Becton, Dickinson and Company) at final antibiotic 
concentrations as follows; Polymyxin B 30units/ml, Amphotericin 3µg/ml, Nalidixic Acid 12µg/ml, Trimethoprim    3µg/ml and Azlocillin 3µg/ml. 
Studies performed in Nijmegen, The Netherlands; Bron, France and Lyon, France were too small and an insignificant number of MABSC isolates were isolated to validate any substantial results. 
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2.6 Discussion 
Annual screening for NTM is recommended in patients who spontaneously produce 
sputum, with the suggested methodology from the CF Foundation and the European 
Cystic Fibrosis Society comprising of decontamination of sputum samples using N-
acetyl-L-cysteine (0.5%)-NaOH (2%), or upon a sample remaining contaminated, it 
should be further treated with either 5% oxalic acid or 1% chlorohexidine (Floto et 
al., 2016). Staining of sputum smears for acid-fast bacilli and culture on both solid 
and liquid media for a minimum of six weeks is also recommended. The use of 
oropharyngeal swabs should be avoided, due to insufficient material for culture 
(Saiman et al., 2014). Transbronchial biopsies are to be circumvented if possible as 
although they can reveal NTM in culture or microscopy and exhibit granulomatous 
inflammation there is a substantial risk of bleeding and pneumothorax occurring. 
Preference should be given to sputum, induced sputum, bronchial washings or 
bronchial lavage samples. Updated evidence-based draft guidelines on the 
Management of Non-tuberculous Mycobacteria in individuals with Cystic Fibrosis 
have recently been published (Floto et al., 2016). 
The limitations of these methods are highlighted in these guidelines and include a 
significant reduction in the viability of mycobacteria due to the decontamination 
process, or only limited elimination of non-mycobacteria requiring further rounds of 
decontamination (De Bel et al., 2013). The method is both costly and labour 
intensive. It is suggested that the currently used and most sensitive method 
following decontamination is an automated growth detection system such as MGIT, 
with simultaneous culture on solid media to possibly increase the diagnostic yield. 
The potential use of BSCA is highlighted in these guidelines, but not overtly 
recommended. 
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There is currently no explicit culture medium for the sole isolation of rapidly-growing 
mycobacteria, as in the case of B. cepacia complex despite the fact that the 
prevalence of rapidly-growing NTM may be considerably higher, as illustrated by 
this study where 54 isolates of mycobacteria were recovered on RGM medium 
(Table 2-8) compared with 30 isolates of B. cepacia complex recovered using BCSA 
(Table 2-9). One reason for this may be the lack of a convenient, rapid and effective 
method for isolation of rapidly-growing NTM. RGM medium provides a simple and 
convenient technique that can be implemented for the culture of all routinely 
submitted sputum samples from patients with CF. Such methodical screening will 
ensure that diagnosis of a significant infection with NTM is not unreasonably 
hindered. For example, a positive sputum culture for MABSC is more likely to 
indicate the presence of NTM-mediated lung damage rather than asymptomatic 
colonization (Seddon et al., 2013; Floto and Haworth, 2015) and multiple positive 
cultures despite treatment is associated with a poor outcome (Esther et al., 2010; 
Qvist et al., 2015). Additionally, routine screening of all submitted sputum samples 
from CF patients may assist in prompt identification of risk factors leading to 
acquisition, subsequent infection and transmission of NTM (Bryant et al., 2013). Any 
screening method may lead to the detection of transient colonisation with 
mycobacteria that may have no clinical significance. This can be problematic, as 
patients may be assumed to be infected and may be unnecessarily segregated from 
other patients. This problem can be alleviated largely by prompt species 
identification of the isolate (Blauwendraat et al., 2012; Harris and Kenna, 2014) to 
assess likely pathogenicity and, wherever possible, prompt submission of further 
sputum samples. 
As media for isolation of B. cepacia complex have been suggested for isolation of 
mycobacteria, this prompted an investigation of different commercial brands of 
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Cepacia selective media in order to compare their ability to support the growth of 
mycobacteria and their selectivity against other bacteria associated with sputum 
samples from CF patients. Cepacia selective agar (bioMérieux; 44347) was at least 
as effective for culture of pure strains of mycobacteria as any other Cepacia 
selective agar (Table 2-7). It was less selective than some other agars and much of 
this could be attributed to lack of inhibition of methicillin-resistant S. aureus. Cepacia 
selective agar was less selective than bioMérieux BSCA but more selective than BD 
OFPBL. 
In 1985, Gilligan et al. were the first to report the design of a selective culture 
medium for B. cepacia, PC medium, for use with sputum samples from patients with 
CF (Gilligan et al., 1985). This medium comprised of polymyxin B, ticarcillin, crystal 
violet and bile salts as selective agents, many of which are frequently used in 
commercial brands. At around the same time, Welch et al. evaluated the use of 
OFPBL medium, exploiting the use of polymyxin B and bacitracin as selective 
agents (Welch et al., 1987). In addition, over a decade later, Henry et al. described 
B. cepacia selective agar (BCSA) that was shown to have superior selectivity when 
compared to PC medium and OFPBL medium. In this medium, polymyxin B and 
crystal violet were retained as selective agents with the addition of gentamicin and 
vancomycin (Henry et al., 1997). In a large trial with 656 clinical samples, Henry et 
al. concluded that BCSA was superior to both OFPBL and PC medium for 
supporting the growth of B. cepacia and suppressing the growth of other flora (Henry 
et al., 1999). In this study the high selectivity of BCSA is confirmed, demonstrating 
much more selectivity than OFPBL, however, six isolates of BCC were inhibited 
using BCSA. 
The growth rate of mycobacteria is slower than most if not all of the other bacterial 
and fungal isolates frequently recovered from sputum samples from patients with 
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CF. For this reason, high selectivity of media is vital in order to inhibit or at least 
restrict the growth of non-mycobacteria so that the mycobacteria do not go 
undetected due to overgrowth by other species. Although BCSA was the most 
selective of the agars designed for recovery of BCC, it was much less selective than 
RGM medium. If BCC is excluded (as BCSA is designed to grow this), 24 non-
mycobacteria were able to grow on BCSA compared with only six on RGM medium. 
A particular flaw of selective agars for BCC is their failure to inhibit fungi, particularly 
Aspergillus species. On extended incubation of these media, the growth of 
Aspergillus can consume the entire culture plate, thus compromising the likelihood 
of isolating mycobacteria. This is particularly problematic with sputum samples from 
CF patients where concomitant isolation of Aspergillus sp. has been frequently 
associated with mycobacteria infection (Esther et al., 2010; Verregghen et al., 2012) 
Middlebrook 7H11 selective agar, designed specifically for the isolation of 
mycobacteria, was superior at inhibiting fungi due to the inclusion of amphotericin. 
However, species such as Aspergillus terreus and Scedosporium apiospermum 
persisted and largely the selectivity of Middlebrook 7H11 selective agar was inferior 
to that of bioMérieux BCSA and Oxoid B. cepacia agar. In contrast, no yeasts or 
fungi were able to grow on RGM medium. From this analysis, it can be concluded 
that RGM medium offers a superior option to any of the other selective agars for 
isolation of rapidly-growing mycobacteria from the sputum of patients with CF.  
Under existing guidelines (Floto et al., 2016) NTM may be undetected for up to a 
year, and occasionally longer if successive conventional cultures are compromised 
by frequent contamination.  
In conclusion, it is proposed that routine systematic use of RGM medium could 
expedite a greater understanding of the true prevalence and clinical significance of 
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rapidly-growing mycobacteria in patients with CF. The superior sensitivity of RGM 
medium over recognised AFB culture strongly supports the proposal that 
decontamination of samples will have an adverse effect upon the viability of 
mycobacteria, as previously described in section 1.9.3. The use of this medium can 
easily be incorporated into any laboratory alongside routine culture for other CF 
pathogens without any requirement for the laborious decontamination of samples 
and potentially facilitate a considerable saving in both labour time and materials cost 
of replacing formal AFB culture. NTM were detected in over twice as many patients 
by performing routine investigation with RGM medium and it is probable that this 
would have been additionally increased with prolonged incubation of up to 28 days.  
Burkholderia cepacia complex is routinely screened for in patients with CF, yet the 
results of the studies completed in Table 2-9 confirm that NTM was isolated at a 
much greater rate than B. cepacia complex so it would seem irrational that screening 
for NTM is only recommended annually. 
This method however will not preclude the need to perform annual screening using 
conventional mycobacterial culture methods, as slow-growing mycobacteria such 
as M. avium may not be consistently detected. However, the existing evidence 
validates the significant potential of such a highly selective medium for the isolation 
of NTM from patients with CF. 
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3. Introduction: Chapter 3 
3.1 Current methods of identification of Mycobacterium abscessus 
complex 
MABSC and M. chelonae are closely related species that cannot always be 
differentiated by clinical laboratories, and prior to 1992, they were thought to be the 
same organism or subspecies within the M. chelonae-abscessus group (Kusunoki 
and Ezaki, 1992). This is particularly problematic as they cause infections requiring 
diverse treatment regimens, with M. chelonae not notably as clinically significant if 
isolated from a patient sample. MABSC however is increasingly acknowledged as a 
substantial cause of lung infection in cystic fibrosis (CF) patients (Esther et al., 
2005), particularly M. abscessus subsp. abscessus, with many CF centres rejecting 
patients colonised with MABSC for lung transplant (Watkins and Lemonovich, 
2012).  
Accurate identification can be accomplished by PCR and sequencing of 
housekeeping gene targets, as previously discussed in section 1.9.6, however many 
reports in the literature describe ambiguous sequencing results from isolates that 
have chimeric house-keeping gene sequences. This is possibly as a result of 
horizontal gene transfer and recombination, which further highlights the difficulties 
in accurate identification and differentiation of these three subspecies (Zelazny et 
al., 2009; Macheras et al., 2014b). 
3.2 Direct observation of non-tuberculous mycobacteria in culture 
medium  
Mycobacteria are grouped according to speed of growth as either rapidly-growing 
mycobacteria or slow-growing mycobacteria. The formation of visible colonies on 
culture media in less than seven days constitutes “rapid” growth, (e.g. as shown by 
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M. abscessus), whilst those necessitating more than seven days are known as slow-
growing, (e.g. M. avium). In general mycobacteria form either rough or smooth 
white/cream coloured colonies, although many species can, like M. kansasii, 
produce pigment generating bright yellow colonies (Lima and Magalhaes, 2014). 
Many rapidly-growing species can grow on MacConkey agar without crystal violet, 
whereas M. tuberculosis and M. bovis do not have this capability, and M. abscessus 
is noted as having the ability to grow in media with 5% sodium chloride. LJ medium 
supplemented with a concentration of 250 mg of hydroxylamine can distinguish 
between NTM and other species of mycobacteria for example M. bovis as NTM do 
not have the capacity to grow in the presence of hydroxylamine. Rapidly-growing 
mycobacteria excluding M. chelonae can grow on Sauton picric medium and Sauton 
agar with 0.2% picric acid (Garcia-Agudo et al., 2011). 
3.3 Biochemical tests used in identification of mycobacteria 
Biochemical tests, such as citrate utilisation or tolerance to sodium chloride, are 
simple to perform, require minimal equipment, and in general are able to correctly 
differentiate between the more common mycobacterial species. Nonetheless, they 
are laborious and due to lengthy incubation times present a delay in final 
identification. Other methods based on mycolic acid analysis, for example high 
performance liquid chromatography and gas liquid chromatography, are challenging 
and costly. Experience in interpretation is essential, and can be limited by 
subjectivity and low specificity. Biochemically unreactive or inert organisms can be 
difficult to identify and phenotypic misidentification can occur due to species 
homogeneity, variability, and the increasing recovery of novel species (Springer et 
al., 1996; Tortoli et al., 2001).  
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At present, there are almost 200 currently established species, a number that 
continues to rise, and in general, biochemical algorithms will only differentiate 
around twenty species. This therefore makes this approach too complex, resulting 
in a characteristic preference towards the more familiar species (Kent and Kubica, 
1985). Despite these challenges, phenotypic methods are still used in some 
laboratories to identify NTM regardless of their recognised limitations. 
3.4 Genotypic methods for the identification of Mycobacterium 
abscessus complex 
The use of nucleic acid probes is a prompt and extensively used procedure for 
identification, however as such a small range of mycobacterial species are covered, 
there are well documented concerns regarding specificity and sensitivity (Lim et al., 
1991; Bull and Shanson, 1992; Viljanen and Olkkonen, 1993). 
The earliest commercially available method was the Gen-Probe AccuProbe (Gen-
Probe Inc.), and more recently, the INNO-LiPA MYCOBACTERIA v2 (Innogenetics 
NV, Ghent, Belgium), Geno-Type MTBC and Genotype Mycobacterium (Hain 
Lifesciences, Nehren, Germany). INNO-LiPA Mycobacteria v2 is still quite 
antiquated in that it integrates M. abscessus and M. chelonae into M. chelonae 
complex (Garcia-Agudo et al., 2011), and as discussed in section 1.9.6, none of 
these kits are not able to identify individual members of the MABSC (Reisner et al., 
1994). 
3.5 Molecular typing of Mycobacterium abscessus complex isolates 
Differentiation of MABSC isolates has been performed using various molecular 
techniques; including variable number tandem repeat (VNTR) analysis, whole 
genome sequencing, multilocus sequence typing (MLST) and multispacer sequence 
typing (MST), pulsed field gel electrophoresis and rep-PCR. 
128 
 
3.5.1 Variable number tandem repeat  
VNTR is a rapid and convenient PCR-based technique targeting variation in tandem 
DNA repeats at specified loci, generally between nine and fifteen, with a numerical 
profile created that is based upon the number of repeats at each locus. This method 
has been successfully used for the differentiation of M. tuberculosis strains for many 
years (Mazars et al., 2001), but is not as well established for MABSC and there are 
varying reviews of its success and accuracy in being able to separate M. abscessus 
complex isolates. A two-tandem repeat locus was demonstrated by Choi et al. 
(2011), which was reported to be able to split the three members of MABSC in 
eighty-five clinical isolates that were all initially identified as M. abscessus subsp. 
abscessus by PCR-restriction fragment length polymorphism analysis of rpoB. 
Using this method, if there is one band on the gel an identification of M. abscessus 
subsp. massiliense is given. If two amplification bands are displayed, they were 
either M. abscessus subsp. abscessus (>393 bp) or M. abscessus subsp. bolletii 
(393 bp), and if there was a single band of >393 bp in length, the result was 
interpreted as M. abscessus subsp. abscessus (Choi et al., 2011). Wong et al. 
described a VNTR assay for M. abscessus complex declaring complete 
reproducibility in 38 clinical isolates (Wong et al., 2012) previously all identified as 
M. abscessus by PCR and HAIN Genotyping (Telenti et al., 1993). A further study 
in 2012 by Harris et al. however performed a comparison of VNTR with the 
Diversilab rep-PCR method and demonstrated that the patients were infected with 
isolates which shared a limited number of VNTR profiles, suggesting the possibility 
of cross contamination having occurred, or a possible mutual environmental source 
of infection (Harris et al., 2012). 
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3.5.2 Rep-PCR for the identification of mycobacteria 
Rep-PCR uses PCR primers that will amplify repetitive sequences in the genome in 
order to give a profile (Healy et al., 2005). A relatively basic commercial kit from 
Diversilab, (bioMerieux) can be used in routine diagnostics, however reports are 
unclear as to whether this method provides representation of same strain isolates, 
or if they are in fact just highly related strains when identical rep-PCR profiles are 
obtained (Harris et al., 2012). 
3.5.3 Multilocus sequence typing and multispacer sequence typing 
MLSA is a previously described technique for the identification of M. abscessus 
isolates to subspecies level (Macheras et al., 2011). Multilocus sequence typing 
(MLST) is an extension of the MLSA method however, a greater number of house-
keeping gene targets are sequenced for MLST, usually around eight. Although 
reproducible and not requiring substantial amounts of DNA, the sequences of the 
house-keeping targets used are well conserved in M. abscessus complex, therefore 
MLST does not provide discrimination of the three subspecies (Macheras et al., 
2014a). Multispacer sequence typing (MST) is a PCR and sequence based 
technique that targets intergenic spacers, which are more variable than the 
housekeeping genes in MLST therefore this technique may offer improved 
discrimination. A recent study described the development of this MST scheme for 
identification of M. abscessus complex and is able to discriminate between the three 
subspecies when combined with phylogenetic analyses (Sassi et al., 2013). 
3.5.4 Whole genome sequencing 
Whole genome sequencing (WGS) provides the most comprehensive technique in 
order to analyse the entire genome. It provides rapid and accurate microbial genome 
sequence information, which is crucial for detecting mutations, discovering 
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significant deletions or insertions, and ascertaining other genetic changes among 
microbial strains. It can also provide an insight into whether cross contamination is 
an issue  as conflicting information has frequently been described (Bryant et al., 
2013; Davidson et al., 2013; Harris et al., 2015).The high degree of resolution 
provided by WGS allows for much finer discrimination of strains than any of the other 
current or previous methodologies.  
3.6 Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) 
As an alternative to chromatographic, biochemical or molecular methods, mass 
spectral analysis has become progressively more widespread for the identification 
of microorganisms (Lau et al., 2014). MALDI-TOF MS can be used for accurate and 
speedy identification of innumerable microorganisms. This technique is based upon 
the detection of highly abundant proteins in a mass range between 2 and 20 kDa by 
computing their mass (m) to charge (z), m/z values generating a characteristic 
spectrum for each microorganism. This can then be used for comparison with stored 
reference spectra and in so doing providing identification of the isolate (Panda et 
al., 2013).  
3.6.1 Principles of MALDI-TOF MS 
MALDI-TOF MS measures a unique molecular fingerprint, specifically the proteins 
found in all microorganisms (Singhal et al., 2015). The distinguishing patterns of 
these extremely abundant proteins can consistently and accurately identify a 
particular microorganism by matching its individual pattern with an extensive 
database to determine the identity to species level. This system is highly accurate 
with a rapid turnaround time and high throughput (96 samples per run) and is cost 
effective. Its ease of use and versatility does not require extensive training for 
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laboratory workers (Marvin et al., 2003). Limitations can however include the need 
for isolated pure colonies, a fresh culture, and on occasions an inability to 
differentiate between closely related organisms and repeat analysis may be required 
(Dhiman et al., 2011). Once the inoculum is dried, the matrix is added. Once this is 
dried the prepared target plate is placed into the ionization chamber where each 
sample is irradiated with momentary pulses of energy from an ultraviolet nitrogen 
laser (337 nm). This process desorbs individual sample and matrix molecules from 
the target plate into the gas phase, with the majority of energy absorbed by the 
matrix, which becomes ionized with a single positive charge. This positive charge is 
consequently transferred from the matrix to native sample proteins through their 
random collision in the gas phase. The ionized proteins are funnelled through a 
positively charged, electrostatic field that accelerates the molecules into the time of 
flight (TOF) mass analyser. The TOF chamber is an empty, pressurized tube that 
allows ions to travel down a field-free region toward the ion detector. The speed at 
which individual ions move through the TOF chamber is dependent on their mass-
to-charge ratio and ions are ultimately separated based on their difference in mass. 
Heavier ions will travel through the mass analyser at a slower velocity than lighter 
ions and as they emerge, they collide with the ion detector, which measures their 
charge and time to impact. Based on standards of known mass, the time to impact 
for each unknown analyte is converted into a mass-to-charge ratio, which is 
illustrated on a mass spectrum. As each spectral profile is attained, the software 
automatically generates a MALDI-TOF spectrum that is matched against a 
reference database in order to provide identification alongside a score value. Using 
a biostatistical algorithm the peak list is compared to reference peaks of organisms 
in the reference database and a log (score) value is given between 0.00 and 3.00. 
The higher the log (score) value, the higher the degree of similarity to a given 
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organism, with values of ≥2.00 indicating a high probability of correct identification 
at the suggested species level (Bruker, 2015). 
3.6.2 The use of MALDI-TOF in the identification of Mycobacterium 
abscessus complex  
Although MALDI-TOF MS has been shown to be a highly accurate method for 
identifying mycobacterial  isolates to species level, this technique has not been 
shown to be able to successfully differentiate between the three subspecies of 
MABSC (Saleeb et al., 2011; Balada-Llasat et al., 2013). A report by Teng et al. 
(2013) suggested that this was achievable, however this report also claimed that M. 
abscessus subsp. bolletii was currently the correct taxonomic name for M. 
abscessus subsp. massiliense and only a limited number of isolates (n = 58) were 
tested. Other reports suggest that although M. abscessus subsp. massiliense can 
be differentiated from M. abscessus subsp. abscessus and M. abscessus subsp. 
bolletii, the latter too are too closely related to be differentiated by MALDI-TOF MS 
(Fangous et al., 2014; Suzuki et al., 2015; Luo et al., 2016).  
3.7 The use of chromogenic and fluorogenic substrates in culture 
media 
Enzymes are present in all microorganisms in vast numbers with quantities and 
varieties produced differing between species and often also between strains. All 
species of bacteria possess a unique enzyme profile comprising of a number of 
enzymes required for growth, nutrition and replication and this differentiation permits 
an appropriate means of identification (Bascomb and Manafi, 1998). 
The biochemical activity within bacteria is known as metabolism, and the majority of 
these biochemical reactions do not transpire spontaneously, but are catalyzed by 
enzymes accelerating the chemical reaction without undergoing any permanent 
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modification themselves (Chubukov et al., 2014). Without enzymes, these reactions 
would be at a rate that was too slow. Many enzymes necessitate the presence of 
other compounds, known as cofactors in order to exert their catalytic activity and 
one property of enzymes that makes them so significant as a diagnostic tool is the 
specificity they exhibit. Certain enzymes require a particular type of bond (linkage 
specificity) or functional group (group specificity), whereas others will only catalyze 
one reaction (absolute specificity), or only act upon a particular steric or optical 
isomer (stereochemical specificity) (Rago et al., 2015).  
Several fluorogenic and chromogenic reactions have been used for detection of 
bacteria. Fluorogenic methods exploit synthetic substances, such as those based 
on 4-methylumbelliferone (4-MU) or 7-amino-4-methylcoumarin (7-AMC) that are 
hydrolysed by bacterial enzymes to release powerful fluorophores. This will produce 
an increase in fluorescence attributable to enzymatic activity (Dyer, 1970), a  
fluctuation in fluorescence or absorbance of a pH indicator (Goodwin and Kavanagh, 
1950), or a change of intensity of fluorescence as a result of adsorbance of 
fluorescent dye within the bacterial cell (Ramsey et al., 1980).  
Hydrolysis of esculin to glucose and esculetin (6,7 dihydroxycoumarin) and 
detection of esculetin by its reaction with iron was first described in bacteria by 
Meulen in 1907 (Ter Meulen 1907, cited in Harrison and van der Leck 1909). This 
reaction was then incorporated into esculin medium to examine water for the 
presence of coliforms by Harrison and van der Leck in 1909 (Harrison and Van Der 
Leck, 1909). 
3.8 Enzyme substrates 
Enzymatic substrates are fundamental tools in biochemistry and are extensively 
used in microbiology to study metabolic pathways, observe metabolism and to 
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detect, count and identify microorganisms. Rapid detection and identification of 
microorganisms is particularly important in microbiology and both chromogenic and 
fluorogenic substrates have proved to be a powerful aid, utilising specific enzymatic 
activities of particular microorganisms, either in conjunction with or as an alternative 
to traditional methods (Maddocks and Greenan, 1975; Manafi and Kneifel, 1991). 
By incorporation of these substrates into primary selective media, colony counts and 
detection can be achieved directly on the isolation plate. The introduction of many 
of these media and identification tests has led to enhanced accuracy and more rapid 
detection of target organisms, frequently decreasing the need for isolation of pure 
cultures and supplementary confirmatory tests (Gee et al., 1999). 
Glycosidases catalyse the hydrolysis of glycosidic linkages, and in so doing degrade 
oligosaccharides and glycoconjugates. These effective and very specific catalysts 
are crucial in biological processes therefore a comprehensive knowledge of their 
function is instrumental in regulating disease (Falk et al., 1990). Peptidases are 
enzymes that catalyse the cleavage of proteins into both shorter fragments, as well 
as into their component amino acids with two major groups being endopeptidases, 
targeting sites within the proteins and exopeptidases, cleaving terminal ends of 
proteins (van Roosmalen et al., 2004). Esterases catalyse the hydrolysis of an ester 
bond into its acid and alcohol. They catalyse three types of reaction; esterification, 
interesterification and transesterification (Xiang et al., 2007). As they do not require 
cofactors, this makes them attractive biocatalysts. Chromogenic substrates allow 
the rapid and simple identification of microorganisms in clinical samples, and when 
exploited in a culture medium can decrease the need for time consuming and labour 
intensive subcultures and biochemical tests (Perry and Freydiere, 2007). 
Developed in 1908 by Wohlgemuth, the first enzyme assay for the detection of 
amylase activity was using starch and iodine (Wohlgemuth, 1908). Maltose 
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disaccharides are produced when amylase catalyses the hydrolysis of starch and a 
colour change of the iodine from dark brown to yellow occurs.  
Chromogenic substrates are molecules designed to imitate metabolic substrates 
and are colourless until they are cleaved by the target enzyme (Perry and Freydiere, 
2007). Once cleaved the released chromogen is usually insoluble and brightly 
coloured. Colonies that possess the enzyme can then be simply differentiated from 
those that do not possess the enzyme. The addition of chromogenic substrates into 
a selective culture medium can allow differentiation and identification of groups of 
bacteria.  
The first commercially available culture medium that utilised a synthetic 
chromogenic substrate was Rambach agar, which uses a chromogenic substrate 
for β-galactosidase known as X-Gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside). Composed of propylene glycol, peptone, yeast extract, sodium 
deoxycholate, neutral red and Xgal, upon incubation at 37oC for 24 hours, 
Salmonella spp will ferment the propylene glycol to generate acid causing 
precipitation of the neutral red and consequently producing colonies with a 
characteristic red colour (Rambach, 1990). 
The chromogenic substrate (X-gal) will facilitate the most common 
Enterobacteriaceae to produce blue or violet colonies whereas most species that 
fail to produce ß-galactosidase (e.g. Proteus spp.) remain colourless. The inhibition 
of Gram-positive microorganisms in the sample is attributed to the sodium 
deoxycholate in the medium. There is a disadvantage to this medium in that it does 
not detect Salmonella typhi, Salmonella paratyphi or some rare strains such as 
Salmonella wassenaar and Salmonella moscow. Additionally, some Salmonella 
strains are able to produce β-galactosidase, for example Salmonella arizonae, 
therefore show as blue/violet colonies on the medium (Manafi, 1996). 
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The most widely used chromogenic substrates are those based on indoxyl or its 
halogenated derivatives such as 5-bromo-6-chloro-indoxyl (forms a magenta dye) 
or 6-chloro-indoxyl (forms a rose pink dye) (See Figure 3-1 below) and their 
popularity is due to their heat resistance, water solubility and their predisposition to 
form strongly coloured indigo-based precipitates upon enzymatic action (Perry and 
Freydiere, 2007).  
 
   
(i) (ii) (iii) 
Figure 3-1: Structure of indoxyl (i) and it halogenated derivatives (ii) 5-bromo-
6-chloro-indoxyl and (iii) 6-chloro-indoxyl 
 
The fluorogenic enzyme substrates used for bacterial detection largely consist of 
derivatives of coumarin, such as 4-methylumbelliferone (4-MU or 7-hydroxy-4-
methylcoumarin) or 7-amino-4-methylcoumarin (7-AMC), (Chilvers et al., 2001), the 
structures of which are shown in Figure 3-2. This is due to the accessibility of an 
extensive range of substrates with diverse metabolic moieties, their non-
carcinogenicity, simplicity of visual detection of the products of enzyme activity with 
UV light sources, and availability of appropriate tools for measurement of 
fluorescence (Manafi et al., 1991). 
The use of fluorogenic substrates for bacterial enzyme detection  was first described 
by Dyer (1970) followed by Dahlen and Linde (1973) who employed an agar plate 
containing the enzyme substrate, 4-methylumbelliferyl-β-D-glucuronide, in order to 
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detect β-glucuronidase activity in microorganisms (Dahlen and Linde, 1973). 
Maddocks and Greenan (1975) subsequently described a ten minute spot test using 
4-MU derivatives outlining a simplistic and rapid alternative to standard biochemical 
tests   and Fujiwara and Tsuru (1978) were the first to use 7-AMC derivatives for the 
measurement of bacterial peptidases (Fujiwara and Tsuru, 1978). 
 
 
 
 
 
 
 
(i)  (ii) (iii) 
Figure 3-2: Structures of fluorescent core molecules (i) coumarin (ii) 7-amino-
4-methylcoumarin (iii) 4-methylumbelliferone 
 
Substrates based on such fluorophores are non-fluorescent when conjugated to a 
metabolically active moiety, for example glucose, and upon hydrolysis the aglycone 
is cleaved from glucose, freeing up the electrons at the hydroxyl group and altering 
the molecule so that it yields a bright blue fluorescent light under UV light at an 
excitation wavelength of 365 nm and emission wavelength of 445 nm (Haughland, 
1996). 
These substrates are more suitable when used in liquid assays, as when used in 
solid agar based media, the fluorescent product will diffuse away from the bacteria 
which expresses the target enzyme making it difficult to differentiate between a 
negative and positive colony in a mixed culture (Manafi et al., 1991).  
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As discussed, there are an abundant number of commercially available kits based 
upon enzyme function, providing a rapid and accurate result within a very short 
space of time (Bascomb and Manafi, 1998) as well as numerous chromogenic and 
fluorogenic media readily obtainable (Manafi et al., 1991), but currently there is 
nothing available for the rapid identification of mycobacteria therefore enzymic 
activity cannot be accurately or promptly estimated.  
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3.9 Aims and objectives 
To screen a collection of fluorogenic and chromogenic enzyme substrates 
(structures are shown in Appendix 4) to characterise the enzymatic profiles of 
mycobacteria and selected Gram-negative strains and to determine whether 
mycobacteria can be differentiated from Gram-negative bacteria in order to exploit 
the use of these substrates within RGM medium. 
To determine if different species within the Mycobacterium abscessus complex (M. 
abscessus subsp. abscessus, M. abscessus subsp. bolletii and M. abscessus 
subsp. massiliense) can be distinguished from each other, and also from lesser 
pathogenic mycobacterial species such as M. chelonae. 
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3.10 Materials 
3.10.1 Bacterial strains used in the evaluation of fluorogenic substrates 
A collection of 45 isolates were used; these included two control strains from the 
National Collection of Type Cultures: E. coli NCTC 10418 and S. aureus NCTC 
6571, 15 Gram-negative isolates; A. xylosoxidans (n = 3), B. multivorans (n = 3), B. 
cenocepacia (n = 2), B. stabilis (n = 1), B. vietnamiensis (n = 1), D. acidovorans (n 
= 1), I. limosus (n = 1), P. aeruginosa (n = 1), P. norimbergenesis (n = 1), S. 
marcescens  (n = 1), and 28 isolates of mycobacteria (M. abscessus subsp. 
abscessus (n = 11), M. abscessus subsp. massiliense (n = 8), M. chelonae (n = 6) 
and M. abscessus subsp. bolletii (n = 3). Further details in Appendix 1. 
3.10.2 Bacterial strains used in the evaluation of chromogenic substrates 
A collection of 20 mycobacteria isolates were used: M. abscessus subsp. abscessus  
(n = 12), M. abscessus subsp. massiliense (n = 5) and M. abscessus subsp. bolletii 
(n = 3) and 31 non-mycobacterial isolates for the evaluation of magenta octanoate; 
Burkholderia cepacia complex (n = 10), A. xylosoxidans (n = 4), P. aeruginosa (n = 
4), Pandoraea spp. (n = 3), S. maltophilia (n = 2), S. marcescens (n = 2), 
Acinetobacter sp. (n = 1), D. acidovorans (n = 1), E. miricola (n = 1), I. limosus (n = 
2) and Ochrobactrum sp. (n = 1). 
For the evaluation of L-ala-ala-ala-4(4’-aminostyryl)-N-methylquinolinium dichloride 
a collection of 12 mycobacteria isolates were used: M. abscessus subsp. abscessus 
(n = 6), M. abscessus subsp. massiliense (n = 4) and M. abscessus subsp. bolletii 
(n = 2). Further details in Appendix 1. 
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A further collection of 11 mycobacteria isolates were used for all other chromogenic 
substrates: M. abscessus subsp. abscessus (n = 6), M. abscessus subsp. 
massiliense (n = 2), M. chelonae (n = 2) and M. abscessus subsp. bolletii (n = 1). 
All isolates used unless stated otherwise were supplied by the Freeman Hospital 
Microbiology Department and were isolated from the sputa of patients with CF. 
Further details can be found in Appendix 1. 
3.10.3 Growth media and general chemicals 
RGM broth was prepared in house using Middlebrook broth base and glycerol as 
described in Appendix 2 with the addition of yeast extract obtained from bioMérieux, 
Marcy l'Etoile, France. OADC supplement was prepared as described previously in 
section 2.4.3. No antimicrobials or agar were added to the broth. Methyl red was 
purchased from Sigma-Aldrich, Poole, UK. 
3.10.4 Fluorogenic enzyme substrates 
4-Methylumbelliferyl lignocerate, 4-Methylumbelliferyl nonanoate, 4-
Methylumbelliferyl riboside, 4-Methylumbelliferyl α-D-glucopyranoside, 4-
Methylumbelliferyl α-D-glucuronide, 4-Methylumbelliferyl α-D-mannopyranoside, 4-
Methylumbelliferyl α-L-idopyranoside, 4-Methylumbelliferyl α-L-iduronide, 4-
Methylumbelliferyl β-D-glucopyranoside and 4-Methylumbelliferyl β-D-glucuronide, 
4-Methylumbelliferyl β-D-ribofuranoside were all obtained from Glycosynth, 
Warrington, UK. 4-Methylumbelliferyl acetate, 4-Methylumbelliferyl 7-β-D-xyloside, 
4-Methylumbelliferyl acetamido-4,6-0-benzylidene-2-deoxy-β-D-glucopyranoside,   
4-Methylumbelliferyl butyrate, 4-Methylumbelliferyl heptanoate, 4-
Methylumbelliferyl N-acetyl-β-D-galactosaminide, 4-Methylumbelliferyl N-acetyl-β-
D-glucosaminide, 4-Methylumbelliferyl palmitate, 4-Methylumbelliferyl p-
guanidinobenzoate hydochlorate, 4-Methylumbelliferyl phosphate, 4-
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Methylumbelliferyl propionate, 4-Methylumbelliferyl stearate, 4-Methylumbelliferyl 
sulfate, 4-Methylumbelliferyl α-D-galactoside, 4-Methylumbelliferyl α-L-
arabinopyranoside, 4-Methylumbelliferyl β-D-cellobioside, 4-Methylumbelliferyl β-D-
fucoside, 4-Methylumbelliferyl β-D-galactoside, 4-Methylumbelliferyl β-D-glucoside, 
4-Methylumbelliferyl β-D-mannopyranoside, 4-Methylumbelliferyl β-D-N,N’-
diacetylchitobioside and 4-Methylumbelliferyl β-D-N,N’-triacetylchitotriose were 
purchased from Sigma-Aldrich, Poole, UK. 4-Methylumbelliferyl laurate was 
obtained from Koch-Light Laboratories Limited, Suffolk, UK. Ac-Met-7-amino-4-
methylcoumarin (AMC), Boc-Leu-Gly-Arg-AMC acetate salt, H-Arg-AMC.2HCl, H-
Arg-AMC.2HCl, H-Asn-AMC.TFA, H-Asp(AMC)-OH, H-Gln-AMC, H-Glu-AMC, H-
Gly-AMC.Hbr, H-Gly-pro-AMC.HBr, H-His-AMC, H-Ile-AMC.TFA, H-Leu-AMC.HCl, 
H-Lys-AMC.acetate, H-Met-AMC acetate salt, H-Orn-AMC.2HCl, H-Phe-AMC.TFA, 
H-Pro-AMC hydrobromide salt (Prolyl), H-Thr-AMC, H-Try-AMC, H-Val-AMC, H-β-
Ala-AMC.TFA, Pyr-AMC, L-alanine-AMC trifluoroacetate salt and Z-Arg-AMC.HCl 
were purchased from Bachem, Saffron Walden, UK. All structures are shown in 
Appendix 4. 
3.10.5 Chromogenic enzyme substrates 
5-bromo-6-chloro-3-indolyl-ß-D-galactopyranoside, 6-chloro-3-indolyl-ß-D-
glucuronide, 6-chloro-3-indolyl-ß-D-glucopyranoside and magenta octanoate were 
purchased from Glycosynth, Warrington, UK. Alizarin-2-α-D-galactopyranoside was 
obtained from Inalco, Italy. Alizarin-2-ß-D-galactopyranoside, Alizarin-2-ß-D-
glucopyranoside, 3,4-cyclohenenoesculetin-ß-D-galactopyranoside, 3,4-
cyclohenenoesculetin-ß-D-glucopyranoside and L-ala-ala-ala-4(4’-aminostyryl)-N-
methylquinolinium dichloride were kindly supplied by Professor Arthur James, 
University of Northumbria, UK. 
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3.10.6 Equipment 
In addition to equipment used in section 2.3.4, a Proline Plus 30-300µl, 8-Channel 
multi pipette from Alpha laboratories, Hampshire, UK was used for dispensing 
substrates into the microtitre trays. Flat-bottomed, 96 well microtitre trays used in 
the evaluation of enzyme substrates were purchased from Sarstedt AG & Co., 
Numbrecht, Germany. The Synergy HT multi-detection microplate reader, obtained 
from BioTek Instruments, Bedfordshire, UK (see section 3.10.6.1) was used to 
measure the change in absorbance in enzyme assays containing chromogenic and 
fluorogenic substrates. 
3.10.6.1 The Synergy HT multi-detection microplate reader 
The Synergy HT multi-detection microplate reader is a microplate reader capable of 
measuring absorbance, fluorescence and luminescence. It utilises a unique dual 
optics design and has both monochromator/xenon flash systems with a silicone 
diode detector for absorbance, which allows the selection of any wavelength for 
endpoint or kinetic measures from 200 nm to 999 nm in 1 nm increments. It also has 
a tungsten halogen lamp with blocking interference filters, excitation and emission 
for wavelength selection and photomultiplier detection for fluorescence (BioTek, 
2017).   
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3.11 Methods 
3.11.1 Culture medium used in the evaluation of chromogenic and 
fluorogenic substrates 
One litre of Middlebrook 10 x strength broth base described in Appendix 2 containing 
40 ml glycerol and 4 g yeast extract was prepared, autoclaved for 10 minutes at 
121oC, cooled and stored at 4oC. As the OADC supplement cannot be autoclaved, 
100 ml was prepared as previously and described in Appendix 2, filter sterilised and 
added to the broth as required at a concentration of 10 ml per 100 ml broth base. 
3.11.2 Preparation of bacterial strains 
All Gram-negative strains were subcultured onto blood agar, and mycobacteria onto 
previously described RGM medium and incubated at 30oC for 72 hours. A bacterial 
suspension was prepared by suspending a loopful of fresh culture in 2 ml broth base 
in a sterile bijou bottle. The cell density of all 45 strains was measured with a 
densitometer and adjusted to a turbidity equivalent to 1.0 McFarland units (approx. 
3.0 x 108 colony forming units (cfu)/ml) using additional broth base where required. 
3.11.3 Evaluation of fluorogenic substrates for both mycobacteria and 
non-mycobacterial isolates 
Fluorogenic substrates were prepared at 2.96 mM and initially dissolved in 200 µl 
N-methyl-2-pyrrolidone and made up to 5.5 ml with broth base. Esterase substrates 
had an additional 300 µl tween 20 added to prevent them precipitating out of solution 
and all were made up to a final volume of 5.5 ml with broth base. Substrates which 
did not go into solution readily at room temperature were heated until fully dissolved 
and clear in colour. 
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A 50 µl volume of each isolate suspension was loaded into the wells of a microtitre 
tray in duplicate, with their position recorded, and an equal volume of the substrate 
solution added. In addition, three negative control organism-free wells were 
prepared, and two controls containing E. coli (NCTC 10418) and S. aureus (NCTC 
6571). Each substrate was tested in duplicate. Microtitre trays were read to obtain 
an initial “time zero” measurement of fluorescence with a fluorescence microtitre 
plate reader using a 365 nm excitation wavelength and a 440 nm emission 
wavelength. Trays were incubated at 30oC for 72 hours after which the fluorescence 
readings were repeated. Average readings after 72 hours incubation are shown in 
Appendix 5. 
3.11.4 Initial evaluation of chromogenic substrates for mycobacterial 
isolates 
Magenta octanoate was evaluated for activity in NTM and L-ala-ala-ala-4(4’-
aminostyryl)-N-methylquinolinium dichloride was evaluated for activity in both NTM 
and a selection of non-mycobacteria, which included a number of common Gram-
negative CF pathogens. Columbia agar was prepared in 200 ml volumes and 
magenta octanoate was added at a concentration of 0.45 g/L. This was dissolved in 
N-methyl-2-pyrrolidone (4.5 ml/L) and tween 20 (7.9 ml/L) then added to the agar 
once cooled to 50oC.  Twenty isolates of NTM were inoculated onto the medium and 
incubated at 30oC for four days. L-ala-ala-ala-4(4’-aminostyryl)-N-methylquinolinium 
dichloride was added at a concentration of 0.1 g/L dissolved in N-methyl-2-
pyrrolidone (1 ml/L) and added to the agar once cooled to 50oC. Twelve isolates of 
NTM and 28 non-mycobacterial isolates were inoculated onto the medium and 
incubated at 30oC for four days. 
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Eight further chromogenic substrates were evaluated to consider if there were any 
benefits to including these in RGM medium. RGM agar was prepared in 100 ml 
volumes as previously described and the following concentrations of each substrate 
added; 5-bromo-6-chloro-3-indolyl-ß-D-galactopyranoside 0.08g/L, 6-chloro-3-
indolyl-ß-D-glucopyranoside 0.2g/L, 6-chloro-3-indolyl-ß-D-glucuronide 0.2g/L, 
alizarin-2-α-D-galactopyranoside 0.05g/L, alizarin-2-ß-D-galactopyranoside 
0.05g/L, alizarin-2-ß-D-glucopyranoside 0.05g/L, 3,4-cyclohexenoesculetin-ß-D-
galactopyranoside 0.3g/L and 3,4-cyclohexenoesculetin-ß-D-glucopyranoside 
0.3g/L. All substrates were dissolved in N-methyl-2-pyrrolidone (1 ml/L) and added 
to the agar once cooled to 50oC. Eleven isolates of NTM were used in total, with five 
inoculated onto each media and incubated at 30oC for four days. Control plates 
containing no substrates were inoculated for all isolates. 
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3.12 Results 
3.12.1 Activity of fluorogenic substrates in both non-mycobacteria and 
mycobacterial isolates 
The results for the activity detected with fluorogenic substrates are shown in Table 
3-1. Mycobacteria were showed most activity with 4-Methylumbelliferyl laurate, 4-
Methylumbelliferyl palmitate, 4-Methylumbelliferyl stearate, 4-Methylumbelliferyl β-
D-galactoside, 4-Methylumbelliferyl β-D-glucoside, H-Leu-AMC.HCl, H-Met-AMC 
acetate salt, H-His-AMC, H-Arg-AMC.2HCl, H-Try-AMC, H-β-Ala-Amc.TFA, L-
alanine-AMC trifluoroacetate salt, Boc-Leu-Gly-Arg-AMC acetate salt and 4-
Methylumbelliferyl phosphate. For all of these however the majority of non-
mycobacteria also demonstrated activity, therefore discriminating between NTM 
and other species would still be problematic. Methyl Red 291 was highly sensitive 
in 23/26 (88.5%) of NTM, with only three isolates of M. chelonae showing no activity. 
Inactivity for all of the non-mycobacteria tested was observed, except for the two 
control organisms tested, S. aureus and E. coli.  No activity was detected with six of 
the substrates for any of the species tested; 4-Methylumbelliferyl propionate, 4-
Methylumbelliferyl p-guanidinobenzoate hydochlorate hydrate, 4-Methylumbelliferyl 
lignocerate, 4-Methylumbelliferyl 7-β-D-xyloside, 4-Methylumbelliferyl α-D-
glucopyranoside and SR266, and two showed 100% sensitivity for all isolates; H-
Leu-AMC.HCl and L-alanine-AMC trifluoroacetate salt. None of the fluorogenic 
substrates tested was able to successfully differentiate between M. chelonae or 
between subspecies of the M. abscessus complex. 
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Table 3-1: Percentage of isolates possessing enzyme activity with a range of fluorogenic substrates 
 (n) 4MA 4MPr 4MB 4MH 4MN 4MLa 4MPgh 4MPa 4MSt 4MLi 4Mara 4Mxyl 4Mribs 4Mribf 
A. xylosoxidans 3 0 0 0 0 0 100 0 0 0 0 0 0 33.3 33.3 
B. cenocepacia 2 0 0 0 50 0 50 0 50 0 0 0 0 100 100 
B. multivorans 3 0 0 0 0 0 100 0 66.7 66.7 0 0 0 0 0 
B. stabilis 1 0 0 0 100 0 100 0 100 100 0 0 0 100 100 
B. vietnamiensis 1 0 0 0 0 0 0 0 0 0 0 0 0 100 0 
D. acidovorans 1 0 0 0 0 0 0 0 100 0 0 0 0 0 0 
I. limosus 1 0 0 0 0 0 0 0 0 0 0 0 0 100 100 
P. norimbergenis 1 0 0 0 0 0 0 0 0 0 0 0 0 100 0 
P. aeruginosa 1 100 0 0 0 0 100 0 100 100 0 0 0 100 100 
S. marcescens 1 0 0 100 100 0 100 0 100 100 0 100 0 100 100 
M. abscessus* 12 0 0 0 8.3 8.3 100 0 100 100 0 33.3 0 75 25 
M. bolletii** 2 0 0 0 0 0 100 0 100 100 0 0 0 0 0 
M. massiliense*** 8 0 0 0 0 0 100 0 100 100 0 33.3 0 66.7 16.7 
M. chelonae 6 0 0 0 25 12.5 100 0 100 100 0 62.5 0 87.5 25 
S. aureus 1 0 0 0 0 0 0 0 0 0 0 100 0 100 100 
E. coli 1 0 0 0 0 0 0 0 100 0 0 0 0 100 100 
                
 (n) 4Mfuc 4Mglupα 4Mglupβ 4Mmanα 4Mgalα 4Mgalβ 4Mgluβ 4Mldo 4Manβ 4Mcurβ 4Mldu 4MNgal 4MNglu 4Mcel 
A. xylosoxidans 3 0 0 0 0 0 100 0 0 0 0 0 0 0 0 
B. cenocepacia 2 0 0 50 0 0 50 50 0 0 0 0 0 0 50 
B. multivorans 3 0 0 0 0 0 33.3 0 0 0 0 0 0 0 0 
B. stabilis 1 0 0 0 0 0 100 0 0 0 0 0 0 0 0 
B. vietnamiensis 1 0 0 100 0 0 100 0 0 0 0 0 0 0 0 
D. acidovorans 1 0 0 0 0 0 100 0 0 0 100 0 0 0 100 
I. limosus 1 0 0 100 100 0 100 100 0 0 0 0 0 0 0 
P. norimbergenis 1 0 0 0 0 0 100 0 0 0 0 0 0 0 0 
P. aeruginosa 1 0 0 0 0 0 100 0 0 0 0 0 0 0 0 
S. marcescens 1 0 0 100 100 100 100 100 0 100 100 100 100 0 100 
M. abscessus* 12 33.3 0 100 91.7 83.3 100 100 33.3 83.3 83.3 58.3 0 8.3 66.7 
M. bolletii** 2 0 0 100 100 50 100 100 0 50 100 50 0 0 0 
M. massiliense*** 8 0 0 83.3 100 0 100 100 0 66.7 83.3 16.7 0 0 16.7 
M. chelonae 6 25 0 100 100 75 100 100 62.5 75 100 62.5 37.5 50 75 
S. aureus 1 100 0 0 0 0 100 0 0 0 100 0 0 0 0 
E. coli 1 0 0 0 0 0 100 0 0 0 0 0 0 0 0 
*M. abscessus subsp. abscessus, **M. abscessus subsp. bolletii, ***M. abscessus subsp. massiliense 
 
Key : 4MA : 4-Methylumbelliferyl acetate, 4MPr : 4-Methylumbelliferyl propionate, 4MB: 4-Methylumbelliferyl butyrate, 4MH: 4-Methylumbelliferyl heptanoate, 4MN : 4-Methylumbelliferyl nonanoate, 4MLa : 4-Methylumbelliferyl laurate, 4MPgh : 4-Methylumbelliferyl p-guanidinobenzoate hydochlorate hydrate, 4MPa : 4-Methylumbelliferyl 
palmitate, 4MSt : 4-Methylumbelliferyl stearate, 4MLi : 4-Methylumbelliferyl lignocerate, 4Mara : 4-Methylumbelliferyl α-L-arabinopyranoside, 4Mxyl : 4-Methylumbelliferyl 7-β-D-xyloside, 4Mribs :  4-Methylumbelliferyl riboside, 4Mribf : 4-Methylumbelliferyl β-D-ribofuranoside, 4Mfuc : 4-Methylumbelliferyl β-D-fucoside, 4Mglupα : 4-
Methylumbelliferyl α-D-glucopyranoside, 4Mglupβ : 4-Methylumbelliferyl β-D-glucopyranoside, 4Manα : 4-Methylumbelliferyl α-D-mannopyranoside, 4Mgalα : 4-Methylumbelliferyl α-D-galactoside, 4Mgalβ : 4-Methylumbelliferyl β-D-galactoside, 4Mgluβ : 4-Methylumbelliferyl β-D-glucoside, 4MIdo : 4-Methylumbelliferyl α-L-idopyranoside, 
4Manβ : 4-Methylumbelliferyl β-D-mannopyranoside, 4Mcurβ : 4-Methylumbelliferyl β-D-glucuronide, 4Midu : 4-Methylumbelliferyl α-L-iduronide, 4MNgal : 4-Methylumbelliferyl N-acetyl-β-D-galactosaminide, 4MNglu : 4-Methylumbelliferyl N-acetyl-β-D-glucosaminide, 4Mcel : 4-Methylumbelliferyl β-D-cellobioside, 
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Table 3-1 continued: Percentage of isolates possessing enzyme activity with a range of fluorogenic substrates 
 (n) Pro Val Thr Ile Leu Orn Gln MetH His Phe ArgH Try MetA Ala 
A. xylosoxidans 3 100 0.0 0 0.0 100 0 100 100 33.3 100 100 100 0 0 
B. cenocepacia 2 50 0.0 0 0.0 100 0 100 100 50 100 50 100 0 100 
B. multivorans 3 100 0.0 0 0.0 100 0 33.3 33.3 0 100 33.3 100 0 100 
B. stabilis 1 100 0.0 0 100 100 0 100 100 100 100 100 100 0 100 
B. vietnamiensis 1 100 100 100 100 100 100 100 100 100 100 100 100 0 0 
D. acidovorans 1 0 0.0 0 0 100 0 100 100 0 100 100 100 0 0 
I. limosus 1 100 100 100 100 100 0 100 100 100 100 100 100 0 100 
P. norimbergenis 1 100 0.0 0 0 100 0 100 100 0 100 100 100 0 0 
P. aeruginosa 1 0 0.0 0 0 100 0 100 0 0 100 100 100 0 100 
S. marcescens 1 100 100 100 100 100 100 100 100 100 100 100 100 0 100 
M. abscessus* 12 91.7 91.7 91.7 91.7 100 100 100 100 100 100 100 100 33.3 100 
M. bolletii** 2 50 50 50 100 100 50 50 100 100 100 100 100 0 100 
M. massiliense*** 8 100 100 83.3 100 100 83.3 100 100 100 10 100 100 0 100 
M. chelonae 6 100 100 100 100 100 100 100 100 100 100 100 100 62.5 100 
S. aureus 1 0 0 0 0 100 0 100 100 100 100 100 100 0 0 
E. coli 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
                
 (n) AAMC GlyP Boc 4MPh 4MSu SR123 SR124 S521 SR266 MR291 7N3CA    
A. xylosoxidans 3 100 0 0 100 0 0 0 0 0 0 100    
B. cenocepacia 2 100 0 50 100 0 0 0 0 0 0 0    
B. multivorans 3 100 0 0 100 0 0 0 0 0 0 66.7    
B. stabilis 1 100 0 0 100 0 0 0 0 0 0 0    
B. vietnamiensis 1 100 100 0 100 0 0 0 0 0 0 0    
D. acidovorans 1 100 0 0 100 100 0 0 0 0 0 100    
I. limosus 1 100 0 100 100 0 0 0 0 100 0 0    
P. norimbergenis 1 100 0 0 100 0 0 0 0 0 0 0    
P. aeruginosa 1 100 0 100 0 0 0 0 0 100 0 0    
S. marcescens 1 100 100 100 100 0 0 0 0 100 0 100    
M. abscessus* 12 100 0 100 100 33.3 0 8.3 0 91.7 100 16.7    
M. bolletii** 2 100 0 100 100 0 0 0 0 100 100 0    
M. massiliense*** 8 100 0 100 100 66.7 16.7 16.7 0 100 100 0    
M. chelonae 6 100 12.5 100 100 50 0 0 0 62.5 50 0    
S. aureus 1 0 0 100 100 0 0 0 0 100 100 100    
E. coli 1 100 0 0 100 0 0 0 0 100 100 100    
*M. abscessus subsp. abscessus, **M. abscessus subsp. bolletii, ***M. abscessus subsp. massiliense 
 
Key : Pro : H-Pro-AMC hydrobromide salt (Prolyl), Val : H-Val-AMC, Thr : H-Thr-AMC, Ile : H-Ile-AMC.TFA, Leu : H-Leu-AMC.HCl, Orn : H-Orn-AMC.2HCl, Gln : H-Gln-AMC, MetH : H-Met-AMC acetate salt, His : H-His-AMC, Phe :  H-Phe-AMC.TFA, ArgH : H-Arg-AMC.2HCl, Try : H-Try-AMC, MetA : Ac-Met-AMC, Ala : H-β-Ala-Amc.TFA, 
AAMC : L-alanine AMC trifluoroacetate salt, GlyP : H-Gly-pro-AMC.HBr, Boc : Boc-Leu-Gly-Arg-AMC acetate salt, 4MPh : 4-Methylumbelliferyl phosphate, 4MSu : 4-Methylumbelliferyl sulfate, SR123 : , SR124 : , S521 : , SR266 : , MR291 : Methyl Red 291, 7N3CA : 7-nitrocoumarin-3-carboxylic acid.  
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None of the fluorogenic substrates specifically stood out with a profile that would 
indicate they would be of any benefit if they were included in RGM medium for the 
differentiation of NTM and other non-NTM species. 
3.12.2 Activity of chromogenic substrates in non-tuberculous 
mycobacteria 
All isolates of mycobacteria demonstrated a colour change with magenta octanoate 
and grew as purple colonies except one isolate of M. abscessus subsp. bolletii, 
which failed to grow. No colour change was observed on all control plates (see Table 
3-2 and Figure 3-3) below. This indicated that production of a C8-esterase was a 
consistent feature of the mycobacteria that were tested that were able to grow in the 
presence of this substrate. 
  
151 
 
Table 3-2: Appearance and growth of NTM isolates with magenta octanoate 
MABSC Subspecies Isolate 
Number 
Growth After 4 
Days 
Colour of 
Colonies 
M. abscessus complex (chimeric) 1000 + purple 
M. abscessus subsp. abscessus 1034 + purple 
M. abscessus subsp. abscessus 1042 + purple 
M. abscessus subsp. abscessus 1044 ++ purple 
M. abscessus subsp. abscessus 1045 +++ purple 
M. abscessus subsp. abscessus 1047 +++ purple 
M. abscessus subsp. abscessus 1050 + purple 
M. abscessus subsp. abscessus 1051 +++ purple 
M. abscessus subsp. abscessus 1052 + purple 
M. abscessus subsp. abscessus 1053 +++ purple 
M. abscessus subsp. abscessus 1054 +++ purple 
M. abscessus subsp. abscessus 1055 + purple 
M. abscessus subsp.  bolletii 3015 +++ purple 
M. abscessus subsp.  bolletii 3016 No Growth N/A 
M. abscessus subsp.  bolletii 3017 +++ purple 
M. abscessus subsp. massiliense 3010 +++ purple 
M. abscessus subsp. massiliense 3011 ++ purple 
M. abscessus subsp. massiliense 3012 +++ purple 
M. abscessus subsp. massiliense 3014 +++ purple 
M. abscessus subsp. massiliense 3015 + purple 
    
 
 
 
   
Figure 3-3: Isolates 3017 M. abscessus subsp. bolletii and 1054 M. abscessus 
subsp. abscessus shown with magenta octanoate (left) added and control 
plate without magenta octanoate (right) 
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Results for L-ala-ala-ala-4(4’-aminostyryl)-N-methylquinolinium dichloride are 
shown below in Table 3-3 and Figure 3-4 and Figure 3-5. No colour change was 
observed on all control plates. 
 
 
Figure 3-4: Non-tuberculous mycobacteria isolates with L-ala-ala-ala-4(4’-
aminostyryl)-N-methylquinolinium dichloride included in the agar 
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Table 3-3: Appearance and growth of NTM isolates with L-ala-ala-ala-4(4’-
aminostyryl)-N-methylquinolinium dichloride 
 
Species Reference Growth After 4 
Days 
Colour of 
colonies 
 
Non-tuberculous mycobacteria 
   
M. abscessus complex 1000 + white 
M. abscessus subsp. abscessus 1034 +/- white 
M. abscessus subsp. abscessus 1042 +/- white 
M. abscessus subsp. abscessus 1044 +/- white 
M. abscessus subsp. abscessus 1054 ++ white 
M. abscessus subsp. abscessus 1055 ++ white 
M. abscessus subsp. bolletii 3015 ++ white 
M. abscessus subsp. bolletii 3016 + white 
M. abscessus subsp. massiliense 3010 +/- white 
M. abscessus subsp. massiliense 3011 + white 
M. abscessus subsp. massiliense 3012 + white 
M. abscessus subsp. massiliense 3013 + White 
 
Non-mycobacterial isolates    
A..xylosoxidans 7010 ++ pink 
A..xylosoxidans 7015 ++ pink edges 
A..xylosoxidans 7027 +++ pale pink 
A..xylosoxidans 7037 ++ pink 
Acinetobacter sp. 8003 ++ pink 
B. cenocepacia 7009 ++ pink 
B. cenocepacia 7012 + red 
B. cepacia 8007 +++ pink 
B. contaminans 8008 ++ red 
B. multivorans 7017 ++ red 
B. multivorans 7022 ++ red 
B. multivorans 7024 ++ red 
B. multivorans 7036 + pink 
B. stabilis 7026 ++ red 
B. vietnamiensis 7032 + pink 
D. acidovorans 7008 +++ red 
E. miricola 8025 +++ red 
I..limosus 7007 ++ red 
I..limosus 7011 ++ no colour 
Ochrobactrum sp. 7031 ++ pale pink 
P. aeruginosa 7004 +++ pink 
P. aeruginosa 8017 + pink/red 
P. aeruginosa 8011 ++ pale pink 
P. aeruginosa 8012 +++ pink 
P. apista 8020 + pink 
P. norimbergenis 7018 + pink 
P. pnomenusa 8021 + pink 
S. marcesens 7019 +++ red 
S. marcesens 7020 +++ red 
S. maltophilia 8022 +++ red 
S. maltophilia 8023 +++ red 
 
154 
 
 
Figure 3-5: Showing growth and colouration of Gram-negative isolates as 
follows:  A. xylosoxidans x4 (top left), Acinetobacter spp, B. cenocepacia x2, 
B. cepacia (top centre), B. contaminans, B. multivorans x3 (top right), B. 
multivorans, B. stabilis, B. vietnamiensis, D. acidovorans (bottom left), E. 
miricola, I. limosus x2, P. aeruginosa (bottom centre) and P. apista, P. 
norimbergenis, P. pnomenusa, S. marcescens (bottom right) with L-ala-ala-
ala-4(4’-aminostyryl)-N-methylquinolinium dichloride encompassed in the 
agar 
 
Five of the eleven NTM strains were inoculated onto each RGM (minus antibiotics) 
with chromogenic substrates added and results are shown below in Table 3-4 and 
Figure 3-6. No colour change of NTM was observed on any control plates. 
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Figure 3-6: The appearance of isolates 1010 M. abscessus subsp. abscessus 
and 1029 M. abscessus subsp. abscessus using the substrates A – H as 
shown in Table 3-4 and control plate containing no chromogenic substrates 
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Table 3-4: The appearance of NTM inoculated onto RGM medium with the addition of various chromogenic substrates 
ID Species A B C D E F G H 
2002 M. chelonae        pale 
orange/white 
2014 M. chelonae        pale 
orange/white 
1010 M. abscessus subsp. abscessus white white white pale pink/white white white  pale 
orange/white 
1013 M. abscessus subsp. abscessus white white white      
1026 M. abscessus subsp. abscessus white white white      
1027 M. abscessus subsp. abscessus        pale 
orange/white 
1029 M. abscessus subsp. abscessus    pale pink/white white white white  
1032 M. abscessus subsp. abscessus    pale pink/white white white white  
3002 M. abscessus subsp. massiliense white white white pale pink/white white white white  
3007 M. abscessus subsp. massiliense    pale pink/white white/blue white white/blue pale 
orange/white/ 
blue 
3016 M. abscessus subsp. bolletii white white white    white  
 
Key: A; 5-bromo-6-chloro-3-indolyl-ß-D-galactopyranoside, B; 3,4-cyclohenenoesculetin-ß-D-galactopyranoside, C; alizarin-2-ß-D-galactopyranoside, D; 6-chloro-3-indolyl-ß-D-glucopyranoside,  
E; 3,4-cyclohenenoesculetin-ß-D-glucopyranoside, F; alizarin-2-ß-D-glucopyranoside, G; 6-chloro-3-indolyl-ß-D-glucuronide, H; alizarin-2-α-D-galactopyranoside. Good (++) growth of all species was observed after 
4 days incubation at 30oC. 
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3.13 Discussion 
 
Rapid species-level identification of mycobacteria is of high importance in patients 
with CF in order for accurate and prompt treatment to be provided in patients 
deemed to require therapy. Identification of mycobacteria to species level by 
conventional biochemical tests have lengthy turnaround times subsequently leading 
to delays in diagnosis, as well as giving ambiguous and unreproducible results. The 
phenotype of many mycobacterial species can also be exceptionally variable. 
The aim of this study was to evaluate a range of chromogenic and fluorogenic 
substrates containing coumarin derivatives 4-methylumbelliferone (4-MU) or 7-
amino-4-methylcoumarin (7-AMC) to look at the presence or absence and quantities 
of a range of mycobacterial glycosidases, peptidases and esterases for their 
capability to discriminate between M. abscessus complex and the less pathogenic 
M. chelonae, as well as the potential to differentiate between the three members of 
the M. abscessus complex, (M. abscessus, M. massiliense and M. bolletii) and 
additionally to ascertain whether mycobacteria can be differentiated from Gram-
negative bacteria recurrently found in the sputum of patients with CF, and 
occasionally recovered on RGM medium.  
If such a substrate was available, incorporation into a primary isolation medium such 
as RGM could greatly increase the appeal of the medium allowing for easy 
enumeration and detection directly on the isolation plate, subsequently providing a 
rapid and effective means of identifying pathogenic NTM in a CF sputum sample, 
which could potentially harbour a diverse range of bacterial species. This will also 
eliminate the need for subculture or further biochemical tests. 
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The use of umbelliferone derivatives were reported to be a sensitive technique in 
the detection of mycobacterial group-specific hydrolases such as  lipases, 
phosphatases or glucosidases, and it has been advocated they may be appropriate 
for investigating the glycosidase activity of slow-growing mycobacteria, (Grange and 
Clark, 1977; Grange, 1978; Slosarek, 1980). Mycobacterium nonchromogenicum, 
Mycobacterium szulgai and Mycobacterium marinum exhibited characteristic 
enzyme activities which distinguished them from the other species, with M. marinum 
being unique amongst mycobacteria for its very obvious α-L-fucosidase activity 
(Grange and McIntyre, 1979). 
The methods employed in this study would not prove to be technically difficult or 
time consuming, and substrates could be incorporated into the medium, however 
the results established that the use of these would not provide any additional benefit 
to RGM.  
As mycobacteria appear on RGM as bright white colonies, either smooth or rough, 
and other species that are able to grow generally appear blue or pink, mycobacteria 
are already quite distinguishable on the medium, however to differentiate M. 
abscessus complex from less pathogenic M. chelonae or M. mucogenicum will still 
require further testing and sequencing. 
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4. Introduction: Chapter 4 
4.1 The epidemiology of non-tuberculous mycobacterial infections  
Non-tuberculous mycobacteria (NTM) are opportunistic pathogens whose sources 
include water, dust and soil. They are not contaminants, but somewhat typical 
inhabitants of these environments. By occupying the same surroundings as 
humans, this allows frequent exposure to occur on a daily basis from these sources 
via inhalation and/or ingestion (Cook, 2010; Falkinham et al., 2015). 
NTM represent a substantial threat emerging in patients with CF, with until recently, 
limited reports presenting conflicting results of global prevalence. 
Estimates of the prevalence of NTM in the CF population have ranged from 1.3% in 
1984 (Smith et al., 1984) to 32.7% in a US study in 2005 (Rodman et al., 2005). The 
largest published studies to date looked at 986 (Olivier et al., 2003), 1216 (Esther 
et al., 2010) and 1582 (Roux et al., 2009) individuals with CF, and reported positive 
NTM cultures of 13.0%, 13.7% and 6.6% respectively. 
The predisposing factors for acquisition of NTM are still largely unknown though 
recently a large US study reported possible risk factors for NTM using CF patient 
registry data from 2003 to 2011 (Binder et al., 2013). Limitations of this study were 
that not all incidences of NTM were reported, and it may also include patients that 
were only transiently colonised and not experiencing true NTM disease. No such 
study has been completed in Europe. There are a wide range of infections caused 
by rapidly-growing mycobacteria (RGM), but in recent years, members of the 
MABSC have emerged as major pathogens in patients suffering from CF.  
The most fundamental difference between M. tuberculosis, M. leprae and non-
tuberculous mycobacterial disease is that person-to-person transmission seems to 
be extremely rare in the latter, with limited reports of this occurring, and disease 
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almost certainly arising due to NTM being extensively dispersed in the environment. 
Defining the epidemiology of NTM is particularly challenging as unlike M. 
tuberculosis, the documentation of NTM infection is not compulsory or enforced and 
therefore does not necessitate reporting to Public Health authorities. This is due to 
the fact it is not considered a major public health concern, as there is very little 
evidence to substantiate human-to-human transmission. In a recent study, whole-
genome sequencing of M. abscessus in CF patients indicated human-to-human 
transmission can occur, however this study has yet to be replicated (Bryant et al., 
2013). 
An accurate understanding of the true epidemiology of NTM disease is still lacking. 
It is also arduous to precisely quantify the true prevalence of NTM as a positive 
culture could indicate transient colonization and does not always indicate genuine 
clinical infection. 
An increase in NTM infection could in part be due to improved diagnostic techniques 
as well as recognition of the significance of NTM, however current evidence does 
show a genuine increase globally (Griffith et al., 2007; Weiss and Glassroth, 2012; 
Wentworth et al., 2013) and in a number of studies an escalation of cases can be 
witnessed where no variation in intensity of monitoring or modifications in culture 
techniques have occurred. Other explanations for the increase have been 
suggested, for example, a rise in environmental exposure due to home water 
heaters and shower aerosols (Falkinham, 2011; Thomson et al., 2013a; Feazel et 
al., 2009) and an upsurge in the use of antibiotics, including chronic use of 
medications impairing host immunity (Renna et al., 2011; Catherinot et al., 2013a).  
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4.2 The global incidence of non-tuberculous mycobacterial disease 
Evidence suggests that the increase in the prevalence of NTM over the past few 
decades will continue to rise with multifactorial causes. The increasing age of the 
population, along with an escalation in the occurrence of diseases such as diabetes 
mellitus or chronic obstructive pulmonary disease, as well as a rise in the use of 
immunosuppressant medication would seem to play a major role in the increase of 
NTM (Winthrop et al., 2009). Another factor is NTM being abundant in the 
environment, in water and water supply systems, aerosols, decaying vegetation, soil 
and biofilms, swimming pools and hot tubs (Fjallbrant et al., 2013), therefore 
exposure to NTM would appear to occur on a daily basis (September et al., 2004; 
Falkinham, 2009). Increased awareness by physicians and enhanced culture 
techniques may also play a substantial role, leading to increased rates of detection 
and more prompt and accurate identification. 
A vast collaborative study by NTM-NET collected species identification data for 
20,182 patients, from 62 laboratories in 30 countries across six continents 
(Hoefsloot et al., 2013). Each hospital or reference laboratory was invited to provide 
data from patients where NTM was isolated from pulmonary samples, provided that 
number exceeded 30, within the year 2008, as well as providing the species and 
method of identification. One isolate per species per patient qualified for analysis. 
Results showed that 91.3% (18,418) of all isolates were identified to species or 
complex level, and the remaining 1,764 could not be identified beyond 
Mycobacterium species (other than M. tuberculosis). The six most frequent species 
recovered, and accounting for 80% of all isolates, were M. avium complex (MAC; 
47%), M. gordonae (11%), M. xenopi (8%), M. fortuitum complex (7%), M. kansasii 
(4%) and MABSC (3%).  
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Out of the rapidly-growing mycobacteria, MABSC and M. fortuitum were the most 
frequently isolated, however significant geographical variances were observed with 
the highest number of rapid growers encountered in East Asia making up 27% of all 
NTM isolates in comparison to North America (17.9%), South America (16%) and 
Europe (14%). It was also noted that within Asia, significant differences occurred 
with 6.6% of all isolates being rapid growers compared to 50% in Taiwan and 28.7% 
in South Korea.  
In Europe M. avium was the most frequently isolated NTM, accounting for 44% of 
all species isolated in Northern Europe and 31% in Southern Europe. This is 
consistent with other reports (Olivier et al., 2003; Floto et al., 2016), although in 
many European centres MABSC has overtaken all other species as the most 
commonly isolated RGM (Sermet-Gaudelus et al., 2003), (Roux et al., 2009; Esther 
et al., 2010; Qvist et al., 2015).  
In individuals with CF, acquisition of NTM is largely associated with age, and 
prevalence would seem to increase after patients reach adulthood. MABSC 
however is isolated at all ages, whereas MAC does not seem to be recovered until 
patients are considerably older (Olivier et al., 2003; Pierre-Audigier et al., 2005; 
Catherinot et al., 2013b). 
4.3 Environments providing favourable conditions for the transmission 
of non-tuberculous mycobacteria 
NTM are reported to be common in all natural environments, and transmission is 
thought to occur via ingestion, inoculation or inhalation (Gangadharam and Jenkins, 
1998). Rapidly growing mycobacteria withstand a much more extensive range of 
temperature, salinity, oxygen tension and pH than other pathogenic bacteria, with a 
higher tolerance to standard disinfectants such as chlorine (Le Dantec et al., 2002). 
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Their capacity for biofilm formation and ability to grow at low carbon levels also 
enables their survival in both natural and manmade environments, including water 
systems (Falkinham, 1996). 
The original emphasis of NTM environmental investigations centred on natural 
waters and soils (Falkinham et al., 1980; Brooks et al., 1984). However, with the 
outbreak of AIDS and HIV in the early 1980’s reports of NTM infections were 
increasing and led to the deduction that NTM were widely distributed within the 
environment (Greene et al., 1982). 
NTM are able to colonise drinking water distribution systems due to their cell surface 
hydrophobicity preventing flushing from the system and their ability to form biofilms 
(Bendinger et al., 1993; Torvinen et al., 2004). In untreated water systems, NTM are 
poor competitors for nutrients due to their slow growth rates, however as the typical 
disinfection process kills off any competitors for nutrients, they are able to thrive 
(Taylor et al., 2000). NTM are also somewhat heat-resistant and have been 
recovered from household plumbing where temperatures have been set to up to 
55oC, and even higher for some NTM species such as M. xenopi (Falkinham, 2011; 
Schulze-Robbecke and Buchholtz, 1992). Low oxygen concentrations due to 
reduced or discontinuous water flow does not impede NTM growth, as they are able 
to acclimatise and endure low concentrations of oxygen (Dick et al., 1998; Lewis 
and Falkinham, 2015). However, in areas of high levels of oxygen, quantities of NTM 
were lower (Kirschner et al., 1992). 
High numbers of NTM are found in soil, where due to their hydrophobicity they can 
adhere to soil particles and be aerosolised as dusts (De Groote et al., 2006). In a 
study by Narang et al., 26 isolates comprising of seven species of NTM, including 
three M. abscessus, were reported to have been isolated from water and soil 
samples in India where samples were obtained from household and work areas of 
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NTM positive patients (Narang et al., 2009). The methods used for identification of 
species in this report encompassed phenotypic testing including growth at varying 
temperatures on different media and several biochemical tests as well as PCR 
restriction analysis of hsp65 genes using HeaIII and BstE2 restriction enzymes 
(Telenti et al., 1993). However, none of the environmental isolates correlated with 
any of the patient isolates. 
NTM have also been associated with metal removal fluids (Wu et al., 2015), and it 
has been suggested that hypersensitivity pneumonitis in exposed workers may be 
connected to NTM present in metal removal fluid aerosols. However as these fluids 
are diluted with water in order to form an emulsion, it is highly probable that the 
water is in fact providing the source of the NTM (Kapoor and Yadav, 2012; Wu et 
al., 2015). 
The most commonly reported cause of NTM-associated hypersensitivity 
pneumonitis is via aerosolisation of contaminated hot-tub and swimming pool water, 
with numerous reports describing patients who developed NTM hypersensitivity 
pneumonitis from these sources following frequent use (Embil et al., 1997; Rickman 
et al., 2002; Glazer et al., 2007). 
There have been very few accounts of MABSC isolated from any of the above 
sources, with the majority of rapidly growing NTM documented being M. chelonae, 
M. fortuitum, M. gordonae, M. mucogenicum, and M. kansasii (Falkinham, 2009).  
Due to many taxonomic changes over the years, particularly relating to MABSC and 
M. chelonae, which is frequently isolated from the environment, caution should be 
applied in interpreting many of these reports describing the isolation of MABSC from 
the environment, as they were typically reported prior to these being designated as 
separate species in 1992 when M. abscessus was still thought to be a subspecies 
of M. chelonae (Kusunoki and Ezaki, 1992). In more recent publications, the 
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presence of MABSC is seldom reported, however in a recent case M. abscessus 
was said to be isolated from drinking water in Brisbane (Thomson et al., 2013b), 
and from skin infections detected after the 2004 tsunami in South-East Asia 
(Appelgren et al., 2008). In South Africa, M. abscessus was reported to have been 
isolated from drinking water distribution centres (September et al., 2004), and in 
ready to eat vegetables in Mexico (Cerna-Cortes et al., 2015). 
4.4 Reducing exposure to non-tuberculous mycobacteria 
Recommendations to avoid NTM exposure for those who are susceptible, for 
example patients with CF, include disinfection of showerheads by submerging in 
undiluted bleach for thirty minutes, or by replacing the showerhead with one that 
produces streams rather than a fine mist as this type generates lower numbers of 
droplets containing NTM (Aksamit et al., 2014).  
Raising the temperature of water heaters to 55oC has been shown to reduce NTM, 
and as the highest number are recovered in the sediment at the bottom of the heater, 
periodically draining and refilling can greatly reduce numbers of NTM (Johnson and 
Odell, 2014). 
It is recommended by National Jewish Health (National Jewish Health, 2015) that 
water is boiled for ten minutes at 100oC for drinking and cooking, as well as avoiding 
water from built in refrigerator taps. Care should be taken to avoid if possible 
granular activated carbon water filters, as the pores of these filters are not small 
enough to prevent the passage of bacteria, and NTM can attach and grow on the 
carbon bound organics and metals due to their resistance to disinfectants. Filters 
that have pore sizes less than 0.2 micrometres can prevent NTM; however, these 
are costly and can congest easily requiring frequent changing. Humidifiers should 
be avoided as they can generate aerosols with high numbers of NTM, and the 
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substitution of piped water for well water can be of benefit, as this harbours 
significantly less NTM. Commercial potting soil containing peat and the dust 
generated from this is rich in NTM, therefore moistening garden soils can reduce 
dust inhalation (Huitt, 2015).  
4.5 Non-tuberculous mycobacteria biofilm formation and its 
significance. 
The formation of biofilms leads to an increase in resistance to antimicrobials (Hoiby 
et al., 2010), and there have been several reports of biofilm development by NTM. 
In one study by El Helou et al, M. abscessus subsp. abscessus was observed to 
have a more rapid biofilm growth, which could be a factor in the pathogenicity of this 
species (El Helou et al., 2013). Growth conditions can influence the time for biofilm 
formation, and tap water was shown to promote biofilm perhaps due to its content 
of nutrients for mycobacteria (Howard et al., 2006; Esteban et al., 2008). 
In a report by Steed and Falkinham, M. avium cells grown in biofilms have been 
reported to be more resistant to chlorine in comparison to those grown in suspension 
in the same medium (Steed and Falkinham, 2006). Other elements may also 
contribute to biofilm formation in mycobacteria, such as the long-chain mycolic acids 
in their cell envelopes. Glycopeptidolipids coat the cell wall and have been 
suggested to be important for attaching the mycobacterial biofilm to surfaces (Recht 
and Kolter, 2001). In a study of showerheads in the US, the presence of pink 
pigmented Methylobacterium was associated with the absence of NTM and it was 
discovered that biofilms of methylobacteria inhibit the adherence of M. avium to 
stainless steel (Feazel et al., 2009). 
The major factor of NTM ecology, epidemiology and physiology is the existence of 
their lipid rich outer membrane with long chain mycolic acids contributing to their 
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hydrophobicity and impermeablility (see section 1.3 in Chapter 1). These 
characteristics make possible a high resistance to antimicrobials and disinfectants, 
and favour attachment to surfaces. Their slow rates of growth can also contribute to 
their persistence by allowing time for adaptation to any changes in their 
environment. 
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4.6 Aims and objectives 
In order to further understand potential environmental sources of NTM, in particular 
M. abscessus complex, a large study was performed on sampling taken from areas 
within the local environment, in homes and from animals and various food items. 
Samples were also obtained from the local CF adult and paediatric outpatient 
centres and inpatient wards. 
RGM medium (as described in Chapter 2) was used for the culture of all samples 
as it was thought to be the most relevant and effective for isolating NTM in 
comparison to other media commercially available where contamination by non-
NTM could be anticipated. 
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4.7 Materials 
Water samples were collected in sterile containers purchased from BDH, Poole, UK 
and filtered using Gelman Sciences vacuum control box model 4205 and filter funnel 
manifold 3-place polyurethane 629-4205 with GN-6 metricel 0.45 µm 47 mm grid 
sterile membrane disc filters purchased from Gelman Sciences, Portsmouth, UK.  
Sterile polywipes MW 729A were purchased from Medical Wire and Equipment, 
Wiltshire, UK. Sterilisation of media and equipment where appropriate was 
performed using a LTE Touchclave-R autoclave (LTE Scientific Ltd. Oldham, UK). 
Ingredients for RGM medium were purchased as described in Chapter 2. All plates 
were incubated in a LEEC 30oC incubator obtained from Laboratory and Electrical 
Engineering Company, Nottingham, UK. All isolates were identified using MALDI 
biotyper (Bruker, Coventry, UK). Stringent wash solution, hybridisation buffer, 
conjugate, substrate and rinse solutions used in the HAIN hybridisation procedure 
(Section 4.8.5.3.2) were all purchased from HAIN Lifescience, Nehren, Germany. 
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4.8 Methods 
4.8.1 Culture medium 
RGM medium was used for the processing of all samples and prepared as described 
in Appendix 2. RGM broth was made up as in section 3.10.3 in Chapter 3 and a 10 
ml aliquot added to sterile 20 ml plastic universals. 
4.8.2 Environmental samples  
Samples were collected from various items and locations (shown in Table 4-1). New 
sterile disposable gloves were worn for each sample taken, so as not to introduce 
any contamination. A 10 x 5 cm sterile polywipe premoistened in phosphate buffer 
was used to thoroughly wipe down each area, and stored in an individual sterile 
sealed bag to transfer to the laboratory. Polywipes were aseptically placed onto 
RGM medium and spread over the whole plate to maximise transfer of any material. 
Plates were incubated at 30oC for ten days.  
 
Table 4-1: Environmental areas tested for non-tuberculous mycobacteria 
No. Environmental area sampled 
1 Washing up sponge 
2 Floor Dust 
3 Kitchen bench 
4 House phone 
5 Toilet seat 
6 Sink draining board 
7 Sofa (leather) 
8 Hallway (door handles, surfaces, floor) 
9 Bathroom (basin, showerhead) 
10 Kitchen (basin, shelves, taps) 
11 Living room (table, sofa, mantelpiece, handle, light switch) 
12 Chicken egg 
13 Can of diet coca cola lid 
14 Horse manure 
15 Countryside soil 
16 Bus seats  
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Table 4-1 continued: Environmental areas tested for non-tuberculous 
mycobacteria 
No. Environmental area sampled 
17 Cash machine  
18 Computer desk 
19 Window sill dust 
20 Laptop keyboard 
21 House plant 
22 Grass 
23 Cigarette ash 
24 Lab Coat Microbiology Research Dept. 
25 Medical Student Shirt 
26 Medical Student ID Badge 
27 Cigarette (Lambert and Butler) - Interior 
28 Cigarette (Lambert and Butler) - Filter 
29 Paediatric Outpatients Green Area Reception Desk (Not cleaned) 
30 Paediatric Outpatients Red Area Children’s Desk (Not cleaned) 
31 C1 Consultants Desk 
32 C1 Sink 
33 C1 Children's Desk & Chair 
34 C1 BP Cuff 
35 C1 Pillow 
36 C1 Couch 
37 C1 Couch Blue Roll 
38 C2 Consultants Desk 
39 C2 Sink 
40 C2 Children's Desk & Chair 
41 C2 BP Cuff 
42 C2 Couch 
43 C2 Pillow 
44 C2 Stethoscope 
45 C3 Consultants Desk 
46 C3 Sink 
47 C3 Children's Desk & Chair 
48 C3 BP Cuff 
49 C3 Couch 
50 C3 Pillow 
51 C3 Children's Toys 
52 C4 Consultants Desk 
53 C4 Sink 
54 C4 Children's Desk & Chair 
55 C4 BP Cuff 
56 C4 Couch 
57 C4 Pillow 
58 C4 Couch Blue Roll 
59 C4 Stethoscope 
60 C5 Consultants Desk 
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Table 4-1 continued: Environmental areas tested for non-tuberculous 
mycobacteria 
No. Environmental area sampled 
61 C5 Sink 
62 C5 Children’s desk & chair 
63 C5 BP Cuff 
64 C5 Couch 
65 C5 Pillow 
66 C5 Children's Toys 
67 Treatment Room Desk 
68 Treatment Room Couch 
69 Treatment Room Sink 
70 Treatment Room Pillow 
71 Treatment Room Cuff 
72 Treatment Room Height Machine 
73 Treatment Room Weight Machine 
74 Treatment Room Nurse's Trolley 
75 Treatment Room Children's Toys 
76 Treatment Room Child's Wheelchair 
77 Adult C1 Patient chair 
78 Adult C1 Bed 
79 Adult C1 Desk 
80 Adult C1 Sink 
81 Adult C2 Patient chair 
82 Adult C2 Bed 
83 Adult C2 Desk 
84 Adult C2 Sink 
85 Adult C3 Patient chair 
86 Adult C3 Bed 
87 Adult C3 Desk 
88 Adult C3 Sink 
89 Adult C4 Patient chair 
90 Adult C4 Bed 
91 Adult C4 Desk 
92 Adult C4 Sink 
93 Adult C5 Patient chair 
94 Adult C5 Bed 
95 Adult C5 Desk 
96 Adult C5 Sink 
97 Adult C6 Patient chair 
98 Adult C6 Bed 
99 Adult C6 Desk 
100 Adult C6 Sink 
101 Adult C7 Patient chair 
102 Adult C7 Bed 
103 Adult C7 Desk 
104 Adult C7 Sink 
105 Adult C8 Patient chair 
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Table 4-1 continued: Environmental areas tested for non-tuberculous 
mycobacteria 
No. Environmental area sampled 
106 Adult C8 Bed 
107 Adult C8 Desk 
108 Adult C8 Sink 
109 Adult C8 Observation machine 
110 Adult C9 Patient chair 
111 Adult C9 Bed 
112 Adult C9 Desk 
113 Adult C9 Sink 
114 Lung function room 1 sink 
115 Lung function room 1 spirometer tubes 
116 Lung function room 1 desk 
117 Lung function room 1 chair 
118 Lung function room 2 sink 
119 Lung function room 2 spirometer 1 
120 Lung function room 2 spirometer 2 
121 Lung function room 2 spirometer 3 
122 Lung function room 2 HD pft chair/glass 
123 Ward 52 C6 room sink 
124 Ward 52 C6 showerhead 
125 Ward 52 C7 room sink 
126 Ward 52 C7 WC sink 
127 Ward 52 C7 armchair 
128 Ward 52 C7 showerhead 
129 Ward 52 C8 WC sink 
130 Ward 52 C8 room sink 
131 Ward 52 C8 room armchair 
132 Ward 52 C8 room bathroom door handles 
133 Ward 52 C8 room showerhead 
134 Ward 52 C10 room sink 
135 Ward 52 C10 WC sink 
136 Ward 52 C10 showerhead 
137 Ward 52 C10 O2 wall mounts 
138 Ward 52 C10 armchair 
139 Ward 52 C10 window sill 
140 Ward 52 C10 patient table 
141 Ward 52 C10 bed 
142 Ward 52 C11 WC sink 
143 Ward 52 C11 room sink 
144 Ward 52 C11 showerhead 
145 Ward 52 C11 armchair 
146 Ward 52 Corridor observation machine 
147 Ward 52 Corridor patient chair 
148 Flower Petal 
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Table 4-1 continued: Environmental areas tested for non-tuberculous 
mycobacteria 
No. Environmental area sampled 
149 Flower Stem 
150 Flower Soil 
151 Flower Root 
 
4.8.3 Water Samples 
Sampling was completed on hospital water from showers, sink units and drinking 
fountains from around the CF wards, waiting areas, consultant and patient treatment 
rooms at the Royal Victoria Infirmary, Newcastle upon Tyne, UK. Samples were also 
taken from local homes, local rivers and ponds and various bottled waters, juices 
and carbonated fruit drinks (as shown in Table 4-2). From each area, 500 ml 
volumes were collected and stored in sterile bottles. GN-6 metricel membrane disc 
filters, diameter 47 mm, pore size 0.45 μm were used and 250 ml was filtered using 
the membrane filtration apparatus. Membrane filters were then aseptically placed 
onto RGM medium and plates were incubated at 30oC for ten days.  
 
Table 4-2: Water samples tested for non-tuberculous mycobacteria 
No. Water sampling area 
1 House 1 bathroom hot 
2 House 1 bathroom cold 
3 House 1 Kitchen hot 
4 House 1 kitchen cold 
5 House 1 toilet 
6 House 1 outdoor tap 
7 House 2 bathroom hot 
8 House 3 bathroom cold 
9 House 2 kitchen cold 
10 House 2 outdoor tap 
11 House 2 shower hot 
12 Pathology Dept. Freeman Hospital Male Bathroom Hot 
13 Pathology Dept. Freeman Hospital Male Bathroom Cold 
14 Pathology Dept. Freeman Hospital Female Bathroom Hot 
15 Pathology Dept. Freeman Hospital Female Bathroom Cold 
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Table 4-2 continued: Water samples tested for non-tuberculous 
mycobacteria 
No. Water sampling area 
16 Freeman Hospital Outpatient Drinking Water 
17 Pathology Dept. Freeman Hospital Kitchen Hot 
18 Pathology Dept. Freeman Hospital Kitchen Cold 
19 Ward 52 CF Unit C6 Shower 
20 Ward 52 CF Unit C6 WC Sink 
21 Ward 52 CF Unit C6 Room Sink 
22 Ward 52 CF Unit C8 Shower 
23 Ward 52 CF Unit C8 WC Sink 
24 Ward 52 CF Unit C8 Room Sink 
25 Ward 52 CF Unit C10 Shower 
26 Ward 52 CF Unit C10 WC Sink 
27 Ward 52 CF Unit C10 Room Sink 
28 Ward 52 CF Unit C7 Shower 
29 Ward 52 CF Unit C11 Shower 
30 Adult CF Clinic Waiting Rm Drinking Fountain 
31 Adult CF Clinic C1 sink 
32 Adult CF Clinic C5 sink 
33 Adult CF Clinic C6 sink 
34 Adult CF Clinic C7 sink 
35 Adult CF Clinic C8 sink 
36 Adult CF Clinic C9 sink 
37 Paediatric C1 sink 
38 Paediatric C2 sink 
39 Paediatric C3 sink 
40 Paediatric C4 sink 
41 Paediatric C5 sink 
42 Paediatric treatment room sink 
43 Paediatric drinking water outpatients main waiting area 
44 Paediatric drinking water green (area 1) 
45 Paediatric drinking water red (area 2) 
46 Evian bottled water 
47 Eden Falls bottled water 
48 Asda Smart Price bottled water 
49 Highland Spring bottled water 
50 Buxton bottled water 
51 Ouseburn River 
52 Paddy Freeman Pond, High Heaton 
53 Coca-Cola 
54 Fanta Zero 
55 Tango 
56 Sun Magic Orange Juice 
57 Sun Magic Pineapple Juice 
58 Sun Magic Apple Juice 
59 Volvic Touch of Fruit Cherry 
177 
 
Table 4-2 continued: Water samples tested for non-tuberculous 
mycobacteria 
No. Water sampling area 
60 Volvic Touch of Fruit Lemon/Lime 
61 Ribena 
62 Robinsons Fruit Shoot Orange 
63 Robinsons Fruit Shoot Apple/Blackcurrant 
64 Pepsi cola 
 
4.8.4 Food Samples 
Various unsystematic food items from local supermarkets and outdoor markets, both 
pre-packed and loose (see Table 4-3) were collected. Each sample was aseptically 
diced, mashed and transferred into 10 ml sterile RGM broth and incubated at 30oC. 
After ten days’ incubation, 10 µl aliquots were taken from each broth and inoculated 
onto RGM medium and incubated for a further ten days at 30oC.  
 
Table 4-3: All foods tested for non-tuberculous mycobacteria 
No Food samples tested 
1 Brussel Sprouts 
2 Salad Cress 
3 Salad Cress Soil 
4 Cheese 
5 Spring Onion - White 
6 Spring Onion - Green 
7 Strawberry  
8 Raspberry 
9 Sweet and Crunchy prepacked salad 
10 Coleslaw prepacked mix 
11 Iceberg Lettuce 
12 Blackberry 
13 Sliced Red Onions 
14 Grape - Red 
15 Grape - Green 
16 Mushrooms 
17 Savoy Cabbage 
18 Grower's Selection - Red Onion 
19 Grower's Selection - Courgette 
20 Grower's Selection - Red Pepper 
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Table 4-3 continued: All foods tested for non-tuberculous mycobacteria 
No Food samples tested 
21 Grower's Selection - Yellow Pepper 
22 Celery 
23 Cucumber 
24 Smoked Haddock 
25 Salad Tomato 
26 Casserole Vegetables - Carrot 
27 Casserole Vegetables -  Potato 
28 Casserole Vegetables - Swede 
29 Casserole Vegetables - Leek 
30 Casserole Vegetables - White Onion 
31 Swede 
32 Mix Veg - Carrot 
33 Mix Veg - Broccoli 
34 Mix Veg - Cauliflower 
35 Twin Pack - Baby Corn 
36 Twin Pack - Fine Beans 
37 Beansprouts 
38 Plum 
39 Potato 
40 Radish 
41 Red Apple 
42 Orange Pulp 
43 Orange Zest 
44 Lemon Pulp 
45 Lemon Zest 
46 Banana 
47 Green Apple 
48 Red Pepper 
49 Large Potato 
50 New Potato 
51 Parsnip 
52 Sweet Potato 
53 Pear 
54 Onion 
55 Whole Milk 
56 Cottage Cheese 
57 Single Cream 
58 Organic Yogurt 
59 Soil – Onion from allotment 
60 Flat Cap Mushrooms 
61 Shallot 
62 Jersey Royal Potato 
63 Beansprouts 
64 Almonds 
65 Dried Papaya 
66 Dried Cranberry 
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Table 4-3 continued: All foods tested for non-tuberculous mycobacteria 
No Food samples tested 
67 Pick and mix sweets (loose) 
68 Bread (uncut from bakery) 
69 Ham (loose) 
70 Flat Leaf Parsley 
71 Cherry 
72 Ginger 
73 Butter (Lurpak) 
74 Cheese (Hard) 
75 Stir Fry Chicken (from butcher) 
76 Stir Fry Onion (from butcher) 
77 Stir Fry Carrot (from butcher) 
78 Stir Fry Marinade (from butcher) 
79 Mixed Grill Beef Burger (from butcher) 
80 Mixed Grill Herb Burger (from butcher) 
81 Mixed Grill Herb Sausage (from butcher) 
82 Mixed Grill Beef Sausage (from butcher) 
83 Mixed Grill Pork Sausage (from butcher) 
 
Uninoculated control plates, broth and equipment from all sample sets were 
incubated at both 30oC and 37oC for ten days. Unused swabs were also placed onto 
RGM plates, spread over the whole plate, and incubated at both 30oC and 37oC for 
ten days as shown in Table 4-4.  
 
Table 4-4: Negative controls used in all sampling 
No. Controls 
1 Control Broth 30oC 
2 Control Broth 37oC 
3 Control Plate 30oC 
4 Control Plate 30oC 
5 Water Filter 
6 Scalpel 
7 Methylated Spirit 
8 Control Sponge (not used) 30oC 
9 Control Sponge (not used) 37oC 
10 Control Broth 30oC 
11 Control Broth 37oC 
12 Control Plate 30oC 
13 Control Plate 30oC 
14 Water Filter 
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Table 4-4 continued: Negative controls used in all sampling 
No. Controls 
15 Scalpel 
16 Methylated Spirit 
17 Control Sponge (not used) 30oC 
18 Control Sponge (not used) 37oC 
19 Control Broth 37oC 
20 Control Broth 30oC 
21 Control Plate 37oC 
22 Control Plate 30oC 
23 Water Filter 
24 Scalpel 
25 Methylated Spirit 
26 Sponge (unused) 
27 Sponge (unused) 
 
4.8.5 Methods of identification of all isolates recovered 
4.8.5.1 Matrix-assisted laser/desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) 
All bacterial growth from all types of sample were sub-cultured onto Columbia blood 
agar to obtain pure cultures and identified using MALDI-TOF MS. For those isolates 
that were not able to be identified full extractions were performed and identification 
was attempted a second time using MALDI-TOF MS. 
4.8.5.1.1 Preparation of sample for MALDI-TOF MS 
A single colony was isolated and applied as a thin but visible film onto the MALDI 
target plate using a sterile wooden stick. This was overlaid with 2 µl of matrix (alpha-
cyano-4-hydroxycinnamic acid in 50% acetonitrile and 2.5% trifluoroacetic acid) and 
allowed to air dry. This is the suggested method as recommended by Bruker 
(Bruker, 2017). 
For difficult to identify isolates or suspected mycobacteria, an extraction process 
had to be adhered to in order to disrupt cell wall structures. After numerous protocols 
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were evaluated, the method adopted was one recommended by Saleeb et al.  Using 
a 1 µl loop, a visible amount of cells were suspended in 70% ethanol and briefly 
centrifuged. The supernatant was discarded and the pellet re-suspended in 50 µl 
formic acid, vortexed for five minutes and 50 µl 100% acetonitrile added and 
vortexed for a further five minutes. The sample was then centrifuged at maximum 
speed for two minutes and 2 µl placed onto the MALDI target plate, air-dried and 
overlaid with matrix as previously described (Saleeb et al., 2011). 
4.8.5.2 Gram-staining and staining for acid-fast bacilli  
Gram-staining was performed on all isolates that could not be identified by MALDI-
TOF MS. An auramine and/or Zeihl Neelsen stain was also performed in order to 
assess the likelihood of mycobacteria and eliminate any non-mycobacteria.  
4.8.5.2.1 Staining of heat fixed films by auramine phenol for the detection by 
fluorescence of acid and alcohol-fast organisms 
A 1 µl sterile plastic loopful of each isolate was spread over an individual slide, 
keeping away from the slide edges and avoiding making the smear too thick. The 
slides were then heat fixed by placing on a hot plate for two minutes. Auramine 
phenol stain was poured onto the heat fixed slide and left for 15 minutes then 
washed off with water.  Acid-alcohol (1% v/v) was poured on and left for one minute, 
washed off and then the process was repeated for a further two minutes. This staged 
approach to decolourising the slides takes account of the fact that the first minute 
will elute the auramine phenol from the slide, consequently diluting the effect of the 
acid-alcohol. The second phase (two minutes) will therefore be at full strength. Acid-
alcohol was washed off and the slide was counter stained with (0.02% w/v) aqueous 
solution of thiazine red for 30 seconds before being rinsed with water and allowed 
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to dry. Slides were examined using U.V microscopy using a x40 non-cover glass 
lens. 
4.8.5.2.2 Staining of heat fixed films by Ziehl-Neelson for the detection of acid 
and alcohol-fast organisms 
Slides were prepared and heat fixed as for auramine staining then flooded with 
strong carbol fuchsin. Using a lighted metal rod consisting of cotton wool soaked in 
industrial methylated spirit the slides were gently heated until just steaming and then 
allowed to stand for five minutes. Slides were heated again until steaming and left 
for a further five minutes before being rinsed well with water. Slides were then 
decolourised several times for 2-5 minutes with a 3% v/v acid-alcohol solution, 
rinsing with tap water between each application.  To counter-stain, 1% methylene 
blue was added for 30 seconds before slides were rinsed with water and allowed to 
dry. Immersion oil was added to each slide and examined using a light microscope 
and x40 and x100 lenses. 
4.8.5.2.3 Gram-staining of unidentified isolates to eliminate any non-
mycobacteria  
Slides were prepared and heat fixed as for auramine and ZN staining. Once the 
slides were cooled down crystal violet was added, left for 60 seconds, and then 
washed briefly with water. Gram’s iodine was added and left for 60 seconds before 
being washed off with water. Slides were then flooded with 95% acetone for three 
seconds and washed off. Safranin was then added to slides as a counter-stain and 
left for 30 seconds before being washed off. Slides were then examined under the 
oil immersion lens (100x objective). 
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4.8.5.3 HAIN Genotyping protocol for the identification of clinically relevant 
mycobacterial species using BEEBlot G45 Automated Platform 
All AFB positive isolates were sub-cultured onto Columbia blood agar and prepared 
for identification using HAIN Genotyping (HAIN Lifescience, 2015). Five commonly 
encountered control species previously typed by VNTR profiing at Public Health 
Colindale, UK and listed in Appendix 1, were also tested to validate the HAIN 
Genotyping results.  These included M. abscessus subsp. abscessus (n = 1), M. 
chelonae (n = 1), M. immunogenum (n = 1), M. abscessus subsp. massiliense (n = 
1) and M. mucogenicum (n = 1). 
4.8.5.3.1 Sample preparation for extraction of DNA 
A 10 µl loopful of pure bacteria was suspended in 1 ml of PCR grade water and 
centrifuged at 10,000g for 15 minutes.  The supernatant was poured off and the 
pellet re-suspended in 300l of PCR grade water.  Tubes were then incubated for 
20 minutes in a 90oC heating block. At the end of the heating process, tubes were 
removed and placed directly into a sonicating water bath. After 15 minutes the tubes 
were centrifuged at 21,000g for five minutes and 200l of the supernatant was 
transferred to a new, labelled 1.5 ml screw capped pointed tube for PCR. 
4.8.5.3.2 Amplification of extracted mycobacterial DNA 
Mastermix was made up using the following amounts per sample; 3.5 µl sterile 
water, 5.0 µl 10 x buffer, 1.0 µl MgCl2, 35.0 µl primer nucleotide mix and 0.5 µl Taq 
DNA polymerase and gently vortexed. Capped 0.2 ml PCR tubes were labelled for 
each sample and 45 µl of mastermix was added to each one along with 5 µl of 
extracted DNA and briefly vortexed. Specific primer information is proprietary and 
not in the public domain (K. Geber  2017, personal communication, 31 July).  
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4.8.5.3.3 Running the Amplification Cycler. 
Tubes were loaded into the block along with a contamination control sample 
containing 5 µl water in place of DNA, and the amplification profile was set as shown 
in Table 4-5. Once completed, the amplified samples were ready for the Hain 
genotyping. 
 
Table 4-5: Amplification profile for DNA 
Number of cycles Temperature Time 
   
1 95oC 15 minutes 
 
10 95oC 
58oC 
30 seconds 
2 minutes 
 
20 95oC 
53oC 
70oC 
25 seconds 
40 seconds 
40 seconds 
 
1 70oC 8 minutes 
   
   
   
4.8.5.3.4 Hybridisation Test Procedure 
Common Mycobacteria (CM) or Additional Species (AS) test strips were removed 
from storage at 4oC and allowed to come to room temperature whilst the BEEBlot 
G45 automated platform was pre-warmed to 45oC. A volume of 20 µl of denaturation 
solution was added to each of the wells followed by 20 µl of amplified sample, 
carefully mixed by pipetting up and down and incubated at room temperature for five 
minutes. Stringent wash solution, hybridisation buffer, conjugate, substrate and 
rinse solutions were placed in the appropriate sections in the BBBlot and when 
prompted one strip was placed into each well, ensuring they were completely 
covered by the solution and the coated side facing upwards. Once the cycle was 
completed strips were removed and pasted onto a kit evaluation sheet by aligning 
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the bands CC and UC with respective lines on the sheet. This procedure was 
repeated for any samples requiring further identification with the Additional Species 
(AS) kit. 
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4.9 Results 
From all of the testing performed, a total of 298 separate samples (Table 4-1 to 4.3) 
were taken from various locations comprising 83 food items, 64 water samples and 
151 environmental areas. From these, 272 individual isolates were recovered (see 
Table 4-6 and Table 4-7) and 196 showed no growth. This included 92 from 
environmental samples, 161 from water sampling and 19 from foods. All control 
plates (n = 27) were negative after ten days’ incubation. 
 
Table 4-6: Description of all areas tested for NTM 
Area Growth Identification 
Environmental areas     
Washing up sponge + M. peregrinum x 2  
+ Gram-negative 
Floor Dust + Gram-negative 
Kitchen bench + Gram-negative 
House phone NG   
Toilet seat NG   
Sink draining board + Streptococcus oralis x 2  
+ Gram-negative 
Sofa (leather) NG   
Hallway (door handles, surfaces, floor) + Chryseobacterium sp. 
Bathroom (basin, showerhead) + Gram-negative  
+ D. acidovorans x 5  
+ M. fortuitum  
+ Mycobacterium species 
Kitchen (basin, shelves, taps) + Gram-negative 
Living room (table, sofa, mantelpiece, 
handle, light switch) 
NG 
 
Chicken egg NG   
Can of diet coca cola lid NG 
 
Horse manure + Gram-negative  
+ Chryseobacterium sp.x 2  
+ Gram-negative  
+ Myroides odoratus  
+ A. fumigatus x 2 
Countryside soil + Chyrseobacterium oranimense  
+ Gram-negative  
+ Arthrobacer sp.  
+ M. peregrinum  
+ A. fumigatus 
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Table 4-6 continued: Description of all areas tested for NTM 
Area Growth Identification 
 
+ Achromobacter sp.  
+ Chryseobacterium sp. 
Bus seats + Gram-negative  
Cash machine NG   
Computer desk + M. peregrinum 
Window sill dust + M. peregrinum x 2  
+ Fusarium sp. 
Laptop keyboard NG   
House plant + Achromobacter sp.  
+ M. peregrinum  
+ Mycobacterium species  
+ Fusarium sp. X 2  
+ Fusarium oxysporum 
Grass NG   
Cigarette ash NG   
Lab Coat Microbiology Research Dept. + Gram-negative  
+ M. chelonae 
Medical Student Shirt NG   
Medical Student ID Badge NG   
Cigarette (Lambert and Butler) - 
Interior 
+ Bacillus sp. X 2 
Cigarette (Lambert and Butler) - Filter NG   
Paediatric Outpatients Green Area 
Reception Desk (Not cleaned) 
NG   
Paediatric Outpatients Red Area 
Children’s Desk (Not cleaned) 
NG   
C1 Consultants Desk + Gram-negative 
C1 Sink + Gram-negative x 2 
C1 Children's Desk & Chair NG   
C1 BP Cuff NG   
C1 Pillow NG   
C1 Couch NG   
C1 Couch Blue Roll NG   
C2 Consultants Desk NG   
C2 Sink + D. acidovorans x 2 
C2 Children's Desk & Chair NG   
C2 BP Cuff NG   
C2 Couch NG   
C2 Pillow NG   
C2 Stethoscope NG   
C3 Consultants Desk NG   
C3 Sink + Gram-negative x 2  
+ M. chelonae 
C3 Children's Desk & Chair NG   
C3 BP Cuff NG   
C3 Couch NG   
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Table 4-6 continued: Description of all areas tested for NTM 
Area Growth Identification 
C3 Pillow NG   
C3 Children's Toys NG   
C4 Consultants Desk NG   
C4 Sink + D. acidovorans 
C4 Children's Desk & Chair NG   
C4 BP Cuff NG   
C4 Couch NG   
C4 Pillow NG   
C4 Couch Blue Roll NG   
C4 Stethoscope NG   
C5 Consultants Desk NG   
C5 Sink + D. acidovorans  
+ M. chelonae 
C5 Children’s desk & chair NG   
C5 BP Cuff NG   
C5 Couch NG   
C5 Pillow NG   
C5 Children's Toys NG   
Treatment Room Desk NG   
Treatment Room Couch NG   
Treatment Room Sink + M. chelonae  
+ Gram-negative  
+ M. chelonae  
+ D. acidovorans x 2 
Treatment Room Pillow NG   
Treatment Room Cuff NG   
Treatment Room Height Machine NG   
Treatment Room Weight Machine NG   
Treatment Room Nurse's Trolley NG   
Treatment Room Children's Toys + Gram-negative 
Treatment Room Child's Wheelchair NG   
Adult C1 Patient chair NG   
Adult C1 Bed NG   
Adult C1 Desk NG   
Adult C1 Sink + Mycobacterium species x 2 
Adult C2 Patient chair NG   
Adult C2 Bed NG   
Adult C2 Desk NG   
Adult C2 Sink +  Mycobacterium species 
Adult C3 Patient chair NG   
Adult C3 Bed NG   
Adult C3 Desk NG   
Adult C3 Sink +  Mycobacterium species 
Adult C4 Patient chair NG   
Adult C4 Bed NG   
Adult C4 Desk NG   
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Table 4-6 continued: Description of all areas tested for NTM 
Area Growth Identification 
Adult C4 Sink + D. acidovorans 
Adult C5 Patient chair NG   
Adult C5 Bed NG   
Adult C5 Desk NG   
Adult C5 Sink + M. chelonae 
Adult C6 Patient chair NG   
Adult C6 Bed NG   
Adult C6 Desk NG   
Adult C6 Sink + Mycobacterium species x 2 
Adult C7 Patient chair NG   
Adult C7 Bed NG   
Adult C7 Desk NG   
Adult C7 Sink NG   
Adult C8 Patient chair NG   
Adult C8 Bed NG   
Adult C8 Desk NG   
Adult C8 Sink NG   
Adult C8 Observation machine NG   
Adult C9 Patient chair NG   
Adult C9 Bed NG   
Adult C9 Desk NG   
Adult C9 Sink + Mycobacterium species x 2 
Lung function room 1 sink NG   
Lung function room 1 spirometer tubes NG   
Lung function room 1 desk NG   
Lung function room 1 chair NG   
Lung function room 2 sink + Mycobacterium species 
Lung function room 2 spirometer 1 NG   
Lung function room 2 spirometer 2 NG   
Lung function room 2 spirometer 3 NG   
Lung function room 2 HD pft 
chair/glass 
NG   
Ward 52 C6 room sink + Mycobacterium species x 2 
Ward 52 C6 showerhead + D. acidovorans 
Ward 52 C7 room sink NG   
Ward 52 C7 WC sink + Mycobacterium species 
Ward 52 C7 armchair NG   
Ward 52 C7 showerhead + Mycobacterium species x 2 
Ward 52 C8 WC sink + M. mucogenicum 
Ward 52 C8 room sink + Mycobacterium species 
Ward 52 C8 room armchair NG   
Ward 52 C8 room bathroom door 
handles 
NG   
Ward 52 C8 room showerhead + M. mucogenicum  
+ Mycobacterium species 
Ward 52 C10 room sink + Mycobacterium species 
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Table 4-6 continued: Description of all areas tested for NTM 
Area Growth Identification 
 
+ Mycobacterium species 
Ward 52 C10 WC sink NG   
Ward 52 C10 showerhead NG   
Ward 52 C10 O2 wall mounts NG   
Ward 52 C10 armchair NG   
Ward 52 C10 window sill NG   
Ward 52 C10 patient table NG   
Ward 52 C10 bed + M. peregrinum 
Ward 52 C11 WC sink + D. acidovorans 
Ward 52 C11 room sink + M. mucogenicum x 2 
Ward 52 C11 showerhead + M. mucogenicum 
Ward 52 C11 armchair NG   
Ward 52 Corridor observation machine NG   
Ward 52 Corridor patient chair NG   
Flower Petal NG   
Flower Stem NG   
Flower Soil NG   
Flower Root NG   
   
Waters    
House 1 bathroom hot + Curtobacterium flaccumfaciens  
+ M. chelonae 
House 1 bathroom cold + M. mucogenicum x 2 
House 1 Kitchen hot NG   
House 1 kitchen cold + M. mucogenicum  
+ M. chelonae x 2 
House 1 toilet + Microbacterium sp.  
+ Gram-negative  
+ M. chelonae x 4 
House 1 outdoor tap + Curtobacterium flaccumfaciens  
+ Gram-negative  
+ Arthrobacter sp. 
House 2 bathroom hot + Mycobacterium species x 3  
+ Gram-negative 
House 3 bathroom cold + Mycobacterium species 
House 2 kitchen cold + Mycobacterium species  
+ Mycobacterium species 
House 2 outdoor tap NG   
House 2 shower hot + Gram-negative x 3  
+ Chryseobacterium indologenes  
+ Mycobacterium species  
+ Gram-negative 
Pathology Dept. Freeman Hospital 
Male Bathroom Hot 
+ Gram-negative 
Pathology Dept. Freeman Hospital 
Male Bathroom Cold 
+ M. chelonae 
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Table 4-6 continued: Description of all areas tested for NTM 
Area Growth Identification 
 
+ Gram-negative 
Pathology Dept. Freeman Hospital 
Female Bathroom Hot 
+ Gram-negative 
 
+ Chryseobacterium sp. 
Pathology Dept. Freeman Hospital 
Female Bathroom Cold 
+ Gram-negative 
 
+ M. mucogenicum  
+ Mycobacterium species 
Freeman Hospital Outpatient Drinking 
Water 
+ Mycobacterium species 
Pathology Dept. Freeman Hospital 
Kitchen Hot 
NG   
Pathology Dept. Freeman Hospital 
Kitchen Cold 
+ Gram-negative 
Ward 52 CF Unit C6 Shower + Mycobacterium species x 2 
Ward 52 CF Unit C6 WC Sink + Mycobacterium species x 5 
Ward 52 CF Unit C6 Room Sink + Mycobacterium species x 2 
Ward 52 CF Unit C8 Shower + Mycobacterium species x 3 
Ward 52 CF Unit C8 WC Sink + Mycobacterium species  
+ Gram-negative  
+ D. acidovorans x 4 
Ward 52 CF Unit C8 Room Sink + D. acidovorans x 4 
Ward 52 CF Unit C10 Shower + Mycobacterium species x 2  
+ D. acidovorans 
Ward 52 CF Unit C10 WC Sink + Gram-negative  
+ Mycobacterium species 
Ward 52 CF Unit C10 Room Sink + M. chelonae x 3  
+ Mycobacterium species 
Ward 52 CF Unit C7 Shower + M. chelonae x 2 
Ward 52 CF Unit C11 Shower + M. chelonae x 4  
+ Mycobacterium species 
Adult CF Clinic Waiting Rm Drinking 
Fountain 
+ M. chelonae x 4 
 
+ Mycobacterium species 
Adult CF Clinic C1 sink + M. chelonae  
+ Mycobacterium species  
+ Lactobacillus sp. 
Adult CF Clinic C5 sink + Mycobacterium species x 5 
Adult CF Clinic C6 sink + D. acidovorans x 4  
+ Mycobacterium species  
+ Flavobactrium lindanitolerans  
+ Fusarium sp. 
Adult CF Clinic C7 sink + Mycobacterium species x 2 
Adult CF Clinic C8 sink + Mycobacterium species  
+ D. acidovorans  
+ D. acidovorans 
Adult CF Clinic C9 sink + Chryseobacterium indologenes  
+ D. acidovorans 
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Table 4-6 continued: Description of all areas tested for NTM 
Area Growth Identification 
 
+ Chryseobacterium indologenes  
+ Gram-negative 
Paediatric C1 sink + D. acidovorans x 2  
+ M. chelonae  
+ Mycobacterium species 
Paediatric C2 sink + D. acidovorans x 3  
+ M. chelonae x 2 
Paediatric C3 sink + D. acidovorans x 2  
+ M. chelonae x 2 
Paediatric C4 sink + M. chelonae x 2  
+ Mycobacterium species 
Paediatric C5 sink + Mycobacterium species  
+ D. acidovorans  
+ M. chelonae x 2 
Paediatric treatment room sink + D. acidovorans x 2 
Paediatric drinking water outpatients 
main waiting area 
+ D. acidovorans x 2 
 
+ Mycobacterium species  
+ M. chelonae  
+ Mycobacterium species 
Paediatric drinking water green 
(area 1) 
+ M. chelonae x 3 
 
+ Mycobacterium species 
Paediatric drinking water red (area 
2) 
+ M. chelonae x 4 
 
+ Mycobacterium species 
Evian bottled water NG   
Eden Falls bottled water + Gram-negative  
+ UNKNOWN 
Asda Smart Price bottled water + Gram-negative  
+ Gram-negative  
+ Gram-negative 
Highland Spring bottled water NG   
Buxton bottled water NG   
Ouseburn River + Morganella morganii x 2  
+ Delftia acidovorans x 2  
+ Serratia liquefaciens  
+ Klebsiella oxytoca 
Paddy Freeman Pond, High Heaton + Delftia acidovorans x 2  
+ Gram-negative x 2  
+ A. flavus x 2  
+ Serratia fonticola x 2 
Coca-Cola NG   
Fanta Zero NG   
Tango NG   
Sun Magic Orange Juice NG   
Sun Magic Pineapple Juice NG   
193 
 
Table 4-6 continued: Description of all areas tested for NTM 
Area Growth Identification 
Sun Magic Apple Juice NG   
Volvic Touch of Fruit Cherry NG   
Volvic Touch of Fruit Lemon/Lime NG   
Ribena NG   
Robinsons Fruit Shoot Orange NG   
Robinsons Fruit Shoot 
Apple/Blackcurrant 
NG   
Pepsi cola NG    
    
Foods     
Brussel Sprouts NG   
Salad Cress + D. acidovorans 
Salad Cress Soil NG   
Cheese + Gram-negative 
Spring Onion - White + D. acidovorans 
Spring Onion - Green + D. acidovorans 
Strawberry NG   
Raspberry NG   
Sweet and Crunchy prepacked salad + Serratia sp. 
Coleslaw prepacked mix NG   
Iceberg Lettuce NG   
Blackberry NG   
Sliced Red Onions NG   
Grape - Red NG   
Grape - Green NG   
Mushrooms NG   
Savoy Cabbage NG   
Grower's Selection - Red Onion NG   
Grower's Selection - Courgette NG   
Grower's Selection - Red Pepper NG   
Grower's Selection - Yellow Pepper NG   
Celery + D. acidovorans 
Cucumber NG   
Smoked Haddock NG   
Salad Tomato NG   
Casserole Vegetables - Carrot NG   
Casserole Vegetables -  Potato NG   
Casserole Vegetables - Swede + Burkholderia gladioli 
Casserole Vegetables - Leek NG   
Casserole Vegetables - White Onion + D. acidovorans 
Swede NG   
Mix Veg - Carrot NG   
Mix Veg - Broccoli + Lactobacillus sp. 
Mix Veg - Cauliflower NG   
Twin Pack - Baby Corn NG   
Twin Pack - Fine Beans NG   
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Table 4-6 continued: Description of all areas tested for NTM 
Area Growth Identification 
Beansprouts NG   
Plum + Gram-negative 
Potato NG   
Radish + Pandoraea sp. 
Red Apple NG   
Orange Pulp NG   
Orange Zest NG   
Lemon Pulp NG   
Lemon Zest NG   
Banana NG   
Green Apple NG   
Red Pepper NG   
Large Potato NG   
New Potato + Gram-negative 
Parsnip + Gram-negative 
Sweet Potato + Gram-negative 
Pear NG   
Onion + Mycobacterium species 
Whole Milk NG   
Cottage Cheese NG   
Single Cream NG   
Organic Yogurt NG   
Soil – Onion from allotment + M. mucogenicum 
Flat Cap Mushrooms NG   
Shallot NG   
Jersey Royal Potato + Gram-negative 
Beansprouts NG   
Almonds + UNKNOWN 
Dried Papaya NG   
Dried Cranberry NG   
Hard Candy (pick and mix) NG   
Brazil Nut Toffee (pick and mix) NG   
Milk Bottle (pick and mix) NG   
Fizzy Cola (pick and mix) NG   
Gummy Bear (pick and mix) NG   
Cherry Lips (pick and mix) NG   
Bread (uncut from bakery) NG   
Ham (loose) NG   
Flat Leaf Parsley NG   
Cherry NG   
Ginger +  UNKNOWN 
Butter (Lurpak) NG   
Cheese (Hard) NG   
Stir Fry Chicken (from butcher) NG  
Stir Fry Onion (from butcher) NG  
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Table 4-6 continued: Description of all areas tested for NTM 
Area Growth Identification 
Stir Fry Carrot (from butcher) NG  
Stir Fry Marinade (from butcher) NG  
Mixed Grill Beef Burger (from butcher) NG  
Mixed Grill Herb Burger (from butcher) NG  
Mixed Grill Herb Sausage (from 
butcher) 
NG  
Mixed Grill Beef Sausage (from 
butcher) 
NG  
Mixed Grill Pork Sausage (from 
butcher) 
NG  
 
   
Controls    
Control Broth 30oC NG  
Control Broth 37oC NG  
Control Plate 30oC NG  
Control Plate 30oC NG  
Water Filter NG   
Scalpel NG   
Methylated Spirit NG   
Control Sponge (not used) 30oC NG   
Control Sponge (not used) 37oC NG   
Control Broth 30oC NG   
Control Broth 37oC NG   
Control Plate 30oC NG   
Control Plate 30oC NG   
Water Filter NG   
Scalpel NG   
Methylated Spirit NG   
Control Sponge (not used) 30oC NG   
Control Sponge (not used) 37oC NG   
Control Broth 37oC NG   
Control Broth 30oC NG   
Control Plate 37oC NG   
Control Plate 30oC NG   
Water Filter NG   
Scalpel NG   
Methylated Spirit NG   
Sponge (unused) NG   
Sponge (unused) NG   
   
Those areas/isolates highlighted in bold were sent to Public Health, Colindale, UK to verify 
identities. 
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Out of 272 individual isolates recovered, 130 were identified as mycobacteria (65 
unknown mycobacterial species), 118 were Gram-negative, 11 Gram-positive and 
10 fungi. Three isolates were unable to be identified by any methods used, however 
although these were all AFB positive, they were not identified as mycobacteria by 
HAIN (see Table 4-7).  
Using the GenoType Mycobacterium CM, a species-specific probe shows if 
members of the genus Mycobacterium are present, and in this case, further 
differentiation with GenoType Mycobacterium AS is recommended. Due to this, 
presumptuous identifications of M. mucogenicum could be given for some if not all 
of the 65 mycobacterial isolates that were not identified to species level. This is due 
to all but one of these being recovered from water samples/sinks where the majority 
of Mycobacterial isolates were either M. chelonae or M. mucogenicum. It could also 
be possible that had the HAINS CM test been repeated, many of these could be 
identified as M. chelonae. However, time and cost was a big factor in this, and the 
main aim was to try to isolate MABSC. 
The most frequently isolated Gram negative species in this study (43.2% of all 
Gram-negatives identified), was D. acidovorans, commonly found in water or soil, 
rarely a cause of infection, and usually only in immunocompromised individuals 
(Chun et al., 2009). All isolates in this study were found in either water, sinks or food 
(onions, celery, and cress). This species is not often reported in CF patients 
(Marchandin et al., 2012).  
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Table 4-7: Species identification of recovered isolates in all areas tested 
Species n Species n 
Gram-negative isolates 118 Gram-positive isolates 11 
Achromobacter sp. 2 Arthrobacter spp. 2 
B. gladioli 1 Bacillus spp. 2 
D. acidovorans 51 Curtobacterium 
flaccumfaciens 
2 
Chryseobacterium sp. 9 Lactobacillus spp. 2 
Flavobacterium lindanitolerans 1 Microbacterium sp. 1 
Other Gram-negative (by Gram-
stain) 
45 Streptococcus oralis 2 
Klebsiella oxytoca 1   
Morganella morganii 2 Non-tuberculous 
mycobacteria 
130 
Myroides odoratus 1 M. chelonae 46 
Pandoraea sp. 1 M. fortuitum 1 
Serratia spp. 4 M. mucogenicum 10 
  M. peregrinum 8 
Fungal isolates 10 Mycobacterium spp. 65 
A. flavus 2   
A. fumigatus 3   
Fusarium spp. 5   
    
Unidentified  
(non-mycobacterial) isolates 
3 TOTAL ISOLATES 272 
    
 
4.9.1 Identification of all recovered isolates 
All 272 isolates underwent analysis by MALDI-TOF MS, and 94 were given a score 
value of >2.0 or higher indicating secure Genus identification and probable species 
identification (Saffert et al., 2011). A further 45 isolates were identified as non-
mycobacteria by Gram stain, auramine and/or ZN stain.  
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4.9.1.1 HAIN Genotyping for the Identification of clinically relevant 
mycobacterial species using BEEBlot G45 Automated Platform 
A total of 133 isolates (plus an additional five as controls) underwent HAIN 
Genotyping for common mycobacteria. Out of these 130 were positively identified 
as mycobacteria. Three isolates remained unidentified, although they were not 
identified as mycobacteria by HAIN. 
4.9.1.2 Evaluation and interpretation of HAIN results 
Positive bands were noted and species determined using the HAIN CM and AS 
evaluation charts as shown in Figure 1-9 and Figure 1-10. 
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4.10 Discussion 
For many years, it has become apparent that due to the lack of evidence of person-
to-person transmission of NTM, it was generally accepted that the source of NTM 
infection in humans is the environment. It is well documented that NTM are said to 
be ubiquitous inhabitants within the environment, sharing a variety of ecological 
habitats with humans, including water, household plumbing, hot tubs, spas, peat 
and soil (Embil et al., 1997; De Groote et al., 2006; Falkinham, 2009; Feazel et al., 
2009; Thomson et al., 2013b; Thomson et al., 2013a).  
Discounting MABSC, other species of mycobacteria, e.g. M. chelonae, were found 
in abundance in many samples in this study. It cannot therefore be disregarded that 
the possibility of MABSC in the environment may possibly be overgrown in culture 
by other more plentiful mycobacterial species and thereby remain undetected. It 
could therefore be a challenge to detect MABSC if present in very small amounts 
(Ripoll et al., 2009). Out of all the mycobacteria isolated in this study, 35.4% were 
identified as M. chelonae; all were isolated either from sinks within the CF units or 
from waterborne sources. However, despite the wide array of areas tested in this 
study, there were no MABSC isolated from any of the samples. This would imply 
that M. chelonae can easily be isolated in copious amounts within the environment, 
particularly in water sources. 
Regardless of progress in understanding the ecology and epidemiology of NTM, 
there are still many unanswered questions. Although MABSC is understood to be 
acquired from the environment, reports of this are particularly lacking, and for those 
that do exist, their true credentials are questionable due to the identification of M. 
chelonae and MABSC still very much being confused. At the time of their writing, 
reports prior to 1992 identifying M. abscessus from the environment cannot be 
certain to be accurate, as M. abscessus and M. chelonae were not then designated 
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as separate species. Even some current reports cannot be taken at face value due 
to the identification methods used, for example, issues with HAIN Genotyping as 
described in Section 1.9.6. Although HAIN was used to identify a number of 
mycobacterial isolates in this study, control organisms, which had previously been 
identified by VNTR provided accurate results. A selection of M. chelonae from 
isolated species in this study (as shown by bold text in Table 4-6) were also sent to 
Public Health England, Colindale, UK to be verified by VNTR in order to confirm that 
the HAIN results were accurate. 
Recent developments in HAIN Genotyping mean that there is now an updated 
technique on the market; however, at the time of this study this was not available. 
This method, known as HAIN Genotype NTM-DR VER 10, and shown in Figure 4-1, 
is said to provide reliable results and is able to differentiate between the three 
members of the MABSC complex (HAIN Lifescience, 2017). The banding patterns 
significantly differ to that of previous HAIN Genotype Mycobacterium CM for M. 
abscessus and M. chelonae as shown in Section 1.9.6 Figure 1-9.
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Figure 4-1: HAIN Genotype NTM-DR showing a difference in banding patterns between M. abscessus complex and M. chelonae
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Recent evidence also now exists to confirm that there is widespread transmission 
of MABSC within the global CF community in a study performed by Bryant et al., 
2016. Previously, the majority of reports published indicated that patients with CF 
were infected with strains thought to be acquired environmentally that were 
genetically dissimilar, however upon carrying out whole genome sequencing in a 
single CF centre in the UK, two clusters of patients were infected with identical or 
virtually identical MABSC isolates. Social network analysis suggested that these 
were likely to have been acquired from within the hospital setting via fomite 
transmission (Bryant et al., 2013). 
Whole genome sequencing from several CF centres globally was carried out on 
1080 isolates from 517 individual patients in order to see if cross contamination 
could be the most plausible source of infection rather than independent acquisition 
from the environment. Although there were large genetic dissimilarities found 
between many isolates, multiple clades of almost undistinguishable isolates, mainly 
M. abscessus subsp. abscessus and M. abscessus subsp. massiliense, from areas 
that were very diverse geographically were identified. This suggests that the spread 
of circulating clones of MABSC is prevalent within the global CF patient community. 
The majority of patients were infected with clustered rather than unclustered 
isolates, and predominantly with M. abscessus subsp. abscessus clusters 1 and 2 
and M. abscessus subsp. massiliense cluster 1. Individual transmission events were 
also able to be determined, as well as likely mechanisms of transmission between 
patients, and it was concluded that fomite spread and airborne transmission were 
feasible explanations (Bryant et al., 2016). 
Despite this new evidence, no isolates of MABSC were isolated in this study from 
any hospital surfaces or equipment, and neither from rooms that were at the time 
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occupied by patients with CF, one known to be infected with M. abscessus subsp. 
massilense. 
The presence of a vast number of genes and operons within the genome of MABSC 
that are involved in resistance to arsenic and encoding cysteine desulferases is 
undoubtedly a trademark of a soil or aquatic dwelling environmental organism 
(Ripoll et al., 2009). However MABSC also contains many genes known to be 
involved in intracellular survival and is furnished with lipase encoding genes in order 
to obtain energy from eukaryotic host-derived lipids. It has far fewer ABC 
transporters or two-component sensor histidine kinases than M. smegmatis, 
signifying that MABSC may specialise in intracellular parasitism. An acceptable 
assumption is that MABSC have advanced to evade predators such as free living 
amoebas that share the same environment (Adekambi et al., 2004). Soil dwelling 
amoebas are plentiful at soil-plant boundaries supporting the growth of plant 
parasites, including bacteria, which amoebas feed upon. As the MABSC genome 
encodes a large number of salicylate hydroxylases it enables MABSC to resist the 
salicylic acid mediated protection mechanisms of plants suggesting that MABSC 
resides in close contact with plants and so consequently also amoebas (Ripoll et 
al., 2009).  
Many reports predict a continuous rise in the incidence of interactions between NTM 
and humans, likely resulting in more clinical cases of environmentally-derived NTM 
(Prevots and Marras, 2015). This can be attributed to several factors, including the 
use of chlorine for the disinfection of drinking water, medical devices, and in 
industrial settings used to sterilise habitats, thereby selecting for NTM by reducing 
or eliminating competitors (Marras and Daley, 2002; Johnson and Odell, 2014). 
Another factor is the growing proportion of the population predisposed to 
environmental NTM infection, such as those individuals with immunosuppressive 
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disorders, for example increasing incidences of transplantations, AIDS, and simply 
age. Novel environmental mycobacteria will also continue to be identified as more 
rapid and sophisticated identification methods are developed (Primm et al., 2004). 
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5. Introduction: Chapter 5 
5.1 Current treatment approaches to non-tuberculous mycobacterial 
infection  
Treatment of NTM infections is either by drug therapy, surgery, or a combination of 
both of these, however treatments can be lengthy, complex, very costly and are 
recurrently accompanied by drug related toxicities and side effects. These are 
frequently somewhat severe and consequently signify a substantial healthcare 
concern (van Ingen et al., 2010). Standard M. tuberculosis treatments are typically 
ineffective against NTM (Raju et al., 2016), therefore for rapidly-growing 
mycobacteria, treatment regimens are predominantly based upon in vitro drug 
susceptibility testing. Results of the susceptibility testing can differ considerably 
between species due to huge variabilities in growth rates between species, as well 
as innate resistance to antibacterial drugs. Although there remains a lack of 
correlation between in vitro drug susceptibility results and in vivo treatment 
outcomes, susceptibility testing can still be beneficial to those patients who have 
failed to respond to first line treatments, or have suffered from reoccurrence of a 
prior NTM infection (Griffith et al., 2007) and treatments should still be guided by 
drug susceptibility results (Floto et al., 2016). 
5.2 Recommended antibiotic treatments for pulmonary infection due to 
Mycobacteria abscessus complex in patients with cystic fibrosis  
There can be a huge variation of treatments between patients with infection caused 
by MABSC. This is due to a lack of clinical trial data to support any particular 
treatment approach, but will largely consist of a preliminary intensive phase with an 
oral macrolide, usually azithromycin plus intravenous amikacin with one or more 
additional intravenous antibiotics. This is usually cefoxitin, tigecycline or imipenem 
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for between three to twelve weeks dependent on the patients’ response to treatment 
and severity of infection, as well as their tolerance to particular drugs. This is 
followed by a continuation phase of an oral macrolide, clarithromycin or preferably 
azithromycin, and inhaled amikacin with the addition of two to three other antibiotics 
such as minocycline, linezolid, clofazimine or moxifloxacin (See Figure 5-1 and  
Table 5-1 below). 
Clarithromycin has a slightly enhanced in vitro activity in comparison to 
azithromycin, however it would appear that clarithromycin also induces greater 
erm41 gene expression therefore may be less effective than azithromycin against M. 
abscessus subsp. abscessus. Conversely, this is not the case for M. abscessus 
subsp. massiliense where both macrolides appear to be equally effective (Choi et 
al., 2012). There is however conflicting published data regarding the impact of the 
erm41 gene expression with each of these drugs, with Maurer et al reporting no 
significant differences in clarithromycin and azithromycin resistance in M. 
abscessus subsp. abscessus therefore suggesting that no preference should be 
given to either of these drugs in order to limit macrolide resistance (Maurer et al., 
2014b). 
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Figure 5-1: Typical MABSC treatment schedule as recommended by the US Cystic Fibrosis Foundation and European 
Cystic Fibrosis Society (Floto et al., 2016) 
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Table 5-1: Current guidelines for recommended antibiotic dosing regimens in 
the treatment of MABSC pulmonary disease in patients with cystic fibrosis 
(Floto et al., 2016) 
 
Antibiotic Route Dose suitable for children and 
adolescents 
Dose suitable for adults 
Amikacin Intravenous* Children: 15-30 mg/kg/dose once 
daily 
Adolescents: 10-15 mg/kg/dose 
once daily 
Maximum dose 1500 mg daily 
10-30 mg/kg once daily  
OR  
15 mg/kg/day in 2 doses  
Daily to 3 x weekly dosing  
Nebulised*Ɨǂ 250-500 mg/dose once or twice 
daily 
250-500 mg once or twice daily 
Azithromycin Oral Children: 10-12 mg/kg/dose once 
daily 
Adolescents : As adult dose 
Maximum dose 500 mg 
250-500 mg once daily 
Cefoxitin Intravenous 50 mg/kg/dose three times daily 
Maximum dose 12 g a day 
200 mg/kg/dose in three divided 
doses daily 
Maximum dose 12 g a day 
Clarithromycin Oral 7.5 mg/kg/dose three times daily 
Maximum dose 500 mg 
500 mg twice daily 
Intravenous Not recommended  
Clofazimine Oral Ɨ¥ 1-2 mg/kg/dose once daily 
Maximum dose 100 mg 
50-100 mg once a day 
Imipenem Intravenous 15-20 mg/kg/dose twice daily 
Maximum dose 1000 mg 
1 g twice daily 
Linezolid Oral ** < 12 years old: 10 mg/kg/dose 
three times daily 
≥12 years old: 10 mg/kg/dose 
once or twice daily 
Maximum dose 600 mg 
600 mg once or twice daily 
Intravenous ** < 12 years old: 10 mg/kg/dose 
three times daily 
≥12 years old: 10 mg/kg/dose 
once or twice daily 
Maximum dose 600 mg 
600 mg once or twice daily 
Moxifloxacin Oral 7.5-10 mg/kg/dose once daily 
Maximum dose 400 mg daily 
400 mg once daily 
Minocycline Oral 2 mg/kg/dose once daily 
Maximum dose 200 mg daily 
100 mg twice daily 
Tigecycline Intravenous Ɨπ 8-11 years old: 1.2 mg/kg/dose 
three times daily  
Maximum dose 500 mg 
≥12 years old: 100 mg loading 
dose then 50 mg once or twice 
daily 
100 mg loading dose then 50 mg 
once or twice daily 
*Adjust dose according to levels. The usual starting dose is 15 mg/kg aiming for peak level of 20-30 
µg/ml and trough levels of <5-10 µg/ml 
** Usually given with high dose (100 mg daily) pyridoxine (vitamin B6) to reduce the risk of 
cytopaenias 
Ɨ As tolerated 
ǂ Mixed with saline 
¥ Only available in the USA via an Investigational New Drug Application (IND) application to the 
Food and Drug Administration (FDA) 
π Many practitioners recommend pre dosing with one or more anti-emetics before dosing and/or 
gradual dose escalation from 25 mg daily to minimise nausea and vomiting 
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Clinical improvement in patients suffering from infection with MABSC would appear 
to be frequently unsuccessful (Maurer et al., 2014a), and culture conversion is not 
attainable for a great many patients, although data on treatment outcomes is still 
very limited. MABSC  exist in the lungs in many forms, including within macrophages 
and in biofilms posing vast difficulties to access, therefore creating a great challenge 
to systemically administered antibiotics (Cipolla et al., 2015).  
5.3 Liposomal amikacin for inhalation in patients with non-tuberculous 
mycobacterial pulmonary disease 
Increasing attention is now being paid to the possible use of Arikace, liposomal 
amikacin for inhalation (LAI), for the treatment of NTM infection in patients with 
cystic fibrosis (CF) via delivery of the antibiotic in higher concentrations (Olivier et 
al., 2016). Liposomes are microscopic membranous vesicles with an aqueous 
centre that can be used as a transporter for pharmaceutical drugs (Rose et al., 
2014). These vesicles can incorporate lipid-soluble drugs into the membrane and 
water-soluble drugs into their aqueous spaces and release their contents by 
interacting with cells by adsorption, endocytosis, lipid exchange, or fusion.  The 
drugs are then dispersed into the body at a close proximity to the site of the lung 
infection.   
5.3.1 Arikace clinical trials completed and in progress for use against 
non-tuberculous mycobacterial infection 
In a randomised placebo controlled phase 2 clinical trial (clinical trial identifier 
NCT01315236), patients received a daily dose of 590 mg of LAI (or placebo) in 
addition to their ongoing treatments. Results indicated that LAI was effective in 
attaining negative sputum culture for NTM caused by MAC, however this was not 
observed for those patients with MABSC (Biller et al., 2015; Olivier et al., 2016). 
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Other clinical trials involving arikace ongoing at present are “Open-label Safety 
Extension Study Assessing Safety and Tolerability of LAI in Patients Who 
Participated in Study INS-212” (NCT02628600) and Phase 3 “Study to Evaluate 
Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug 
Regimen Alone” (NCT02344004) which is due for completion in October 2016 
(ClinicalTrails.gov., 2016).  
5.4 Antibiotic resistance mechanisms in Mycobacteria abscessus 
complex 
MABSC has multiple innate antibiotic resistance mechanisms (Figure 5-2), but the 
most important development has been the discovery of an inducible erythromycin 
methylase resistance gene (erm41) (Nash et al., 2009). The erm41 gene marginally 
differs between M. abscessus complex subspecies with M. abscessus subsp. 
abscessus having a complete erm41gene with ten sequevars (Brown-Elliott et al., 
2015). Sequevars with nucleotide T28 are associated with a complete fully 
functional gene and inducible clarithromycin resistance, and sequevars with 
nucleotide C28 are associated with a non-functional gene and linked to 
clarithromycin susceptibility. In M. abscessus subsp. bolletii, the erm41 gene is 
similar to T28 in M. abscessus subsp. abscessus; however, the erm41 gene of M. 
abscessus subsp. massiliense is known to have two deletions, rendering it non-
functional. Sequence analysis of the erm41 gene has been used to classify M. 
abscessus complex subspecies (Rubio et al., 2015). 
M. abscessus subsp. abscessus may initially appear susceptible to macrolides, 
however upon exposure to these drugs resistance can develop. Until inducible 
resistance due to erm41 was defined, clarithromycin was effectively the drug of 
choice for M. abscessus subsp. abscessus. It was then revealed that although a 
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strain may seem to be susceptible after three days in vitro incubation, due to 
induction of the synthesis of a methyltransferase, clarithromycin resistance occurred 
if incubation was extended to fourteen days,  (Nash et al., 2009). Similarly, this could 
also occur if the isolate was pre-incubated with clarithromycin (Maurer et al., 2014b). 
 
 
Figure 5-2: Mycobacterial cell wall and mechanisms of drug resistance (van 
Ingen et al., 2012) 
 
As shown in Figure 5-2, the mechanisms of drug resistance can derive from the high 
content of lipids, as well as many mechanisms that control cell wall content including 
low porin count, efflux pumps, active biotransformation by cytosolic enzymes and 
inducible resistance mechanisms (van Ingen et al., 2012).  
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5.4.1 Macrolide resistance 
Resistance to macrolides occurs by post transcriptional methylation of the 23S 
rRNA, a component of the large 50S subunit which prevents the drug from attaching 
(Nessar et al., 2012). Macrolides such as azithromycin, clarithromycin, erythromycin 
and telithromycin are a class of bacteriostatic antibiotics that target the rRNA, 
preventing ribosomal translocation by binding reversibly to the P site of the 50S 
subunit of the ribosome and preventing peptidyltransferase from adding the peptidyl 
group attached to the tRNA to the next amino acid consequently inhibiting protein 
synthesis. Changes or modifications to the 50S ribosomal subunit, the target binding 
site for macrolides, will confer resistance to macrolides (Menninger, 1995).  
M. abscessus subsp. abscessus and M. abscessus subsp. bolletii are both known 
to carry the inducible full length erm41 gene, while M. abscessus subsp. massiliense 
has a truncated erm41 gene that is dysfunctional due to two distinctive deletions at 
bases 64-64 and 159-432 resulting in macrolide susceptibility (Kim et al., 2010a). 
Conflicting reports however have claimed that strains of M. abscessus subsp. 
massiliense do exist harbouring a full length functional erm41 gene said to have 
possibly emerged by means of horizontal gene transfer from either M. abscessus 
subsp. abscessus or M. abscessus subsp. bolletii (Choi et al., 2012; Shallom et al., 
2013) 
While having a full length erm41 gene typically results in macrolide resistance, some 
strains of M. abscessus subsp. abscessus with a full length erm41 are non-functional 
due to a T to C modification at position 28 (T28C) that likely results in an altered 
conformation of erm41. This results in a failure to bind adequately to domain V, the 
region where macrolides bind to the ribosome (Bastian et al., 2011).         
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5.4.2 Aminoglycoside resistance 
Aminoglycosides, such as kanamycin, amikacin or tobramycin are key bactericidal 
drugs in the treatment of MABSC, targeting the 16S rRNA in the ribosome, and 
inhibiting protein synthesis by interfering with the proof reading process and causing 
errors in synthesis with premature termination (Shakil et al., 2008). A spontaneous 
single A to G mutation at position 1408 (A1048G) affecting the 16S rRNA of M. 
abscessus subsp. abscessus  isolates was reported to be associated with 
resistance to aminoglycosides (Prammananan et al., 1998). As M. abscessus 
subsp. abscessus  only has one copy of the rRNA operon, this makes the 
occurrence of a single mutation more probable (Sassi and Drancourt, 2014). Many 
other single mutations affecting the 16S rRNA instigating resistance to 
aminoglycosides (T1406A, C1409T and G1491T) have been reported (Nessar et 
al., 2012). 
5.4.3 The role of the mycobacterial cell wall in antibiotic resistance 
The role of the complex hydrophobic mycobacterial cell wall shown in Chapter 1, 
Figure 1-1 has been widely observed, and many of its properties play a large part in 
the poor diffusion of antibiotics as discussed in Chapter 1 (Jarlier and Nikaido, 
1990). Genomic analysis has also revealed the presence of other prospective drug 
resistance elements such as putative β-lactamases, aminoglycoside 
phosphotransferases and aminoglycoside acetyltransferases (Ripoll et al., 2009). 
5.4.4 Efflux pumps conferring antibiotic resistance in mycobacteria 
The use of efflux pumps as a means of eradicating antimicrobial compounds was 
first defined in 1978 (Levy and McMurry, 1978) followed by active membrane-bound 
antimicrobial transport proteins conferring antibiotic resistance to tetracycline’s 
being described in Escherichia coli by means of expulsion from the cell (Ball et al., 
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1980). Prior to this they were known only for upholding a role of protecting against 
toxicities by maintaining cell homeostasis by pumping toxic agents out of the cell 
(Alvarez-Ortega et al., 2013). They are now known to be involved in antibiotic 
resistance in mycobacteria with numerous being discovered (Szumowski et al., 
2013) contributing to resistance of drugs such as isoniazid, rifampicin, clofazimine, 
ciprofloxacin, linezolid, tetracycline and streptomycin (Nessar et al., 2012; 
Rodrigues et al., 2013; Pal et al., 2014; Fonseca et al., 2015). The genome of 
MABSC encodes for several proteins involved in antimicrobial efflux systems 
including members of the major facilitator superfamily (MFS), ATP binding cassette 
(ABC) transporters, mycobacterial membrane protein large (MmpL) family of 
transporters and a multidrug resistance Stp protein comparable to that defined in 
the resistance to spectinomycin and tetracycline in M. tuberculosis (Ramon-Garcia 
et al., 2007). 
5.4.5 Other mechanisms known to contribute to mycobacterial drug 
resistance 
MABSC contains a 23319 base pair mercury resistance plasmid identical to the 
pMM23 mercury resistance plasmid of M. marinum (Stinear et al., 2008) which 
carries a mercury resistance operon flanked by two genes MAB_p04c and 
MAB_p10, encoding site-specific recombinases (Ripoll et al., 2009). However, 
although mercury resistance has been studied comprehensively in other species, 
additional research is needed to elucidate mercury resistance in mycobacteria. 
Mycobacterial resistance to ethambutol is thought to occur due to mutations in the 
embCAB operon that encodes arabinosyl transferases, recognised targets of 
ethambutol (Palomino and Martin, 2014). Mutations conferring nucleotide 
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substitutions at amino acid residue 306 in embB is reported to cause ethambutol 
resistance (Sreevatsan et al., 1997). 
In sequences of conserved regions known as quinolone resistance-determining 
regions (QRDR) in the DNA gyrase subunits GyrA and GyrB it was revealed that the 
presence of alanine at position 83 within GyrA QRDR and arginine and asparagine 
at positions 447 and 464 respectively, within GyrB QRDR confer resistance to 
fluoroquinolones in MABSC, M. avium, M. intracellulare, M. marinum and M. 
chelonae (Guillemin et al., 1998) 
MABSC is known to produce numerous enzymes that can potentially damage or 
modify antibiotics, causing their inactivation. These include an Ambler class A ß-
lactamase, a rifampin ADP-ribosyl transferase, an aminoglycoside 2′-N-
acetyltransferase and at least twelve homologs of aminoglycoside 
phosphotransferases, four homologs of monooxygenases potentially involved in 
resistance to rifampin and tetracyclines, two FolP homologs conferring resistance 
to cotrimoxazole, one homolog of UDP-N-acetylglucosamine 1-
carboxyvinyltransferase MurA conferring resistance to fosfomycin, and two 
homologs of 23S rRNA methylases conferring resistance to macrolides (Vester and 
Douthwaite, 2001). MABSC also produce enzymes that could modify 
aminoglycoside drugs by transferring acetyl or phosphate residues on crucial 
positions within the antibiotic, causing their inactivation (Ripoll et al., 2009). 
5.5 Challenges of diagnosis and treatment of Mycobacteria abscessus 
As it is difficult to distinguish between colonisation and true infection, the decision 
of whether to treat MABSC infection or not embraces many challenges. Antibiotic 
susceptibilities can greatly differ between MABSC subspecies, particularly members 
of the MABSC, and monotherapy will often fail to produce a cure.  
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Current multidrug therapy recommendations remain contentious, with success for 
very few patients and failure for the majority (Griffith et al., 2007) as well as high 
rates of resistance being reported for many of these antibiotics (Wallace et al., 2001; 
Yang et al., 2003; Chihara et al., 2010; Bastian et al., 2011).   
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5.6 Aims and objectives  
Standard therapies for both MABSC and M. tuberculosis as well as additional 
antimicrobials that are not generally used for treatment of mycobacterial infection 
were evaluated in order to establish the minimum inhibitory concentrations and 
establish whether any may be used for the successful treatment of MABSC.  
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5.7 Materials 
5.7.1 Bacterial strains used in antimicrobial testing of non-tuberculous 
mycobacteria 
A collection of 100 NTM isolates from 94 adult and paediatric patients were tested, 
with the exception of one isolate of M. abscessus subsp. bolletii that was derived 
from an environmental sample. Clinical isolates were derived from CF sputum 
samples by standard methods and previously stored at -20oC in glycerol/skimmed 
milk. These included M. abscessus subsp. abscessus (n = 56), M. chelonae (n = 
23), M. abscessus subsp. massiliense (n = 7), M. abscessus subsp. bolletii (n = 3), 
M. fortuitum (n = 3), M. llatzerense (n = 2), M. salmoniphilum (n = 2), M. 
immunogenum (n = 1), M. intracellualare (n = 1), M. mucogenicum (n = 1), and M. 
septicum (n = 1). Further details can be found in Appendix 1. 
The species and subspecies identity of all strains had been previously confirmed by 
sequencing of at least two of three housekeeping genes (rpoB, hsp65 and sodA) 
using previously described methods (Blauwendraat et al., 2012). NCTC control 
strains were also used; S. aureus NCTC 6571, C. perfringens NCTC 8797 and E. 
coli NCTC 10418. All frozen isolates were subcultured on Columbia agar with 5% 
horse blood prior to testing.  
5.7.2 Growth media 
Mueller-Hinton agar (CM0337) and Mueller-Hinton broth (CM0405) were supplied 
from Oxoid Ltd, Basingstoke, UK and prepared according to manufacturer’s 
instructions. Blood agar was prepared from Columbia agar powder (CM0331) 
(Oxoid) and 5% defibrinated horse blood supplied by TSC Biosciences, 
Buckingham, UK. 
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5.7.3 Antimicrobials 
Rifampicin was supplied by Duchefa Biochemie BV, Haarlem, The Netherlands, 
moxifloxacin was obtained from Bayer HealthCare Pharmaceuticals, Berlin, 
Germany, azithromycin from Aspire Pharma Ltd, Petersfield, UK, meropenem from 
Fresenius Kabi Ltd, Cheshire, UK, tobramycin from Medimpex UK Ltd, London, UK, 
ciprofloxacin was obtained from Fannin, Northamptonshire, UK, doripenem from 
Janssen-Cilag, Buckinghamshire, UK and tigecycline was obtained from Pfizer, 
Hampshire, UK. All other antimicrobials were all purchased from Sigma-Aldrich, 
Poole, UK 
5.7.4 Equipment 
All equipment as described in previous sections 2.3.4 and 3.10.6.  
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5.8 Methods 
5.8.1 Preparation of the medium for agar dilutions for a range of single 
antimicrobials against rapidly-growing mycobacteria 
Mueller Hinton agar was made up according to manufacturer’s instructions where 
90 ml of sterile deionised water was added to 3.8 g agar. These were autoclaved at 
116oC for 10 minutes. Each antimicrobial was dissolved in 20 ml of sterile distilled 
water, with the exception of clarithromycin, clofazimine and rifampicin, which were 
first dissolved in 200 µl of N-Methyl-2-pyrrolidone then added to 19.8 ml sterile 
distilled water. The dissolved antimicrobials were filter sterilised and diluted down to 
10 x the strength of each target concentration with sterile distilled water and 10 ml 
was added to 90 ml Mueller-Hinton agar giving a total volume of 100 ml. For each 
target concentration, five plates were prepared in sterile Petri dishes and allowed to 
set. 
5.8.2 Investigation of various antimicrobials using agar-based dilutions 
against rapidly-growing mycobacteria isolates from patients with cystic 
fibrosis 
The following ranges of antimicrobials were used in the initial MIC agar dilution 
testing, and were selected based on known breakpoints published by the European 
Committee on Antimicrobial Susceptibility Testing Guidelines (EUCAST, 2014) and 
a review of the current literature; amikacin 4 – 128 mg/L, azithromycin 0.125 – 4 
mg/L, cefoxitin 2 – 64 mg/L, chloramphenicol 2 – 64 mg/L, ciprofloxacin 0.25 – 8 
mg/L, clarithromycin 0.5 – 16 mg/L, clindamycin 0.125 – 4 mg/L, clofazimine 0.125 
– 4 mg/L, doripenem 0.5 – 16 mg/L, doxycycline 0.25 – 8 mg/L, erthyromycin 0.25 
– 8 mg/L, fusidic acid 0.125 – 4 mg/L, gentamicin 2 – 64 mg/L, imipenem 1 – 32 
mg/L, isoniazid 0.125 – 4 mg/L, kanamycin 0.125 – 4 mg/L, linezolid 0.5 – 16 mg/L, 
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meropenem 0.5 – 16 mg/L,  metronidazole 0.5 – 16 mg/L, minocycline 8 – 256 mg/L, 
moxifloxacin 1 – 32 mg/L, rifampicin 4 – 128 mg/L, streptomycin 0.5 – 16 mg/L, 
teicoplanin 0.25 – 8 mg/L, tigecycline 0.125 – 4 mg/L, tobramycin 0.125 – 4 mg/L, 
trimethoprim-sulfamethoxazole 0.125 – 4 mg/L, spectinomycin 0.125 – 4 mg/L and 
resorcinol 0.0625 – 2 mg/L. All tests were performed in duplicate on separate 
occasions. 
5.8.3 Bacterial strains and culture onto medium containing single 
antimicrobial agents 
A suspension containing 2 ml sterile saline (0.85%) and turbidity equivalent to a 0.5 
McFarland standard (approx. 1.5 x 108 CFU/ml) was prepared for each isolate. For 
the rough colony types, where clumping occurred, vortexing with three sterile 3 mm 
glass beads for 10 minutes effectively dispersed all clumps.  Each medium type was 
inoculated using a multipoint inoculator with a 1 µl aliquot of each isolate (i.e. approx. 
1.5 x 105 CFU). Results were recorded after five days incubation at 30oC with the 
exception of metronidazole, which was incubated for five days anaerobically at 
37oC. Mueller-Hinton control plates were set up and each one inoculated with 20 of 
the 100 mycobacterial isolates. S. aureus and E. coli were included to serve as 
control organisms and C. perfringens as an anaerobic control. 
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5.9 Results 
The data for all of the mycobacterial isolates tested and antimicrobial agents are 
shown in Table 5-2 below with the MIC50 and MIC90 of M. abscessus subsp. 
abscessus, M. chelonae and M. abscessus subsp. massiliense shown in Table 5-3. 
The agar dilution method used follows the principle of establishing the lowest 
concentration of the serially diluted antibiotic concentration that completely inhibits 
bacterial growth.  
Results show that the majority of antimicrobials were ineffective against M. 
abscessus subsp. abscessus, at the ranges tested. 
From the recommended treatment regimes, the results for M. abscessus subsp. 
abscessus show that cefoxitin had a range of MIC 8->64 mg/L. All but two isolates 
had a MIC of 8-64 mg/L with a MIC50 32 mg/L and MIC90 64 mg/L. Clarithromycin 
had a range of MIC <0.5->16 mg/L, with 24 (42.9%) isolates having a MIC <0.5 
mg/L, MIC50  2 mg/L and MIC90 16 mg/L. Tigecycline had a range of MIC <0.125->4 
mg/L with 24 (42.9%) isolates having a MIC ≤2 mg/L and both the MIC50 and MIC90 
4 mg/L. Although minocycline had a range of <8 - >256, both MIC50 and MIC90 were 
>256 mg/L with only 15 (26.8%) isolates having a MIC of 256 mg/L or less, and only 
one with a MIC of <8 mg/L. Results for moxifloxacin showed that 53 isolates (94.6%) 
had a MIC >4 mg/L, and for linezolid 46 (82.1%) isolates had a MIC ≥16 mg/L. All 
isolates had a MIC >128 mg for amikacin, >4 mg/L for clofazimine and 49 (87.5%) 
isolates had a MIC >16 mg/L for imipenem. Azithromycin had a range of 0.5->4 
mg/L, with 43 isolates (76.8%) >4 mg/L and MIC50 and MIC90 both >4 mg/L.  
Results for M. abscessus subsp. massiliense show for all recommended guideline 
treatments clarithromycin was the only one antibiotic that seemed to show any 
activity with a MIC range of <0.5->16 mg/L with 6/7 (85.7%) isolates having a MIC 
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<0.5 mg/L and only one isolate had a MIC >16 mg/L. Tigecycline had a range of 0.5-
4 mg/L with 5/7 isolates MIC 4 mg/L. 
M. abscessus subsp. massiliense isolates showed greater susceptibility than M. 
abscessus subsp. abscessus for azithromycin with both MIC50 and MIC90 of 4 mg/L 
(MIC range 1->4 mg/L) with only one isolate having a higher MIC than 4 mg/L 
whereas only 23.2% (13/56) of M. abscessus subsp. abscessus had a MIC 4 mg/L 
or lower for azithromycin. 
The three isolates of M. abscessus subspecies bolletii tested showed resistance to 
all antimicrobials tested except clarithromycin with two isolates having a MIC <0.5 
mg/L and one isolate MIC 4mg/L. All other antimicrobials appear to be ineffective 
demonstrating resistance. 
Clarithromycin also demonstrated superior results to all other antimicrobials tested 
for M. chelonae with a range of <0.5-8 mg/L, 19/23 (82.6%) isolates having a MIC 
<0.5 mg/L, and MIC50 <0.5 mg/L and MIC90 2 mg/L.  
Mycobacteria fortuitum showed susceptibility to tigecycline with two isolates having 
a MIC <0.125 mg/L and one MIC 0.5 mg/L. However, ciprofloxacin demonstrated 
three differing MIC’s, <0.125 mg/L, 0.5 mg/L and >4 mg/L and moxifloxacin ranged 
from <0.125 mg/L to >4 mg/L. 
For species where there were only one or two isolates tested, for example M. 
salmoniphilum and M. llatzerense, it is not possible to determine accurate 
susceptibility profiles, for example for the two isolates of M. salmoniphilum 
conflicting MIC’s were shown for streptomycin, 4 mg/L and <0.5 mg/L. As with M. 
llatzerense, MIC’s of 1 mg/L and <0.5 mg/L were shown for meropenem. 
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The three control strains shown in Table 5-4 demonstrated MIC’s within the 
acceptable range for each antimicrobial tested according the EUCAST guidelines 
(EUCAST, 2014). 
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Table 5-2: Range of MIC’s of NTM species using a selection of twenty-nine single antimicrobials (mg/L) 
* Trimethoprim/Sulfamethoxazole 
  
 Antimicrobial Mycobacterial species 
  M. abscessus M. massiliense M. bolletii M. chelonae M. fortuitum M llatzerense M.salmoniphilum M. mucogenicum M.immunogenum M. septicum M intracellulare  
  n = 56 n = 7 n = 3 n = 23 n = 3 n = 2 n = 1 n = 1 n = 2 n = 1 n = 1 
R
e
c
o
m
m
e
n
d
e
d
 
tr
e
a
tm
e
n
ts
 
Amikacin >128 >128 64 - >128 >128 64 - >128 64 <4 >128 >128 128 >128 
Azithromycin 0.5->4 1->4 2 - >4 1->4 >4 1 - 2. 0.25 >4 1 >4 1 
Cefoxitin 8 - >64 16 - 64 64 - >64 >64 16 - 64 4 <2 - 4 64 16 >64 >64 
Clarithromycin <0.5 - >16 <0.5 - >16 <0.5 - 4 <0.5 - 8 <0.5 - >16 <0.5 >16 <0.5 <0.5 >16 >16 
Clofazimine >4 >4 >4 >4 >4 >4 <0.125 >4 >4 2 >4 
Imipenem 1->16 2->16 >16 >16 16 - >16 1 >16 2 16 16 >16 
Linezolid <0.5 - >16 8 - >16 4 - >16 16 - >16 >16 <0.5 <0.5 >16 >16 >16 16 
Minocycline <8 - >256 <8 - >256 64 - >256 <8 - >256 <8 - 32 <8 <8 >256 <8 128 32 
Moxifloxacin 1 - >4 >4 1 - >4 <0.125 - >4 <0.125 - >4 >4 0.5 >4 2 0.25 >4 
Tigecycline <0.125 - >4 0.5 - 4 0.125 - 4 <0.125 - 1 0.5 - <0.125 <0.125 <0.125 2 1 <0.125 0.25 
             
 Chloramphenicol 32 - >64 >64 >64 64 - >64 >64 8 >64 >64 >64 >64 >64 
 Ciprofloxacin 4 - >4 >4 <0.125 - >4 <0.125 - >4 <0.125 - >4 0.5 4 >4 1 1 >4 
 Clindomycin >4 >4 >4 >4 >4 >4 0.25 - 0.5 >4 >4 >4 >4 
 Doripenem 8 - >16 >16 16 - >16 >16 16 - >16 16 2 >16 >16 16 >16 
 Doxycycline 2 - >8 >8 >8 <0.25 - >8 8 - >8 1 - 2. <0.5 >8 1 >8 >8 
 Erythromycin 1 - >8 >8 8 - >8 1 - >8 >8 8 1 >8 8 >8 4 
 Fusidic Acid 1 - >4 >4 <0.125 - >4 4 - >4 >4 1 - 2. 1 2 >4 >4 >4 
 Gentamicin 16 - >64 64 - >64  4 - >64 32 - 64 16 - 32 4 - 8. 32 >64 32 8 16 
 Isoniazid >4 >4 >4 2 - >4 >4 >4 <0.125 >4 >4 >4 >4 
 Kanamycin 2 - >4 >4 <0.125 - >4 4 - >4 >4 0.5 4 2 >4 >4 >4 
 Meropenem 2 - >16 >16 <0.5 - >16 8 - >16 8 - >16 <0.5 - 1 <0.5 2 8 8 >16 
 Metronidazole >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 
 Resorcinol >2 >2 >2 >2 >2 >2 >2 >2 >2 >2 >2 
 Rifampicin <2 - >128 64 - >128 >128 >128 32 - >128 64 - 128 <2 - 4 >128 >128 >128 >128 
 Teicoplanin 4 - >8 >8 <0.25 - >8 >8 >8 8 - >8 4 >8 >8 >8 >8 
 Tobramycin 16 - >16 >16 <0.5 - >16 8 - >16 >16 16 <0.5 >16 16 16 8 
 Trim-Sulf* <0.125->4 2->4 2 - >4 4->4 >4 <0.125 4 0.25 1 0.5 >4 
 Spectinomycin >8 >8 >8 >8 >8 >8 >8 >8 >8 >8 >8 
 Streptomycin 16 - >16 >16 >16 >16 >16 8 <0.5 - 4 >16 >16 >16 >16 
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Table 5-3: MIC’s, MIC50 and MIC90 of M. abscessus subsp. abscessus, M. abscessus subsp. massiliense and M. chelonae using a 
selection of twenty-nine single antimicrobials (mg/L) 
   
 Antimicrobial M. abscessus subspecies abscessus M. chelonae M. abscessus subspecies massiliense 
  n = 56 n = 23 n = 7 
  RANGE MIC50 MIC90 RANGE MIC50 MIC90 RANGE MIC50 MIC90 
R
e
c
o
m
m
e
n
d
e
d
 
tr
e
a
tm
e
n
ts
 
Amikacin >128 >128 >128 >128 >128 >128 >128 >128 >128 
Azithromycin 0.5->4 >4 >4 1->4 2 >4 1->4 4 4 
Cefoxitin 8 - >64 32 64 >64 >64 >64 16 - 64 64 64 
Clarithromycin <0.5 - >16 2 16 <0.5 - 8 <0.5 2 <0.5 - >16 <0.5 <0.5 
Clofazimine >4 >4 >4 >4 >4 >4 >4 >4 >4 
Imipenem 1->16 >16 >16 >16 >16 >16 2->16 >16 >16 
Linezolid <0.5 - >16 >16 >16 16 - >16 16 >16 8 - >16 >16 >16 
Minocycline <8 - >256 >256 >256 <8 - >256 128 >256 <8 - >256 >256 >256 
Moxifloxacin 1 - >4 >4 >4 <0.125 - >4 >4 >4 >4 >4 >4 
Tigecycline <0.125 - >4 4 4 <0.125 - 1 1 1 0.5 - 4 4 4 
           
 Chloramphenicol 32 - >64 >64 >64 64 - >64 >64 >64 >64 >64 >64 
 Ciprofloxacin 4 - >4 >4 >4 <0.125 - >4 >4 >4 >4 >4 >4 
 Clindamycin >4 >4 >4 >4 >4 >4 >4 >4 >4 
 Doripenem 8 - >16 >16 >16 >16 >16 >16 >16 >16 >16 
 Doxycycline 2 - >8 >8 >8 <0.25 - >8 >8 >8 >8 >8 >8 
 Erythromycin 1 - >8 >8 >8 1 - >8 >8 >8 >8 >8 >8 
 Fusidic Acid 1 - >4 >4 >4 4 - >4 >4 >4 >4 >4 >4 
 Gentamicin 16 - >64 >64 >64 32 - 64 32 64 64 - >64 >64 >64 
 Isoniazid >4 >4 >4 2 - >4 4 >4 >4 >4 >4 
 Kanamycin 2 - >4 >4 >4 4 - >4 >4 >4 >4 >4 >4 
 Meropenem 2 - >16 >16 >16 8 - >16 >16 >16 >16 >16 >16 
 Metronidazole >16 >16 >16 >16 >16 >16 >16 >16 >16 
 Resorcinol >2 >2 >2 >2 >2 >2 >2 >2 >2 
 Rifampicin <2 - >128 >128 >128 >128 >128 >128 64 - >128 >128 >128 
 Teicoplanin 4 - >8 >8 >8 >8 >8 >8 >8 >8 >8 
 Tobramycin 16 - >16 >16 >16 8 - >16 8 16 >16 >16 >16 
 Trim-Sulf* <0.125->4 >4 >4 4->4 >4 >4 2->4 >4 >4 
 Spectinomycin >8 >8 >8 >8 >8 >8 >8 >8 >8 
 Streptomycin 16 - >16 >16 >16 >16 >16 >16 >16 >16 >16 
           
* Trimethoprim/Sulfamethoxazole    
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Table 5-4: Control Organisms, range of antimicrobial tested and EUCAST MIC 
ranges (mg/L) 
 
 
* M. tuberculosis treatments 
** Reported as effective against M. ascessus in paper by Chopra et al, 2007 
Where range tested was higher/lower than control MIC, this was due to the range for that antimicrobial being 
specifically chosen due to journal reports of a MIC using MABSC. 
  
Recommended  
Treatment 
Range 
Tested 
MIC of 
Control 
S. aureus 
NCTC 6571 
C. perfringens 
NCTC 8797 
E. coli  
NCTC 10418 
Amikacin 4-128 16   8-16 
Azithromycin 0.125-4 1 0.5-2   
Cefoxitin 2-64 4 1-4   
Clarithromycin 0.5-16 0.5 0.125-0.5   
Clofazimine* 0.125-4 >4    
Imipenem 1-32 2   2-8 
Linezolid 0.5-16 4 1-4   
Minocycline 8-256 <8 0.06-0.5   
Moxifloxacin 0.125-4 0.125 0.016-0.125   
Tigecycline 0.125-4 1   1-2 
Other 
Antimicrobials 
     
Chloramphenicol 2-64 8 2-16   
Ciprofloxacin 0.125-4 1   0.5-1 
Clindamycin 0.125-4 0.25 0.06-0.25   
Doripenem 0.5-16 2   1-2 
Doxycycline 0.25-8 0.5 0.125-0.5   
Erythromycin 0.25-8 0.5 0.25-1   
Fusidic Acid 0.125-4 0.25 0.06-0.25   
Gentamicin 2-64 4   2-4 
Isoniazid* 0.125-4 >4    
Kanamycin 0.125-4 2   0.25-8 
Meropenem 0.5-16 2   2-8 
Metronidazole** 0.5-16 4  0.125-0.5  
Resorcinol** 0.0625-2 >2    
Rifampicin* 4-128 4    
Teicoplanin 0.25-8 0.5 0.25-1   
Tobramycin 0.125-4 1 0.125-1   
Trim-Sulf* 0.125-4 0.125 ≤0.5   
Spectinomycin 0.125-4 >8   8-64 
Streptomycin* 0.5-16 16   2-16 
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5.10 Discussion 
It is well documented that a reliable and successful antimicrobial regimen for 
MABSC infection, in particular M. abscessus subsp. abscessus, which is the most 
pathogenic and chemotherapy resistant of all rapidly growing NTM, still remains to 
be identified (Jeon et al., 2009; Nessar et al., 2012; Pang et al., 2013). Effective 
treatments are particularly challenging as there are no definitive guidelines as to 
which antimicrobial(s) should be given and it is widely held that they are resistant to 
all first line anti-tuberculosis agents such as streptomycin, isoniazid, ethambutol, 
rifampicin and pyrazinamide, resulting in very limited therapeutic choices and a high 
treatment failure rate (Oh et al., 2014; Talati et al., 2008).   
It has been suggested that any treatment regimen containing clarithromycin is more 
effective in patients with M. abscessus subsp. massiliense pulmonary disease than 
in those with M. abscessus subsp. abscessus. Clarithromycin inducible resistance 
shown in M. abscessus subsp. abscessus clinical strains is partly accountable for 
the lack of success of antibiotic therapies containing clarithromycin (Koh et al., 
2011). Based on this, the CLSI guidelines recommended that the incubation period 
of MABSC strains, in cases where results at day 3 may indicate susceptibility, 
should ideally be extended up to 14 days (Clinical and Laboratory Standards 
Institute, 2011). It is evident from the results in Table 5-2 and Table 5-3 that the MIC 
of M. abscessus subsp. massiliense (both MIC50 and MIC90 <0.5 mg/L) is notably 
lower than those shown for M. abscessus subsp. abscessus (MIC50 2 mg/L and 
MIC90 16 mg/L) inferring that inducible resistance may be occurring. 
There is no current reliable evidence that antibiotic treatment is always beneficial, 
however the UK CF Trust Antibiotic Working Group specify that ATS criteria for 
diagnosis should be followed (Floto et al., 2016).  This specifies that minimum 
evaluation is to include a high-resolution computed tomography (HRCT) scan, three 
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or more sputum samples positive for acid-fast bacilli, and exclusion of other 
disorders. In those with CF who have suspected NTM infection, it is essential to first 
treat their typical pathogens and then evaluate whether anti-mycobacterial therapy 
is justified (Griffith et al., 2007). There is no consensus on standardised NTM 
treatments, and these can vary depending on many factors such as the extent of 
the infection, the type of NMT isolated, underlying conditions, differing in-vitro and 
in-vivo effectiveness, and the toxicity of many NTM therapies, particularly with long-
term use. 
From the MICs obtained, the majority of NTMs tested in this study could be 
successfully treated, however, M. abscessus subspecies abscessus remains 
elusive to almost all antibiotics tested. Clarithromycin (MIC50 2 mg/L and MIC90 16 
mg/L) and tigeclycline (MIC50 and MIC90 both 4 mg/L) were the most promising, 
however for infections involving M. abscessus subsp. abscessus, antibiotic 
regimens based on in vitro susceptibilities are not shown to be active in vivo (Oh et 
al., 2014). Encouraging synergistic in vitro activity for tigecycline with clarithromycin 
has been shown in a study by Huang et al (2013), supporting the results obtained 
in this study (Huang et al., 2013). None of the other antibiotics tested were effective 
against M. abscessus subsp. abscessus. 
Antibiotic sensitivities would not appear to be routinely performed upon first isolation 
of MABSC, and from the results obtained in this study none of the recommended 
treatments are effective for every strain, and can range from very low to extremely 
high MIC’s, for example minocycline with a range of <8 - >256 mg/L which would 
not be suitable for patient treatments. For species where only a small number of 
isolates were tested, for example M. fortuitum, the MIC was different for each of the 
three isolates, this would indicate that it is huge challenge to obtain a typical and 
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reliable strategy when considering treatments, and each isolate should be looked at 
individually as MIC’s can vary dramatically within the same species or subspecies. 
This study would appear to verify that it is only the most commonly routinely used 
antimicrobials which have any effect on MABSC, for example clarithromycin, in 
particular against M. abscessus subsp. abscessus. None of the frontline M. 
tuberculosis antimicrobials tested have shown to have effects on MABSC likely to 
be clinically relevant, however many of these did seem to exhibit activity against M. 
salmoniphilum, for example clofazimine and isoniazid, again reinforcing that species 
must be correctly identified as successful treatments can be so varied between 
species. 
Amikacin, a semi-synthetic aminoglycoside derivative of kanamycin, is 
acknowledged as one of the fundamental antimicrobials in the treatment of MABSC 
and it is typically reported that MABSC exhibit in vitro susceptibility to this 
antimicrobial (Novosad et al., 2016).However the results in this study contradict this 
and all isolates tested were shown to be resistant. The Mab_3168c gene involved 
in cell wall synthesis could feasibly be making the MABSC cells less penetrable to 
amikacin as well as acetylating the antimicrobial, rendering it inactive, and this could 
conceivably explain the results in this study.  In a report by Tsai et al (2013), it is 
claimed that to further confirm that the Mab_3168c gene conferred resistance to 
amikacin, it was introduced into another mycobacteria species; M. smegmatis. This 
established that the amikacin MIC value was two-fold higher. It was also suggested 
that the inactivation of Mab_3168c may change the structure of the MABSC cell 
wall, resulting in a change in colony morphotype, reduced cellular aggregation and 
the ability to survive inside macrophages as well as increased susceptibility to 
amikacin (Tsai et al., 2013).  
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Chopra et al, (2011), showed both metronidazole, a nitroimidazole class antibiotic 
mainly used for the treatment of anaerobic bacteria, and the antiseptic resorcinol 
were effective against M. abscessus subsp. abscessus, reporting MIC’s of <0.015 
mg/L and 0.09 mg/L respectively. However these results were based on only one 
type strain of M. abscessus subsp. abscessus (ATCC 19977) and no clinical isolates 
were tested (Chopra et al., 2011). Results from this study do not support these 
findings, and using a range taken either side of the MIC reported by Chopra et al 
(2011), resorcinol has an MIC of >2 mg/L for all isolates tested, using a 
concentration range between 0.0625-2 mg/L, and metronidazole has a MIC of >16 
mg/L for all isolates tested, using a range between 0.5-16 mg/L. A similar study was 
conducted by Mukherjee et al (2012), but even at the highest concentration tested 
(2mM), metronidazole was ineffective against M. abscessus subsp. abscessus as 
reported by Chopra et al (2011) (Mukherjee et al., 2012). 
Incomplete information can be very misleading to clinicians who are looking at trying 
novel treatments for any patient. An example of how testing of only one isolate 
cannot be reliably used for patient treatment plans is in this study where only three 
isolates of M. fortuitum were tested. Results for ciprofloxacin showed three varying 
MIC’s of <0.125 mg/L, 0.5 mg/L and >4 mg/L.  For the same antibiotic, the three 
isolates of M. abscessus subsp. bolletii had MIC’s of between <0.125->4 mg/L. 
MABSC, in particular M. abscessus subsp. abscessus, exhibit resistance to almost 
all known Food and Drug administration (FDA) approved antimicrobials, and this 
combined with the lack of novel antibiotics being discovered is hampering efforts to 
improve current treatment plans. 
A suggestion could be to perform antimicrobial synergy testing, for example using 
checkerboard assays, time kill curves or multiple-combination bactericidal testing of 
currently recommended antimicrobial treatments alongside others that are not 
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ordinarily used for MABSC treatments, but could possibly display synergy when 
combined. This however may still not provide a standard treatment regime as many 
isolates of MABSC have such varying antimicrobial susceptibility profiles. 
New anti-tuberculosis drugs such as the diarylquinoline Bedaquiline, formerly 
TMC207 and R207910, and the first drug in a novel class appropriate for the 
treatment of multi-drug resistant tuberculosis since Rifampin in 1971, was FDA 
approved in December 2012 with very promising results (Philley et al., 2015). This 
drug has a novel mechanism of action and structurally differs from all other available 
M. tuberculosis front line agents by interfering with the bacterial energy metabolism. 
It works by inhibiting mycobacterial adenosine 5’-triphosphate (ATP) synthase, by 
binding to subunit c of the enzyme that is vital for the generation of energy in M.  
tuberculosis (Mahajan, 2013).  
In a report by Philey et al (2015), Bedaquiline appears to be effective for the 
treatment of not only multi-drug resistant tuberculosis, but also against MABSC and 
MAC, however larger studies are required in order to substantiate results as this 
report only consisted of ten patients, six with MAC and four with MABSC (Philley et 
al., 2015). Pang et al (2017) also more recently reported that Bedaquiline had 
moderate in vitro activity against NTM with MIC50 and MIC90 of 0.03 m/L and 16 
mg/L for MAC and MIC50 and MIC90 of 0.13 mg/L and >16 mg/L for MABSC (Pang 
et al., 2017). 
Further studies on resistant strains are urgently required and it should also be noted 
that the treatment of MABSC cannot reliably be guided by in vitro susceptibility 
testing. The ATS guidelines state that “At present, there is no reliable or dependable 
antibiotic regimen, even based on in vitro susceptibilities, including parenteral 
agents, to produce a cure for M. abscessus lung disease” (Floto et al., 2016), and 
this was also noted in a report by Jeon et al, where it was indicated “The optimal 
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therapeutic regimen and duration of treatment for M. abscessus lung disease has 
not been established” (Jeon et al., 2009). It is vital that clinicians distinguish the 
MABSC subspecies of any patient isolate, and if M. abscessus subsp. abscessus is 
identified, is the erm41 gene active.  
The accessibility of MABSC genomes and the development of genetic methods in 
order to study MABSC represent major advancements in this field, particularly for 
M. abscessus subsp. abscessus, the most virulent and antibiotic resistant of the 
MABSC subspecies however it is evident from this study and all published literature 
that more effective antimicrobials are urgently needed. 
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6. Final discussion and future research 
6.1 Review and final discussion  
This thesis is centred on MABSC, the development of a novel culture medium for 
the isolation of MABSC in patients with CF, methods of identification, the acquisition 
of MABSC and in vitro susceptibility studies. Current culture methods are fraught 
with difficulties, particularly for the polymicrobial samples often presented from 
patients with CF where the overgrowth of more rapidly-growing bacterial species 
can prevent MABSC from being detected in any given sample. Improvements in the 
isolation of MABSC are urgently required in order to offer the possibility of a more 
rapid and accurate diagnosis. 
MABSC is an important pathogen responsible for an extensive array of infections 
and is now thought to be the most prominent Mycobacterium alongside MAC in 
patients with CF. The major threat of MABSC is its intrinsic resistance to almost all 
known antimicrobials, particularly M. abscessus subsp. abscessus which is said to 
be one of the most resistant microorganisms known (Nessar et al., 2012).  
Many changes in the nomenclature and taxonomic classification of MABSC over the 
years have made diagnosis and identification problematic. Many current journal 
articles still refer to M. chelonae-abscessus complex (Simmon et al., 2011), and 
many dispute the existence of M. abscessus subsp. Massiliense (Leao et al., 2011). 
In Chapter Two a novel culture medium (RGM) was developed for the isolation of 
MABSC in patients with CF. Various enrichment and selective agents were 
evaluated against isolates of MABSC and frequently encountered Gram-negative 
species seen in patients with CF and a combination of the most effective agents 
resulted in the formulation of RGM medium. This was evaluated and compared 
against currently used culture methods both liquid and solid, using samples from 
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patients with CF in many centres across the UK, Europe and the United States with 
very promising results. From the analysis, it can be concluded that RGM medium 
offers a superior option compared with any of the other selective agars for isolation 
of rapidly-growing mycobacteria from the sputum of patients with CF. It is also 
anticipated that RGM medium will be made commercially available in due course. 
Chapter three looks at the possibility of incorporating chromogenic or fluorogenic 
substrates into RGM medium in order to improve it further, and a variety of these 
were investigated. Unfortunately, none of these substrates provided any improved 
specificity or sensitivity for the detection of MABSC or were able to differentiate 
between MABSC and Gram-negative bacteria found commonly in the sputum of 
patients with CF, therefore were not suitable for inclusion into the medium. Also 
investigated was the possibility of differentiating between MABSC and less 
pathogenic M. chelonae; however, none of the substrates investigated were able to 
provide such a distinction. 
Chapter four discussed the acquisition of MABSC in patients with CF, and 
investigated whether this is undeniably an environmentally acquired pathogen, or is 
it transferred via person-to-person transmission. Although numerous areas and 
sources were investigated, no isolates of MABSC were isolated from the 
environment. M. chelonae was frequently isolated, particularly in water samples, 
however this is not now commonly viewed as a pathogenic species and it may well 
be that due to the many taxonomic changes, any M. chelonae that were considered 
pathogenic previously were in fact MABSC isolates. There are still very few reports 
substantiating person-to-person transmission of MABSC and the majority of articles 
will still maintain that MABSC is acquired only from the environment. 
Chapter five is centered on the current treatment approaches to MABSC. Progress 
in this area of research has been inadequate and slow, and it is believed that once 
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MABSC is acquired it can still not be referred to as a curable disease. It is very much 
unknown why some patients can be seen to improve with therapy and some cannot, 
however the correct identification is imperative, as M. abscessus subsp. massiliense 
would appear to be more straightforwardly treatable than M. abscessus subsp. 
abscessus or more the rarely isolated M. abscessus subsp. bolletii.  
More effective treatments are urgently required as presently there is no optimum 
therapeutic regimen or ideal time period of treatment in order to produce a cure for 
MABSC infection. 
  
  
239 
 
6.2 Future Research 
The field of research associated with MABSC is large, offering many opportunities 
that could be explored for future research: 
 One line of interest would be in the continued investigation of RGM medium 
in order to establish whether it could be of benefit in the isolation of slow-
growing mycobacteria affecting patients with CF such as MAC. This was 
briefly investigated by Plongla et al. (University of North Carolina, School of 
Medicine in Chapel Hill, USA). They demonstrated that extended incubation 
of RGM for 28 days afforded the isolation of slow-growing species including 
MAC, M. gordonae, M. arupense/nonchromogenicum and M. nebraskense 
(Plongla et al., 2017). 
 In addition, a liquid version of RGM could be developed for use in the MGIT 
system to replace what is currently used, as regular contamination of more 
rapidly-growing species still remains a problem in this area with many 
cultures of patient samples having to be abandoned. 
 There is a large amount of further antibiotic work that could be undertaken, 
including Multiple Combination Bactericidal Testing of both currently 
administered and previously untested antimicrobials as well as novel 
compounds and antimicrobials in combinations of two, three and even four 
with the anticipation that previously untested combinations may demonstrate 
synergy against multi-resistant MABSC isolates, in particular M. abscessus 
subsp. abscessus. As the techniques currently employed to differentiate 
between the subspecies of MABSC are complex, not all laboratories are able 
to do this therefore a more rapid, cost effective method is required. 
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 More research is needed into how MABSC is acquired by patients with CF. 
Whole genome sequencing has provided limited evidence of person-to-
person transmission where it was identified to be indirect rather than direct, 
however there are still currently very few reports of this and the majority of 
publications maintain MABSC is acquired environmentally. 
 
In conclusion, the amount of exploration that is still required with regards to MABSC 
is significant, and there is scope for a large amount of research that could still be 
undertaken.  
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7. Appendices 
Appendix 1: All isolates used in the development and evaluation of RGM 
medium, chromogenic and fluorogenic substrate testing and antimicrobial 
susceptibility testing throughout this thesis 
 
Isolate 
Reference Species Isolate Origin 
Chapter 
2 
Chapter 
3 
Chapter 
4 
Chapter 
5 
1000 
M. abscessus complex 
(chimeric) Paediatric CF patient, UK 
2.4.2 
2.4.15 3.10.2 
 
5.7.1 
1001 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
  
5.7.1 
1002 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
   
1003 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
   
1004 
M. abscessus subsp. 
abscessus CF patient, UK    5.7.1 
1005 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
   
1007 
M. abscessus subsp. 
abscessus CF patient, UK    5.7.1 
1008 
M. abscessus subsp. 
abscessus CF patient, UK  3.10.1  5.7.1 
1009 
M. abscessus subsp. 
abscessus CF patient, UK  3.10.1  5.7.1 
1010 
M. abscessus subsp. 
abscessus CF patient, UK  
3.10.1 
3.10.2   
1013 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
3.10.1 
3.10.2 
  
1014 
M. abscessus subsp. 
abscessus CF patient, UK    5.7.1 
1015 
M. abscessus subsp. 
abscessus CF patient, UK    5.7.1 
1016 
M. abscessus subsp. 
abscessus CF patient, UK    5.7.1 
1019 
M. abscessus subsp. 
abscessus CF patient, UK    5.7.1 
1020 
M. abscessus subsp. 
abscessus CF patient, UK    5.7.1 
1021 
M. abscessus subsp. 
abscessus CF patient, UK    5.7.1 
1023 
M. abscessus subsp. 
abscessus CF patient, UK  3.10.1   
1024 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
  
5.7.1 
1025 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
   
1026 
M. abscessus subsp. 
abscessus CF patient, UK  
3.10.1 
3.10.2  5.7.1 
1027 
M. abscessus subsp. 
abscessus CF patient, UK  
3.10.1 
3.10.2   
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Isolate 
Reference Species Isolate Origin 
Chapter 
2 
Chapter 
3 
Chapter 
4 
Chapter 
5 
1029 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
3.10.1 
3.10.2 4.8.5.3 5.7.1 
1030 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 3.10.1 
  
1032 
M. abscessus subsp. 
abscessus CF patient, UK  
3.10.1 
3.10.2  5.7.1 
1033 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
   
1034 
M. abscessus subsp. 
abscessus Adult CF patient, UK 
2.4.2 
2.4.15 3.10.2 
 
5.7.1 
1035 
M. abscessus subsp. 
abscessus CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
1036 
M. abscessus subsp. 
abscessus CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
1037 
M. abscessus subsp. 
abscessus CF patient, UK 
2.4.9 
2.4.10 
2.4.12 
2.4.15 
  
5.7.1 
1038 
M. abscessus subsp. 
abscessus CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
1039 
M. abscessus subsp. 
abscessus CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
1040 
M. abscessus subsp. 
abscessus CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
1041 
M. abscessus subsp. 
abscessus CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
1042 
M. abscessus subsp. 
abscessus Adult CF patient, UK 
2.4.2 
2.4.15 3.10.2 
 
5.7.1 
1043 
M. abscessus subsp. 
abscessus CF patient, UK 
2.4.9 
2.4.10 
2.4.12 
2.4.15 
  
5.7.1 
1044 
M. abscessus subsp. 
abscessus Adult CF patient, UK 
2.4.2 
2.4.15 3.10.2 
 
5.7.1 
1045 
M. abscessus subsp. 
abscessus Paediatric CF patient, UK 
2.4.2 
2.4.10 
2.4.12 
2.4.15 3.10.2 
 
5.7.1 
1046 
M. abscessus subsp. 
abscessus CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
1047 
M. abscessus subsp. 
abscessus Paediatric CF patient, UK 
2.4.2 
2.4.15 3.10.2 
 
5.7.1 
1048 
M. abscessus subsp. 
abscessus CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
1049 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
  
5.7.1 
1050 
M. abscessus subsp. 
abscessus Adult CF patient, UK 
2.4.2 
2.4.15 3.10.2 
 
5.7.1 
1051 
M. abscessus subsp. 
abscessus Paediatric CF patient, UK 
2.4.2 
2.4.15 3.10.2 
 
5.7.1 
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Isolate 
Reference Species Isolate Origin 
Chapter 
2 
Chapter 
3 
Chapter 
4 
Chapter 
5 
1052 
M. abscessus subsp. 
abscessus Paediatric CF patient, UK 
2.4.2 
2.4.10 
2.4.12 
2.4.15 3.10.2 
 
5.7.1 
1053 
M. abscessus subsp. 
abscessus Adult CF patient, UK 
2.4.2 
2.4.10 
2.4.12 
2.4.15 3.10.2 
 
5.7.1 
1054 
M. abscessus subsp. 
abscessus Paediatric CF patient, UK 
2.4.2 
2.4.15 3.10.2 
 
5.7.1 
1055 
M. abscessus subsp. 
abscessus Adult CF patient, UK 
2.4.2 
2.4.10 
2.4.12 
2.4.15 
2.5.6 3.10.2 
 
5.7.1 
1056 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.9 
  
5.7.1 
1058 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15 
  
5.7.1 
1061 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15   5.7.1 
1062 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15 
  
5.7.1 
1063 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15 
  
5.7.1 
1064 
M. absessus complex 
(chimeric) CF patient, Ireland 2.4.15 
  
5.7.1 
1065 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15 
  
5.71 
1066 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15 
  
5.7.1 
1067 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15 
  
5.7.1 
1068 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15 
  
5.7.1 
1069 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15 
  
5.7.1 
1070 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15 
  
5.7.1 
1071 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15 
  
5.7.1 
1072 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15 
  
5.7.1 
1073 
M. abscessus subsp. 
abscessus CF patient, UK  3.10.1  5.7.1 
1074 
M. abscessus subsp. 
abscessus CF patient, Ireland 2.4.15 
  
5.7.1 
1075 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
  
5.7.1 
1076 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
  
5.7.1 
1078 
M. abscessus subsp. 
abscessus CF patient, UK 2.4.15 
   
2000 M. chelonae CF patient, UK 2.4.15 
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Isolate 
Reference Species Isolate Origin 
Chapter 
2 
Chapter 
3 
Chapter 
4 
Chapter 
5 
2001 M. chelonae CF patient, UK 2.4.15 
  
5.7.1 
2002 M. chelonae CF patient, UK 2.4.15 
3.10.1 
3.10.2 
 
5.7.1 
2003 M. chelonae CF patient, UK 2.4.15 
  
5.7.1 
2004 M. chelonae CF patient, UK 2.4.15 3.10.1 4.8.5.3 
 
2005 M. chelonae CF patient, UK 2.4.15 3.10.1 
 
5.7.1 
2007 M. chelonae CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
2008 M. chelonae CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
2009 M. chelonae CF patient, UK 
2.4.9 
2.4.15 
   
2010 M. chelonae CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
2011 M. chelonae CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
2012 M. chelonae CF patient, UK 
2.4.9 
2.4.15 3.10.1 
 
5.7.1 
2013 M. chelonae CF patient, UK 
2.4.9 
2.4.15 3.10.1 
  
2014 M. chelonae CF patient, UK 
2.4.9 
2.4.15 
3.10.1 
3.10.2 
  
2015 M. chelonae CF patient, UK 
2.4.9 
2.4.15 
   
2016 M. chelonae CF patient, Ireland    5.7.1 
2017 M. chelonae CF patient, Ireland    5.7.1 
2018 M. chelonae CF patient, Ireland    5.7.1 
2019 M. chelonae CF patient, Ireland    5.7.1 
2020 M. chelonae CF patient, Ireland    5.7.1 
2021 M. chelonae CF patient, Ireland    5.7.1 
2022 M. chelonae CF patient, Ireland    5.7.1 
2023 M. chelonae CF patient, Ireland    5.7.1 
2024 M. chelonae CF patient, Ireland    5.7.1 
2025 M. chelonae CF patient, Ireland    5.7.1 
2026 M. chelonae CF patient, Ireland    5.7.1 
2027 M. chelonae CF patient, Ireland    5.7.1 
2028 M. chelonae CF patient, Ireland    5.7.1 
2029 M. chelonae CF patient, Ireland    5.7.1 
2047 M. chelonae CF patient, UK 2.4.15 
   
2048 M. chelonae CF patient, UK 2.4.15 
   
2049 M. chelonae CF patient, Ireland 2.4.15 
   
3000 
M. abscessus subsp. 
massiliense CF patient, UK 2.4.15 
   
3001 
M. abscessus subsp. 
massiliense CF patient, UK 2.4.15 3.10.1 
  
3002 
M. abscessus subsp. 
massiliense CF patient, UK 2.4.15 3.10.2 
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Isolate 
Reference Species Isolate Origin 
Chapter 
2 
Chapter 
3 
Chapter 
4 
Chapter 
5 
3003 
M. abscessus subsp. 
massiliense CF patient, UK  3.10.1   
3004 
M. abscessus subsp. 
massiliense CF patient, UK 2.4.15 
  
5.7.1 
3005 
M. abscessus subsp. 
massiliense CF patient, UK  3.10.1   
3006 
M. abscessus subsp. 
massiliense CF patient, UK  3.10.1   
3007 
M. abscessus subsp. 
massiliense CF patient, UK  
3.10.1 
3.10.2   
3009 
M. abscessus subsp. 
massiliense CF patient, UK 
2.4.9 
2.4.15 3.10.1 4.8.5.3 5.7.1 
3010 
M. abscessus subsp. 
massiliense Adult CF patient, UK 
2.4.2 
2.4.15 3.10.2 
 
5.7.1 
3011 
M. abscessus subsp. 
massiliense Adult CF patient, UK 
2.4.2 
2.4.15 
2.5.6 3.10.2 
 
5.7.1 
3012 
M. abscessus subsp. 
massiliense Adult CF patient, UK 
2.4.2 
2.4.10 
2.4.12 
2.4.15 
3.10.1 
3.10.2 
 
5.7.1 
3013 
M. abscessus subsp. 
massiliense Adult CF patient, UK 
2.4.2 
2.4.10 
2.4.12 
2.4.15 
3.10.1 
3.10.2 
 
5.7.1 
3014 
M. abscessus subsp. 
massiliense Paediatric CF patient, UK 
2.4.2 
2.4.15 3.10.2 
 
5.7.1 
3015 
M. abscessus subsp. 
massiliense Paediatric CF patient, UK 
2.4.2 
2.4.15 
3.10.1 
3.10.2 
  
3016 M. abscessus subsp. bolletii  Paediatric CF patient, UK 
2.4.2 
2.4.10 
2.4.12 
2.4.15 
3.10.1 
3.10.2 
 
5.7.1 
3017 M. abscessus subsp. bolletii  
Environmental isolate from 
sink. CF unit, RVI, Newcastle 
upon Tyne, UK 
2.4.2 
2.4.10 
2.4.12 
2.4.15 
2.5.6 
3.10.1 
3.10.2 
 
5.7.1 
3019 M. abscessus subsp. bolletii  CF patient, Ireland 2.4.15 
  
5.7.1 
3020 
M. abscessus subsp. 
massiliense CF patient, Ireland 2.4.15 
   
4008 M. llatzerense CF patient, UK 2.4.15 
  
5.7.1 
4009 M. llatzerense CF patient, UK 2.4.15 
  
5.7.1 
4010 M. mucogenicum CF patient, UK 2.4.15 
 
4.8.5.3 5.7.1 
4011 M. salmoniphilum CF patient, UK 2.4.15 
   
4013 M. salmoniphilum CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
4014 M. salmoniphilum CF patient, UK 
2.4.9 
2.4.15 
  
5.7.1 
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Isolate 
Reference Species Isolate Origin 
Chapter 
2 
Chapter 
3 
Chapter 
4 
Chapter 
5 
4015 M. immunogenum CF patient, UK 
2.4.9 
2.4.15 
 
4.8.5.3 5.7.1 
4016 M. intracellulare CF patient, UK 2.4.9 
  
5.7.1 
4017 M. fortuitum CF patient, UK. PHE, UK 2.4.15 
  
5.7.1 
4018 M. fortuitum CF patient, UK. PHE, UK 2.4.15 
  
5.7.1 
4019 M. fortuitum CF patient, UK. PHE, UK 2.4.15 
  
5.7.1 
4048 M. septicum CF patient, UK    5.7.1 
462213 Morganella morganii CF patient, UK 2.4.15    
7000 Achromobacter xylosoxidans CF patient, UK 2.4.15    
7001 Burkholderia cenocepacia CF patient, UK 2.4.15 3.10.1   
7002 Achromobacter xylosoxidans CF patient, UK 2.4.15 3.10.1   
7003 Achromobacter xylosoxidans CF patient, UK 2.4.15    
7004 Pseudomonas aeruginosa CF patient, UK 2.4.15 
3.10.1 
3.10.2   
7005 Achromobacter xylosoxidans CF patient, UK 2.4.15    
7006 Burkholderia multivorans CF patient, UK 2.4.15 3.10.1   
7007 Inquilinus.limosus CF patient, UK 
2.4.14 
2.4.15 
3.10.1 
3.10.2 
  
7008 Delftia acidovorans CF patient, UK 2.4.15 
3.10.1 
3.10.2   
7009 Burkholderia cenocepacia CF patient, UK  3.10.2   
7010 Achromobacter xylosoxidans CF patient, UK  3.10.2   
7011 Inquilinus.limosus CF patient, UK 2.4.15 3.10.2   
7012 Burkholderia cenocepacia CF patient, UK 2.4.15 3.10.2   
7013 Burkholderia multivorans CF patient, UK 2.4.15    
7014 Achromobacter xylosoxidans CF patient, UK 2.4.15    
7015 Achromobacter xylosoxidans CF patient, UK  3.10.2   
7016 Burkholderia multivorans CF patient, UK 2.4.15    
7017 Burkholderia multivorans CF patient, UK 2.4.15 3.10.2   
7018 Pandoraea norimbergenis CF patient, UK 2.4.15 
3.10.1 
3.10.2   
7019 Serratia marcescens CF patient, UK 2.4.15 
3.10.1 
3.10.2   
7020 Serratia marcescens CF patient, UK 
2.4.14 
2.4.15 3.10.2 
  
7021 Achromobacter xylosoxidans CF patient, UK 2.4.15    
7022 Burkholderia multivorans CF patient, UK 2.4.15 
3.10.1 
3.10.2   
7023 Achromobacter xylosoxidans CF patient, UK  3.10.1   
7024 Burkholderia multivorans CF patient, UK  3.10.2   
7026 Burkholderia stabilis CF patient, UK 2.4.15 
3.10.1 
3.10.2   
7027 Achromobacter xylosoxidans CF patient, UK  3.10.2   
7029 Burkholderia multivorans CF patient, UK 2.4.15    
7031 Ochrobactrum sp. CF patient, UK 2.4.15 3.10.2   
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Reference Species Isolate Origin 
Chapter 
2 
Chapter 
3 
Chapter 
4 
Chapter 
5 
7032 Burkholderia vietnamiensis CF patient, UK 
2.4.14 
2.4.15 
3.10.1 
3.10.2 
  
7034 Burkholderia cenocepacia CF patient, UK 2.4.15 3.10.1   
7036 Burkholderia cenocepacia CF patient, UK 2.4.15 
3.10.1 
3.10.2   
7037 Pseudomonas  aeruginosa CF patient, UK 
2.4.7 
2.4.15 
2.5.6 
3.10.1 
3.10.2 
  
7038 Pseudomonas  aeruginosa CF patient, UK 
2.4.7 
2.4.15 
   
7039 Pseudomonas  aeruginosa 
Non-CF parent of CF patient, 
UK 
2.4.7 
2.4.15 
2.5.6 
   
7040 Pseudomonas  aeruginosa CF patient, UK 
2.4.7 
2.4.15 
   
7041 Pseudomonas  aeruginosa CF patient, Denmark 
2.4.7 
2.4.15 
   
7042 Pseudomonas  aeruginosa 
Paediatric CF patient, 
Melbourne, Australia 
2.4.7 
2.4.15 
   
7043 Pseudomonas  aeruginosa 
Adult CF patient, Brisbane, 
Australia 
2.4.7 
2.4.15 
   
7044 Pseudomonas  aeruginosa 
Adult CF patient, Hobart, 
Australia 
2.4.7 
2.4.14 
2.4.15 
   
7045 Pseudomonas  aeruginosa CF patient, Germany 
2.4.7 
2.4.15 
   
7046 Pseudomonas  aeruginosa CF patient, Germany 
2.4.7 
2.4.15 
   
7047 Pseudomonas  aeruginosa CF patient, Germany 
2.4.7 
2.4.15 
   
7048 Pseudomonas  aeruginosa 
Paediatric CF patient, 
Seattle, USA 
2.4.7 
2.4.15 
   
7049 Pseudomonas  aeruginosa 
Paediatric CF patient, 
Seattle, USA 
2.4.7 
2.4.15 
   
7050 Pseudomonas  aeruginosa 
Paediatric CF patient, 
Seattle, USA 
2.4.7 
2.4.15 
   
7051 Pseudomonas  aeruginosa 
Paediatric CF patient, 
Seattle, USA 
2.4.7 
2.4.15 
   
7052 Pseudomonas  aeruginosa 
Paediatric CF patient, 
Seattle, USA 
2.4.7 
2.4.15 
   
7053 Pseudomonas  aeruginosa ATCC 15692 Infected wound 
2.4.7 
2.4.15 
   
7054 Pseudomonas  aeruginosa Human burn isolate, UK 
2.4.7 
2.4.15 
   
7055 Pseudomonas  aeruginosa Clinical non-CF patient, UK 
2.4.7 
2.4.15 
   
7056 Pseudomonas  aeruginosa CF patient, UK 
2.4.7 
2.4.15 
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7057 Pseudomonas  aeruginosa CF patient, Germany 
2.4.7 
2.4.15 
   
7058 Pseudomonas  aeruginosa CF patient, Lisbon, Portugal 
2.4.7 
2.4.15 
   
7059 Pseudomonas  aeruginosa CF patient, Lisbon, Portugal 
2.4.7 
2.4.15 
   
7060 Pseudomonas  aeruginosa 
Non-CF bronchiectasis 
patient, UK 
2.4.7 
2.4.15 
   
7061 Pseudomonas  aeruginosa 
Non-CF urine sample, 
Poland 
2.4.7 
2.4.15 
   
7062 Pseudomonas  aeruginosa Keratitis eye isolate, UK 
2.4.7 
2.4.15 
   
7063 Pseudomonas  aeruginosa 
Chronic CF patient, Boston, 
USA 
2.4.7 
2.4.15 
   
7064 Pseudomonas  aeruginosa CF patient, Denmark 
2.4.7 
2.4.15 
   
7065 Pseudomonas  aeruginosa 
Non-CF clinical patient, 
Leuven, Belgium 
2.4.7 
2.4.15 
   
7066 Pseudomonas  aeruginosa Non-CF burn, Michigan, USA 
2.4.7 
2.4.15 
   
7067 Pseudomonas  aeruginosa 
Lake water, Lake Tamaco, 
Japan 
2.4.7 
2.4.15 
   
7068 Pseudomonas  aeruginosa 
LMG 14084: Water, 
Bucharest, Romania 
2.4.7 
2.4.15 
   
7069 Pseudomonas  aeruginosa 
Hospital environment, 
Prague, Czech Republic 
2.4.7 
2.4.15 
   
7070 Pseudomonas  aeruginosa CF patient, Hobart, Australia 
2.4.7 
2.4.15 
   
7071 Pseudomonas  aeruginosa Tobacco plant, Philippines 
2.4.7 
2.4.15 
   
7072 Pseudomonas  aeruginosa CF patient, Germany 
2.4.7 
2.4.15 
   
7073 Pseudomonas  aeruginosa ICU acute infection, Spain 
2.4.7 
2.4.15 
   
7074 Pseudomonas  aeruginosa COPD patient, USA 
2.4.7 
2.4.15 
   
7075 Pseudomonas  aeruginosa ICU acute infection, France 
2.4.7 
2.4.15 
   
7076 Pseudomonas  aeruginosa Keratitis, Manchester, UK 
2.4.7 
2.4.15 
   
7077 Pseudomonas  aeruginosa CF patient, Germany 
2.4.7 
2.4.15 
   
7078 Pseudomonas  aeruginosa 
Community acquired 
pneumonia, UK 
2.4.7 
2.4.15 
   
7079 Pseudomonas  aeruginosa CF patient, Germany 
2.4.7 
2.4.15 
   
7080 Ralstonia mannitolilytica CF patient, UK 2.4.15    
7081 Ralstonia mannitolilytica CF patient, UK 2.4.15    
7082 Ralstonia mannitolilytica CF patient, UK 2.4.15    
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Chapter 
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7083 Ralstonia mannitolilytica CF patient, UK 2.4.15    
7084 Ralstonia mannitolilytica CF patient, UK 2.4.15    
7085 Ralstonia mannitolilytica CF patient, UK 2.4.15    
7086 Ralstonia mannitolilytica CF patient, UK 2.4.15    
76024 M. avium CF patient, UK. PHE, UK 2.4.18    
76150 M. avium CF patient, UK. PHE, UK 2.4.18    
76525 M. avium CF patient, UK. PHE, UK 2.4.18    
76773 M. avium CF patient, UK. PHE, UK 2.4.18    
76831 M. avium CF patient, UK. PHE, UK 2.4.18    
76832 M. avium CF patient, UK. PHE, UK 2.4.18    
76147 M. intracellulare 
Non-CF patient, UK. PHE, 
UK 2.4.18    
76223 M. intracellulare 
Non-CF patient, UK. PHE, 
UK 2.4.18    
76017 M. tuberculosis complex 
Non-CF patient, UK. PHE, 
UK 2.4.18    
76089 M. tuberculosis complex 
Non-CF patient, UK. PHE, 
UK 2.4.18    
76463 M. tuberculosis complex 
Non-CF patient, UK. PHE, 
UK 2.4.18    
77041 M. tuberculosis complex 
Non-CF patient, UK. PHE, 
UK 2.4.18    
77042 M. tuberculosis complex 
Non-CF patient, UK. PHE, 
UK 2.4.18    
77043 M. tuberculosis complex 
Non-CF patient, UK. PHE, 
UK 2.4.18    
8001 Achromobacter xylosoxidans CF patient, UK 
2.4.7 
2.4.14 
2.4.15 
   
8002 Achromobacter sp. CF patient, UK 
2.4.9 
2.4.15 
   
8003 Acinetobacter sp. CF patient, UK 
2.4.7 
2.4.15 3.10.2 
  
8004 Burkholderia multivorans CF patient, UK 
2.4.7 
2.4.14 
2.4.15 
2.5.6 
   
8005 Burkholderia stabilis CF patient, UK 
2.4.9 
2.4.15 
   
8006 Burkholderia cenocepacia IIIA  CF patient, UK 
2.4.7 
2.4.15 
   
8007 Burkholderia cepacia (G1) CF patient, UK 
2.4.7 
2.4.14 
2.4.15 3.10.2 
  
8008 Burkholderia contaminans  CF patient, UK 
2.4.7 
2.4.14 
2.4.15 3.10.2 
  
8009 Pseudomonas  aeruginosa NCTC 10662 
2.4.7 
2.4.14 
2.4.15 
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8010 Pseudomonas  aeruginosa CF patient, UK 
2.4.7 
2.4.14 
2.4.15 
   
8011 Pseudomonas aeruginosa CF patient, UK 
2.4.9 
2.4.15 3.10.2 
  
8012 Pseudomonas aeruginosa CF patient, UK 
2.4.9 
2.4.15 3.10.2 
  
8013 Pseudomonas aeruginosa CF patient, UK 
2.4.9 
2.4.15 3.10.2 
  
8014 Pseudomonas  aeruginosa CF patient, UK 
2.4.7 
2.4.15 
   
8015 Pseudomonas  aeruginosa CF patient, UK 
2.4.7 
2.4.15 
   
8016 Pseudomonas  aeruginosa CF patient, UK 
2.4.7 
2.4.15 
2.5.6 
   
8017 Pseudomonas aeruginosa CF patient, UK 
2.4.9 
2.4.15 
   
8018 Pseudomonas  aeruginosa CF patient, UK 
2.4.7 
2.4.15 
   
8019 Pseudomonas  aeruginosa CF patient, UK 
2.4.7 
2.4.15 
2.5.6 
   
8020 Pandoraea apista CF patient, UK 
2.4.7 
2.4.14 
2.4.15 3.10.2 
  
8021 Pandoraea pnomenusa CF patient, UK 
2.4.7 
2.4.14 
2.4.15 3.10.2 
  
8022 Stenotrophomonas maltophilia CF patient, UK 
2.4.7 
2.4.15 3.10.2 
  
8023 Stenotrophomonas maltophilia CF patient, UK 
2.4.7 
2.4.15 3.10.2 
  
8024 Stenotrophomonas maltophilia CF patient, UK 2.4.15    
8025 Elizabethkingia miricola CF patient, UK 
2.4.9 
2.4.15 3.10.2 
  
8029 Stenotrophomonas maltophilia NCTC 10257 
2.4.9 
2.4.14 
2.4.15 
   
8030 Acinetobacter baumannii ATCC 19606 
2.4.9 
2.4.14 
2.4.15 
   
8031 Providencia rettgeri NCTC 7475 
2.4.7 
2.4.15 
   
8032 Citrobacter freundii NCTC 9750 
2.4.7 
2.4.15 
   
8033 Streptococcus pyogenes NCTC 8309 
2.4.7 
2.4.15 
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8034 Streptococcus salivarius NCTC 8618 
2.4.7 
2.4.15 
   
8035 Streptococcus gordonii NCTC 7865 
2.4.7 
2.4.15 
   
8036 Escherichia coli NCTC 10418 
2.4.7 
2.4.14 
2.4.15 3.10.1 
  
8037 Raoultella planticola NCTC 9528 
2.4.7 
2.4.14 
2.4.15 
   
8038 Enterobacter cloacae NCTC 11936 
2.4.7 
2.4.14 
2.4.15 
2.5.6 
   
8039 Serratia marcescens NCTC 10211 
2.4.7 
2.4.15 
   
8040 Streptococcus pneumoniae NCTC 12977 
2.4.7 
2.4.15 
   
8064 Burkholderia ambifaria LMG 19467 2.4.15    
8065 Burkholderia ambifaria LMG 19182 2.4.15    
8066 Burkholderia anthina LMG 20980 2.4.15    
8067 Burkholderia anthina LMG 20983 2.4.15    
8068 Burkholderia cenocepacia LMG 18832 2.4.15    
8069 Burkholderia cenocepacia LMG 18830 2.4.15    
8070 Burkholderia cenocepacia LMG 18828 2.4.15    
8071 Burkholderia cenocepacia LMG 18829 2.4.15    
8072 Burkholderia cenocepacia LMG 18863 2.4.15    
8073 Burkholderia cenocepacia LMG 16656 2.4.15    
8074 Burkholderia cepacia LMG 18821 2.4.15    
8075 Burkholderia cepacia LMG 1222 2.4.15    
8076 Burkholderia dolosa LMG 21820 2.4.15    
8077 Burkholderia dolosa LMG 18943 2.4.15    
8078 Burkholderia multivorans LMG 18824 2.4.15    
8079 Burkholderia multivorans LMG 18822 2.4.15    
8080 Burkholderia multivorans LMG 16660 2.4.15    
8081 Burkholderia multivorans LMG 17588 2.4.15    
8082 Burkholderia multivorans LMG 13010 2.4.15    
8083 Burkholderia pyrrocinia LMG 21824 2.4.15    
8084 Burkholderia pyrrocinia LMG 14191 2.4.15    
8085 Burkholderia stabilis LMG 14294 2.4.15    
8086 Burkholderia stabilis LMG 18870 2.4.15    
8087 Burkholderia vietnamiensis LMG 18835 2.4.15    
8088 Burkholderia vietnamiensis LMG 10929 2.4.15    
8089 Burkholderia vietnamiensis LMG 16232 2.4.15    
       
       
  
253 
 
Isolate 
Reference Species Isolate Origin 
Chapter 
2 
Chapter 
3 
Chapter 
4 
Chapter 
5 
9001 Staphylococcus aureus ATCC 6571 
2.4.7 
2.4.14 
2.4.15 3.10.1 
  
9002 Staphylococcus aureus MRSA NCTC 11939 
2.4.7 
2.4.15 
   
9003 Enterococcus faecalis NCTC 775 
2.4.7 
2.4.14 
2.4.15 
   
9004 Staphylococcus epidermidis NCTC 11047 
2.4.7 
2.4.15 
   
9005 Enterococcus faecium NCTC 7171 
2.4.7 
2.4.15 
   
9006 Bacillus subtilis NCTC 9372 
2.4.7 
2.4.15 
   
9007 Enterobacter aerogenes CF patient, UK 
2.4.7 
2.4.15 
   
9008 Neisseria flavescens CF patient, UK 
2.4.7 
2.4.15 
   
9009 Moraxella  catarrhalis CF patient, UK 
2.4.7 
2.4.15 
   
9010 Haemophilus influenzae  NCTC 11931 
2.4.7 
2.4.15 
   
9011 Candida albicans ATCC 90028 
2.4.7 
2.4.14 
2.4.15 
2.5.6 
   
9012 Candida glabrata NCPF 3943 
2.4.7 
2.4.15 
2.5.6 
   
9013 Aspergillus fumigatus CF patient, UK 
2.4.7 
2.4.15 
2.5.6 
   
9014 Aspergillus fumigatus CF patient, UK 
2.4.7 
2.4.15 
   
9015 Aspergillus terreus CF patient, UK 
2.4.7 
2.4.15 
2.5.6 
   
9016 Scedosporium apiospermum CF patient, UK 
2.4.7 
2.4.15 
2.5.6 
   
9017 Scedosporium prolificans CF patient, UK 
2.4.7 
2.4.15 
2.5.6 
   
9018 Geosmithia argillacea CF patient, UK 
2.4.7 
2.4.15 
2.5.6 
   
9059 Candida albicans CF patient, UK 2.4.15    
9110 Staphylococcus aureus MRSA 
14 EMRSA15 1758/98   
MRSA European Collection 2.4.15    
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9111 Staphylococcus aureus MRSA 
15 EMRSA15 14956 
MRSA European Collection 2.4.15    
9112 Staphylococcus aureus MRSA 
3 FIN 7481 (E14) 
MRSA European Collection 2.4.15    
9113 Staphylococcus aureus MRSA 
4 FIN 54511 (E6) 
MRSA European Collection 2.4.15    
9114 Staphylococcus aureus MRSA 
5FIN 54518 (E7) 
MRSA European Collection 2.4.15    
9115 Staphylococcus aureus MRSA 
6FRA 462 
MRSA European Collection 2.4.15    
9116 Staphylococcus aureus MRSA 
7 FRA 920 
MRSA European Collection 2.4.15    
9117 Staphylococcus aureus MRSA 
8 FRA 95034 (4b) 
MRSA European Collection 2.4.15    
9118 Staphylococcus aureus MRSA 
9 GER 131/98 
MRSA European Collection 2.4.15    
9119 Staphylococcus aureus MRSA 
10 GER 1966/97 
MRSA European Collection 2.4.15    
9120 Staphylococcus aureus MRSA 
11 GER 2594 1/97 
MRSA European Collection 2.4.15    
9121 Staphylococcus aureus MRSA 
12 GER 2594 2/97 
MRSA European Collection 2.4.15    
9122 Staphylococcus aureus MRSA 
13 EMRSA15 1729/98 
MRSA European Collection 2.4.15    
9123 Staphylococcus aureus MRSA 
14 EMRSA15 1758/98 
MRSA European Collection 2.4.15    
9124 Staphylococcus aureus MRSA 
15 EMRSA15 14956 
MRSA European Collection 2.4.15    
9125 Staphylococcus aureus MRSA 
16 EMRSA15 12484/98 
MRSA European Collection 2.4.15    
9126 Staphylococcus aureus MRSA 
17 EMRSA15 14185/98 
MRSA European Collection 2.4.15    
9127 Staphylococcus aureus MRSA 
18 EMRSA15 16822/98 
MRSA European Collection 2.4.15    
9128 Staphylococcus aureus MRSA 
19 EMRSA 19972/98 
MRSA European Collection 2.4.15    
9129 Staphylococcus aureus MRSA 
20 EMRSA 20460/98 
MRSA European Collection 
 2.4.15    
9130 Staphylococcus aureus MRSA 
21 EMRSA15 21268/98 
MRSA European Collection 2.4.15    
9131 Staphylococcus aureus MRSA 
22 EMRSA15 21698/98 
MRSA European Collection 2.4.15    
9132 Staphylococcus aureus MRSA 
23 EMRSA15 2501/98 
MRSA European Collection 2.4.15    
9133 Staphylococcus aureus MRSA 
24 EMRSA15 6323/98 
MRSA European Collection 2.4.15    
9134 Staphylococcus aureus MRSA 
25 EMRSA16 00036/98 
MRSA European Collection 2.4.15    
9750 Citrobacter freundii NCTC 9750 2.4.15    
PHE1 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.5.6 
2.4.15 
   
PHE10 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
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PHE11 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE12 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE13 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE14 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE15 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE16 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE17 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE18 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE19 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE2 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE20 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE21 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE25 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE27 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE29 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE3 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE30 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE31 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE33 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE34 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE35 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE36 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE37 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE38 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
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PHE39 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE4 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE40 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE41 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE42 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE43 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE44 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE45 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE46 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE47 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE48 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE5 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE50 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE53 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE55 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE59 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE61 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE62 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE63 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE66 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE74 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE78 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE8 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 2.4.15 
   
PHE80 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
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PHE81 M. chelonae CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE9 M. chelonae CF patient, UK. PHE, UK 2.4.15 
   
PHE90 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
PHE99 
M. abscessus subsp. 
abscessus CF patient, UK. PHE, UK 
2.4.9 
2.4.15 
   
 
 
Pseudomonas aeruginosa International Reference Panel: Gram-negative 
isolate reference numbers 7039 – 7079 Pseudomonas aeruginosa  
International Reference Panel (De Soyza et al., 2013) 
 
NCTC: National Collection of Type Cultures, Colindale, UK. 
 
ATCC: American Type Culture Collection, Manassas, United Sates. 
 
CF Patient, UK: Isolates from Microbiology Department, Freeman Hospital, 
Newcastle upon Tyne, UK from patients with CF 
 
CF Patient, Ireland: Isolates from St Vincent’s University Hospital, Dublin, Ireland 
from patients with CF 
 
NCPF: National Collection of Pathogenic Fungi, Colindale, UK. 
 
PHE Isolates: Public Health England Laboratory, Freeman Hospital, Newcastle 
upon Tyne UK from patients with CF 
 
LMG: LM-UGent hosts the BCCM/LMG Bacteria Collection, which maintains over 
20000 strains, representing some 700 genera and 4.500 species. Available at 
http://bccm.belspo.be/about-us/bccm-lmg 
 
MRSA European Collection: A collection of 25 strains representing the most 
frequently encountered MRSA types isolated in Europe were provided by Public 
Health England, Colindale, London, United Kingdom, as freeze-dried cultures. The 
collection included strains isolated in Belgium, Finland, France, Germany, and the 
United Kingdom. Available at http://jcm.asm.org/content/42/10/4519.long 
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Appendix 2: Ingredients and how to prepare 500 ml RGM medium  
 
 
QUANTITY PRODUCT SUPPLIER PRODUCT 
CODE 
5 g Bacteriological Agar no. 1 
(LP0011) 
Oxoid LP0011B 
2 g Yeast Extract bioMérieux 03904110 
50 ml 10 x Strength Middlebrook Broth 
Base 
(see below)  
375 ml Deionised H2O   
   
 
 
Autoclave (while in autoclave, prepare the OADC supplement and 
Antimicrobials) 
 
  
 
Make up 50 ml OADC Supplement using 50 ml previously sterilised 
and cooled deionised H2O (prepared as required) 
 
  
 
Add in: 
 
 
 
 
QUANTITY PRODUCT SUPPLIER PRODUCT 
CODE 
2.5 g Bovine Serum Albumin Sigma-Aldrich A2153 
1 g Dextrose Sigma-Aldrich G7528 
0.002 g Catalase Sigma-Aldrich C9322 
31.5 µl Oleic Acid Sigma-Aldrich O1008 
   
 
 
Filter sterilise  
 
  
 
Dissolve the following each  in 5 ml deionised H2O except the Amp B 
which is first dissolved in 200 µl NM2P and then added to 4.8 ml 
deionised H2O 
 
 
 
  
 
QUANTITY PRODUCT SUPPLIER PRODUCT 
CODE 
0.036 g Colistin methanesulfonate bioMérieux N/A 45% pure 
0.2 g Fosfomycin Sigma-Aldrich P5396 
0.0125 g Glucose-6-Phosphate Sigma-Aldrich G7879 
0.0025 g Amphotericin B Duchefa Biochemie BV A0103.0005 
0.016 g C390  Biosynth 16100/3  
   
 
Once agar is cooled to 50oC, add 50 ml of OADC supplement and 
the 5 x 5 ml of the above antimicrobials and G-6-P (Total volume 500 
ml).  Pour plates. 
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** 0.01g (10mg) Biotin dissolved in 1ml water and 500µl used (0.005g)  
** 0.01g (10mg) Copper Sulphate dissolved in 1ml water and 500µl used (0.005g) 
 
 
  
1 Litre Middlebook Broth Base (10 x strength) 
  
 
Dissolve the following in 960 ml deionised H2O 
 
 
  
QUANTITY PRODUCT SUPPLIER PRODUCT 
CODE 
5 g Ammonium Sulphate BDH 100333B 
5 g L-Glutamic Acid Sigma-Aldrich G2128 
25 g Disodium Phosphate Sigma-Aldrich S7907 
10 g Monopotassium Phosphate Sigma-Aldrich P5655 
1 g Sodium Citrate BDH 102425M 
0.5 g Magnesium Sulphate Sigma-Aldrich M1880 
0.005 g Calcium Chloride BDH 22311.297 
0.005 g Biotin* Sigma-Aldrich B4501 
0.01 g Copper Sulphate** Sigma-Aldrich C1297 
0.01 g Zinc Sulphate Sigma-Aldrich Z4750 
0.01 g Pyridoxine Sigma-Aldrich P9755 
0.4 g Ferric Ammonium Citrate Sigma-Aldrich F5879 
40 ml Glycerol  Sigma-Aldrich G7757 
    
 
 
Check pH is 6.6 +/-0.2 and adjust accordingly 
 
Split into 100 ml volumes and autoclave. Store in fridge until 
required. 
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Appendix 3: Antimicrobial supplement for use in MB/BacT bottles 
 
 
Bottle A: 10 mL Middlebrook 7H9 broth (bioMérieux ref: 259797) supplemented with 
selective supplement (bioMérieux reference: 259760 containing: Reconstitution 
Fluid: oleic acid, glycerol, bovine serum albumin, and amaranth in water. MB/BacT® 
Antibiotic Supplement Lyophilized supplement with: amphotericin B, azlocillin, 
nalidixic acid, polymyxin B, trimethoprim, and vancomycin). 
 
Bottle B:  10 mL Middlebrook 7H9 broth (bioMérieux ref: 259797) supplemented 
with Reconstitution Fluid: oleic acid, glycerol, bovine serum albumin, and amaranth 
in water containing in-house selective formulation comprising fosfomycin, C390, 
colomycin, glucose-6-phosphate and amphotericin. 
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Appendix 4: Ethical approval for clinical samples used in the evaluation of 
RGM 
 
 
This PhD form is part of an ongoing research project into the development of 
improved diagnostic methods for the detection of pathogenic bacteria. The project 
has formal approval from the Research and Development Department of the 
Newcastle Upon Tyne Hospitals NHS Trust (Project registration number: 02999). 
The project does not require specific approval from the research ethics committee 
and this has previously been endorsed by the head of the Research and 
Development Office (Newcastle Upon Tyne Hospitals NHS Trust) and the Chair of 
the local research ethics committee, subject to a number of conditions that must be 
strictly adhered to. These conditions are: 
 
 Clinical samples used in this study will only be those that are sent to the 
laboratory for routine investigation i.e. no additional samples will be 
requested specifically for the study. 
 
 All samples will be anonymised by Biomedical Scientists who have legitimate 
access to patient identifiable information and who are processing the 
samples as part of their routine workload before they are passed to the 
student. 
 
 Any additional test(s) performed on the sample would always be within the 
scope of the test that has been requested by the clinician. Test that require 
specific informed consent e.g. HIV testing would not be performed.  
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 The fact that extra tests may be performed on patient samples would in no 
way impact on the routine processing of the samples using the standard 
operating procedures of the laboratory or the reporting of results.  
 
 Any data obtained from additional tests would not be reported and would not 
be allowed to impact on patient management in any way.  Data would be 
used solely for the evaluation of methods within the project. 
 
 On occasion, evaluations may be sponsored by commercial companies 
interested in the performance of new diagnostic products.  On such 
occasions, no patient identifiable data will be released to such companies.  
 
These agreed criteria allow the routine assessment of new laboratory methods 
(such as a new culture medium or a new piece of instrumentation) without the 
requirement of applying for formal ethical approval. Such evaluations are frequent 
and are part of normal laboratory development. The laboratory is positively 
discouraged from sending trivial requests to the ethics committee for projects for 
which we already have clear guidance as they have a high workload of genuine 
requests to consider. 
In the later stages of the project, it is possible that: 
 Additional samples may not be requested specifically for the purposes of this 
project.  
 Clinical information may be required from patient’s notes to assess the 
clinical significance of pathogens that are isolated. 
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No such work will be carried out unless formal approval is provided by the local 
research ethics committee following the standard application process. It is highly 
likely that informed written patient consent will be required in such instances. 
Prof. John Perry 
Clinical Scientist 
Head of Clinical Microbiology Research 
Newcastle Upon Tyne Hospitals NHS Trust 
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Appendix 5: Structures of substrates used for fluorogenic testing in Chapter 3 
Name Chemical Structure Molecular Weight Molecular Formula 
4-Methylumbelliferyl lignocerate 
 
 
526.79 C34H54O4 
4-Methylumbelliferyl β-D-glucopyranoside 
 
338.31 C16H18O8 
4-Methylumbelliferyl sulfate 
 
294.32 C10H7KO6S 
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Name Chemical Structure Molecular Weight Molecular Formula 
4-Methylumbelliferyl β-D-N,N'-
diacetylchitobioside hydrate 
 
582.55 C26H34N2O13·xH2O 
4-Methylumbelliferyl β-D-N,N'-
triacetylchitotriose 
 
785.75 C34H47N3O15 
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Name Chemical Structure Molecular Weight Molecular Formula 
4-Methylumbelliferyl α-L-iduronide 
 
352.30 C16H16O9 
4-Methylumbelliferyl α-D-glucuronide 
 
352.30 C16H16O9 
: 4-Methylumbelliferyl β-D-mannopyranoside 
 
338.31 C16H18O8 
  
267 
 
Name Chemical Structure Molecular Weight Molecular Formula 
4-Methylumbelliferyl α-L-idopyranoside 
 
338.31 C16H18O8 
4-Methylumbelliferyl β-D-glucoside 
 
338.31 C16H18O8 
4-Methylumbelliferyl β-D-galactoside 
 
338.31 C16H18O8 
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Name Chemical Structure Molecular Weight Molecular Formula 
4-Methylumbelliferyl α-D-galactoside 
 
338.31 C16H18O8 
4-Methylumbelliferyl α-D-mannopyranoside 
 
338.30 C16H18O8 
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Name Chemical Structure Molecular Weight Molecular Formula 
4-Methylumbelliferyl β-D-fucoside 
 
322.31 C16H18O7 
4-Methylumbelliferyl β-D-cellobioside 
 
500.45 C22H28O13 
4-Methylumbelliferyl stearate 
 
442.63 C28H42O4 
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Name Chemical Structure Molecular Weight Molecular Formula 
4-Methylumbelliferyl α-L-arabinopyranoside 
 
308.28 C15H16O7 
4-Methylumbelliferyl propionate 
 
232.23 C13H12O4 
4-Methylumbelliferyl laurate 
 
358.50 C22H30O4 
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Name Chemical Structure Molecular Weight Molecular Formula 
4-Methylumbelliferyl nonanoate 
 
316.40 C19H24O4 
4-Methylumbelliferyl riboside/4-
Methylumbelliferyl β-D-ribofuranoside 
 
308.30 C15H16O7 
4-Methylumbelliferyl α-D-glucopyranoside 
 
338.30 C16H18O8 
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Name Chemical Structure Molecular Weight Molecular Formula 
4-Methylumbelliferyl β-D-glucuronide 
 
352.30 C16H16O9 
4-Methylumbelliferyl acetate 
 
218.21 C12H10O4 
4-Methylumbelliferyl  7-β-D-xyloside 
 
308.28 C15H16O7 
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Name Chemical Structure Molecular Weight Molecular Formula 
4-Methylumbelliferyl acetamido-4,6-0-
benzylidene-2-deoxy-β-D-glucopyranoside 
 
467.47 C25H25NO8 
4-Methylumbelliferyl butyrate 
 
246.26 C14H14O4 
4-Methylumbelliferyl heptanoate 
 
288.34 C17H20O4 
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Name Chemical Structure Molecular Weight Molecular Formula 
4-Methylumbelliferyl N-acetyl-β-D- 
galactosaminide 
 
379.36 C18H21NO8 
4-Methylumbelliferyl N-acetyl-β-D-
glucosaminide 
 
379.36 C18H21NO8 
4-Methylumbelliferyl palmitate  
 
414.58 C26H38N3O4 
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Name Chemical Structure Molecular Weight Molecular Formula 
4-Methylumbelliferyl p-guanidinobenzoate 
hydrochlorate hydrate 
 
373.79 C18H15N3O4·HCl·xH2O 
4-Methylumbelliferyl phosphate 
 
256.15 C10H9O6P 
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Name Chemical Structure Molecular Weight Molecular Formula 
H-Gly-AMC.Hbr 
 
232.24 C12H12N2O3 
H-Pro-AMC hydrobromide salt (Prolyl) 
 
272.30 C15H16N2O3 
H-Val-AMC 
 
274.32 C15H18N2O3 
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Name Chemical Structure Molecular Weight Molecular Formula 
H-Thr-AMC 
 
276.29 
 
C14H16N2O4 
Pyr-AMC 
 
286.29 C15H14N2O4 
H-Ile-AMC.TFA 
 
288.35 C16H20N2O3 
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Name Chemical Structure Molecular Weight Molecular Formula 
H-Leu-AMC.HCl 
 
288.35 C16H20N2O3 
H-Asn-AMC.TFA 
 
286.29 C14H15N3O4 
H-Orn-AMC.2HCl 
 
289.33 C15H19N3O3 
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Name Chemical Structure Molecular Weight Molecular Formula 
H-Asp(AMC)-OH 
 
290.28 C14H14N2O5 
H-Gln-AMC 
 
303.32 C15H17N3O4 
H-Lys-AMC.acetate 
 
303.36 C16H21N3O3 
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Name Chemical Structure Molecular Weight Molecular Formula 
H-Glu-AMC 
 
304.30 C15H16N2O5 
H-Met-AMC acetate salt 
 
306.39 C15H18N2O3S 
H-His-AMC 
 
312.33 C16H16N4O3 
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Name Chemical Structure Molecular Weight Molecular Formula 
H-Phe-AMC.TFA 
 
322.36 C19H18N2O3 
H-Arg-AMC.2HCl 
 
331.38 C16H21N5O3 
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Name Chemical Structure Molecular Weight Molecular Formula 
H-Try-AMC 
 
338.36 C19H18N2O4 
Ac-Met-AMC 
 
348.42 C17H20N2O4S 
H-β-Ala-AMC.TFA  
 
360.29 C13H14N2O3.C2HF3O2 
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Name Chemical Structure Molecular Weight Molecular Formula 
Boc-Leu-Gly-Arg-AMC acetate salt 
 
601.70 C29H43N7O7 
H-Gly-pro-AMC.HBr 
 
410.27 C17H19N3O4.HBr 
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Name Chemical Structure Molecular Weight Molecular Formula 
Z-Arg-AMC.HCl 
 
465.51 C24H27N5O5 
L-alanine-AMC trifluoroacetate salt 
 
360.29 C13H14N2O3·C2HF3O2 
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Appendix 6: Average spectrophotometer readings for fluorogenic substrates after 72 hours incubation 
Species 4MA 4MPr 4MB 4MH 4MN 4MLa 4MPgh 4MPa 4MSt 4MLi 4Mara 4Mxyl 4Mribs 
A. xylosoxidans -263 76 97 -10 325 1316 -4 4 -20 -72 -61 -30 -14 
A. xylosoxidans -112 -40 -23 123 80 319 -112 1 -17 -64 -246 -18 -14 
A. xylosoxidans -113 -64 48 95 -16 977 -1 -4 -21 -81 -222 -12 251 
B. cenocepacia -473 -738 -1102 434 -1089 1156 -247 291 41 -85 -177 -59 400 
B. cenocepacia -844 -872 -895 -1193 -94 248 -488 -108 -120 -127 -317 6 231 
B. multivorans -689 -600 -481 -547 -48 672 -417 -57 -69 -88 -1286 -57 -15 
B. multivorans -959 -763 -532 327 -689 2817 -474 1060 484 -14 -1220 -62 -9 
B. multivorans -500 -568 -698 -283 -262 2002 -207 994 143 -40 -348 -6 -6 
B. stabilis 144 298 394 1028 435 2017 -261 3828 2428 48 20 113 143 
B. vietnamiensis -212 -165 -320 77 -17 -52 -120 8 -23 -75 -75 26 773 
D. acidovorans -44 -19 -94 118 83 -120 94 133 7 15 -141 90 -19 
I. limosus -344 -126 7 -18 -288 26 -79 21 -8 -43 159 53 272 
P. norimbergenis 48 -39 100 323 56 179 31 32 5 -63 79 16 57 
P. aeruginosa 703 534 331 -52 594 2222 -169 3897 2592 -51 -20 36 167 
S. marcesens -951 -696 2184 1769 115 2894 -314 4515 2998 134 2278 -28 402 
M. abscessus  -480 -289 -165 62 380 1566 -21 970 277 -67 90 158 537 
M. abscessus  -342 -293 -224 -34 -354 1315 11 313 94 -117 99 32 217 
M. abscessus  -331 -245 -174 -6 521 1455 -21 500 191 6 370 -1 179 
M. abscessus  -467 -220 -202 -20 -379 1449 -3 672 151 6 78 16 30 
M. abscessus  -402 -172 -264 -3 -200 1453 15 1076 330 100 346 11 260 
M. abscessus  -211 -236 -249 75 111 1147 22 940 207 -87 448 41 148 
M. abscessus  -264 -216 -246 -49 149 967 -5 740 168 1 245 69 8 
M. abscessus  -310 -112 -462 58 -74 1188 -23 474 288 -91 -62 -1 -8 
M. abscessus  -70 -2 57 367 516 1651 -104 1196 377 30 37 30 83 
M. abscessus  -211 -247 -14 276 1030 1731 1 859 193 -72 372 43 17 
M. abscessus  -425 -340 -147 55 490 1453 -89 382 183 -93 309 63 32 
M. abscessus  -337 -359 -78 24 471 1523 -83 671 156 -104 137 53 87 
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Average spectrophotometer readings for fluorogenic substrates after 72 hours incubation continued 
 
Species 4MA 4MPr 4MB 4MH 4MN 4MLa 4MPgh 4MPa 4MSt 4MLi 4Mara 4Mxyl 4Mribs 
M. bolletii -366 -275 -179 21 399 1468 0 780 184 -101 63 5 16 
M. bolletii (ENV) -334 -256 -99 79 -2004 1374 -23 738 226 -87 152 25 17 
M. chelonae -257 -254 -268 -27 386 1465 -42 986 292 -93 351 113 81 
M. chelonae -467 -144 -159 38 -286 1306 -9 313 124 -100 -59 -17 -3 
M. chelonae -793 -416 -536 -53 1 1376 -95 681 194 -91 393 -12 42 
M. chelonae -412 -203 -360 -89 -10 1197 5 204 119 -44 161 4 14 
M. chelonae -579 -244 -248 -126 80 1573 -78 995 243 0 283 84 195 
M. chelonae -819 -318 -351 -209 102 895 -120 1344 347 14 326 54 150 
M. massiliense -119 21 -90 352 449 1457 68 585 219 27 261 51 31 
M. massiliense -238 -153 18 188 289 1817 69 609 216 -82 617 100 151 
M. massiliense -53 -206 205 313 251 1613 -2 745 250 -105 475 52 250 
M. massiliense 0 30 42 262 -1661 1647 54 1454 332 -94 594 43 68 
M. massiliense 72 12 120 333 -1611 1709 16 526 157 -113 370 47 80 
M. massiliense 82 57 158 329 -1332 1761 58 695 376 -114 232 16 20 
M. massiliense -20 -10 104 225 1003 1580 104 605 146 -75 368 12 143 
M. massiliense -321 -337 100 261 84 1630 86 1632 261 -53 337 49 220 
S. aureus + Ctrl 122 63 -298 -120 -246 -65 86 12 -14 -118 5069 -33 169 
E. coli + Ctrl 42 -151 8 -661 -154 18 44 77 24 -84 18 -11 168 
Neg Ctrl -112 85 -52 -143 24 44 -78 14 7 -103 -33 -27 -2 
Neg Ctrl -141 92 -87 -36 -75 10 3 -17 -3 -1 14 -4 -12 
Neg Ctrl 251 -177 139 179 51 -54 75 2 -4 105 18 30 12 
Neg Ctrl Totals -2 0 1 -1 1 0 -1 -2 0 1 -2 -1 -2 
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Average spectrophotometer readings for fluorogenic substrates after 72 hours incubation continued 
              
Species 4Mribf 4Mfuc 4Mglupα 4Mglupβ 4Mmanα 4Mgalα 4Mgalβ 4Mgluβ 4MIdo 4Manβ 4Mcurβ 4MIdu 4MNgal 
A. xylosoxidans -54 -3 168 32 -21 6 851 9 -4 -28 6 4 -839 
A. xylosoxidans -53 -7 -49 4 -18 3 871 -33 -7 -23 -7 1 -725 
A. xylosoxidans 2715 -10 56 75 -20 2 955 -8 -7 -20 -7 1 -761 
B. cenocepacia 356 -8 -543 -4 -8 -8 -55 -54 -24 -56 -42 -8 -105 
B. cenocepacia 510 -10 -1353 156 -8 -2 896 142 -7 0 -26 -5 -112 
B. multivorans -67 -11 -1483 -120 2 -4 -173 -57 -37 -62 -34 -10 -203 
B. multivorans -69 -15 -1369 -115 -2 -7 -197 -74 -26 -78 -31 -13 -210 
B. multivorans -63 -13 -630 -38 -11 -6 567 -73 -29 -82 -47 -23 -173 
B. stabilis 1207 -1 318 33 -15 4 1206 -11 1 -26 -5 3 -195 
B. vietnamiensis -31 -5 -308 176 -15 -2 608 -5 -15 -23 -2 0 -191 
D. acidovorans -42 -3 -505 50 -23 -3 1342 69 -6 -8 144 -13 -313 
I. limosus 1566 10 163 670 57 3 1062 1099 -1 -37 2 2 192 
P. norimbergenis 185 2 478 43 -6 7 1232 18 6 -6 13 10 -112 
P. aeruginosa 6393 3 -242 33 -13 -1 1173 -2 -3 -16 -9 -2 -220 
S. marcesens 6296 1 -1400 3735 313 218 1395 7186 -4 41 258 279 2201 
M. abscessus  39 408 239 1657 511 20 1701 2267 30 187 137 23 38 
M. abscessus  108 56 388 1256 803 80 2083 1612 44 185 120 25 125 
M. abscessus  216 355 488 1690 709 53 1485 1287 79 243 145 27 130 
M. abscessus  48 3 126 1047 853 11 1669 293 15 35 23 7 -93 
M. abscessus  545 8 573 2885 1250 94 2482 3181 42 300 179 142 115 
M. abscessus  221 94 678 3930 1630 120 2336 3774 46 319 108 26 196 
M. abscessus  581 160 579 1499 381 13 2191 3030 38 171 2 30 123 
M. abscessus  6 27 -139 450 637 11 1880 1156 16 40 57 9 83 
M. abscessus  586 37 787 307 275 35 1683 248 24 35 55 15 185 
M. abscessus  31 81 815 977 999 29 2160 4600 60 409 192 40 247 
M. abscessus  143 2 406 294 245 8 1682 845 30 89 110 32 94 
M. abscessus  101 156 419 860 11 10 2391 1234 29 138 71 19 241 
M. bolletii 35 -1 431 673 378 38 2644 2049 41 242 161 27 182 
M. bolletii (ENV) 28 -1 180 132 247 7 1665 207 27 35 55 18 164 
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Average spectrophotometer readings for fluorogenic substrates after 72 hours incubation continued 
              
Species 4Mribf 4Mfuc 4Mglupα 4Mglupβ 4Mmanα 4Mgalα 4Mgalβ 4Mgluβ 4MIdo 4Manβ 4Mcurβ 4MIdu 4MNgal 
M. chelonae 289 14 93 794 600 8 1692 838 23 78 89 25 103 
M. chelonae -49 -6 -122 256 705 3 1445 1243 24 107 66 14 22 
M. chelonae 240 -6 506 703 447 7 1806 357 12 33 65 15 54 
M. chelonae -23 -5 90 94 524 7 1558 277 12 19 47 11 17 
M. chelonae 177 59 422 1902 665 7 2072 897 16 53 -56 10 -25 
M. chelonae 278 26 -228 1284 1877 9 1870 1453 20 54 57 20 25 
M. massiliense 63 148 603 286 186 4 1923 341 13 30 46 13 191 
M. massiliense 445 90 940 546 431 54 1766 1371 53 234 157 42 193 
M. massiliense 126 88 920 905 376 25 3239 3539 56 373 205 43 279 
M. massiliense 358 36 1236 1289 932 36 2673 2525 68 353 193 42 409 
M. massiliense 104 86 718 592 821 13 2253 717 36 75 88 24 272 
M. massiliense -29 84 413 542 339 7 1814 1174 36 -74 85 19 305 
M. massiliense 158 51 1194 1677 732 66 2900 1793 46 256 174 37 404 
M. massiliense 229 169 899 3043 1009 59 3265 4899 58 346 208 39 349 
S. aureus + Ctrl 4659 273 56 85 -3 4 4418 37 9 -16 295 22 18 
E. coli + Ctrl 3292 6 214 51 -8 3 1211 -2 -1 -26 -3 -6 -50 
Neg Ctrl -53 3 74 30 -4 2 38 -4 -14 -11 -2 -14 45 
Neg Ctrl -54 -3 -541 16 3 3 -1 -8 9 7 1 5 -45 
Neg Ctrl 108 1 468 -46 1 -5 -37 12 6 4 1 8 -1 
Neg Ctrl Totals 1 1 1 -1 0 1 1 0 1 0 1 -1 0 
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Average spectrophotometer readings for fluorogenic substrates after 72 hours incubation continued 
              
Species 4MNglu 4Mcel Pro Val Thr Ile Leu Orn Gln MetH His Phe ArgH 
A. xylosoxidans -2552 -1 501 34 33 17 140 85 180 118 -10 137 69 
A. xylosoxidans -2490 -7 678 37 17 14 315 -26 441 81 -2 211 235 
A. xylosoxidans -2876 -8 827 33 53 2 309 -46 2432 117 898 247 181 
B. cenocepacia -1312 -20 -166 10 3 -26 2584 -432 2615 429 56 2620 1873 
B. cenocepacia -1030 13 677 18 3 5 275 -199 2786 79 -18 661 -39 
B. multivorans -1478 -16 1107 -5 -44 -19 269 -474 45 50 -55 213 -35 
B. multivorans -1677 -18 199 3 -33 -11 140 -462 -137 83 -55 112 -28 
B. multivorans -875 -14 676 8 -19 -7 199 -297 -54 32 -53 155 89 
B. stabilis -113 3 5361 89 27 46 1449 13 521 323 73 1199 657 
B. vietnamiensis -526 -2 8241 350 372 3933 9014 1800 918 3257 122 527 7279 
D. acidovorans -2906 22 19 -54 24 20 415 -226 362 3029 -40 282 166 
I. limosus -344 5 6920 1571 453 2130 10040 101 1772 735 214 9669 1189 
P. norimbergenis -79 3 1482 70 40 38 1151 108 1313 260 7 392 560 
P. aeruginosa -690 -9 14 40 7 2 357 -68 902 4 -45 180 2566 
S. marcesens -1764 568 8106 2409 7816 3954 3774 1336 7833 8388 2634 6456 1562 
M. abscessus  -25 11 1912 1053 1693 742 7800 2081 1742 3513 2391 8235 6669 
M. abscessus  4 19 3960 1905 1182 1659 7824 2694 1191 3799 4715 6870 6055 
M. abscessus  443 16 1055 851 2954 504 7221 1522 1963 4452 1378 7995 7088 
M. abscessus  -293 6 903 425 729 380 5480 1458 572 931 975 6159 4791 
M. abscessus  -1544 8 2025 1086 1920 516 7371 2312 1558 4413 2238 7459 6680 
M. abscessus  -1028 30 3812 1975 2519 1321 8144 3532 2688 4110 3848 8522 7451 
M. abscessus  -2442 14 3229 1010 1865 1315 7554 2156 2101 4633 4916 8670 7414 
M. abscessus  -184 11 1261 2414 781 1189 7694 2087 666 1629 853 7031 4900 
M. abscessus  296 9 1448 747 784 855 7442 2514 2113 4010 2739 8652 7874 
M. abscessus  430 18 1351 1124 1216 594 7932 1752 1431 4489 3477 7887 6230 
M. abscessus  62 -3 43 56 37 22 2157 421 161 2623 4123 2106 7672 
M. abscessus  773 23 2771 1630 1956 1110 8390 2858 2718 5403 2655 8422 7237 
M. bolletii 434 7 1048 726 1352 395 6843 2675 1803 2497 2950 7573 6873 
M. bolletii (ENV) 395 4 46 93 20 149 1907 142 -13 1459 1598 1703 670 
M. chelonae 216 2 305 215 211 158 5149 1612 770 2622 3550 5838 7399 
M. chelonae 160 1 1618 743 561 736 5781 215 1203 683 1346 5153 5034 
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Average spectrophotometer readings for fluorogenic substrates after 72 hours incubation continued 
              
Species 4MNglu 4Mcel Pro Val Thr Ile Leu Orn Gln MetH His Phe ArgH 
M. chelonae 149 0 151 742 105 231 2335 717 951 1838 932 4829 6504 
M. chelonae -41 5 454 550 65 302 4535 840 136 310 658 1328 5771 
M. chelonae -1850 3 451 288 363 179 4705 1696 1190 4828 4585 6968 7430 
M. chelonae 242 12 1555 830 1199 821 7769 2950 2433 2169 3118 8523 8559 
M. massiliense 497 6 695 481 466 414 4904 805 1120 4485 2678 7033 4991 
M. massiliense 541 34 3224 3238 2242 1696 8548 4182 2260 2144 3283 8972 8106 
M. massiliense 820 25 2945 1494 3310 904 8144 3096 2978 5381 4652 8947 8793 
M. massiliense 1173 20 1774 800 1061 413 5820 1792 1952 3468 1903 7875 7413 
M. massiliense 522 3 584 370 791 210 5014 691 702 4917 4331 7636 7006 
M. massiliense 851 15 3047 2310 2632 1308 9453 2916 2053 2665 2498 8185 6412 
M. massiliense 764 36 3361 1719 2476 1343 8952 4050 3248 3495 3660 9337 8488 
M. massiliense 996 36 3912 3344 3880 2140 9366 4222 3516 5689 4634 9463 8472 
S. aureus + Ctrl -371 -3 28 10 28 22 346 46 31 78 60 398 615 
E. coli + Ctrl -228 -3 3 34 14 12 48 -23 -39 9 18 27 36 
Neg Ctrl -95 -1 -1 26 -20 -3 18 -3 -21 -4 -2 3 -5 
Neg Ctrl -32 -3 -20 -66 -2 -12 -3 -99 17 3 0 -14 -8 
Neg Ctrl 127 4 19 39 21 14 -15 102 3 1 1 11 14 
Neg Ctrl Totals 0 1 -2 -1 -2 0 0 1 -1 0 -1 0 1 
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Average spectrophotometer readings for fluorogenic substrates after 72 hours incubation continued 
 
Species Try MetA Ala AAMC GlyP Boc 4MPh 4MSu 123 124 521 266 MR291 7N3CA 
A. xylosoxidans 87 20 -13 1470 -484 19 170 -730 -1 -0.5 4 -1.5 -0.5 1951 
A. xylosoxidans 151 18 -4 2083 -302 18 267 -991 -0.5 -0.5 -4.5 0.5 0.5 1422 
A. xylosoxidans 274 16 30 1476 -272 19 2346 152 -1.5 1 -2.5 0.5 1 3119 
B. cenocepacia 2239 5 639 1884 -474 354 4276 -1464 -1 0.5 -1.5 1.5 0 -31 
B. cenocepacia 519 11 826 3302 -310 10 4283 -1568 0 0 -0.5 1.5 0.5 456 
B. multivorans 145 0 1776 1334 -1425 3 2900 945 0 0.5 -4.5 1 0.5 3015 
B. multivorans 79 -4 1646 2417 -1590 16 4856 580 -1.5 0.5 -6 1 0.5 506 
B. multivorans 105 -4 1250 2206 -1136 18 5545 -227 -1 0 -2.5 2.5 0 1551 
B. stabilis 489 6 938 4254 -108 18 6010 -643 -0.5 0 -5 -1.5 0.5 240 
B. vietnamiensis 425 3 44 4082 1282 13 3024 606 0.5 0 -1.5 -1 -0.5 -594 
D. acidovorans 410 -9 44 2847 -143 15 109 5787 0 1.5 -5 -2.5 1 2266 
I. limosus 10049 1 280 4763 -82 310 61 -1137 -2.5 -0.5 1.5 9 1 -1082 
P. norimbergenis 299 31 23 3378 -59 3 298 -930 0 0.5 1.5 2 0 -2077 
P. aeruginosa 121 9 1530 483 -330 82 -7 278 1 0 -9.5 5.5 0.5 -3469 
S. marcesens 8601 11 7935 8628 2683 4273 4412 -1302 1 0 -3 8 2 2229 
M. abscessus  6793 12 1321 4949 -17 412 106 2415 0 1.5 1 7 2.5 -2113 
M. abscessus  6495 51 1413 7074 297 610 117 1327 0.5 2.5 -1.5 9 17.5 -418 
M. abscessus  6874 36 2334 4362 197 553 102 826 0.5 1 0 10 13.5 -1977 
M. abscessus  3972 14 1186 7027 -106 111 120 740 -0.5 1 -0.5 8 9.5 -120 
M. abscessus  6776 8 2510 7037 -44 388 174 3452 0 0.5 -3 29 14.5 -1012 
M. abscessus  7510 20 3662 7862 337 843 84 1889 -1 2 -1 12 9 -42 
M. abscessus  6534 21 3303 5955 437 1173 113 2562 0.5 0.5 0 21 5.5 -214 
M. abscessus  6416 4 332 2410 -147 102 97 -302 0 1 -7.5 -4 3 3052 
M. abscessus  6354 17 2195 3457 462 431 62 -278 0.5 0.5 -0.5 80.5 2.5 3778 
M. abscessus  5928 60 2968 4968 651 927 170 2544 -0.5 1 4 15 8 -2798 
M. abscessus  2570 19 1796 4609 -175 147 70 -124 0 0.5 -1 7.5 6.5 -3376 
M. abscessus  7553 51 3096 3670 360 1329 233 1718 0.5 1.5 -0.5 10.5 5.5 -3561 
M. bolletii 5848 8 1427 2931 -137 391 171 1923 -0.5 0.5 -1 51 3.5 -3288 
M. bolletii (ENV) 3053 12 1795 4540 186 227 108 802 0 1 -4 14 8.5 -521 
M. chelonae 4645 1 2477 4779 -2 362 102 2021 0.5 1 -6.5 16.5 6.5 -3266 
M. chelonae 791 6 1109 3080 -249 58 67 -768 0.5 0 -3.5 7 3 -1873 
M. chelonae 4318 1 1849 4014 -430 56 224 3067 1.5 1.5 -2 7 3.5 -578 
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Average spectrophotometer readings for fluorogenic substrates after 72 hours incubation continued 
 
Species Try MetA Ala AAMC GlyP Boc 4MPh 4MSu 123 124 521 266 MR291 7N3CA 
M. chelonae 695 3 1155 5710 -103 102 111 -741 0.5 2 0.5 13.5 5 -371 
M. chelonae 7174 5 4458 5629 365 528 207 2929 0.5 0 -2 15.5 6.5 -789 
M. chelonae 7961 17 2993 5928 104 395 134 3800 0 2 -4.5 27 4.5 -885 
M. massiliense 5088 13 1424 1789 108 467 91 1928 -0.5 1.5 -4.5 1.5 7.5 -970 
M. massiliense 7288 59 1941 4033 483 646 95 1315 -0.5 0.5 6.5 20.5 2.5 -3831 
M. massiliense 8544 37 2526 6277 596 970 266 1918 0 1 5 18 2 -3647 
M. massiliense 3297 24 2017 5596 616 589 191 4392 0 1.5 5.5 20.5 2 -3574 
M. massiliense 8300 42 2052 4718 527 605 175 2337 0.5 1.5 1 3.5 2 -1842 
M. massiliense 6832 28 954 1566 369 381 76 3445 1 0.5 3 5 1.5 -3671 
M. massiliense 8555 33 1804 7052 125 460 213 1491 0.5 1.5 2 28.5 5 -2222 
M. massiliense 8514 42 3318 6362 800 1111 228 3180 0.5 2.5 4.5 13.5 5.5 -573 
S. aureus + Ctrl 293 15 15 8 70 173 6158 -1504 0 0 -2 3.5 0.5 6359 
E. coli + Ctrl 17 11 2 1964 85 -11 6368 -1566 -1 -0.5 2 2.5 1 6545 
Neg Ctrl 15 2 18 33 114 -3 7 -281 -0.5 0.5 0.5 0 0.5 191 
Neg Ctrl -14 -4 -22 -24 -171 1 -4 58 0 0.5 -2.5 -2 -1 203 
Neg Ctrl -2 1 3 -9 56 2 -4 222 0 -0.5 1 3 -0.5 -394 
Neg Ctrl Totals 0 -1 -2 1 -1 0 -1 -1 -1 1 -1 1 -1 1 
 
M. abscessus: M. abscessus subsp. abscessus 
M. bolletii : M. abscessus subsp. bolletii 
M. massiliense : M. abscessus subsp. massiliense 
Key : 4MA : 4-Methylumbelliferyl acetate, 4MPr : 4-Methylumbelliferyl propionate, 4MB: 4-Methylumbelliferyl butyrate, 4MH: 4-Methylumbelliferyl heptanoate, 4MN : 4-Methylumbelliferyl 
nonanoate, 4MLa : 4-Methylumbelliferyl laurate, 4MPgh : 4-Methylumbelliferyl p-guanidinobenzoate hydochlorate hydrate, 4MPa : 4-Methylumbelliferyl palmitate, 4MSt : 4-Methylumbelliferyl 
stearate, 4MLi : 4-Methylumbelliferyl lignocerate, 4Mara : 4-Methylumbelliferyl α-L-arabinopyranoside, 4Mxyl : 4-Methylumbelliferyl 7-β-D-xyloside, 4Mribs :  4-Methylumbelliferyl riboside, 4Mribf : 
4-Methylumbelliferyl β-D-ribofuranoside, 4Mfuc : 4-Methylumbelliferyl β-D-fucoside, 4Mglupα : 4-Methylumbelliferyl α-D-glucopyranoside, 4Mglupβ : 4-Methylumbelliferyl β-D-glucopyranoside, 
4Manα : 4-Methylumbelliferyl α-D-mannopyranoside, 4Mgalα : 4-Methylumbelliferyl α-D-galactoside, 4Mgalβ : 4-Methylumbelliferyl β-D-galactoside, 4Mgluβ : 4-Methylumbelliferyl β-D-glucoside, 
4MIdo : 4-Methylumbelliferyl α-L-idopyranoside, 4Manβ : 4-Methylumbelliferyl β-D-mannopyranoside, 4Mcurβ : 4-Methylumbelliferyl β-D-glucuronide, 4Midu : 4-Methylumbelliferyl α-L-iduronide, 
4MNgal : 4-Methylumbelliferyl N-acetyl-β-D-galactosaminide, 4MNglu : 4-Methylumbelliferyl N-acetyl-β-D-glucosaminide, 4Mcel : 4-Methylumbelliferyl β-D-cellobioside, Pro : H-Pro-AMC 
hydrobromide salt (Prolyl), Val : H-Val-AMC, Thr : H-Thr-AMC, Ile : H-Ile-AMC.TFA, Leu : H-Leu-AMC.HCl, Orn : H-Orn-AMC.2HCl, Gln : H-Gln-AMC, MetH : H-Met-AMC acetate salt, His : H-
His-AMC, Phe :  H-Phe-AMC.TFA, ArgH : H-Arg-AMC.2HCl, Try : H-Try-AMC, MetA : Ac-Met-AMC, Ala : H-β-Ala-Amc.TFA, AAMC : L-alanine AMC trifluoroacetate salt, GlyP : H-Gly-pro-
AMC.HBr, Boc : Boc-Leu-Gly-Arg-AMC acetate salt, 4MPh : 4-Methylumbelliferyl phosphate, 4MSu : 4-Methylumbelliferyl sulfate, SR123 : , SR124 : , S521 : , SR266 : , MR291 : Methyl Red 291, 
7N3CA : 7-nitrocoumarin-3-carboxylic acid. 
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